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Abstract  
The prognosis of human immunodeficiency virus (HIV) has been dramatically 
improved over the years owing to more widespread access and earlier use of 
antiretroviral drug therapy. Consequently, HIV-positive patients are no longer 
dying from AIDS related illnesses but increasingly are experiencing non-
infectious complications such as end-stage kidney disease (ESKD).  
The prevalence of ESKD among 7,307 black HIV-positive patients in the UK 
CHIC cohort increased from 0.44% in 2000/2001 to 1.09% in 2010/2011. 
Kidney transplantation was increasingly used to treat ESKD. Among those 
suitable for transplantation, survival on dialysis and post-kidney transplantation 
was similar (89% and 85% at five years, respectively, p=0.53).   
97 HIV-positive kidney transplant recipients were identified in the United 
Kingdom. Of those that met the study criteria (n=78), 34% received a kidney 
allograft from a living donor and the median follow-up period was 31 (19, 55) 
months. Patient survival at 1 and 3 years post-KT was excellent at 97·3% and 
94·8%, respectively, and the corresponding graft survival rates were 97.3% and 
90.0%. Delayed graft function was encountered in 16 patients (21%), all of 
whom had received a kidney from a deceased donor. The cumulative incidence 
of allograft rejection (AR) at 1 year was 58% and 21% among patients on 
ciclosporin (CsA) and tacrolimus (Tac) respectively. Choice of calcineurin 
inhibitor (CNI) was significantly associated with AR (hazard ratio for Tac vs. 
CsA 0.25 [95% CI 0.11, 0.57], p=0.001).  
  
- 5 - 
Complex drug interactions complicated post-transplant management of HIV/KT 
recipients. CNI doses for patients who received ritonavir-boosted protease 
inhibitor (PI) containing cART were significantly lower throughout the first year 
post-KT (30~fold for ciclosporin, 100~fold for tacrolimus) compared to those 
receiving PI-sparing antiretroviral regimens. By week 4 post-transplant, more 
than half of the patients in both CNI groups had achieved target trough 
concentrations i.e. 50% Tac vs 57% for CsA. Patients in whom mycophenolate 
(MMF) concentrations were routinely measured experienced significantly 
reduced cumulative incidence of latent virus infections, even after adjusting for 
cytomegalovirus prophylaxis (20% vs 84% respectively, p=0.0001).  
In conclusion, these data presented in this thesis demonstrate the increasing 
burden of ESKD despite the widespread use of cART. Findings corroborate the 
feasibility of kidney transplantation in HIV-positive patients albeit with a high 
rate of delayed graft function and allograft rejection. Poor allograft outcomes 
may have been complicated by suboptimal immunotherapy owing to the 
pharmacokinetic interactions between antiretroviral and immunosuppressant 
drugs. The use of tacrolimus may be the preferred CNI for use in KT in HIV-
positive individuals, and monitoring of mycophenolate drug concentrations may 
be beneficial in this patient population.   
 
  
- 6 - 
Acknowledgements 
First, I would like to thank my PhD supervisors Dr Frank Post and Professor 
Graham Davies for first giving me the opportunity to undertake this PhD 
research programme; their support, guidance and encouragement they have 
given me over the past 6 years. Over the years, they have pushed me to 
discover, develop and achieve my potential within research.  
I would like to thank patient study ID 100001, the very first HIV infected patient 
who was admitted onto the ward while I was training in renal medicine in 2007. 
While taking a medical history, it became apparent what a long journey the 
patient had been through from being diagnosed of HIV to soon after developing 
kidney failure due to HIV-associated nephropathy and finally receiving a kidney 
allograft 6 years later. Post-transplant management was complicated by the 
multiple and complex drug interactions between antiretroviral and 
immunosuppressant drugs. This inspired my proposal to Mr John Farrell, Chief 
Pharmacist to sponsor me to undertake a PhD to study HIV kidney 
transplantation. I would also like to thank Wendy Spicer, Helen Atkinson, Meera 
Thacker, Iqbal Desai, Neal Marshall, Shireen Rahhal, Caroline Ashley and 
Leonie Swaden at the Royal Free Pharmacy Department for their continual 
support with my PhD research. A special thanks to Dr Sanjay Bhagani, 
Consultant HIV physician and Dr Mark Harber, Consultant Renal physician who 
gave me an opportunity to learn about the management of HIV kidney patients 
in their multidisciplinary clinic. Another special thanks to Professor Margaret 
Johnson for approving the study and to all HIV physicians including Dr Sabine 
Kinloch for providing access to their patients at the Ian Charleson Day Centre, 
Royal Free hospital.   
  
- 7 - 
Thank you to all the HIV and renal clinicians, transplant surgeons, pharmacists 
and nurses who contributed their time and expertise to making this multicentre 
study a success. I would like to specially thank Dr Rachel Hilton, Consultant 
nephrologist at Guys and St Thomas’ hospital; Dr Jeremy Levy, Consultant in 
renal medicine at Imperial College London and Dr Rachael Jones, Consultant 
HIV physician at Chelsea and Westminster – the list is not exhaustive and is 
outlined in Appendix C. Thank you to HIV Pharmacy Association, the Renal 
Pharmacy Group, British Transplant Society, British HIV Association and the 
Solid Organ Transplant Pharmacy group for their support in this research.    
 
I acknowledge and thank Miss Sophie Jose for her assistance with: 1) data 
mining from UKCHIC database 2) performing statistical analyses using the 
denominator UKCHIC data to determine trends in prevalence and incidence of 
ESKD and the factors associated with ESKD in HIV infection. I also thank 
Professor Caroline Sabin for her comments that greatly improved the 
manuscript for this chapter (Appendix A). I would also like to thank Colette 
Smith and Lucy Campbell both medical statisticians who provided ongoing 
guidance and teaching on statistical analyses in HIV research. Colette Smith 
was the coordinator for the Methodological and Statistical Issues in Clinical HIV 
Research four day short course that I undertook during my PhD training run by 
the HIV Epidemiology and Statistics Group, Royal Free Centre for HIV 
Medicine, University College London (UCL) Medical School. 
 
  
- 8 - 
Many thanks to all patients who contributed to this research. It is my hope that 
the outcomes discussed in this thesis will translate into improved clinical care, 
to provide hope to HIV infected individuals waiting for a kidney transplant and to 
restore their quality of life after transplantation. At the point of writing, three 
healthy and HIV negative babies were born to two HIV positive kidney 
transplant recipients – 30 years on from the discovery of HIV, this is a testament 




- 9 - 
Table of Contents 
Dedication ...................................................................................................................................... 2 
Declaration ..................................................................................................................................... 3 
Abstract .......................................................................................................................................... 4 
Acknowledgements ........................................................................................................................ 6 
Table of Contents ........................................................................................................................... 9 
Table of Figures ........................................................................................................................... 10 
Table of Tables ............................................................................................................................ 13 
Glossary ....................................................................................................................................... 16 
Chapter 1. Introduction ........................................................................................................... 18 
Chapter 2. Burden of End-Stage Kidney Disease & Barriers to KT in HIV Infection ............. 58 
Chapter 3. HIV Kidney Transplantation ............................................................................... 103 
Chapter 4. Calcineurin Inhibitors and Rejection in HIV/KT .................................................. 157 
Chapter 5. Achieving Therapeutic Drug Concentrations in HIV/KT Recipients ................... 198 
Chapter 6. Mycophenolate Therapeutic Drug Monitoring in HIV/KT Recipients .................. 234 
Chapter 7. Conclusions & Future Work ............................................................................... 286 
Appendix A ................................................................................................................................. 296 
References ................................................................................................................................. 313 
  
- 10 - 
Table of Figures 
Figure 1: Trends in HIV Infection in the United Kingdom ..................................................... 19 
Figure 2: Global Impact of Antiretroviral Therapy on AIDS-related Deaths ........................ 21 
Figure 3: Ageing & HIV ............................................................................................................. 32 
Figure 4: Causes of Death in the Swiss HIV Cohort Study ................................................... 40 
Figure 5: Trends in Permanent Renal Replacement Therapy in the United Kingdom ....... 47 
Figure 6: Trends in Permanent Replacement Therapy by Treatment Modality in the United 
Kingdom ..................................................................................................................................... 47 
Figure 7: Cumulative Incidence of AIDS in Transplant Recipients (1985-1992) ................. 51 
Figure 8: Risk of Developing End-Stage Kidney Disease in HIV Infected Individuals ....... 60 
Figure 9: Number of HIV Infected Individuals in UK CHIC Study Stratified by Centre ...... 77 
Figure 10: Full Patient Disposition for HIV/ESKD Cases Identified from the UKCHIC Study
 .................................................................................................................................................... 78 
Figure 11: Trends of ESKD in HIV Infected Individuals ........................................................ 84 
Figure 12: Number of patients under follow-up with ESKD, suitable for kidney 
transplantation, and having received a kidney transplant, stratified by calendar year..... 89 
Figure 13: Kaplan-Meier plots showing survival of patients with ESKD, stratified by a) 
pre-KT, b) post-KT, and c) unsuitable for KT. ........................................................................ 92 
Figure 14: Patient disposition for UK HIV/KT cases transplanted up to 2013 .................. 120 
Figure 15: UK HIV/KT by Transplant Year ............................................................................ 121 
Figure 16: Patient and Graft Survival after HIV Kidney Transplantation ........................... 124 
Figure 17: Allograft Rejection in HIV Kidney Transplant Recipients ................................. 130 
Figure 18: Graft Function Post-Transplantation Stratified By Acute Rejection at 1 Year 132 
Figure 19: Predicted Slopes of estimated Graft Function (eGFR) stratified a priori by 
Allograft Rejection with 95% CIs ........................................................................................... 133 
Figure 20: Post-Transplant CD4 T-Cell Counts .................................................................... 135 
Figure 21: Diagram of T-cell Mediated Rejection and the different mechanisms of action of 
immunosuppressive drugs .................................................................................................... 158 
Figure 22: Patient Disposition for UK HIV/KT Cases Stratified By Those on Ciclosporin 
and Tacrolimus Based Immunosuppression Therapy ........................................................ 176 
Figure 23: Cumulative incidence of acute allograft rejection ............................................. 181 
- 11 - 
Figure 24: Post-Transplant Allograft Function .................................................................... 182 
Figure 25: Changes in CD4+ T Cell Count Post-KT stratified by CNI choice .................... 184 
Figure 26: Post-Transplant CMV Infection Stratified by CNI Choice at KT ....................... 185 
Figure 27: Patient disposition for UK HIV/KT cases stratified by those on Ciclosporin and 
Tacrolimus based Immunosuppression Therapy ................................................................ 216 
Figure 28: Overall Distribution of Tacrolimus Ctrough Concentrations in the First Year Post-
HIV/KT ....................................................................................................................................... 219 
Figure 29: Overall Distribution of Ciclosporin Ctrough Concentrations in the First Year 
Post-HIV/KT ............................................................................................................................. 219 
Figure 30: Tacrolimus and Ciclosporin Dosing and Ctrough Concentrations Stratified by 
cART Choice ............................................................................................................................ 223 
Figure 31: Trough drug concentrations (Ctrough) in the first year following KT in HIV 
positive patients ...................................................................................................................... 224 
Figure 32: Mycophenolate Chemical Structure ................................................................... 234 
Figure 33: Mycophenolic Acid Plasma Concentration Time Profile .................................. 235 
Figure 34: Patient disposition for UK HIV/KT cases stratified by those with 
Mycophenolate TDM ............................................................................................................... 254 
Figure 35: Histogram of overall mycophenolate dosing irrespective of TDM stratification
 .................................................................................................................................................. 258 
Figure 36: Mean (+/-SD) Mycophenolate doses in the first year post-KT .......................... 259 
Figure 37: Graph representing overall mycophenolic acid plasma concentrations 
achieved in the first year post-HIT/KT .................................................................................. 260 
Figure 38: Median (IQR) Mycophenolate Ctrough plasma concentrations categorised by 
weeks in first year post-KT .................................................................................................... 261 
Figure 39: Median (IQR) Mycophenolic Acid Plasma Ctrough Concentrations Stratified By 
CNI Choice for the First Four Months Post-HIV/KT ............................................................. 262 
Figure 40: Median (IQR) Mycophenolic Acid Plasma Ctrough Concentrations for HIV/KT 
Recipients Maintained on Tacrolimus .................................................................................. 263 
Figure 41: Graph representing the proportion of patients taking mycophenolate in the 
first year post-HIV/KT stratified a priori by TDM status ...................................................... 264 
Figure 42: Cumulative incidence of Adverse Events (AE) stratified by MMF TDM and by 
AE type in the first year post-transplantation ...................................................................... 269 
- 12 - 
Figure 43: First Allograft Rejection Episodes at 1 year Post-HIV/KT Stratified by 
Mycophenolate TDM ............................................................................................................... 273 
Figure 44: Graph representing estimated glomerular filtration rate (eGFR) determined by 
CKD-EPI post-HIV/KT stratified by Mycophenolate TDM .................................................... 274 
 
  
- 13 - 
Table of Tables 
Table 1: Risk of AIDS or Mortality for HIV-1 Infected Patients maintained on Combination 
Antiretroviral Therapy Stratified by CD4 T Cell Count at cART Initiation ........................... 28 
Table 2: Kidney Diseases in HIV Infection.............................................................................. 38 
Table 3: The Kidney Effects of Antiretroviral Drug Therapy & Antiretroviral Dose 
Adjustment for Renal Impairment ........................................................................................... 42 
Table 4: Summary of acute rejection in kidney transplantation in HIV positive patients 
(HIV+ prior to transplantation) restricted to publications preceding 2010a ........................ 55 
Table 5: Information Collected for the UK CHIC Study (UK-CHIC, 2004) ............................ 66 
Table 6: List of AIDS Defining Illnesses ................................................................................. 72 
Table 7: Characteristics of Included/Excluded HIV+ Patients in UK CHIC/ESKD Study ... 79 
Table 8: Characteristics of patients according to ESKD status over follow-up ................. 81 
Table 9: Aetiology of Kidney Disease in HIV/ESKD Individuals ........................................... 82 
Table 10: Results from univariable and multivariable Poisson regression analyses to 
identify factors associated with ESKD ................................................................................... 86 
Table 11: Results from univariable and multivariable Poisson regression analyses to 
identify factors associated with ESKD with sensitivity analyses, with last CD4 count/VL 
carried forward .......................................................................................................................... 87 
Table 12: Characteristics of patients according to ESKD treatment modality over follow-
up ................................................................................................................................................ 90 
Table 13: HIV Disease Specific Kidney Transplantation Inclusion Criteria ...................... 104 
Table 14: HIV Disease Specific Kidney Transplantation Absolute Exclusion Criteria .... 105 
Table 15: HIV Disease Specific Kidney Transplantation Exclusion Criteria ..................... 105 
Table 16: Baseline Data Collected in the UK HIV Kidney Transplant Study ..................... 112 
Table 17: Post-transplant Data Collected in the UK HIV Kidney Transplant Study ......... 113 
Table 18: Types of Allograft rejection ................................................................................... 115 
Table 19: Baseline HIV Kidney Transplant Recipient Characteristics ............................... 123 
Table 20: HIV Kidney Transplant - Donor characteristics ................................................... 123 
Table 21: Mean (+/- SD) Calcineurin Inhibitor Doses & Mean (+/-SD) Whole Blood 
Concentrations in HIV Infected Kidney Transplant Recipients .......................................... 128 
- 14 - 
Table 22: Summary of HIV+ Patients that Experienced Viral Load Blips Post-
Transplantation ....................................................................................................................... 134 
Table 23: Baseline Patient Characteristics at Kidney Transplantation Stratified According 
to CNI Immunosuppression Therapy .................................................................................... 178 
Table 24: Factors Associated with Allograft Rejection in the First Year Post-KT ............ 187 
Table 25: Summary of Metabolism and Transporter Mechanisms of Commonly Used 
Immunosuppressant Drugs in Kidney Transplantation ...................................................... 200 
Table 26: Summary of Metabolism and Transporter Mechanisms of Antiretroviral Drugs
 .................................................................................................................................................. 206 
Table 27: Calcineurin Inhibitor and Antiretroviral Drug-Drug Interaction Table .............. 207 
Table 28: Summary of Evidence (case studies, case series, prospective studies) of CNI 
and Drug Interactions with PI-Containing Antiretroviral Drug Therapy ............................ 209 
Table 29: Summary of Evidence (case studies, case series, prospective studies) of CNI 
and Drug Interactions with PI-Containing Antiretroviral Drug Therapy ............................ 210 
Table 30: Baseline patient characteristics at kidney transplantation according to CNI 
immunosuppression therapy ................................................................................................. 218 
Table 31: Immunosuppression drug therapy management in the first year post-transplant
 .................................................................................................................................................. 218 
Table 32: Mean (±SD) calcineurin doses & Mean (±SD) whole blood concentrations in HIV 
positive kidney transplant recipients .................................................................................... 222 
Table 33: Antiretroviral / Mycophenolate Drug Interaction Table ...................................... 240 
Table 34: Baseline patient characteristics at kidney transplantation according to 
Mycophenolate TDM status.................................................................................................... 255 
Table 35: Baseline immunosuppression and antiretroviral drug therapy stratified by MMF 
TDM ........................................................................................................................................... 256 
Table 36: Reasons for first mycophenolate dose discontinuations stratified by TDM* .. 265 
Table 37: Reasons for Mycophenolate dose reduction stratified by TDM* ....................... 265 
Table 38: Factors Associated with Mycophenolate Discontinuation in the First Year Post-
HIV/KT ....................................................................................................................................... 267 
Table 39: Results from univariate and multivariate cox-proportional hazard analyses to 
identify factors associated with latent viral infections in the first year post-transplant . 271 
- 15 - 
Table 40: Results from univariate cox-proportional hazard analyses to identify factors 
associated with treatment limiting cytopenias in the first year post-transplant .............. 272 
Table 41: Non-compartmental Pharmacokinetic Analysis - Calculated PK parameters 




- 16 - 
Glossary 
ABO  Blood group incompatible 
cART  Combination antiretroviral therapy 
ADE  Adverse events 
AR  Acute allograft rejection 
ARVs  Antiretroviral drugs 
ATG   Anti-Thymocyte Globulin 
AUC  Area under the curve 
BKV  BK-virus 
BKVN  BK-virus associated nephropathy 
BPAR  Biopsy proven allograft rejection 
C0  Concentration at time zero 
C2  Concentration at 2-hours post-dose 
C4  Concentration at 4-hours post-dose 
Cmax  Maximum concentration 
Cmin  Minimum concentration 
Cpre-dose  Pre-dose concentration 
Ctrough  Trough concentration 
CIT  Cold ischaemic times 
CMV  Cytomegalovirus 
CMVN  Cytomegalovirus-associated nephropathy 
CNI  Calcineurin inhibitors 
CRF  Calculated Reaction Frequency 
CsA  Ciclosporin A 
CYP450 Cytochrome P450 enzyme 
DGF   Delayed Graft Function 
eGFR  Estimated glomerular filtration rate  
EBV  Epstein-Barr Virus 
EMIT  Enzyme multiplied immunoassay technique 
ESKD  End-stage kidney disease 
FSGS  Focal segmental glomerulosclerosis 
HAART  Highly active antiretroviral therapy 
HBV  Hepatitis B virus 
HCV  Hepatitis C virus 
HIV  Human immunodeficiency virus 
HIV+  HIV-positive individual 
HIV-  HIV-negative individual 
HIV/ESKD HIV-associated end-stage kidney disease 
HIV/KT  HIV kidney transplantation  
HIV/KTR HIV-positive Kidney Transplant Recipient 
HIVAN  HIV-associated nephropathy 
- 17 - 
HLA   Human leukocyte antigen 
HPV  Human papilloma virus 
ICKD  Immune complex kidney disease 
INI  Integrase inhibitor 
IS  Immunosuppression 
IST  Immunosuppressive drug therapy 
IVIG  Intravenous immunoglobulin 
IVMP  Intravenous methylprednisolone 
KT  Kidney transplantation 
LC-MS/MS Liquid chromatography–mass spectrometry 
LOCF  Last observation carried forward 
LVI  Latent viral infection 
MMF  Mycophenolate 
MPA  Mycophenolic acid 
MPAG  Mycophenolic acid-7-O-glucuronide 
NNRTI  Non-nucleoside reverse transcriptase inhibitors  
NRTI  Nucloside/tide reverse transcriptase inhibitors 
PI  Protease inhibitors  
PI/r  Ritonavir boosted protease inhibitors 
PK  Pharmacokinetic 
PRA  Panel reactive antibody 
PVN  Polyomavirus nephropathy 
pRRT  Permanent renal replacement therapy 
SIR  Standardised incidence ratios 
SLK  Simultaneous liver-kidney transplant 
SPK  Simultaneous pancreas-kidney transplant 
Tac  Tacrolimus 
TDM  Therapeutic drug monitoring 
UK  United Kingdom 
WIT  Warm ischaemic time 
 
  
- 18 - 
Chapter 1. Introduction  
1.1. The Burden of HIV  
The global epidemic of the human immunodeficiency virus continues to grow. 
Since the discovery of the HIV virus there has been an estimated 78 million 
people infected with HIV. Today, there is an estimated 35 million people living 
with HIV in the world which is representative of 0.8% of the adult population 
(age range 15 – 49). The burden of HIV varies between countries with sub-
Saharan Africa being the worst affected. It is estimated that 70% of all HIV 
infected people globally reside in sub-Saharan Africa (UNAIDS, 2013, WHO, 
2015a). By 2013, there was approximately 2.3 million HIV infected people living 
in North American and Western/Central Europe (AVERT, 2013). In Western and 
Central Europe, the prevalence of HIV is low (0.2%) however, steadily 
increasing. In 2013 there were 80% more new HIV cases compared to 2004 in 
Europe (WHO, 2015a). 
In the United Kingdom, there is an estimated 107, 800 people living with HIV. 
The number of new HIV diagnoses has been increasing year on year which is a 
reflection of the growing prevalence of HIV in the UK (see Figure 1). The 
estimated overall prevalence is 2.8 per 1000 population with majority being 
male (63%), men who have sex with men (MSM) (40%) and of white ethnicity 
(48%). By comparison to other European countries, the UK has a low proportion 
of HIV infected people who have acquired HIV by injectable drug use (HPA, 
2014). Of the 114,000 HIV infected people who inject drugs in Western Europe, 
2% are from the UK (AVERT, 2013). By contrast, the UK has a high proportion 
of patients of black ethnicity (42%) compared to other European countries 
(HPA, 2014).  
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In 2012, among the new HIV cases that acquired HIV through heterosexual 
contact in Europe (n=3160) of those who originated from sub-Saharan African 
countries more than half (58%) were living in the UK (ECDC, 2013). In North 




Figure 1: Trends in HIV Infection in the United Kingdom 
 
 
Graph representing the number of HIV infected individuals living in the United Kingdom between 
1998 to 2014.  Data includes HIV infected individuals accessing HIV care services in the UK, 
newly diagnosed individuals and number of patients that died year on year.  Data obtained from 
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The growing prevalence of HIV is suggested to be attributable to the use of 
antiretroviral therapy which has significantly improved morbidity and mortality. 
However, despite the wide coverage of antiretroviral therapy, the incidence of 
HIV has not been impacted in certain groups. A reduction in the incidence of 
HIV among heterosexuals and in injectable drug users that has been observed 
is thought to be due to the implementation of effective preventative strategies 
and programmes. However, the availability of effective antiretroviral therapy is 
thought to have increased risk behaviour among men who have sex with men 
thereby increasing the incidence of HIV in this group (Degenhardt et al., 2010, 
Mayer and Mimiaga, 2011, Beyrer et al., 2013, Birrell et al., 2013, Desai et al., 
2013, Zaidi et al., 2013, Maartens et al., 2014).  
 
Since the advent of antiretroviral therapy in the 1990s, the survival of HIV 
infected people has dramatically improved. In spite of this, HIV/AIDS continues 
to be one of the deadliest epidemics of the 20th Century (Bongaarts, 2011) (see 
Figure 2). The number of AIDS related deaths peaked in 2005 at 2.3 million but 
has since declined to 1.6 million in 2012. This decline has been credited to 
antiretroviral therapy use. From 1996 to 2012, it has been estimated that ART 
use has averted 6.6 million deaths worldwide (UNAIDS, 2013). About 39% of all 
HIV infected individuals globally have access to antiretroviral therapy. Of the 
12.9 million HIV infected people on ART globally, 11.7 million were from low 
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Figure 2: Global Impact of Antiretroviral Therapy on AIDS-related Deaths  
 
Estimated number of AIDS related deaths, with and without antiretroviral therapy, in low and 
middle income countries between1995 to 2012. Number of deaths due to AIDS-related illnesses 
(black bars); number of deaths averted due to ART (grey bars). Globally, 15 million people had 




In the UK, 90% of those accessing HIV care in 2013 were prescribed ART 
(HPA, 2014). However, even with about one third of all HIV infections globally 
being managed with ART, AIDS continues to be the leading cause of death in 
this population. A 12 year longitudinal study (1999 to 2011) using a large HIV 
cohort (n=49,731) from high income countries found that the proportion of 
deaths associated with AIDS, liver disease, cardiovascular disease and non-
AIDS cancer was 29%, 13%, 11% and 15% respectively (Smith et al., 2014). 
The AIDS related deaths were associated with uncontrolled HIV virological 
control, low CD4 T cell count and older age. This emphasises the importance of 
early HIV diagnosis prior to developing advanced disease and effective HIV 
treatment with antiretroviral therapy (Scourfield et al., 2011, Smith et al., 2014, 
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(n=16,134) over a 22 year period (1988 to 2010) observed an approximated 50 
fold decrease in AIDS associated mortality (11.0 to 0.211 per 100 person years 
respectively). Other important factors associated with risk of death are hepatitis 
B and C co-infection (Weber et al., 2013). In the United Kingdom, the number of 
AIDS related deaths declined 3 fold from 2004 (n=1,020) to 2013 (n=320) (HPA, 
2014). Majority of the AIDS related deaths were due to advanced HIV disease 
among people that were diagnosed late. The most common AIDS related 
illnesses were Pneumocystis jirovecii pneumonia (32%, 470/1470), 
Mycobacterium tuberculosis (14%, 200), Kaposi sarcoma (9%, 130) and 
oesophageal candidiasis (9%, 130). The proportion of late diagnoses (CD4 T 
cell count < 350 cells/mm3) in the UK represent 42% of those newly diagnosed 
with HIV. This reflects the need to increase the coverage of HIV testing (HPA, 
2014).    
The prolonged survival of HIV infected individuals also alludes to an ageing 
population. In the UK, one in four people living with HIV are over the age of 50 
(HPA, 2014). According to the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) analysis, the average life expectancy of a 
20 year old individual initiating antiretroviral therapy was 51.4 years in 2007; 
meaning the patient could expect to live to 71.4 years of age (Samji et al., 
2013). This is near normal life expectancy which is estimated at 71 years from 
birth globally and ranging from 66 to 79 in middle and high income countries 
(WHO, 2015c). With HIV infected people living longer, there is an associated 
increased risk of non-AIDS related comorbidities such as cardiovascular, renal, 
non-AIDS related cancers or neurological diseases. Furthermore, there is the 
risk of drug related toxicities with prolonged use of antiretroviral drug therapy 
(Gazzola, 2010).   
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1.2. Management of HIV Infection  
Zidovudine was the first antiretroviral drug that was licensed in 1987.  
Zidovudine is a thymidine analogue, which inhibits the transcription of HIV-1 
virus. However, zidovudine as a monotherapy agent proved to be ineffective 
(Mitsuya et al., 1985, Fischl et al., 1987, Larder et al., 1989, Hammer et al., 
1996, Broder, 2010b, Broder, 2010a). In the early to mid-1990s, antiretroviral 
drugs that targeted different stages of the HIV virus were developed. The rapid 
turnover of HIV virions and CD4 T target cells made it impossible to eradicate 
the virus. Furthermore, there was the emergence of HIV viral mutations and 
resistance to antiretroviral agents. It wasn’t until 1997 when highly active 
antiretroviral therapy (HAART) was used to manage HIV infection. HAART 
included the combination of three antiretroviral drugs; two nucleoside reverse 
transcriptase inhibitors as the ‘backbone’ and a third agent either a protease 
inhibitor or a non-nucleoside reverse transcriptase inhibitor. HAART proved 
highly effective in decreasing viral loads to clinically undetectable levels (<50 
copies/mL) (Wei et al., 1995, Gulick et al., 1997, Hammer et al., 1997, Laskey 
and Siliciano, 2014). The first clinical trial tested the combination of two NRTIs, 
lamivudine plus zidovudine or stavudine, and one protease inhibitor, indinavir. 
Study participants were HIV-1 infected, with CD4 T cell counts less than 200 
cells/mm3 and received at least 3 months of zidovudine monotherapy. The 
primary outcome measure of efficacy was the development of new or recurrent 
AIDS defining illness or death. Of 1156 patients, 8% developed an AIDS 
defining illness or died after a median follow-up of 38 weeks; 6% in the 
treatment arm (lamivudine plus zidovudine (or stavudine) plus indinavir) 
compared 11% of the comparator arm (lamivudine plus zidovudine (or 
stavudine)) (p=0.001). Reductions in HIV-1 RNA concentrations were 
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significantly lower in the treatment arm compared to the comparator arm (2.1 
log10 vs 1.0 log10, p=0.007) (Hammer et al., 1997). Mortality and slowed HIV 
disease progression soon became the benchmark of HIV treatment thus termed 
as ‘highly active antiretroviral therapy’. However, early antiretroviral drug 
formulations required high dosages, in some instances up to 22 pills per day, for 
optimal treatment. The high pill burden accompanied with profound drug 
interactions with the ARVs induced severe adverse events. Adverse events in 
people receiving HAART soon became apparent and were associated with poor 
adherence rates, treatment limiting toxicities and subsequent virological failure 
(Molaghan, 1997, SK, 1997). An early HAART study that included 143 HIV 
infected patients observed a viral load reduction to <500 copies/mL at 6 months 
in less than half of the patients (47%) (SK, 1997). The disappointing study 
results was attributed to poor HAART adherence and an associated 15-fold 
increased risk of virological treatment failure (Max and Sherer, 2000). 
Innovations in drug formulation have since been made available which have 
improved the efficacy of antiretroviral drugs. An example of this was Atripla® 
the first single antiretroviral pill containing efavirenz, emtricitabine, and tenofovir 
(Julg and Bogner, 2008). Today, there are more than 25 antiretroviral agents 
and six classes that target the different stages of the viral life cycle as follows 
(BHIVA et al., 2014, HHS, 2015): 
• Nucleoside reverse transcriptase inhibitors 
• Protease inhibitors 
• Non-nucleoside reverse transcriptase inhibitors 
• Fusion inhibitors 
• Integrase inhibitors 
• Chemokine receptor 5 (CCR5) antagonists  
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Despite the effectiveness of HAART, now referred to as combination 
antiretroviral therapy (cART), it is not curative. The establishment of HIV 
reservoirs very early on in infection is thought to prevent sterilising immunity 
thereby propagating HIV persistence (Pierson et al., 2000). The primary aims of 
cART therefore are to: achieve and maintain full HIV viral suppression; 
immunological restoration and/or preservation; and reduce HIV associated 
morbidity and mortality (BHIVA et al., 2014, HHS, 2015). Furthermore, the use 
of cART reduces the risk of HIV transmission associated with a high viral load 
(Quinn et al., 2000, Cohen et al., 2011). Full HIV viral load suppression in the 
early cART era was aimed at <400 copies/mL (Max and Sherer, 2000). In 
recent years, an undetectable HIV viral load is considered at <50 copies/mL 
(BHIVA et al., 2014, HHS, 2015). There are new ultrasensitive assays that can 
quantify HIV RNA levels as low as 1 copy/mL (Williams et al., 2014). 
Over the last decade, the choice and timing of cART initiation has been much 
debated. Immunological status, HIV viral load, stage of HIV infection, HIV 
related and non-related co-morbidities, viral co-infections and existing 
malignancies are some of the factors considered when initiating cART. Some 
researchers have argued that starting cART very early on in infection would 
reduce the size of the HIV reservoir and reduce the initial viral ‘set point’ thus 
improve the clinical disease course (Wasserheit, 1992, Henrard et al., 1995). 
Although, initiating cART during primary HIV infection has cost implications and 
there is the added risk of treatment limiting toxicities with chronic ART use. 
Majority of clinical guidelines have made recommendations of cART initiation 
based on immunological status (CD4 T cell count), presence of an AIDS 
defining illness, pregnancy, high HIV viral load (> 100,000 copies/mL), HIV-
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related illnesses (e.g. kidney disease, liver disease), co-infections, drug 
resistance profiling and cost (Churchill et al., 2015, HHS, 2015).  
Initiating cART guided by CD4 T cell count varies between guidelines. Early 
guidelines recommended starting cART when CD4 T cell counts were < 200 
cell/mm3. This recommendation was based on early clinical trials (Hammer et 
al., 1996, Hammer et al., 1997, Hogg et al., 2001, Palella et al., 2003). 
Furthermore, low CD4 T cell counts < 200 cells/mm3 was associated with a high 
risk of opportunistic infections, AIDS defining illnesses, non-AIDS morbidity and 
death (Hammer et al., 1997, Mocroft et al., 1998, HTCG, 1999, Hogg et al., 
2001, Palella et al., 2003, Baker et al., 2008, When To Start et al., 2009, Zolopa 
et al., 2009, HHS, 2010, Nelson et al., 2011). The Strategies for Management of 
Antiretroviral Therapy (SMART) trial observed that initiating cART when CD4 T 
cell counts were <250 cells/µL was associated with a three times higher rate of 
AIDS or death compared to a CD4 T cell count > 350 cells/µL 
(SMARTStudyGroup et al., 2008b, When To Start et al., 2009, Cohen et al., 
2011). More recent recommendations consider starting cART at CD4 T cell 
counts between 350 and 500 cell/mm3 (WHO, 2013, BHIVA et al., 2014, HHS, 
2015) or any count even if > 500 cells/mm3 (Hoen et al., 2014, 
INSIGHTStartStudyGroup et al., 2015, Tabernilla and Poveda, 2015). The most 
recent British HIV Association guidelines (2015) recommend initiating cART 
immediately irrespective of CD4 T cell count for primary HIV infected individuals 
and within two weeks for those that present with advanced HIV disease and 
CD4 T cell count <200 cell/mm3 .  
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Data for initiating cART at CD4 T cell counts between 350 and 500 cell/mm3 
showed reduced HIV disease progression although the effect on mortality was 
conflicting. Evidence for initiating cART at CD4 T cell counts >500 cells/mm3 
was less conclusive though there was some benefit in the prevention of HIV 
transmission by fully suppressing the viral load (HHS, 2015). Table 1 
summarises the studies that support initiation of cART when CD4 T cell counts 
between 350 and 500 cell/mm3 and > 500 cells/mm3. There are also longevity 
benefits with early cART initiation. An HIV individual diagnosed at 35 years of 
age and starting cART at CD4 T cell count < 100 cell/mm3 is predicted to live to 
62 years of age while starting at CD4 T cell count > 200 cells/mm3 is thought to 
extend life expectancy by 10 years to 72 years of age (Antiretroviral Therapy 
Cohort, 2008, Justice, 2010). 
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Table 1: Risk of AIDS or Mortality for HIV-1 Infected Patients maintained on Combination Antiretroviral Therapy Stratified by CD4 T Cell Count at cART Initiation  
Study N CD4 Count at cART Initiation 
(cells/mm3) 
Risk of Mortality** 
HR (95 CI) 
Reference 




(When To Start et al., 2009) 
ART-CC 
 
24,444 251 to 350  
351 to 450  
1·13 (0·80–1·60) 
Ref 
(When To Start et al., 2009) 
NA-ACCORD 8,362  <350  
351 – 500 
RR (95 CI): 1.69 (1.26–2.26)* 
Ref 
(Kitahata et al., 2009) 




(Kitahata et al., 2009) 
HIV-CAUSAL 8,392 <350  
351 – 500 
1.38 (1.23–1.56) 
Ref 
(Collaboration et al., 2011) 
CASCADE 5,527 200 – 349 
350 – 499 









(SMARTStudyGroup et al., 2008a) 
START 
 
4,685 Immediate initiation irrespective of CD4 T cell count  
Deferred initiation to <350 
0.58 (0.28-1.17) 
Ref 
(INSIGHTStartStudyGroup et al., 2015) 
HPTN 052 1,763 <250 
250 - 550 
Ref 
0.73 (0.52–1.03)*‡ 
(Grinsztejn et al., 2014) 
CIPRA HT-001 816 <200 
200 - 350 
4.0 (1.6-9.8) 
Ref 
(Severe et al., 2010) 
Key: ART Cohort Collaboration (ART-CC); HR, Hazard Ratio; RR, Risk Ratio; 95 (CI), 95% Confidence Interval; Ref, Reference 
*Risk of AIDS & Mortality; ** P <0.05; ‡P=0.074 
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Recommendations on the choice of cART regimen also varied between 
guidelines and were largely driven by clinical efficacy and cost-effectiveness 
studies. In the UK, the current guidelines recommend treatment for therapy 
naïve HIV positive individuals two NRTI, tenofovir plus emtricitabine or, abacavir 
plus lamivudine as an alternative and a third agent (Churchill et al., 2015). The 
choice of third agent should include first line either: a protease inhibitor 
(atazanavir or darunavir) with ritonavir as a pharmacokinetic enhancer (PI/r); or 
NNRTI (rilpivirine); or INI (dolutegravir, raltegravir or elvitegravir with cobicistat 
pharmacokinetic enhancer). Efavirenz, an NNRTI is reserved as an alternative 
third agent. The USA guideline recommendations are similar with the exception 
of the choice of PI/r which excludes ritonavir boosted atazanavir due to the high 
rate treatment limiting toxicities observed in clinical trials (Lennox et al., 2014, 
HHS, 2015). Efavirenz is also excluded from the guidelines due to central 
nervous system related toxicities and possible association with suicide (Mollan 
et al., 2014, HHS, 2015).  
INI-based regimens are considered to have high virological efficacy, fewer drug 
interactions and much improved safety profile compared to other ARVs albeit 
with a low genetic barrier to resistance (Blanco et al., 2011, Walmsley et al., 
2013, Molina et al., 2015). Where adherence is of concern, PI/r-based regimens 
are much preferred due to the high genetic barrier to resistance (Lathouwers et 
al., 2011, Soriano et al., 2011, HHS, 2015). However, recent data demonstrates 
dolutegravir having a high genetic barrier to resistance (Llibre et al., 2015).  
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Prescribing patterns in the UK have changed over the years. In the late 1990s 
majority of patients were initiated on protease inhibitor containing cART 
compared to NNRTI containing cART. One observational cohort study with 
14,252 patients demonstrated 2% vs 19% respectively initiated NNRTI vs PI 
containing cART in 1996. This dramatically changed in the early to mid-2000s 
where 75% initiated NNRTI containing cART vs 14-18% PI containing cART 
(Easterbrook et al., 2008). Even with effective cART treatment that resulted in 
immune restoration and fully suppressed HIV viral load, the HIV population are 
experiencing significantly increased co-morbidities. This is thought to be as a 
result of: the extended life expectancy with ART use; an ageing HIV population; 
long-term adverse events with antiretroviral use; direct HIV viral effect; and 
chronic inflammatory responses driven by chronic HIV infection (Gazzola, 2010, 
Baranoski et al., 2014, Crawford et al., 2014, Lorenc et al., 2014, Warriner et 
al., 2014).        
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1.3. HIV and Co-morbidities  
Effective antiretroviral therapy has vastly improved the survival of people living 
with HIV. Longevity and the ageing HIV population has increased the risk of 
developing non-HIV related comorbidities including renal disease, liver disease, 
cardiovascular disease, chronic lung disease, diabetes, neurologic conditions 
(e.g. HIV-associated dementia) and non-AIDS related malignancies (Friis-Moller 
et al., 2003b, Grinspoon, 2009, Falade-Nwulia and Thio, 2011, Aberg, 2012, 
Medapalli et al., 2012, Manji et al., 2013, Rodriguez-Penney et al., 2013). This 
section will briefly discuss the common co-morbidities observed in the HIV 
infected population.  
Aging & HIV 
In the UK and USA about one third of all HIV infected patients are over the age 
of 50 (CDC, 2011, HPA, 2014). The chronic inflammatory responses and 
immunosenescence during HIV infection is thought to be the cause of these 
combined HIV and age related co-morbidities (Aberg, 2012). Despite the 
effective HIV suppression and somewhat improved immunological function with 
antiretroviral therapy, evidence of persistent inflammation and lower CD4 T cell 
counts increase the risk of non-AIDS comorbidities (Deeks and Phillips, 2009). 
Aside from inflammation, HIV infected individuals differ greatly to HIV uninfected 
patients in lifestyle and socioeconomic status that may further increase the risk 
of developing comorbidities. Figure 3 shows a conceptual model of aging in 
people living with HIV. Among HIV infected individuals, smoking, alcohol and 
drug use is highly prevalent (Justice, 2010). It is estimated that 40 to 75% of 
HIV infected individuals smoke cigarettes (Pacek and Cioe, 2015). Cigarette 
smoking has been known to increase the risk of AIDS and non-AIDS related 
diseases (Calvo-Sanchez et al., 2013, Helleberg et al., 2013, Shirley et al., 
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2013, Helleberg et al., 2015). Chronic obstructive pulmonary disease, lung 
cancer, atherosclerotic disease, decreased bone mineral density, human 
papillomavirus (HPV) and related cancers are but some of the comorbidities 
associated with smoking in HIV infected individuals (Castellsague and Munoz, 
2003, Minkoff et al., 2004, Shirley et al., 2013).    
Figure 3: Ageing & HIV 
 
Figure 3 Adapted from “HIV and Aging: Time for a New Paradigm” (Justice, 2010). Conceptual 
model of aging with HIV infection. Viral hepatitis and continual substance use (e.g. smoking, 
alcohol, drug use, etc) aggravate immune dysfunction and chronic inflammation thereby 
worsening co-morbid disease and both HIV and non-HIV treatment toxicities. 
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Cardiovascular disease & HIV 
Aside from inflammatory and lifestyle factors, metabolic complications such as 
cardiovascular disease and diabetes are common among the aging HIV 
infected individuals (Falutz, 2011, Petoumenos and Worm, 2011). Lipid 
changes and atherosclerotic changes associated with low levels of high-density 
lipoprotein and high levels of low-density lipoprotein cholesterol are 
predominant among HIV individuals. This is brought about by direct HIV effects, 
ageing and metabolic complications associated with continuous antiretroviral 
therapy use (Kaplan et al., 2011) (Lagathu et al., 2004, Giralt et al., 2010, 
Falutz, 2011). Epidemiology studies have reported almost 2 fold increased risk 
of cardiovascular disease among HIV infected individuals on cART compared 
with HIV uninfected patients (Islam et al., 2012, Martin-Iguacel et al., 2015). 
Arterial inflammation, coronary artery plaque, carotid artery intima-media 
thickness and HIV associated lipodystrophy with antiretroviral therapy have 
been observed in HIV infected patients (Abd-Elmoniem et al., 2014, Freitas et 
al., 2014, Post et al., 2014, Samuel et al., 2014).  
 
The D:A:D study was the first observational cohort study, that included 49,734 
HIV infected patients, which showed an association of cART treatment and 
cardiovascular disease (Friis-Moller et al., 2003a, Martin-Iguacel et al., 2015). 
The study reported an increased relative risk (26%) of acute myocardial 
infarctions from prolonged use of cART (4 to 6 years). Antiretroviral therapy 
induced lipodystrophy is also known to contribute to the development of 
atherosclerotic lesions (Guaraldi et al., 2010). Lipodystrophy occurs more 
commonly with protease inhibitors and thymidine nucleoside reverse 
transcriptase inhibitors compared to NNRTI and other classes of antiretroviral 
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therapy (Guaraldi et al., 2014). There are also differences in dyslipidemic, 
atherogenic and prothrombotic effects between individual antiretroviral drugs 
within the same class (Martin-Iguacel et al., 2015). An example of this was 
demonstrated in the SENSE study where efavirenz use was associated with 
greater lipid elevations compared to Etravirine (Fatkenheuer et al., 2012, 
Guaraldi et al., 2014). At the end of the 48 week study, compared to etravirine 
patients on efavirenz demonstrated greater change in HDL (+0.15 mmol/L, 
p=0.004), LDL (+0.35 mmol/L, p=0.005), total cholesterol (+0.61 mmol/L, 
p<0.0001) and triglycerides (+0.33 mmol/L, p=0.03). In another study, total 
cholesterol and triglycerides were significantly raised with efavirenz compared 
with rilpivirine (Wilkin et al., 2012). By the end of the 192 week study, the mean 
change in lipids from baseline for rilpivirine vs efavirenz respectively was: total 
cholesterol (-17 (35) vs -41 mg/dl, p<0.001); LDL (-10 vs -22 mg/dl, p<0.01); 
HDL (+5 vs +11 mg/dl, p<0.001).  In the D:A:D observational cohort study the 
risk of myocardial infarction (MI) was lower in those on NNRTI but higher with PI 
containing cART (D.A.D.StudyGroup et al., 2007). An overall of 345 fatal/non-
fatal myocardial infarctions were observed; 90.4% and 60.9% of the events 
respectively occurred in patients that had a median of 3.7 years of PI exposure 
versus 2.1 years of NNRTI exposure.  
The D.A.D study group also found an almost two fold increase in risk of 
developing a myocardial infarction with abacavir exposure (RR 1.89) 
(D.A.D.StudyGroup et al., 2008). The association of abacavir exposure and MI 
remained even after adjusting for renal impairment (Post and Campbell, 2008, 
Martin-Iguacel et al., 2015).  Although, there were criticisms that the D.A.D 
study did not address underlying cardiovascular risk, especially in those 
patients at high risk of CVD, as a confounding factor. A recent update analysis 
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within the D.A.D cohort observed a 98% increase in MI rate with current 
abacavir use and a rate ratio of 1.98 adjusted for CVD risk factors including 
renal, dylipidaemia and hypertension. The associated CVD risk with abacavir 
use remained when analyses were split before and after 2008 when the first 
study was published (Sabin, 2014).      
Liver disease & HIV      
Liver disease is one of the major causes of death which accounts for 14 – 18% 
of all deaths among HIV infected individuals. In the post-cART era, liver disease 
is largely due to hepatitis B / C co-infection and medication related toxicity 
(Antiretroviral Therapy Cohort, 2010, Price and Thio, 2010). An estimated 30% 
of HIV infected individuals in the USA and Europe are co-infected with hepatitis 
C. Worldwide 10% of all people living with HIV are infected with hepatitis B. HIV 
infected individuals are 3 to 6 times more likely to develop chronic hepatitis B 
after acute exposure compared to HIV uninfected individuals (Bodsworth et al., 
1991, Price and Thio, 2010). An accompanying low CD4 T cell count (<200 
cells/mm3) further compromises immunity to HBV among HIV infected patients 
(Kim et al., 2008). ART-associated hepatotoxicity is one of the most common 
serious adverse effects with an approximate 10% incidence rate (Sulkowski et 
al., 2000, Puoti et al., 2009, Price and Thio, 2010). Different mechanisms known 
to induce ART-associated liver toxicity include hypersensitivity reactions, 
mitochondrial toxicity, direct drug toxicity or drug metabolism and immune 
reconstitution inflammatory syndrome (IRIS) (Anderson et al., 2010, Price and 
Thio, 2010). Furthermore, immune restoration in viral co-infected HIV infected 
patients compromises the liver causing cirrhosis and hepatic dysfunction 
(Zylberberg et al., 1998, Drake et al., 2004, Price and Thio, 2010).  
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Aside from ART use, alcohol, older age, female gender and concomitant anti-
tuberculosis medications are all factors associated with ART-associated liver 
damage (Hoffmann et al., 2007, Soriano et al., 2008, Puoti et al., 2009, Price 
and Thio, 2010). Drug interactions and co-medication are other additional 
factors that may increase risk of ART related liver toxicity. For example, 
HIV/HCV co-infected individuals receiving HCV treatment with ribavirin and 
pegylated interferon have demonstrated an increased risk of mitochondrial 
toxicity and anaemia with zidovudine containing cART (Soriano, 2006, Price 
and Thio, 2010). Another example, is the higher incidence of liver steatosis 
observed when stavudine is co-medicated with HCV treatment (McGovern et 
al., 2006).        
 
Bone disease & HIV 
Low bone mineral density is expected among the ageing population. HIV 
infection and the chronic use of antiretroviral drugs are independent risk factors 
for the development of osteoporosis (Duvivier et al., 2009, McComsey et al., 
2011, Guaraldi et al., 2014). The inflammatory responses associated with HIV 
infection are thought to cause an imbalance in bone turnover, osteoporosis and 
bone loss (Ofotokun and Weitzmann, 2011). Reduced vitamin D levels are 
associated with certain antiretroviral drugs, such as efavirenz containing cART, 
and renal insufficiency (Dao et al., 2011, Viard et al., 2011, Childs et al., 2012). 
In the EuroSIDA cohort, vitamin D deficiency was observed in approximately 
83% of HIV infected patients on ART (n=1985) (Viard et al., 2011). 
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Neurological complications of HIV 
Neurological damage that is associated with cognitive impairment has become 
increasingly common in the ageing HIV infected population (Becker et al., 2004, 
Kissel et al., 2005, Sacktor et al., 2007). In the CHARTER study, an estimated 
40% of HIV infected patients were diagnosed with neurocognitive impairment 
(Heaton et al., 2010). Neuroimaging studies in HIV infected individuals have 
shown changes to both grey and white matter that demonstrates an increased 
risk of HIV-associated neurocognitive disorders including dementia (Valcour et 
al., 2004, Larussa et al., 2006). Other factors that may potentiate neurological 
damage include: substance misuse; central nervous system (CNS) ART related 
toxicities; ageing; syphilis; and HCV co-infection (Guaraldi et al., 2014).    
 
HIV & the Kidney 
Renal disease is an important comorbid condition in HIV infection. Abnormal 
renal function of any cause is estimated in 30% of all HIV infected individuals 
(Gupta et al., 2005). The aetiology of kidney disease in HIV infected individuals 
has been well studied.  Direct HIV and immunological effects, both 
immunodeficiency and chronic inflammatory effects; have been implicated in the 
development of kidney disease in HIV infected individuals. HIV infection of the 
renal epithelial cells, immune complex deposits in the renal tissue and 
thrombotic microangiopathy induced by HIV are other known causes of HIV-
associated kidney disease (Kimmel et al., 1993a, Ahmed et al., 2002, Ross et 
al., 2006). Although, the spectrum of kidney diseases differs in HIV infected 
individuals with advanced immunodeficiency compared to those with well 
controlled HIV disease. Table 2 summarises kidney diseases in HIV infection.  
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Table 2: Kidney Diseases in HIV Infection 
HIV Related Non HIV Related 
HIV-associated nephropathy Membranoproliferative GN 
HIV-related immune complex disease 





Thrombotic microangiopathy Post-infectious GN 
 Classic FSGS 
 Diabetic nephropathy 
 Amyloidosis 
 Membranous glomerulopathy 
 Minimal change disease 
 IgA nephropathy 
 ART related toxicity  
Renal tubular dysfunction 
Acute tubular injury 
Tubulointerstitial nephritis 
Interstitial fibrosis  and tubular atrophy 
Key: GN – glomerular nephropathy; IgA - Immunoglobulin A; FSGS - Focal segmental glomerulosclerosis; 
ART – Antiretroviral drug therapy  
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In the pre-HAART era, HIV associated nephropathy was the most common form 
of kidney disease among HIV infected patients. The incidence of HIVAN and 
other kidney diseases associated with advanced HIV disease are therefore 
expected to decline with HAART use (Atta et al., 2008, Post et al., 2008, Wyatt 
et al., 2008b, Post and Holt, 2009). However, no reduction but instead a plateau 
in the occurrence of HIVAN has been observed in the post-HAART era. An 
example of this was observed in the USA where in 1990 there were 150 cases 
of HIVAN compared to 2700 cases at the end of 2005 (Schwartz et al., 2005, 
Wyatt et al., 2008a).  The increase in cases was thought to be due to an 
improvement in HIV survival with antiretroviral use. Furthermore, a decline in 
kidney disease as a cause of death in HIV infected individuals has also been 
observed, (see Figure 4) (Weber et al., 2013).   
 
With the introduction of HAART, other factors associated with an ageing 
population and chronic multi-medication use has contributed to the development 
of kidney disease in the HIV population. Other factors associated with kidney 
disease in HIV infection include: HIV as an independent risk factor; black 
ethnicity; diabetes; hypertension; HIV viraemia; drug related renal toxicity; and 
age (Madeddu et al., 2006, Winston et al., 2008, Bruggeman et al., 2009, 
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Figure 4: Causes of Death in the Swiss HIV Cohort Study 
 
 
Graph adapted from Jones R and Post FA presentation at BHIVA Autumn 
Conference (2011) and Ruppik et al CROI Conference. Abstract 789 (2011) 
 
Acute and chronic renal failure is highly prevalent in the HIV population (Wyatt 
et al., 2006, Mocroft et al., 2007, Wyatt et al., 2007, Campbell et al., 2009). In 
ARF specifically, exposure to nephrotoxic agents including ARVs and in some 
instances medication used to treat opportunistic infections have been implicated 
(Gupta et al., 2005). Sepsis, hepatitis B/C co-infection, high viral load, 
immunodeficiency and pre-existing renal impairment are additional factors that 
predispose HIV infected patients to ARF (Ibrahim et al., 2010, Maggi et al., 
2012a). The incidence rate of ARF has been estimated between 2.7 to 5.9 
episodes per 100 person years (Franceschini et al., 2005, Roe et al., 2008). In 
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the general population, the incidence of ARF ranges from 0.9 to 20% in 
developed countries (Lameire et al., 2008). Antiretroviral drug induced toxicity 
can result in rapid decline of renal function. Exposure to indinavir and tenofovir 
respectively have demonstrated a 4.6 and 3.7 fold rapid renal function decline in 
HIV infected patients with existing renal impairment (Campbell et al., 2009).  
ART induced toxicity has several mechanisms including: renal obstruction or 
cryslluria; acute interstitial nephritis; and renal tubular disease (Fine et al., 2008, 
Hamzah et al., 2015b). Table 3 summarises the kidney effects of currently 
available antiretroviral drugs. Renal tubular disease is characterised by three 
distinctive patterns; acute tubular injury, tubulointerstitial nephritis and interstitial 
fibrosis and tubular atrophy. A recent renal biopsy study identified 22.6% (n=60) 
of HIV infected individuals diagnosed with renal tubular disease. Acute tubular 
injury was more common and associated with cART exposure especially 
tenofovir and atazanavir (Hamzah et al., 2015b). In the same study, no 
evidence of tubulointerstitial nephritis, interstitial fibrosis and tubular atrophy 
was associated with ART exposure – tenofovir, atazanavir or lopinavir.  
Tenofovir is the most common antiretroviral drug implicated in nephrotoxicity 
(Fine et al., 2008). Subclinical evidence of proximal tubular dysfunction has 
been observed in 25 to 80% of HIV infected patients taking tenofovir disoproxil 
fumarate formulation (Franceschini et al., 2005, Ray et al., 2006, Nelson et al., 
2007, Hall et al., 2009, Choi et al., 2010, Ando et al., 2011, Maggi et al., 2012b, 
Wyatt, 2014, Hamzah et al., 2015b). The newer formulation, tenofovir 
alafenamide yields lower plasma tenofovir concentrations and consequently 
demonstrated improvements in biomarkers of renal tubular function compared 
to tenofovir DF formulation (Sax et al., 2015).  
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Table 3: The Kidney Effects of Antiretroviral Drug Therapy & Antiretroviral Dose Adjustment for Renal 
Impairment 
ANTIRETROVIRAL DRUG KIDNEY ABNORMAL EFFECTS
ANTIRETROVIRAL RENAL DOSE 
ADJUSTMENT
Abacavir Acute interstitial nephritis No dosage adjustment necessary
Fanconi syndrome 
Didanosine Fanconi syndrome Renal dose adjustment necessary
Acute kidney injury
Nephrogenic diabetes insipidus 
Emtracitabine No kidney effects reported Renal dose adjustment necessary
Lamivudine Renal tubular acidosis Renal dose adjustment necessary
Hypophosphatemia
Stavudine Renal tubular acidosis Renal dose adjustment necessary
Hypophosphatemia 
Tenofovir Disoproxil Fumarate Proximal tubular dysfunction Renal dose adjustment necessary
Fanconi syndrome 
Acute kidney injury
Nephrogenic diabetes insipidus 
Hypophosphatemia
Tenofovir alafenamide fumarate No kidney effects reported No dosage adjustment necessary
Zidovudine No kidney effects reported Renal dose adjustment necessary
Nevirapine No kidney effects reported No dosage adjustment necessary
Delavirdine No kidney effects reported No dosage adjustment necessary
Efavirenz Nephrolithiasis No dosage adjustment necessary
Rilpivirine Reduced creatinine excretion; no renal toxicity effects No dosage adjustment necessary
Amprenavir No kidney effects reported No dosage adjustment necessary
Atazanavir Acute interstitial nephritis No dosage adjustment necessary
Nephrolithiasis No dosage adjustment necessary
Darunavir Nephrolithiasis No dosage adjustment necessary
Fosamprenavir None reported No dosage adjustment necessary
Indinavir Acute kidney injury (acute interstitial nephritis) No dosage adjustment necessary
Chronic kidney disease (acute interstitial nephritis) No dosage adjustment necessary
Nephrolithiasis No dosage adjustment necessary
Intratubular drug precipitation No dosage adjustment necessary
Papillary necrosis No dosage adjustment necessary
Hypertension No dosage adjustment necessary
Renal atrophy No dosage adjustment necessary
Lopinavir Nephrolithiasis No dosage adjustment necessary
Nelfinavir Nephrolithiasis No dosage adjustment necessary
Ritonavir (treatment doses) Acute kidney injury No dosage adjustment necessary
Saquinavir Acute kidney injury in association with ritonavir No dosage adjustment necessary
Tipranavir No kidney effects reported No dosage adjustment necessary
Enfuvirtide Membranoproliferative glomerulonephritis No dosage adjustment necessary
Maraviroc No kidney effects reported Renal dose adjustment necessary
Raltegravir No kidney effects reported No dosage adjustment necessary
Dolutegravir Reduced creatinine excretion; no renal toxicity effects No dosage adjustment necessary
Elvitegravir with cobicistat Reduced creatinine excretion; no renal toxicity effects No dosage adjustment necessary
Cobicistat Reduced creatinine excretion; no renal toxicity effects No dosage adjustment necessary
Pharmacokinetic enhancer
Nucloside/nucleotide reverse transcriptase inhibitors
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al., 1998, Guardiola et al., 1998, Martinez et al., 1998, Benveniste et al., 1999, Cattelan et al., 2000, Gagnon et al., 2000, Jaradat et al., 2000, Krishnan et al., 2000, 
Cattelan et al., 2001, Dieleman et al., 2001, Morris et al., 2001, Salahuddin et al., 2001, van Rossum et al., 2001, Coca and Perazella, 2002, Engeler et al., 2002, 
Kopp et al., 2002, Verhelst et al., 2002, Creput et al., 2003, Karras et al., 2003, Lalezari et al., 2003, Rollot et al., 2003, Schaaf et al., 2003, Brewster and Perazella, 
2004, Izzedine et al., 2004, James et al., 2004, Peyriere et al., 2004, Rifkin and Perazella, 2004, Izzedine et al., 2005, Ahmad, 2006, Chang and Pella, 2006, 
Pacanowski et al., 2006, Wirth et al., 2006, Zimmermann et al., 2006, Chan-Tack et al., 2007, Couzigou et al., 2007, Izzedine et al., 2007, Fine et al., 2008, Gupta, 
2008, Nakatani-Freshwater and Taft, 2008, Izzedine et al., 2009a, Kalyesubula and Perazella, 2011, Gupta, 2012, Ramanathan, 2013, Izzedine et al., 2014, HHS, 
2015, eMC, n.d, PhP, n.d)
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Several factors are known to influence the progression of kidney disease in HIV 
infected patients managed on cART. Chronic kidney disease is characterised by 
sustained proteinuria or albuminuria and estimated glomerular filtration rate < 
60 ml/min/1.73 m2 for more than 3 months (Campbell et al., 2009, Levey et al., 
2009). The prevalence of CKD defined by eGFR < 60ml/min/1.73 m2 is 
estimated at 2.4 to 23.7% (Gupta et al., 2004, Gupta et al., 2005, Cheung et al., 
2007, Wyatt et al., 2007, Fernando et al., 2008, Campbell et al., 2009, Maggi et 
al., 2012a). Proteinuria in HIV infected individuals is quite frequent with an 
estimated 7.2 to 48.5% of patients presenting on urinary screening during 
routine clinical care (Szczech et al., 2002, Gardner et al., 2003, Gupta et al., 
2004, Szczech et al., 2004, Cheung et al., 2007, Wyatt et al., 2007, Fulop et al., 
2010, Estrella et al., 2011, Yanagisawa et al., 2011, Naicker et al., 2015). A 
further estimated 8.7 to 17.8% of HIV infected patients present with albuminuria 
(Szczech et al., 2007, Baekken et al., 2008, Yanagisawa et al., 2011).  
Risk factors associated with developing proteinuria in HIV infected include black 
ethnicity, low CD4 T cell count (< 200 cells/mm3), hepatitis C co-infection and 
HIV viraemia (Yanik et al., 2010, Gravemann et al., 2014). A high level of HIV 
viraemia accompanied with a low CD4 T cell count (< 200 cells/mm3) are both 
strong and independent predictors for developing renal impairment in HIV 
infected patients with proteinuria (HR 3.6 and 2.3 respectively) (Szczech et al., 
2002, Post and Hendry, 2008). Advanced HIV disease which can cause both 
viral and immunological mediated renal diseases may often be accompanied 
with moderate to severe proteinuria (>0.5g/day [normal value < 0.02 g/day 
(Viswanathan and Upadhyay, 2011)) (Post and Hendry, 2008). However, 
disparities among ethnic groups have been observed. A USA cohort study 
demonstrated severe proteinuria (>3g/day) in 45% of African Americans 
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(n=1499/3332) compared to 4% (n=37/927) of Caucasian HIV infected patients 
(Lucas et al., 2008).  
The development of CKD in HIV infected patients is associated with several 
factors that can be HIV related and non-HIV related. These factors include 
ethnicity, older age, AIDS defining illnesses, higher viral load, diabetes, 
hypertension, hepatitis C co-infection, gender, non-AIDS malignancy, specific 
cART use (tenofovir, indinavir, atazanavir, lopinavir) and other co-medication 
(e.g. non-steroidal anti-inflammatory drugs) (Mocroft et al., 2010, Flandre et al., 
2011, Ando et al., 2012, Ryom et al., 2013b). However, immune restoration and 
viral suppression with cART use have demonstrated reduced risk of CKD 
(Kalayjian et al., 2012). 
Ethnicity is an important and independent risk factor for CKD. HIV infected 
individuals of black ethnicity have a genetic predisposition to kidney disease 
owing to the apolipoprotein L1 (APOL 1) and non-muscle myosin heavy chain 9 
(MYH9) genes (Nunez et al., 2010, Hays et al., 2012, Estrella et al., 2013, 
Foster et al., 2013, Johnstone et al., 2013, Colares et al., 2014, Estrella et al., 
2015, Naicker et al., 2015). APOL1 gene risk alleles G1 and G2 are strongly 
associated with developing several forms of kidney disease including focal 
segmental glomerulosclerosis (FSGS), diabetic nephropathy, hypertensive 
nephropathy, and HIVAN (Kao et al., 2008, Kopp et al., 2008, Winkler et al., 
2010, Kopp et al., 2011, Freedman and Murea, 2012, Hays and Wyatt, 2012, 
Pollak et al., 2012, Foster et al., 2013). The prevalence of APOL1 gene risk 
alleles G1 and G2 is estimated at 35% in the African American population 
(Friedman et al., 2011). There is a 7 to 10 fold increased risk of developing 
FSGS and HIVAN in individuals homozygous for APOL1 risk alleles G1 and G2 
(Genovese et al., 2010, Friedman et al., 2011, Kopp et al., 2011, Brown et al., 
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2014). APOL1 gene has also demonstrated a 3 fold increased risk of 
developing end-stage kidney disease in HIV infected individuals (Fine et al., 
2012, Kasembeli et al., 2015). 
Progression to end-stage kidney disease in HIV infected individuals varies with 
underlying kidney disease aetiology. HIV associated nephropathy occurs more 
commonly in patients with advanced HIV disease. HIVAN has demonstrated a 
more rapid progression to ESKD compared to other forms of kidney disease in 
HIV infected patients. Aside from the underlying kidney disease, as previously 
discussed, ethnicity plays an important role in ESKD progression. In HIV 
infected African Americans with existing chronic kidney disease, progression to 
ESKD is significantly more rapid compared to their Caucasian counterparts (HR 
95CI, 17.7 (2.5 – 127.0)) (Lucas et al., 2008). The overall risk of developing 
ESKD in HIV infected patients is almost 50 fold higher in African Americans 
than in Caucasian patients (Eggers and Kimmel, 2004, Lucas et al., 2008). 
Although the widespread use of cART has reduced the incidence of HIVAN, the 
overall prevalence has increased. In the UK, the overall prevalence of ESKD 
among HIV infected individuals has been estimated at 0.31% (Bansi et al., 
2009); almost 6 fold higher than the general population (0.08% (UKRR, 2012)). 
In other European countries and North America respectively, the prevalence 
rates range from 0.36 – 0.64% (Trullas et al., 2008, Mazuecos et al., 2012, 
Bickel et al., 2013, Ryom et al., 2013a, Rasch et al., 2014) and 0.75 – 1.65% 
(Jotwani et al., 2012, Abraham et al., 2015). A further in depth discussion on the 
clinical epidemiology of ESKD in HIV disease is discussed in Chapter 2. 
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1.4. Solid Organ Transplantation in HIV Infection  
End-stage kidney disease is an important co-morbidity in the HIV infected 
population. Conservative management and dialysis are some of the treatment 
modalities available to manage ESKD in HIV infected patients. Although, 
outcomes from a single study suggests poor patient survival rates with the use 
of dialysis (median 20 months) or conservative management (median 6 months) 
(Post and Holt, 2009) (O'Connor and Kumar, 2012).  
Kidney transplantation offers an attractive treatment modality with improved 
morbidity, mortality and quality of life in the general population (Griva et al., 
2013, Calestani et al., 2014). Use of immunosuppressant drug therapy has 
dramatically improved the post-transplant management of kidney transplant 
recipients in the general population (BTS, 2011, 3C.StudyCollaborativeGroup et 
al., 2014). An increased uptake of KT in the general population has been 
observed, (see Figure 5 and 6). By the end of 2013, there were 56,940 patients 
in the general UK population were on permanent renal replacement therapy 
(pRRT) and kidney transplantation was the most common choice of treatment 
modality (52%). The proportion of patients on haemodialysis and peritoneal 
dialysis respectively was 41.6% and 6.4% (UKRR, 2014). The proportion of HIV 
infection in those on pRRT is estimated at 0.51% in the UK (Bansi et al., 2009). 
Patient survival irrespective of treatment modality choice has remained stable 
over the years. One year prevalent survival of ESKD pRRT patients on dialysis 
in 1999 and 2012 respectively was 84.8% and 85.5%. However, patient survival 
when comparing pRRT treatment modalities was worse in those on dialysis 
compared to kidney transplantation. Patient survival at one year of kidney 
transplant recipients was 97.5% in 1999 and ranging from 96 to 99% in 2012 
(UKRR, 2000, UKRR, 2014). 
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 Prevalence of Permanent Renal Replacement Therapy (pRRT) by Treatment Modality  
1997–2013 (UKRR, 2014) 
Trends in pRRT Treatment Modalities from 1998–2013 (UKRR, 2014) 
Figure 5: Trends in Permanent Renal Replacement Therapy in the United Kingdom 
Figure 6: Trends in Permanent Replacement Therapy by Treatment Modality in the United 
Kingdom 
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Kidney transplantation in HIV infected individuals in the pre-HAART era was 
associated with unfavourable outcomes. These observations were owing to the 
poor HIV virological control and severe immunodeficiency prior to the discovery 
of effective antiretroviral therapy. This prompted the decision by some 
Transplant registries to contraindicate the use of donor organs in HIV infected 
candidates (Roland, 2004, Bhagani et al., 2006). There were also concerns of 
opportunistic infections and HIV disease progression with immunosuppressant 
drug use. During the pre-HAART era, kidney transplantation was mostly 
incidental with recipients having acquired HIV by receiving an organ from an 
HIV infected individual (Prompt et al., 1985, al-Sulaiman et al., 1989, Glassock 
et al., 1990, Lang and Niaudet, 1991, Keay et al., 1993, Schvarcz et al., 2000). 
This early experience of kidney transplantation was associated with a high 
mortality rate (46.2% at 2 years) (Trullas et al., 2011b). Better management of 
HIV infection with potent antiretroviral drugs paved the way for kidney 
transplantation as a potential option for people living with HIV. In early 2000s, a 
pilot study was conducted that included a highly selective group of HIV infected 
individuals (n=10) with fully suppressed HIV-1 RNA (< 50 copies/mL) and a 
CD4+ T cell count > 200 cells/mm3 and lacking history of opportunistic 
infections or malignancies (Stock et al., 2003b). Patient and graft survival was 
100% at 1 year albeit a high rate of allograft rejection (50%). Authors also noted 
profound immunosuppressant and antiretroviral drug interactions. Patients 
receiving protease inhibitor containing cART required ¼ of the normal dose of 
ciclosporin. There was no evidence of HIV disease progression. Chapter 3 
contains a further in depth discussion of kidney transplantation. 
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1.5. HIV Kidney transplantation in the early cART era (2005 - 2009) 
– Literature Review 
  
 
In the early 1980s, the HIV virus was discovered as the cause of Acquired 
Immune Deficiency Syndrome (AIDS) (Barre-Sinoussi et al., 1983, Gallo et al., 
1984, Popovic et al., 1984) by which point researchers estimated between 
100,000 and 300, 000 people had been infected globally (Baumann et al., 
1991). At the same time, ciclosporin had been discovered as an 
immunosuppressive agent that would improve kidney transplantation; an area 
that was still in its infancy. During this period, there were the reports of 
transplant recipients having similar infection profiles to AIDS victims some even 
progressing to AIDS (Rubin et al., 1987). Of note was the profound T cell 
lymphopenia in both HIV infected and HIV negative immunosuppressant treated 
transplant recipients that resulted in severe opportunistic infections (Carbone et 
al., 1988).   
 
Preventative measures to halt the spreading of HIV led to the screening of 
biological products, blood or donor organs. It soon became apparent that there 
were solid organ transplant recipients that had been infected through blood 
transfusions, dialysis or by receiving an organ from a HIV positive donor 
(Feduska et al., 1987, Kerman et al., 1987). These early reports were less 
focused on preventing allograft rejection with immunosuppressive agents but 
instead highlighted the complications that were associated with a high risk of 
mortality. Although, emerging data from this period demonstrated that those 
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with secondary HIV infections (acquired post-transplant) did better than primary 
HIV infections (acquired pre-transplant) in that they survived longer despite 
opportunistic infections and superimposed IS therapy (Ribot and Eslami, 1992). 
There was also some debate on whether to withdraw the immunosuppressant 
drugs due to their added risk of acquiring opportunistic infections in HIV infected 
transplant recipients (Margreiter et al., 1986a). By contrast, some case reports 
suggested that post-transplant rejection episodes enhanced HIV viral 
propagation and therefore deemed it necessary to maintain HIV/KT recipients 
on immunosuppressive agents (L'Age-Stehr et al., 1985, Margreiter et al., 
1986b, Neumayer et al., 1986, Oliveira et al., 1986).  Later, a review of 53 
cases of acquired HIV-1 infection at or post-transplantation between 1985-1992, 
demonstrated a profound reduction in the cumulative risk of developing AIDS in 
patients taking ciclosporin compared to other immunosuppressive agents (31% 
vs 90% after 5 years, p=0.001) (see Figure 7) (Schwarz et al., 1993a). This is 
what led to researchers to suspect if ciclosporin had anti-HIV properties as HIV 
targeted activated CD4 cells and ciclosporin impedes T cell activation 
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Life table analysis of 53 primary and secondary HIV infected transplant 
recipients. Comparison by log-rank analysis.  
 
 
There are few reports on kidney transplantation in primary HIV infected patients 
which are summarised in Table 4. Outcomes demonstrated good patient and 
graft survival within the first 12 months; and in one case the patient had a 
remarkable survival of 9 years (Ahuja et al., 1997). Early allograft rejection was 
noted in all but one case in whom ciclosporin monotherapy was used for a 
simultaneous pancreas-kidney transplant (Ahuja et al., 1997). In addition to 
concerns of allograft rejection, there were growing concerns over the risks of 
transplanting HIV infected patients due to the associated high mortality rate 
brought about by post-operative infectious complications (Stock et al., 2003b). 
By this point, the discovery of antiretroviral therapy, the first being 
azidothymidine currently known as zidovudine; revolutionised the management 
of HIV infection (Yarchoan et al., 1986). The use of antiretroviral therapy 
Figure 7: Cumulative Incidence of AIDS in Transplant Recipients (1985-1992)  
A comparison of ciclosporin vs other immunosuppressant drug treatment 
(Schwarz et al., 1993b) 
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resulted in restoration of CD4 T cells which provided for somewhat delay in HIV 
disease progression (Fischl et al., 1987). But it wasn’t until the late 1990s when 
HIV was being managed with the ‘highly active antiretroviral therapy’ (HAART) 
(Gulick, 1997, Hammer et al., 1997).  
HAART regimens often included two nucleoside reverse transcriptase inhibitors 
(NRTIs) and either one non-nucleoside reverse transcriptase inhibitor (NNRTI) 
or one protease inhibitor (Oversteegen et al., 2007). More recently, the 
combination of antiretroviral therapy (cART) could include quad therapy, 
integrase inhibitors or entry inhibitors (DeJesus et al., 2012, Sax et al., 2012). 
This provided for immune recovery with much improved CD4 T cell counts and 
the suppression but not eradication of HIV. HIV kidney transplantation was then 
revisited and the proposal to allow patients who demonstrated (1) good immune 
status CD4 counts > 200 cells/mm3 (2) maintained HIV suppression (<50 
copies/ml) on cART and (3) no active opportunistic infections or 
tumors/neoplasms, to be offered kidney transplantation (AST, 2004). There was 
no guidance on the choice of immunosuppressive therapy but majority used 
ciclosporin based IS therapy. 
The early experience of kidney transplantation in HIV infected patients 
maintained on cART was quite encouraging with patient and graft survival being 
comparable to HIV negative patients, (see Table 4). On the contrary, rejection 
was quite prevalent (calculated pooled AR rate of 34% at 1 year, n=240) 
despite efforts to optimise IS therapy by using triple immunosuppressive agents 
+/- inclusion induction therapy with mono/polyclonal antibody agents. As so few 
patients were taking tacrolimus, it was difficult to ascertain if CNI choice had an 
impact on allograft outcomes. Researchers began to question the efficacy of 
CNIs brought about by drug interactions with antiretroviral agents (refer to 
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Chapter 5 for details on CNI/ART drug interactions). Although, a case series of 
40 HIV infected kidney transplant recipients who were managed with antiCD25 
monoclonal antibody induction therapy and triple IS therapy including 
ciclosporin, sirolimus and prednisolone; had protocol surveillance allograft 
biopsies that revealed acute rejection in 22% and subclinical acute rejection in 
29% of patients. What was interesting about this report was the observed 
temporal increase in HIV-1 viraemia (1570 to 70,000 copies/mL), due to drug 
resistance, that was ascertained through monthly viral load monitoring post-KT. 
Patients regained HIV virological control by switching antiretroviral therapy 
agents (Kumar et al., 2005, Sawinski and Murphy, 2008). These findings were 
in support of previous hypotheses of rejection propagating the HIV virus through 
CD4 T cell activation (Margreiter et al., 1986a).  
Managing the IS/ARV drug interactions in the clinical setting proved quite 
challenging particularly for those taking protease based antiretroviral therapy 
that required significant CNI dose reductions (90-99%) when co-prescribed with 
calcineurin inhibitors (Frassetto et al., 2005, Frassetto et al., 2007, Frassetto et 
al., 2009). Furthermore, some were concerned about the use of polyclonal or 
OKT3 antibody agents as their use in the HIV negative transplant population 
were associated with profound CD4 depletion which made patients more 
susceptible to opportunistic infections (Trullas et al., 2007). Extra emphasis was 
placed on avoiding polyclonal antibodies in the HIV infected KT population 
when Carter et al (2006) reported serious infections requiring hospitalisations in 
patients that received ATG. However, due to the severity of some of the 
rejection episodes, ATG was reserved for treatment of severe allograft rejection 
(Bhagani et al., 2006, Trullas et al., 2010). 
 
- 54 - 
In the United Kingdom, the British HIV Association collaborated with British 
Transplant Society in 2005 to write the national guidance of kidney 
transplantation in HIV infected patients (Bhagani et al., 2006). This offered 
guidance on HIV+ patient selection for KT (refer to Chapter 3 for details) but 
offered no specific guidance on CNI selection, CNI drug concentration targets, 
anti-infective prophylaxis or antiretroviral therapy choice. It was recommended 
that centres use local protocols but suggested they classify HIV+ patients as 
‘high immunological risk’. Although, due to the complexities of CNI/ART drug 
interactions, BHIVA/BTS 2005 guidelines  recommended that HIV infected 
individuals awaiting transplantation receive a pre-transplant CNI trial as a dose 
determining strategy to achieve therapeutic CNI drug concentrations post-KT 
(Bhagani et al., 2006).  
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Table 4: Summary of acute rejection in kidney transplantation in HIV positive patients (HIV+ prior to transplantation) restricted to publications preceding 2010a 
Year of 
Publication 
N Donor type Induction therapy (N) Immunosuppression therapy (N) Acute rejection at 1 year    N 
(%) 
1yr Patient survival  
N (%) 




1980-1985 2 Cadaver Nil CsA plus pred 2 (100) 0 (0) 0 (0) (Rubin et al., 1987, 
Shaffer et al., 1987) 
1981-1986 2 Cadaver Nil CsA plus pred ND 2 (100) 2 (100) (Dummer et al., 1989) 
1984-1987 4 Cadaver Methylprednisolone Aza plus pred and/or CsA 2 (50%) 4 (100) 4 (100) (Ribot and Eslami, 1992) 
1986 1* Cadaver Nil Aza plus pred 1 (100) 1 (100) 1 (100) (Oliveira et al., 1986, 
Rubin et al., 1987) 
1984 2 Cadaver (1) 
Living (1) 
ND Aza plus pred ND 2 (100) 1 (100) (al-Sulaiman et al., 1989) 
1997 1 Cadaver (SPK) Nil CsA monotherapy (switched to pred. >1yr) Nil 1 (100) 1 (100) (Ahuja et al., 1997) 
Post-cART 
1997 – 2004 38 ND Nil (15); ATG (4); OKT3 (3); 
antiCD25 (16) 
CsA (20); Tac (13) 0 (0) 29 (76) 35 (91) (Qiu et al., 2006) 
2000 6 Cadaver (n=4) 
Living (n=2) 
ND CsA plus MMF plus steroids 4 (67) 6 (100) 6 (100) (Stock et al., 2001) 
2000 1 Cadaver AntiCD25 Tac plus MMF plus steroids 0 (0) 1 (100) 1 (100) (Toso et al., 2003a) 
2002 12 Cadaver (n=5) 
Living (n=7) 
AntiCD25 (6) CsA plus SrL plus steroids 4 (33) 12 (100) 12 (100) (Kumar et al., 2002) 
2002 26 ND ND ND 10 (38) 24 (92) 23 (88) (Roland and Stock, 2003) 
2003 10 Cadaver (n=6) 
Living (n=4) 
Nil CsA plus MMF plus steroids 5 (50) 10 (100) 10 (100) (Stock et al., 2003b) 
2000 - 2003 18 Cadaver (n=10) 
Living (n=8) 
AntiCD25 (7) CsA plus MMF plus steroids (9) 
SrL plus MMF plus steroids (3) 
CsA plus SrL plus steroids (2) 
CsA plus MMF (1); MMF plus steroids (2) 
MMF alone (1) 
12 (70) 17 (94) 15 (83) (Roland et al., 2008a) 
2000 – 2004 22 Cadaver (n=21) 
Living (n=1) 
AntiCD25 and polyconal 
antibodies (N, ND) 
Majority on Tac plus MMF plus steroids (N, ND) 8 (38); (4 Tac, 1 CsA, 3 Other) 22 (100) 17 (77) (Trullas et al., 2010) 
2001 - 2004 40 Cadaver (n=36) 
Living (n=4) 
AntiCD25 (40) CsA plus SrL plus steroids 9 (22) 33 (82) 28 (71) (Kumar et al., 2005) 
2001 – 2005 10 Cadaver AntiCD25 (3); ATG (1) Tac plus MMF plus steroids 4 (40) 10 (100) 9 (90) (Mazuecos et al., 2002) 
2004 – 2007 8 Cadaver (n=7) 
Living (n=1) 
AntiCD25 (8) CsA plus MMF plus steroids 1 (13) 8 (100) (88) (Gruber et al., 2008b) 
2005 – 2006 3 Cadaver  ATG (3)  SrL plus MMF plus steroids (2) 
Tac plus MMF plus steroids (1) 
2 (67) 3 (100) 3 (100) (Trullas et al., 2007) 
2007 1 Cadaver (SLK) AntiCD25 CsA plus pred 0 (0) 1 (100) 1 (100) (Ballarin et al., 2008) 
2008 27 Cadaver (n=15) 
Living (n=12) 
ATG (n=10), antiCD25 
(n=11) 
CsA or Tac plus MMF or Aza plus steroids  (25); 
dual/mono therapy (12) 
9 (33) 27 (100) 27 (100) (Gasser et al., 2009) 
2001 – 2009 20 ND ND ND 8 (40) 19 (95) 15 (74) (Mazuecos et al., 2006) 
2005 – 2009 27 Cadaver (n=25) 
Living (n=2) 
AntiCD25 (26), ATG (1) Tac plus MMF plus Steroids (16) 
CsA plus MMF plus Steroids (11) 
4 (15) (98) (96) (Touzot et al., 2010) 
ND 2 Cadaver Nil CsA plus MMF plus Steroids (1) 
Tac plus MMF plus Steroids (1) 
1 (50) 2 (100) 2 (100) (Muller et al., 2006) 
2009 7 Cadaver AntiCD25 (7) Tac plus MMF plus Steroids (7) 0 (0) 7 (100) 7 (100) (Billault et al., 2009) 
Abbreviations: wk – Weeks, m – Months, yr – Years; MSM – men who have sex with men; KT – kidney transplant; CsA – ciclosporin; Tac – tacrolimus; SrL – sirolimus; Pred – prednisolone; AZT – azidothymidine; IS –immunosuppression; OI – opportunistic infections; ND – no data available; ATG – 
antithymocyte globulin; antiCD25 – basiliximab or daclizumab; SPK – simultaneous kidney-pancreas transplant; SLK – simultaneous liver kidney transplant 
aExcludes patients that acquired HIV in the peri- and post-operative period either via donor organ, blood transfusions or other 
*This is the first ever HIV positive patient that was transplanted at Hammersmith hospital, London, UK 
**Suspected HIV positive prior to transplantation; confirmed HIV+ test performed 2 years post-KT 
†Triple ART consisted of nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI). Dual ART included NRTI and NNRTI or PI. 
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1.6. Focus of Thesis 
This thesis will be focused on kidney transplantation in HIV infected individuals in the 
United Kingdom. First, Chapter 2 will include a description of the clinical 
epidemiology of end-stage kidney disease in the HIV infected population in the 
United Kingdom using data from a large UK HIV cohort. Within the same chapter, the 
barriers to and use of kidney transplantation in the HIV/ESKD patients will be 
described. To further contextualise the need for kidney transplantation as a 
treatment modality in the HIV/ESKD population, an investigation was performed to 
determine whether kidney transplantation affords a survival benefit over dialysis in 
those who are suitable for KT. In Chapter 3, an evaluation of the clinical outcomes of 
kidney transplantation in HIV infected patients is performed using data from a 
national observational cohort study. Chapter 4 to 6 focuses on the post-transplant 
management of HIV/KT with immunosuppressant drugs. Using data from the 
national HIV/KT cohort study, an investigation is performed into whether calcineurin 
inhibitor choice (ciclosporin versus tacrolimus) has an impact on allograft outcomes, 
specifically allograft rejection in the first year post-HIV/KT (Chapter 4). In Chapter 5, 
descriptive analyses are peformed to demonstrate the calcineurin inhibitor target 
whole blood drug concentrations achieved in the first year post-HIV/KT. And finally, 
an evaluation is performed into the clinical utility of mycophenolate therapeutic drug 
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UK HIV & GUM Clinics  
(n=288)  
(PHE, 2014) 
Number of people living with HIV in 
2013 (N=107,800) 
(PHE, 2014) 
UK Collaborative HIV Cohort Study, 
21 Centres (1996 to 2012)  
(N>45,000) 
(UK-CHIC, n.d) 
UK-CHIC Centres contributing 
renal data, 8 Centres  
(N=32, 018) 
Clinical Epidemiology of ESKD in 
PLWH, Eligible study participants 
(Chapter 2) 
N=28,632 
Barriers to Kidney 
Transplantation in HIV Infection, 
ESKD patients (Chapter 2) 
N=117  
UK Kidney Transplant Centres  
(n=24) 
(ODT, 2015)  
Number of Kidney Transplants 
Performed in UK 2005 to 2014 
(N=17,045) 
(ODT, 2015)  
UK HIV Kidney Transplant Study, 
40 Transplant Centres & 
Associated HIV Clinics  2005 to 
2013  (Chapters 3 - 6) 
(N=97) 
HIV Kidney Transplantation, Eligible 
study participants (Chapter 3)  
(N=78) 
Calcineurin Inhibitor Drug 
Concentrations in HIV+ Kidney 
Transplant Recipients (Chapter 5)  
(N=56)  
Mycophenolate Therapeutic Drug 
Monitoring in HIV+ Kidney Transplant 
Recipients     (Chapter 6)   
(N=65) 
Impact of Calcineurin Inhibitor 
Choice on Allograft Rejection in 
HIV+ Kidney Transplant 
Recipients (Chapter 4)  
(N=78) 
Link data 
Elements of the PhD Thesis Map 
• Map describes the patient disposition of HIV infected individuals and the 
general kidney transplant population in the United Kingdom.  Overall data 
numbers derived from national databases – Public Health England for HIV 
data and NHSBT for kidney transplant data. 
• The overall structure of the PhD thesis includes 6 chapters. Excluding the 
introduction chapter (Chapter 1), Chapters 3 to 6 (highlighted boxes) are 
results chapters using data from two national observational cohort studies. 
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Chapter 2. Burden of End-Stage Kidney Disease & Barriers to 
Kidney Transplantation (KT) in HIV Infection  
2.1. Introduction 
Kidney disease is a common complication in HIV. End-stage kidney disease 
(ESKD) is a major complication of HIV infection that carries significant morbidity 
and mortality risks (Choi et al., 2007a, Bansi et al., 2009, Jotwani et al., 2012). 
In the pre-HAART era, developing ESKD was associated with a high HIV viral 
load count (Winston et al., 1998, Atta et al., 2005, Jotwani et al., 2012). Other 
risk factors for HIV ESKD include black ethnicity, intravenous drug user and 
hepatitis C co-infection (Choi et al., 2007a, Bansi et al., 2009, Jotwani et al., 
2012). Traditional causal factors for developing kidney disease have also been 
implicated in HIV infected patients e.g. diabetes, hypertension, drug toxicity or 
age, (Weiner et al., 2003). An extensive range of glomerular, vascular and 
tubulo-interstitial diseases have been observed in HIV infected patients 
(Berliner et al., 2008, Campbell et al., 2009, Wyatt et al., 2009, Hamzah et al., 
2015a).  
 
Kidney disease pathology in HIV infection is not completely understood. Direct 
HIV viral effects, associated antibody and immune responses, as well as 
release of proinflammatory cytokines by HIV infected lymphocytes and renal 
cells have all been implicated in HIV renal disease pathogenesis (Bourgoignie, 
1990, Mattana et al., 1993, Shukla et al., 1993, Humphreys, 1995, Singhal et 
al., 1995, D'Agati and Appel, 1997, Klotman, 1999, Conaldi et al., 2000, Ibrahim 
et al., 2010). The dominant aetiology in this population is HIV-associated 
nephropathy (HIVAN) (Bansi et al., 2009), a collapsing glomerulopathy which 
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typically affects immune-compromised patients and presents with severely 
impaired kidney function and heavy proteinuria (Weiner et al., 2003, Post et al., 
2008). Noncollapsing focal and segmental glomerulosclerosis (FSGS), and HIV-
associated immune complex kidney disease (HIVICK) and thrombotic 
microangiopathy (TMA) are other dominant diseases especially with late 
diagnosis of HIV infection or unavailability or unresponsive HIV treatment with 
antiretroviral therapy (Weiner et al., 2003). Further, patients presenting with 
HIVAN are typically of black ethnicity (Bansi et al., 2009, Razzak Chaudhary et 
al., 2015).  
 
HIV infection is an independent risk factor for developing ESKD (Post et al., 
2008, Bansi et al., 2009). In a recent observational cohort study of HIV infected 
patients (n=42,838) in North America over a 9 year period (2000-2009) 
observed the risk of ESKD attributable to HIV infection to be 15, 9, 1.1 and 0.8 
per 10,000 respectively for black males, black females, white males, and white 
females with eGFR=90ml/min/1.73m2, undetectable viral load (<50cps/mL) and 
CD4 T cell count 750 cells/mm3 (Muzaale, 2016), (see Figure 8). This risk was 
adjusted for hypertension, IVDU use and diabetes. By comparison, the 15-year 
risk of ESKD attributable to smoking in comparable HIV negative patients was 
estimated to be 19, 11, 4, and 3 per 10,000 respectively for black males, black 
females, white males, and white females with eGFR=90ml/min/1.73m2.  
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Figure 8: Risk of Developing End-Stage Kidney Disease in HIV Infected Individuals  
 


































Ethnicity / Gender 
Graph shows estimated risk of ESKD in healthy HIV+ individuals stratified by ethnicity and gender. Healthy HIV+ individuals based on 40 year old with undetectable 
HIV virus (<50 copies/mL), no history of diabetes, hypertension or injectable drug use (Muzaale, 2016).  
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The availability and use of cART has dramatically improved the outcome of HIV 
infected patients with ESKD (Lucas et al., 2004, Cremers et al., 2005, Bansi et 
al., 2009). Although cART may slow the rate of kidney disease progression, the 
majority of patients develop ESKD within 5 years of diagnosis (Atta et al., 2006, 
Post et al., 2008). HIV infected individuals of black ethnicity have observed 
faster progression of kidney disease compared to other ethnicities. 
Epidemiological studies have reported a 3 to 6 fold increased risk of developing 
ESKD among patients of black ethnicity compared to other HIV infected 
individuals (Choi et al., 2007a, Lucas et al., 2008, Jotwani et al., 2012). 
In the pre- and early HAART era, dialysis was the only treatment modality 
offered to HIV/ESKD patients although with poor survival outcomes. There were 
theoretical concerns that dialysis would enhance HIV viral replication through 
immune activation and induced pro-inflammatory cytokines (Bingel et al., 1988, 
Osborn et al., 1989, Herbelin et al., 1990, Takahashi et al., 2000, Mandayam 
and Ahuja, 2004). Although there was no evidence of increased HIV plasma 
viral load with dialysis (Ahuja et al., 1999), the one year survival rates for HIV 
infected patients on dialysis were estimated between 56 to 74% (Ahuja et al., 
2002). In the general population, conservative management has been 
associated with a significantly poorer prognosis compared to dialysis. The 
survival rate in non-dialysis HIV negative patients has been estimated as low as 
6 months, especially with existing comorbidities and cardiovascular disease 
(O'Connor and Kumar, 2012).  
With the improved management of HIV infection with HAART, the uptake of 
dialysis as a treatment modality of ESKD increased.  The prevalence of HIV 
infection among dialysis units varied from 0% to 39% (Peterman et al., 1986, 
Morikawa et al., 1988, Chirgwin et al., 1989, Perez et al., 1989, Reiser et al., 
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1990, Marcus et al., 1991, Kimmel et al., 1993b, Rao, 2003).  Despite this, there 
were concerns of HIV transmission via dialysis (Marcus et al., 1991, Velandia et 
al., 1995). However, improper use of dialysis equipment and access needles 
was implicated as the route of HIV transmission (Velandia et al., 1995). 
Conservative management was as an alternative option albeit with worse 
survival rates (Ahuja et al., 2000, Ahuja et al., 2002, Mandayam and Ahuja, 
2004). The advancement of medical technologies along with much improved 
infection control practices greatly reduced the risk of HIV transmission. 
Furthermore, the risk of transmission of blood borne viruses was directly 
correlated to the concentration virus in the blood (DOH, 2002, Rao, 2003). Of 
the blood borne viruses, HIV was considered less infectious (Bingel et al., 1988, 
DOH, 2002). The UK Department of Health guidelines (2002) recommends (1) 
testing of HIV only in those at risk (2) segregation of HIV infected patients 
based on local risk assessments (3) not dialysing HIV infected patients at the 
same time to avoid cross-infection(DOH, 2002).  
Sustained suppression of HIV replication and immune restoration in patients 
who adhere to cART has allowed successful use of kidney transplantation (KT) 
in carefully selected patients with ESKD. Typically, these patients had CD4 cell 
counts >200 cells/mm3, undetectable HIV RNA levels, and free of opportunistic 
disease, malignancy, and severe vascular or hepatic co-morbidity (Stock et al., 
2003b, Roland, 2004, Bhagani et al., 2006, Stock et al., 2010c, Trullas et al., 
2011a, Gathogo et al., 2014). Although overall survival of KT patients has been 
favourable, it remains unclear whether KT affords a survival benefit over dialysis 
in those who are suitable for KT. 
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Purpose of study 
This study aims to describe the clinical epidemiology of end-stage kidney 
disease in HIV infected individuals and, to determine whether kidney 
transplantation affords a survival benefit over dialysis in those who are suitable 
for KT. The specific aims of this study include: 
 
Primary aims 
Using data from a large UK-based multicentre cohort of HIV-infected 
individuals, The UK Collaborative HIV Cohort (UK CHIC) Study: 
Aim 1: To describe the trends in incidence and prevalence of ESKD and the 
factors associated with ESKD. 
Aim 2: To describe the use of and barriers to kidney transplantation as a 
treatment modality for ESKD. 
Aim 3: To describe survival of HIV infected patients with end-stage kidney 
disease (HIV/ESKD) managed by KT and dialysis.  
 
Secondary aim 
To describe the HIV management with combinational antiretroviral therapy 
(cART) stratified by treatment modality (dialysis, KT).  
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2.2. Methods 
Study Design 
The UK CHIC Study 
The United Kingdom Collaborative HIV Cohort (UK CHIC) study is a large 
longitudinal multi-centre observational cohort study that was initiated in 2001. 
The original UK CHIC study steering committee was comprised of 13 HIV 
clinicians, epidemiologists and statisticians from seven HIV clinics; the MRC 
Clinical Trials Unit and the Health Protection Agency- Communicable Disease 
Surveillance Centre (HPA-CDSC). Refer to Appendix B for full UK CHIC Study 
Centre List and UK CHIC Steering Committee members. The study received 
Multi-centre Research Ethics Committee (MREC) and local R&D approvals (UK-
CHIC, 2004). 
The main aim of UK CHIC study was to monitor HIV infected individuals' health 
response to HAART. The study aimed to describe the uptake and response to 
HAART over time, the trends of AIDS-defining illnesses and to identify factors 
associated with immunological and virological responses to HAART (Bansi, 
2011).  
UK CHIC Data collection 
The study collected routine clinical data on HIV infected individuals over the age 
of 16 years. Data was collected from 1st January 1996 onwards. 1996 was the 
year agreed when HAART became available. The original dataset included 
demographics (date of birth, gender, risk-group, ethnicity), AIDS-defining 
diagnoses and deaths, CD4 and CD8 T cell counts, HIV viral loads and HAART 
history (UK-CHIC, 2004).
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Table 5 lists all data variables that were collected in the UK CHIC study. More 
recently, additional data on hepatitis status (B and C) and laboratory markers of 
HAART-related toxicities (including creatinine) were collected (UK-CHIC, 2004). 
All data were collected electronically in accordance with the Data Protection Act 
(1998)(UKParliament, 1998). Data provided were pseudo-anonymised which 
meant the patient’s names were replaced with initials and soundex codes 
(Mortimer and Salathiel, 1995) and all clinic numbers were replaced with a 
unique study identifier (UK-CHIC, 2004). 
  
- 66 - 
Table 5: Information Collected for the UK CHIC Study (UK-CHIC, 2004) 
Demographics Gender  
 Ethnicity  
 Date of birth  
 Primary risk factor for HIV transmission  
Clinical data Date of first recorded HIV positive test  
 Date of last recorded HIV negative test  
 Date of first clinic visit  
 Date of last clinic visit  
 Date of death  
 Cause of death  
 Date and description of each AIDS-defining event  
Laboratory Markers Date and result of CD4 cell count for all available 
measurements 
Date and result of CD8 cell count for all available 
measurements 
Date and result of CD4 percentage for all available 
measurements 
Date and result of CD8 percentage for all available 
measurements 
Date and result of HIV RNA viral load for all available 
measurements 
Antiretroviral Treatment Date of starting all antiretroviral drug 
Date and reasons (maximum 3) for stopping all 
antiretroviral drug 
 
PCP Prophylaxis PCP prophylaxis drug 
Date of starting PCP prophylaxis 
Date of stopping PCP prophylaxis 
Hepatitis Date of hepatitis test 
 Hepatitis test 
 Hepatitis test result (negative/positive/unknown) 
Laboratory marker Normal range and units 
Total cholesterol <5.2 mmol/l 
HDL-cholesterol >1 mmol/l 
LDL-cholesterol <4 mmol/l 
Triglycerides <2.3 mmol/l 
Lactate 0.5-2.0 mmol/l 
Glucose Fasting <5 days: 0.7-4.2 mmol/l 
 Fasting >5 days: 2.9-5.3 mmol/l 
Aspartate aminotransferase 5-40 IU/l 
Alanine transaminase 5-40 IU/l 
Albumin 35-50 g/l 
Bilirubin 5-17 Umol/l 
Alkaline phosphate 42-128 IU/l 
Gamma GT Male: 9-54 IU/l 
 Female: 8-35 IU/l 
Urea 3.0-6.5 mmol/l 
Creatinine 60-97 µmol/l 
White blood count 3.7-9.5 x 109 cells/l 
Haemoglobin Male: 13.5-17.5 g/dl 
 Female: 11.5-15.5 g/dl 
Platelets 140-400 x 109 cells/l 
- 67 - 
Data Quality Assurance 
Database accuracy 
There were several steps followed for data quality assurance carried out by the 
study manager. First, an extensive range of queries were applied to the data 
from each centre to identify missing, invalid, illogical or conflicting demographic 
data. An example of this, an HIV-positive test date occurring prior to a HIV-
negative test date. Any inconsistencies with the data were resolved where 
possible by each centre through clinic databases or medical records. Where 
accurate information was obtained, this information was updated on both the 
source and UK CHIC database (UK-CHIC, 2004). 
Database linkage to death registries 
Patients lost to follow-up were linked to the UK death registries i.e. Office for 
National Statistics (ONS) for England and Wales, and the General Registrar 
Office for Scotland (GRO). Information used to link to death registries included 
date of birth, first name initial, soundex and gender. Linkage to the death 
registries also helped with completing missing data, ‘date of death’ (UK-CHIC, 
2004).  
Database audit 
Regular database audits were carried out to ascertain the accuracy of 
information held. The auditing process included a random selection of 1% of 
patient records from each centre. The centre investigator would then recreate 
the dataset using local databases and medical records. The final dataset was 
then cross checked with the audit data and then fed back to the individual 
centres to rectify any issues that were identified. Accurate data was defined as 
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exact match for date of birth, gender, first-name initial, soundex, ethnicity, 
HAART history and country of origin. Dates for HIV-negative and HIV-positive 
tests were considered accurate if within one year of each other. Date first 
attended clinic or ‘date first-seen’ and dates for initiating/stopping antiretroviral 
therapy were considered accurate if within one month of each other (UK-CHIC, 
2004).  
Duplication 
Due to the possibility of patients attending more than one centre for their HIV 
care, the database was checked for duplicate records. Initially the database was 
searched for exact match for soundex code and date of birth. Patients were 
excluded from further matching processes in the instances where the patient 
was known to have transferred to another centre. If duplicates were found, then 
other clinical or demographic data were searched for matches. HIV diagnosis 
date was considered a match if within one year. Dates were considered a match 
if within one month for date last seen and date of death. Duplicates identified 
within the same centre were deemed indeterminate and considered non-
matches; and no further checks made. Manual checks were carried out when 
the soundex and date of birth matched exactly or soundex and date of birth did 
not match exactly. Once all the checks were performed, true duplicate records 
were merged and where information was insufficient to determine if two records 
matched, these records remained on the database as distinct individual records. 
The initial data check of the UK CHIC study identified 1185 duplicate records 
representative of 8.6% of the cohort (N=13, 833). These duplicate records were 
merged. Of the 1185 duplicate records, 1078 (91.1%) had attended only two 
centres; 95 (8.0%) attended three centres and 12 (1.0%) had attended four 
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different centres. When records were merged, any inconsistences in the data 
collected were resolved by local investigators (UK-CHIC, 2004). 
The UK CHIC / ESKD Study 
By the start of the UK CHIC / ESKD study, there was one additional centre 
contributing data to the UK CHIC database. The data used for this chapter’s 
analyses were derived from eight centres (Appendix B) until 31/12/2012. The 
study was approved by local NHS research and development (R&D) 
departments.  
Definitions 
Permanent renal replacement therapy (pRRT) was defined as either 
commenced on dialysis or having received a kidney allograft for the 
management of ESKD. 
End-stage kidney disease was defined as having an estimated glomerular 
filtration rate (eGFR) <15ml/min for more than 3 months. 
Inclusion Criteria 
Patients were restricted to those with at least one serum creatinine value.  
HIV infected individuals with ESKD were identified from the UK CHIC database 
using the following algorithm: 
1. Using all available serum creatinine values and adjusting for IDMS 
(isotope dilution mass spectrometry), data wer converted to estimated 
glomerular filtration rates (eGFR) using the Modification of Diet in Renal 
Disease (MDRD) equation (Gupta et al., 2005, Grinyo et al., 2009).  
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2. Patients with stage 5 chronic kidney disease, i.e. an eGFR <15 
mL/min/1.73m2, for >3 months were identified (Bansi et al., 2009). 
3. Patients were reviewed by study investigators and included if they had 
commenced pRRT.  
4. Additional data checks were performed where local clinicians at the HIV 
and associated renal centres were asked to identify patients on pRRT 
using local databases and medical records. 
5. The pRRT list generated from UK CHIC was cross matched to the 
clinician identified list.  
Additional ESKD Verification Criteria 
Clinician documented diagnosis of haemodialysis, peritoneal dialysis or kidney 
transplantation on data collection form. 
 
Exclusion Criteria 
1. Patients without serum creatinine data were excluded from the analyses.  
2. Patients that had died prior to 2005. 
3. Patients that dialysed less than 3 months. 
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HIV Kidney Transplantation Assessment Criteria 
Inclusion criteria 
Assessment for eligibility of KT was carried out retrospectively and applied the 
following criteria 
(1) Transplant status at last date of follow-up (FU) i.e. transplanted or 
not transplanted. If patients were transplanted it was assumed that 
they were suitable for KT however, date of suitability was 
determined by criteria 2 below. 
(2) HIV viral suppression (<50 cps/ml) status. This was determined by 
looking retrospectively to the date that the patient had HIV viral 
suppression (<50cps/ml) > 6 months and / or initiated pRRT.  
(3) Medical reason for ineligibility. Of those not transplanted clinicians 
at the local centres reviewed patients and indicated if there was 
any medical reason (s) that precluded transplantation. 
Exclusion criteria 
Other local or national criteria on wait-listing for kidney transplantation were not 
applied to the selection criteria for suitability of KT in this study. This included 
listing or de-listing dates and CD4 T-cell count > 200 cells/mm3.  
Patients who would had become eligible or died pre-2005 were excluded from 
the assessments for eligibility of KT. Patients transplanted pre-2005, when 
transplantation was not being offered as a treatment modality for HIV ESKD 
patients, and those with missing information were also excluded. 
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Table 6: List of AIDS Defining Illnesses  
(Rogstad et al., 2006, Mitchell et al., 2011) 
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Statistical analysis 
Statistical analyses in this chapter were performed using SAS (version 9.3) and 
STATA (version 11.1). Before statistical analysis, data were checked for normal 
distribution. Where there was normal distribution, descriptive statistics including 
means and standard deviations were used. Medians and interquartile ranges 
were used for skewed data. Frequencies and proportions were used to describe 
categorical data. Wilcoxon-ranksum test was used to compare medians; Z-tests 
were used to compare means; and two-sided chi-squared (X2) or Fisher’s exact 
test to compare proportions. Statistical significance level was considered at p < 
0.05. 
Longitudinal Analysis of the Trends in HIV/ESKD  
Trends of ESKD in the HIV infected population were described over time from 
1998-2012 in terms of prevalence, incidence and cumulative incidence rates 
and stratified by ethnicity (black (black-African, black-Caribbean, and black-
other)) and treatment modality (dialysis and kidney transplantation).  
 
The incidence rate was used to describe the number of new ESKD cases in the 
entire HIV infected cohort that met the inclusion criteria for the UK CHIC/ESKD 
study over the study period. Each HIV infected individual contributed time from 
cohort entry which was taken as date of HIV diagnosis to date of last clinic visit 
or 31/12/2012. Study participants were censored at death or date of last clinic 
visit if lost to follow-up. The incidence rate then allowed me to explore the 
relationship between the risk factors and ESKD.  
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The prevalence was used to describe the proportion of individuals in the entire 
HIV infected cohort that were included in the UK CHIC/ESKD study. The 
prevalence provided information on the burden of ESKD in the studied cohort. 
To describe the trends in ESKD, both the incidence and prevalence were 
calculated for select time points during the study period i.e. 2000-2001, 2002-
2003, 2004-2005, 2006-2007, 2008-2009, 2010-2011. ESKD incidence and 
prevalence in the different strata was calculated per 100 person-years of follow-
up (PYFU).  
Cumulative incidence was estimated by a competing-risks regression model, 
treating death as a competing risk, stratified by ethnicity and compared with 
Wald tests. The cumulative incidence described the proportion of the HIV 
infected UK CHIC population included in the analyses that were at risk of 
developing ESKD over the entire cohort follow-up time. Death was included in 
the regression model as a competing risk as it may have confounded the 
estimates of ESKD risk. For example, a patient may have died before 
developing ESKD therefore the overall estimates would be under-represented.  
 
Factors Associated with HIV/ESKD 
Factors associated with ESKD were determined using Poisson regression. The 
Poisson regression model was selected as the event i.e. ESKD was a binary 
outcome. This model determined the rate at which ESKD occurred in the HIV 
infected cohort and allowing for the individual follow-up time which differed 
between study participants over the study period.    
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When performing the analyses to identify the factors associated with ESKD 
analyses; the time dependent covariates considered were age (per 10 years 
older), HIV viral load (per log10 copies/ml), and CD4 T cell count (per 50 
cells/mm3). The time independent covariates were gender, ethnicity, mode of 
HIV acquisition, HBV/HCV co-infection status and if initiated cART at last clinic 
visit. Following univariable analyses all covariates with a p value of <0.05 were 
considered for entry into the multivariable model. 
 
Survival Analyses 
Patient survival was estimated by the Kaplan-Meier method, and survival time 
across the stratified groups (unsuitable for KT and suitable for KT (pre- and 
post-KT)) and was compared with log-rank tests. The time of analysis was 
taken from start date of pRRT until the date of last clinic visit or 31/12/2012.  
 
For the evaluation of mortality, the date of last follow-up or 31/12/2012 or date 
of KT was used and; the cohort was stratified into three groups i.e. transplanted 
(Post-KT) vs. not transplanted – suitable (Pre-KT) vs. unsuitable for KT. The 
post-KT population contributed both (1) time of follow-up from the date they 
were suitable for KT until date of KT and (2) time from KT to date of last follow-
up or 31/12/2012.Crude mortality rates were adjusted for age and ethnicity. 
Crude mortality rates with 95% CI were estimated for each of the stratified 
groups described above.     
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Bias Associated with Missing data 
To address missing data and reduce bias or standard errors, sensitivity 
analyses were performed by the last observation carried forward to impute 
missing values (Horton and Kleinman, 2007). 
 
Cross-sectional data analyses 
Descriptive analyses (frequency and proportions) were used to describe 
antiretroviral drug regimens prescribed in the identified HIV/ESKD cohort. 
Initially, patients were stratified into protease inhibitor (PI) and non-nucleoside 
reverse transcriptase inhibitors (NNRTI) based regimens. A further stratification 
was then applied for those exposed to atazanavir vs. tenofovir vs. other at any 
point from date of HIV diagnosis up to date of last clinic visit. A cross-sectional 
review was then carried out at most recent visit for three time points: pre-KT, at 
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2.3. Results 
HIV/ESKD Patient Characteristics  
Between January 2000 and December 2011, there were 32, 018 HIV infected 
individuals from eight participating HIV clinics that contributed data to the UK 
CHIC study. Refer to Figure 10 for full patient disposition. Of those HIV infected 
individuals that ever attended each centre, 10.6% (3, 388) did not contribute 
any creatinine data and therefore excluded from further analyses, (see Figure 
9).  



















Number Ever Attended Centre Number without Creatinine Data
Graph represents the total number of patients that ever attended each of the eight HIV 
clinics (blue bars) that contributed data to the UK CHIC study. Of those included in the UK 
CHIC study, a number of patients had missing creatinine data (red bars) 
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Of the excluded patients (N=3,388), the proportions to ever attend each 
participating centre were as follows: North Middlesex University hospital 
(43.1%); UCL Mortimer Market (19.1%); Chelsea and Westminster (16.4%); 
Royal Free hospital (8.4%); St Mary’s hospital (8.0%); King’s College hospital 
(6.4%); Brighton & Sussex hospitals (3.1%); and Edinburgh (0.4%). There were 
an additional two patients identified from Edinburgh centre that had not started 















Figure 10: Full Patient Disposition for HIV/ESKD Cases Identified from the 
UKCHIC Study  
 
 







UK CHIC Cohort 
N=32, 018 
Included 
N=2, not included in UK CHIC 
 
Excluded 
No renal data N=3,388 (10.6%) 
Excluded 
N=10, KT Pre-2005 
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Characteristics of HIV+ patients included and excluded from the analyses 
An initial comparative analysis of the patient characteristics of those included 
compared to the excluded group in the UK CHIC/ESKD study was performed, 
(see Table 7). The included/excluded groups demonstrated significant 
differences in all patient characteristic parameters. Within the excluded group 
(N=3,388), there was a higher proportion of patients that were male (61.9%), of 
black ethnicity (49.1%), heterosexual (51.5%), not on ART (77.3%) and had not 
been tested for hepatitis B (85.3%) or C (87.5%).  
 
 
Table 7: Characteristics of Included/Excluded HIV+ Patients in UK 
CHIC/ESKD Study 
 
Characteristic Included Excluded P 
N  28630 3388  
Age, median(IQR) years 35 (29, 41) 35 (29, 42) 0.003 




























CD4 count, median(IQR) cells/mm3 354 (200, 527) 300 (140, 480) <0.001 
Viral load, median(IQR) log10copies/ml 3.9 (1.7, 4.8) 3.9 (2.6, 4.8) <0.001 
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Characteristics of HIV/ESKD patients  
There were a total of 28, 632 patients included in the final analyses. In this 
group, there were a higher proportion of patients that were male (78.6%), of 
other ethnicity (71.6%), men who have sex with men (59.6%), not taking ART 
(68.2%), and not tested for hepatitis B (65.1%) or C (67.2%). The median (IQR) 
number of available creatinine measurements was 16 (5, 30) and 18 (7, 35) for 
those of black and other ethnicity respectively (p<0.0001). The median (IQR) 
follow up was 6.4 (2.5, 11.1) years, during which 1732 individuals (6.0%) died.  
 
Using the selection criteria discussed above, 117 patients (including the two 
additional patients that did not contribute data to the UK CHIC study) were 
identified as having received permanent renal replacement therapy at the 
associated renal centres. The clinical characteristics of 115 ESKD cases (0.4%) 
present in the UK CHIC study dataset and the 28,515 patients without ESKD 
are shown in Table 8 Baseline patient characteristics differed between those 
with ESKD and those with no ESKD for all selected covariates except for time 
since HIV diagnosis, HIV viral load and hepatitis B/C co-infection. At cohort 
entry there were a significantly higher proportion of patients in the ESKD group 
that were older, of black ethnicity, ever had an AIDS (CDC-C) illness, lower 
nadir and overall CD4 T cell count, lower estimated glomerular filtration rate and 
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Table 8: Characteristics of patients according to ESKD status over follow-
up 
 ESKD No ESKD P 
 at cohort entry  
N  115 28515  
Age, median (IQR) years 38 (32, 44) 35 (29, 41) 0.001 
Gender, n (%) male 80 (69.6) 22436 (78.7) 0.02 
Ethnicity, n (%) black 73 (63.5) 7234 (25.4) <0.0001 
Time since HIV diagnosis, 
median (IQR) 
years 1.0 (0.1, 3.8) 0.7 (0.0, 5.7) 0.43 
AIDS (CDC-C), n (%)  28 (24.3) 3401 (11.9) 0.007 
CD4 nadir, median (IQR) cells/mm3 139 (38, 255) 257 (110, 430) <0.0001* 
CD4 count, median (IQR) cells/mm3 218 (89, 357) 355 (201, 528) <0.0001** 
Viral load, median (IQR) log10 copies/ml 4.0 (1.7, 4.8) 3.9 (1.7, 4.8) 0.28† 
eGFR, median (IQR) ml/min/1.73m2 22 (11, 57) 103 (89, 115) <0.0001†† 
Antiretroviral therapy, n (%) yes 52 (45.2) 9065 (31.8) 0.002 
Hepatitis B surface antigen 
positive, n (%) 
 3 (2.6) 548 (5.5) 0.56 x 
Hepatitis C antibody 
positive, n (%) 
 4 (3.5) 671 (7.2) 0.65 xx 
* n=19257, **n=17982, † n=18921, ††n=15117, x n=10071, xx n=9455, ^ incomplete data for 
n=1 patient 
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HIV associated nephropathy (HIVAN) was confirmed on biopsy as the primary 
renal diagnosis in 46% (N=54) of the ESKD patients. 80% of the HIVAN cases 
were in patients of black ethnicity (N=43/54). Other renal diagnoses are 
described in Table 9. 
 
Table 9: Aetiology of Kidney Disease in HIV/ESKD Individuals 
 Aetiology of Kidney Disease N (%) 
HIV Associated Nephropathy (HIVAN) 54 (46) 
Idiopathic chronic kidney disease (ICKD) 15 (13) 
Diabetic Nephropathy  13 (11) 
Amyloid 6 (5) 
Focal segmental glomerulosclerosis (FSGS) 2 (2) 
Other  
• Ascending chronic pyelonephritis  
• Acute tublar necrosis (ATN)  
• Autosomal dominant polycystic kidney disease 
• Congenital kidney disease 
• Congenital posterior urethral valves 
• Drug toxicity 
• Hypertensive nephropathy 
• Haemolytic-uremic syndrome (HUS) 
• Interstitial fibrosis and tubular atrophy (IFTA) 
• Polycystic Kidney disease (PCKD) 
• Reflux nephropathy 
• Renal dysplasia 
• Renal-vascular disease 
• Scarred kidneys 
• Small kidneys 
• Single kidney atherosclerosis 
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Prevalence and Incidence of ESKD  
During the study period, there was a steady increase in ESKD prevalence 
observed among patients of black ethnicity (from 0.44% (95% CI 0.25%, 0.78%) 
in 2000/1 to 1.09% (0.85%, 1.41%) in 2010/11, p=0.008) while the ESKD 
prevalence among those of other ethnic groups remained stable (0.09% 
(0.05%, 0.17%) to 0.15% (0.10%, 0.22%), p=0.87 (see Figure 11A). After 
adjusting for age, the prevalence of ESKD appeared to increase over time in 
those of black ethnicity (0.36% (0.18%, 0.65%) 2000/1 to 1.35% (1.01%, 
1.77%) 2010/11), but not in those of other ethnic groups (0.09% (0.04%, 0.18%) 
to 0.11% (0.07%, 0.17%)). For both patient groups, the incidence of ESKD 
remained unchanged throughout the study period (see Figure 11B). 
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A. Prevalence (%) of ESKD with 95% confidence intervals in those of black and 
other ethnicities, stratified by year of follow-up 
 
B. Incidence of ESKD in those of black and other ethnicities, stratified 
by year of follow-up 
 
Figure 11: Trends of ESKD in HIV Infected Individuals 
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Factors Associated with ESKD  
Excluding antiretroviral drug choice, all other covariates in Table 10 were 
included in the Poisson regression analyses. Results from univariable analyses 
were statistically significant for all covariates except for HIV viral load, having 
started combination ART, hepatitis B – the not tested group, and hepatitis C – 
the co-infected and not tested groups. Statistically significant univariable 
covariates were included in the multivariable analyses with the exception of 
gender and exposure group as these factors were considered highly correlated 
with ethnicity in the UK CHIC cohort. Factors that were independently 
associated with developing ESKD were age (IRR per 10 years older, 1.50 (1.20, 
1.87)), black ethnicity (5.45 (3.42, 8.70)), CD4 count (per 50 cells/mm3 higher, 
0.91 (0.87, 0.95)) and hepatitis B and C co-infection (respectively, 2.89 (1.35, 
6.19) and 3.03 (1.41, 6.54)), Table 10. 
 
For the continuous variables HIV viral load and CD4 T cell count, there were 
missing data for several time points during the follow-up period. In order to 
reduce possible bias brought about by missing data and to confirm validity of 
findings, sensitivity analyses using the last observation carried forward (LOCF) 
method (Cozzi Lepri et al., 1998) was performed. Findings from these analyses 
remained the same confirming that factors including age, black ethnicity, CD4 
count, and hepatitis B and C co-infection were independently associated with 
developing ESKD, Table 11.          
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Table 10: Results from univariable and multivariable Poisson regression 
analyses to identify factors associated with ESKD 
 Univariable Models Multivariable Model 
IRR (95% CI) P IRR (95% CI) P 
Age 
per 10 years older 
 
 




































Mode of acquisition 







5.44 (3.25, 9.10) 










per 50 cells/mm3 higher 
 
 








per log10 copies/ml higher 
 

























3.59 (1.68, 7.65) 







2.89 (1.35, 6.19) 











1.97 (0.93, 4.17) 







3.03 (1.41, 6.54) 





IRR=Incidence Rate Ratio;  CI=Confidence Interval; P=p-value 
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Table 11: Results from univariable and multivariable Poisson regression 
analyses to identify factors associated with ESKD with sensitivity 
analyses, with last CD4 count/VL carried forward 
Characteristics Univariable Models Multivariable Model 
IRR (95% CI) P IRR (95% CI) P 
Age 
per 10 years older 
 
 




































Mode of acquisition 






5.44 (3.25, 9.10) 










per 50 cells/mm3 higher 
 
 








per log10 copies/ml higher 
 




























3.59 (1.68, 7.65) 







2.77 (1.29, 5.94) 











1.97 (0.93, 4.17) 







2.92 (1.35, 6.31) 





IRR=Incidence Rate Ratio;  CI=Confidence Interval; P=p-value 
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Kidney Transplantation (KT) as a Treatment Modality in HIV Infection 
In this section using the 117 ESKD cases identified, analyses were performed 
to assess the barriers to and use of kidney transplantation as a treatment 
modality in HIV infection. Subsequent analyses were performed to describe the 
survival of HIV infected patients with ESKD managed by KT and dialysis. 
 
Barriers to Kidney Transplantation in HIV Infection 
Of the 117 ESKD cases identified, 10 patients that received KT pre-2005 and 
those with insufficient information to be assessed for suitability (N=8), were 
excluded from further analyses. With the use of the KT assessment criteria 
outlined earlier (section 2.2), of the remaining 99 patients, 30 were not suitable 
for kidney transplantation. Viral non-suppression (HIV VL > 400 cps/ml) as a 
reason for ineligibility was noted in 53% (N=16/30) of the cases. Two patients 
declined to have a kidney transplant and the others were ineligible due to co-
morbidities. The co-morbidities reported by the clinicians as reasons for 
ineligibility included: visceral Kaposi sarcoma; progressive multifocal 
leukoencephalopathy (PML); cervical cancer; lymphoma; ischaemic heart 
disease; liver disease; blindness; systemic unwell; sclerosing peritonitis; 
amyloid, pulmonary embolism, seizures and hepatitis C co-infection; and 
peripheral vascular disease. On 31/12/2012, 13 of the ineligible patients were 
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Use of kidney transplantation as a treatment modality for HIV/ESKD patients 
Over the 7 year study period (01/01/2005 to 31/12/2012) there was an 
increasing uptake of KT as a treatment modality for ESKD in HIV infected 
patients, (see Figure 1). Since January 2005, there was a 12 fold increase in 
the number of transplanted HIV/ESKD patients by December 2012 respectively, 
N=2 and N=24. The proportion of patients transplanted in relation to the total 
number of ESKD patients in 2005 was 5% (2/39) vs 31% (24/77) in 2012 (Z 
score p=0.0015).  There was an increase in the number of HIV/ESKD cases 
that were suitable for KT throughout the study period, (range N= 19 to 35). Of 
the 69 ESKD cases that were suitable for KT, 34 (49%) had received a kidney 
allograft. The overall median follow-up time was 25.2 (IQR 12.8, 56.9) months.   
Figure 12: Number of patients under follow-up with ESKD, suitable for 
kidney transplantation, and having received a kidney transplant, stratified 





           
 
 
          
           
           
           
           
           
 



















Suitable for kidney transplantation
Kidney transplant recipients
Graph representing the number of ESKD patients alive on 31st December of each year is 
shown by the black bars; the number of patients who are pre-KT and post-KT are shown 
by the white and grey bars respectively. 
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Table 12: Characteristics of patients according to ESKD treatment 
modality over follow-up 
Characteristic Pre-KT Post-KT Unsuitable 
for KT 
 at becoming 
eligible for 
KT 
at KT  at initiation 
of pRRT 
N  69^ 34 30^ 
Age, median (IQR) years 45 (37, 49) 42 (37, 50) 36 (41, 44) 
Gender, n (%) male 48 (70.6) 21 (61.8) 17 (58.6) 
Ethnicity, n (%) black 49 (72.1) 24 (70.6) 19 (65.5) 
Time since HIV 
diagnosis, median (IQR) 
years 4.2 (1.5, 8.0) 7.6 (6.6, 10.7) 4.5 (2.4, 8.0) 
AIDS (CDC-C), n (%)  23 (33.8) 13 (38.2) 11 (37.9) 
CD4 nadir, median (IQR) cells/mm3 110 (42, 180) 122 (38, 167) 86 (11, 198) 
CD4 count, median 
(IQR) 
cells/mm3 328 (182, 530) 382 (288, 527) 24 (82.8) 
Viral load, median (IQR) log10 copies/ml 1.7 (1.6, 1.7) 1.6 (1.6, 1.7) 3.6 (1.7, 4.9) 
eGFR, median (IQR) ml/min/1.73m2 8 (6, 12) 6 (5, 8) 7 (5, 15) 
Antiretroviral therapy, n 
(%) 
yes 64 (94.1) 34 (100.0) 26 (89.7) 
Hepatitis B surface 
antigen positive, n (%) 
 4 (5.9) 2 (5.9) 3 (10.3) 
Hepatitis C antibody 
positive, n (%) 
 2 (2.9) 1 (2.9) 4 (13.8) 
^ incomplete data for n=1 patient 
KT = kidney transplantation; pRRT = permanent renal replacement therapy; the pre-KT group 
comprises patients awaiting KT and including those who received a KT during the study 
period; the post-KT group comprises patients who received a KT  
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Survival of HIV/ESKD Patients by Treatment Modality 
Survival was calculated for three different groups i.e. HIV/EKSD individuals 
(N=117) pre-KT, post-KT and those unsuitable for KT. The ESKD cases that 
had received a kidney allograft contributed time to both pre-KT and post-KT 
survival analyses. The overall median waiting time of those suitable for KT 
(N=69) since meeting the KT criteria for suitability was 38.6 (IQR 17.1, 54.7) 
months. By December 2012, those suitable for KT that were being worked up 
for or awaiting KT had been followed up for a median of 35.8 (15.0, 66.9) 
months from the date of becoming suitable for KT. Figure 13 shows patient 
survival for the pre-KT and post-KT patients and for those who were unsuitable 
for KT. Survival pre-KT and post-KT was similar (Kaplan-Meier estimates of 
100% and 94% at one year, and 89% and 85% at five years, respectively, 
p=0.53). Survival for patients ineligible for KT was significantly worse (83% at 
one year and 46% and five years, P<0.0001). 
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Figure 13: Kaplan-Meier plots showing survival of patients with ESKD, 
stratified by a) pre-KT, b) post-KT, and c) unsuitable for KT. 
 
Kaplan–Meier survival estimates for patients stratified by KT status. Follow up was measured in 
years from the date patients became suitable for KT (pre-KT), received their first kidney allograft 
(post-KT), or initiated permanent renal replacement therapy (unsuitable). Patients who 
underwent KT could contribute time to both the pre-KT and post-KT cohorts.   
Overall p-value = 0.0001 
Pre-KT vs. Post-KT p-value = 0.55 
- 93 - 
Antiretroviral Drug Regimen for HIV/ESKD Awaiting KT 
A cross-sectional review of the cART regimens of the 69 patients with ESKD 
who were suitable for KT (pre- or post-KT) found that 38 (55%) were on a 
protease inhibitor (PI) and 31 on non-PI (non-nucleoside/tide reverse 
transcriptase inhibitor [NNRTI], nucleoside/tide reverse transcriptase inhibitor 
[NRTI] and/or integrase strand transfer inhibitor [INSTI]) containing cART at the 
most recent clinic visit. Lamivudine and abacavir were the commonest 
prescribed NRTI (in 74% and 51%, respectively), and darunavir and lopinavir 
the commonest prescribed PI (in 33% and 18%, respectively). Due to the known 
risk of ART-associated kidney disease particularly with tenofovir and atazanavir 
exposure (Hamzah et al., 2015a), I performed a cross-sectional descriptive 
analysis. Tenofovir and atazanavir were included in the cART regimen of 11 
(16%) and 4 (6%) patients respectively. 
 
Estimation of HIV/KT Patients in the United Kingdom 
The national estimate of HIV/ESKD patients on 31st December 2012 as 
previously discussed is 289. Of the 117 HIV/ESKD patients identified in the UK-
CHIC cohort there were 42 HIV kidney transplant recipients excluding 10 
patients transplanted pre-2005. We would therefore anticipate 103 HIV/KT 
recipients transplanted between 2005 and 31st December 2012. Data from the 
Organ Donation and Transplantation reported 17,045 patients that were 
transplanted in the UK during the 7 year period. Based on this information, the 
prevalence of HIV infected kidney transplanted recipients is estimated at 0.6%.   
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2.4. Discussion 
Kidney disease is an important co-morbidity in HIV infection. This chapter 
focused on ESKD in the HIV infected population using a large multicentre study 
cohort, UK CHIC. To summarise the findings, HIV associated nephropathy was 
the commonest cause of ESKD representing almost half of all cases with 
majority being patients of black ethnicity. The overall prevalence of ESKD was 
low (0.4%) although, a steady increase was observed among black patients 
while other ethnic groups remained stable. Despite the widespread availability 
of ART and despite guidelines recommending earlier HIV diagnosis and earlier 
ART (Asboe et al., 2012), the incidence rate of ESKD did not decline over the 
study period. Black patients in particular saw a 4 to 5 fold higher ESKD 
incidence rate compared to other ethnic groups (1.14 [95% CI 0.81, 1.47] vs. 
0.24 [0.16, 0.32] per 1000 person years (PY) for black vs. other ethnic patients). 
Since 2005, kidney transplantation was increasingly used as a treatment 
modality for HIV/ESKD patients with one third having received a kidney allograft 
by the end of the study period and another one third awaiting KT. Excellent 
survival rates were observed for HIV/ESKD patients that were suitable for KT, 
100% at one year and 89% at five years.Survival rates of HIV/ESKD patients 
were similar for both dialysis and kidney transplantation treatment modalities, 
89% and 85% at five years, respectively.       
 
In the UK, the prevalence of ESKD in HIV infected individuals was estimated at 
0.31% (Bansi et al., 2009). The present study demonstrated that the prevalence 
of ESKD has continued to increase among HIV positive patients of black 
ethnicity in recent years, and that the incidence of ESKD has not declined 
despite widespread use of cART. Since 2005, KT is increasingly used to 
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manage ESKD, with one third of patients having received a kidney allograft and 
one third of patients being prepared for or awaiting KT. Excellent survival rates 
were observed for patients with ESKD who were suitable for KT even if they 
were maintained on long term dialysis, 100% at one year and 89% at five years.  
The prevalence of ESKD among HIV infected individuals in the UK has 
increased 20-fold from 0.07% in 1998 (Bansi et al., 2009) to 1.35% in 2011. 
This is reflective of the growing HIV population and decline in HIV-related 
deaths owing to the use of effective antiretroviral therapy (PHE, 2015a). The 
overall prevalence in the current dataset (0.4%) although low, is comparable to 
the 0.36-0.64% reported from other European countries (Trullas et al., 2008, 
Mazuecos et al., 2012, Bickel et al., 2013, Ryom et al., 2013a, Rasch et al., 
2014). North America by comparison has a somewhat higher HIV/ESKD 
prevalence estimated between 0.75 – 1.65% (Jotwani et al., 2012, Abraham et 
al., 2015). This may be due to the higher proportion of HIV-infected African 
American that tend to exhibit higher HIV viral loads, have low ART coverage 
and often present with advanced HIV disease compared to than other ethnic 
groups (Lemly et al., 2009). Whereas in the United Kingdom, there has been a 
decline in the rates of late HIV diagnoses - from 58% in 2003 to 40% in 2014 
(PHE, 2015a). Across Europe, the late diagnosis of HIV infected individuals is a 
persistent issue. In 2014, almost two thirds of newly diagnosed HIV infected 
were diagnosed with AIDS defining illnesses (WHO, 2015a).    
In the current dataset, the incidence rate of HIV/ESKD overall was low 0.7 per 
1000PY. When stratified by ethnicities, both black and other ethnic groups failed 
to demonstrate a decline in the incidence of HIV/ESKD despite the widespread 
availability of cART (respectively, 2000 to 2001 1.31 vs. 0.29 per 1000PY and 
2010 to 2011 1.12 vs. 0.23 per 1000PY). However, the incidence remained up 
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to 13 fold higher in the black compared to the other ethnic groups over the study 
period. Data from a large HIV cohort in North America (n=38, 354) 
demonstrated a modest decline in the incidence rate of black patients from 
0.532 to 0.303 per 1000PY and a modest increase in those of non-black 
patients from, and 0.138 to 0.34 per 1000PY (Abraham et al., 2015). Another 
study including HIV infected US Veterans (n=22,156) the crude estimate of 
ESKD was 3 per 1000PY (Jotwani et al., 2012). This is almost a 4 fold 
difference in the incidence rates among black ethnic patients between the UK 
and North America. This observation may be due to the differences in 
antiretroviral prescribing practices where around 2010 the UK had a more 
conservative approach to initiating cART (CD4 counts < 200 cells/mm3 (Nelson 
et al., 2011)) compared to the USA that offered wider access (CD counts 350 to 
500 cells/mm3 (DHHS, 2010)). Furthermore, the eGFR definition of ESKD is 
estimated much higher i.e. <30 mL/min/1.73m2 (Abraham et al., 2015).   
Factors associated with developing ESKD in the present cohort were black 
ethnicity, older age, lower CD4 cell count and hepatitis B/C co-infection. In an 
earlier UK study, multivariable analyses found only black ethnicity and lower 
CD4 cell count to be associated with ESKD (Bansi et al., 2009). Other 
observational cohort observed similar factors in addition to traditional factors, 
diabetes, hypertension, cardiovascular disease, hypoalbuminemia and 
proteinuria and IVDU (Jotwani et al., 2012, Bickel et al., 2013, Ryom et al., 
2013a, Mallipattu et al., 2014, Ryom et al., 2014).  
With the decline in presentation of patients with advanced HIV disease, the 
occurrence of HIVAN has decreased and as a consequence reduced the 
number of HIV/ESKD cases (Wyatt and Klotman, 2007). In the UK, the 
proportion of patients presenting with advanced HIV disease i.e. severely 
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immunocompromised at diagnosis with a CD4 count ˂200 cells/mm3 was 30% 
in 2009 and 28% in 2012 (HPA, 2012). In our cohort the proportion of HIVAN 
cases has decreased from 52.9% (36/68) in 2007 (Bansi et al., 2009) to 46% 
(54/115) cases in 2012. Overall, HIVAN is the most common form of CKD in 
HIV infected and those of African descent (Gerntholtz et al., 2006). Following 
HIVAN diagnosis, progression to ESKD often occurs within months (Weiner et 
al., 2003). Based on this together with reduced access to cART of those eligible 
(35.8% of 21.2 million) (UNAIDS, 2015) it is probable that there is a high 
prevalence of HIV/ESKD in sub-Saharan Africa. HIVAN is the third leading 
cause of kidney disease among patients of black ethnicity in high income 
countries (USRDS, 1999, Gerntholtz et al., 2006). The risk of establishing 
ESKD among African-Americans was 16.2 fold higher in HIV infected patients 
compared to 6.7 fold in uninfected patients (Lucas et al., 2007). The incidence 
of ESKD in a cohort of US veterans was 7.3 fold higher among black patients 
with HIV compared to age and gender matched white participants (Choi et al., 
2007a). In another cohort (n=4259), African-Americans with CKD were found to 
be 9 times more at risk of progressing to ESKD than Caucasian patients 
(hazard ratio 1.9 and 17.7 respectively) (Lucas et al., 2008).   It has been 
thought that the increased risk of ESKD among the black patients could 
possibly be as a consequence of predisposing genetic polymorphisms (Kiryluk 
et al., 2007, Estrella et al., 2015).The susceptibility of black patients to develop 
HIVAN and FSGS has been linked to polymorphisms of the apolipoprotein L-1 
(APOL1) gene which are present in 35% of African and African-American 
patients (Kopp et al., 2011). Black ethnicity is also a risk factor for immune 
complex kidney disease in HIV positive patients (Foy et al., 2013), and for 
diabetes and hypertension in the general population (Norris and Agodoa, 2005). 
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The current dataset reflects the ageing HIV population in the UK. By 2012, 
about a quarter of people living with HIV in the UK were over the age of 50 
(Beer, 2014). In the general population there is a 1 in 40 for men and 1 in 60 for 
women lifetime risk of developing ESKD past middle age (Turin et al., 2012). In 
individuals with reduced kidney function (eGFR 44 – 59ml/min per 1.73 m2), the 
risk of ESKD is considerably higher (estimated 1 in 10 for men, 1 in 30 for 
women). With longer survival in the HIV population there are other competing 
risks factors that were not investigated in the current cohort. Diabetes and 
hypertension are the most common cause of ESRD in the wider population 
(28% in the UK (UKRR, 2012) and 70% in the US (USRDS, 2011)). The 
additive effect of HIV could also worsen the prognosis of diabetic or 
hypertensive nephropathy (Bostrom and Freedman, 2010, Mallipattu et al., 
2013). Furthermore, chronic use of antiretroviral drug therapy has been found to 
be associated with the development diabetes and hypertension (Mocroft et al., 
2010).  
Hepatitis C affects between 240 to 350 million and chronic hepatitis B 375 
million people worldwide (Mohd Hanafiah et al., 2013) (Zhang and Hu, 2015). 
An estimated 9% of HIV individuals in the UK are co-infected with hepatitis C 
(NAT, 2012). HIV-HCV and HBV co-infection have been associated with 
developing CKD and progression to ESKD in several studies (Tsui et al., 2007, 
Izzedine et al., 2009b, Tsui et al., 2009, Fischer et al., 2010, Mocroft et al., 
2012, Peters et al., 2012, Lucas et al., 2013, Mohan et al., 2013).  
The management of ESKD has evolved over the years. The present dataset 
shows an increasing uptake of kidney transplantation as a treatment modality 
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for HIV/ESKD. Sustained suppression of HIV replication and immune 
restoration in patients who adhere to cART has allowed successful use of KT in 
carefully selected patients with ESKD (Stock et al., 2010a, Gathogo et al., 
2014). Typically, these patients had CD4 cell counts >200cells/mm3, 
undetectable HIV RNA levels, and free of opportunistic disease, malignancy, 
and severe vascular or hepatic co-morbidities. The outcomes of KT in HIV 
infection are favourable in terms of patient and graft survival albeit high rates of 
allograft rejection (31 – 44%) (Stock et al., 2010a, Gathogo et al., 2014). An in 
depth analysis on the outcomes of kidney transplantation in HIV disease are 
discussed in Chapter 3. In the present analysis uncontrolled viraemia was the 
main reason that prevented HIV+ patients from receiving a kidney allograft. The 
survival at one and five years was significantly worse among those ineligible for 
KT compared to those eligible (83% and 46% vs 94-100% and 85-89% 
respectively, p<0.0001). In the general population, older age, primary renal 
diagnosis of hypertension and diabetes, race and lower income are several 
factors associated with extended waiting times for KT (Schold et al., 2011).  
In the pre-HAART era, patient survival on dialysis was poor. Before 1995, the 
survival rate of HIV/ESKD on chronic dialysis ranged between 1.2 – 12 months 
(Rodriguez et al., 2003). The use of cART may have explained the survival 
benefit of those on pRRT in the present cohort. An observational study in the 
US reported one year survival rates of 54 to 74% and 2 year survival of 30% of 
HIV/ESKD patients on dialysis (Ahuja et al., 2002, Rodriguez et al., 2003). In a 
French cohort of HIV/ESKD patients on chronic dialysis demonstrated a 1, 2 
year survival respectively of 93.8% and 89.4% (Tourret et al., 2006). Other 
factors known to impact survival of HIV infected patients on pRRT include CD4 
count, IVDU and hepatitis C co-infection. In a multivariate analysis, a higher 
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CD4 count was protective (hazard ratio (95CI), 0.86 (0.80, 0.93) per 50 
cells/mm3 increase) (Ahuja et al., 2003, Rodriguez et al., 2003, Soleymanian et 
al., 2006). There is a low prevalence of IVDU users in the UK and (NAT, 2013). 
The poor uptake of HAART observed among HIV-HCV co-infected patients may 
increase their risk of mortality (Hsu et al., 2001). 
The survival of HIV/ESKD by treatment modality (dialysis vs KT) in the current 
cohort was similar (100% and 94% at one year, and 89% and 85% at five years, 
respectively, p=0.53). This finding was somewhat similar to another prospective 
study in Spain with survival rates of those on the waiting list (n=7) compared to 
those that had received an allograft (n=11) was 72% vs 100% respectively, 
logrank p=0.089 (Martina et al., 2011).     
The excellent survival rates of HIV infected patients on dialysis could be a 
reflection on the improved HIV and renal care. The high levels of medication 
adherence in HIV infected individuals could also explain effective management 
in the HIV/ESKD cohort. Studies have demonstrated that 95% level of 
adherence of HAART is associated with poor virological and immunological 
response (Fischl M, 2000, Paterson et al., 2000, Mannheimer et al., 2002, 
Poppa et al., 2004). This level of adherence is substantially higher compared 
with other chronic illnesses where 50% adherence has been estimated 
(Marinker, 1997). Despite excellent outcomes with dialysis as a treatment 
modality for HIV/ESKD patients, other studies have shown the risk of mortality 
with prolonged dialysis use. In a transplant registry study over an 11 year study 
period (2001 – 2012) found an increase in mortality risk was demonstrated 
among those with longer waiting times (Locke, 2015). The mortality rate ranged 
from 0 to 30.5 per 100PY for waiting times between 0.8 to 6.1 years. There has 
been concern that underexposure and inadequate dose adjustment of 
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antiretroviral drugs with renal insufficiency. A study of HIV infected patients with 
chronic kidney disease demonstrated that HAART exposure was 14%, 24%, 
64% and 49% less respectively for patients with eGFR 30 – 59, 15 – 29, <15 
ml/min/1.72m2 and those on chronic dialysis (Choi et al., 2007b). An associated 
risk of mortality with inadequate HAART dose adjustment was estimated at 
hazard ratio, 1.77; 95%CI, 1.27 – 2.46).    
The strengths of this study the use of a large HIV cohort, the long study period 
(12 years) and the use of local HIV and renal databases for case ascertainment. 
Other key strengths include the near complete dataset with only less than one 
tenth of all UK CHIC patients missing creatinine data. Regardless of these 
strengths, there are several study limitations. There may have been residual 
ascertainment bias because of incomplete creatinine data for UK CHIC patients 
or incomplete recording of HIV-positive diagnoses on renal databases. The 
proportion of black ethnic excluded from the analyses is substantially higher 
than other ethnic groups, 18% vs 6% respectively. Furthermore, some patients 
had died prior to cohort entry, were lost to follow-up or had dialysed less than 
three months. This meant that the incidence and prevalence of ESKD estimates 
may be have been affected. Finally, there may have been some confounding 
introduced by not including other comorbidities as competing risks e.g. 
diabetes, hypertension or cardiovascular disease.   
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2.5. Conclusions 
Over a 12 year study period there was an increasing number of HIV infected 
individuals with ESKD. By the end of the study period, approxiamtely half of 
those eligible for KT had received an allograft. The lack of HIV virological 
control was the primary reason that prevented KT in HIV infected patients. 
There were similar five-year survival rates for transplanted patients and those 
awaiting KT. Despite demonstrating no survival benefit of KT compared to 
dialysis, other benefits of KT were not measured in the current analysis e.g. 
quality of life measures, cardiovascular co-morbidities and health economics 
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Chapter 3. HIV Kidney Transplantation 
3.1. Introduction 
The previous chapter identifies the increasing need for kidney transplantation in 
HIV infected patients with end-stage kidney disease. With the increased patient 
survival following kidney transplantion this chapter looks to determine the 
feasibility of kidney transplantation in HIV infected individuals. Prior to 2010 
there was a paucity of data on the safety and efficacy of HIV kidney 
transplantation. In the transplant setting, HIV infection was also considered an 
absolute contraindication (Spital, 1998, EBPG, 2000, Bhagani et al., 2006). This 
was especially in the pre- and early HAART era when HIV disease was 
associated with a poor life expectancy. This was propagated by concerns of 
using immunosuppressive agents that could precipitate opportunistic infections 
or accelerate HIV disease. The advent of highly effective antiretroviral therapy 
dramatically improved the prognosis of HIV infected individuals (Ahuja et al., 
2000, Holkova et al., 2001, Garcia de Olalla et al., 2002, Hoffmann et al., 2004). 
HIV viral suppression, immune restoration and fewer opportunistic illnesses 
allowed for more stringent solid organ transplant criteria (Stock et al., 2001, 
Roland et al., 2003b, Roland and Stock, 2003). Subsequent published reports 
were able to demonstrate comparable patient survival rates among HIV infected 
transplant recipients compared to their HIV negative counterparts (Erice et al., 
1991, Ahuja et al., 2000, Roland et al., 2003a, Stock et al., 2003b, Toso et al., 
2003b, Abbott et al., 2004, Tan et al., 2004b, Bhagani et al., 2006). However, 
despite the positive findings there was still reluctance in the transplant 
community to consider HIV infected individuals for transplantation. A USA 
transplant survey showed 5 to 9 % in favour of HIV transplantation (Spital, 
1998, EBPG, 2000).  
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In 2005 guidelines were developed in the UK to advise clinicians on kidney 
transplantation in HIV infected patients (Bhagani et al., 2006). The guidelines 
HIV specific inclusion and exclusion criteria summarised in Table 13, Table 14 
and Table 15. The transplant criteria focused on HIV virological control, immune 
status, prior history or existing opportunistic infections and malignancies. The 
guidelines also recommended living donor transplantation rather than cadaveric 
donation. Where living donation was considered, it was advised that the donors 
be informed that “…HIV kidney transplantation was an ‘experimental’ or ‘new’ 
procedure and that the prognosis for graft and patient survival was considered 
significantly less than average.”(Bhagani et al., 2006).  
 
Table 13: HIV Disease Specific Kidney Transplantation Inclusion Criteria 
HIV Disease Specific Inclusion Criteria (Bhagani et al., 2006) 
 CD4  > 200 cells/microlitre for at least six months  
 Undetectable HIV viraemia (< 50 copies/ml) for at least 6 months  
 Demonstrable adherence and a stable HAART regimen for 6 months  
 Absence of AIDS defining illness following successful immune reconstitution 
after HAART 
 Available anti-retroviral treatment options in the future (this must be discussed 
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Table 14: HIV Disease Specific Kidney Transplantation Absolute Exclusion 
Criteria 
HIV Specific Absolute Exclusion Criteria (Bhagani et al., 2006) 
 Previous or current infections that are at high risk of re-activating with immune 
suppression: 
o Aspergillus – infection or colonisation 
o Any multi-resistant fungal infections 
o Cytomegalovirus (CMV) disease with any activity and unresponsive to 
first line therapy 
o Influenza or RSV infection within 30 days 
o Active bacterial infections 
o Mycobacterial infections – unless there is clear evidence of successful 
treatment 
 Advanced cardiopulmonary disease 
 History of neoplasms except solid tumours adequately treated and disease free 
survival documented for > five years  
 HTLV-1 positive patients 
 Patients with significant human papilloma virus (HPV) associated advanced 
cervical and anal intraepithelial neoplasia (CIN/AIN III) and carcinoma in situ 
need to be excluded 
 Hepatic cirrhosis (F4 fibrosis by Metavir if HBV/HCV co-infection) and evidence 
of active viral replication if HBV/HCV co-infected 
 Pregnancy 
 Continuing use of illicit recreational drugs 
 
Table 15: HIV Disease Specific Kidney Transplantation Exclusion Criteria 
HIV Disease Specific Exclusion Criteria (Bhagani et al., 2006) 
 Documented history of progressive multifocal leukoencephalopathy (PML) 
 Extracutaneous Kaposi’s Sarcoma (KS) 
 EBV and HHV8-related lymphoproliferative disorders (Lymphoma and multicentric 
Castleman’s syndrome) 
 CD4 count < 200 cells/microliter 
 Persistent HIV viraemia despite HAART 
 Continuing non-compliance with anti-retroviral therapy 
 More than three-class HIV resistance and lack of future HIV treatment options 
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Concerns of allograft rejection from early reports prompted transplant listing 
criteria such as HLA DR graft match and avoidance of expanded criteria donors 
for cadaveric donation. Pre-transplant assessment included vaccinations, 
cytology screening, cardiovascular and ophthalmology review for active CMV 
retinitis. There was no strict guidance on post-transplant immunosuppressant 
management however; the guidelines suggested that consideration be given to 
the risk of allograft rejection in the HIV infected population. The use of immune 
depleting agents such as polyclonal (e.g. antithymocyte globulin) or OKT3 
antibodies was contraindicated. However, interleukin-2 inhibitory agents (e.g. 
basiliximab, daclizumab) were permitted. Recommended maintenance 
immunosuppression was to include calcineurin inhibitor, mycophenolate and 
tapering glucocorticoids. A four week pre-transplant calcineurin inhibitor and 
mycophenolate dose finding trial as a strategy to manage drug interactions with 
certain antiretroviral drugs.   
Since the publication of the UK guidelines more than 5 years prior to initiating 
this study, there was a paucity of data to describe the outcomes of HIV kidney 
transplantation. Furthermore, there was an increasing demand for 
transplantation that in the general population improved patient survival and 
quality of life (Burra and De Bona, 2007, Landreneau et al., 2010, Rambod et 
al., 2011). The focus of this chapter is to describe the UK experience of kidney 
transplantation performed in HIV infected patients. 
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Purpose of study 
The main purpose of the UK HIV Kidney Transplant (UK HIV/KT) Study was to 
evaluate the clinical outcomes of kidney transplantation in HIV positive patients 
with fully suppressed HIV RNA levels. The specific aims of this study include: 
Primary aims 
Aim 1: An evaluation of kidney transplantation in HIV disease on patient survival 
Hypothesis (H0) 1.1: Kidney transplantation in HIV-positive patients has 
comparable patient survival outcomes to the general UK population. 
Aim 2: An evaluation of kidney transplantation in HIV disease on allograft 
survival 
Hypothesis (H0) 1.2: Kidney transplantation in HIV-positive patients has 
comparable graft survival outcomes to the general UK population. 
Aim 3: An evaluation of kidney transplantation in HIV disease on allograft 
rejection 
Hypothesis (H0) 1.3: Kidney transplantation in HIV-positive patients has 
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Secondary aims 
Aim 1: A description of host/donor baseline clinical characteristics as outlined in 
Table 16. 
Aim 2: Descriptive analyses of post-transplant allograft function in HIV/KT 
recipients in the first year of follow-up and at last clinic visit. 
Aim 3: Descriptive analyses of HIV management post-transplantation restricted 
to first year of follow-up and at last clinic visit. 
Aim 4: Descriptive analyses of post-transplant immunosuppressant drug 
therapy management restricted to the first year of follow-up and last clinic visit. 
Aim 5: Descriptive analyses of post-transplant management of pharmacokinetic 
drug interactions between specific antiretroviral and immunosuppressant drug 
interactions. 
Aim 6: A description of post-transplant complications in HIV/KT recipients. 
Specific complications include opportunistic infections, HIV disease 
progression, tumours and malignancies.   
Aim 7: Descriptive analysis of post-transplant changes in CD4 T cell counts in 
HIV/KT recipients restricted to first year of follow-up.  
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3.2. Methods 
The UK HIV/KT Study was initiated in 2009 by a steering committee made up of 
clinicians, statisticians, nurses and pharmacists (Appendix B). Data from this 
study were used for analyses presented in Chapter 3 to 6 of this thesis.  
Study Design 
This was a national, observational cohort study that included 40 Transplant and 
referring HIV centres (Appendix C).  
Ethics Approval 
The study was approved in 2009 by a Multicentre Research Ethics Committee 
(MREC) (reference 09/H1014/36) (Appendix D) and local centre NHS 
Research and Development (R&D) departments.   
Funding 
No Funding was received to conduct this study. 
Patient Enrolment 
Case ascertainment was determined by clinicians at the local centres. Clinicians 
were invited to participate in the study by advertisements placed through 
specialist clinical networks. Specialist clinical networks included: British HIV 
Association; HIV Pharmacy Association; British Transplant Society; and the UK 
Renal Pharmacy Group. Cases were also linked from the UK-CHIC database. 
Link data used were date of birth, ethnicity and date of transplant.  
Local databases and medical records were searched to identify patients coded 
as having a “positive HIV antibody test” and “kidney transplant”. Clinic lists and 
clinician recall were also used to identify cases.  
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Data were used from HIV positive individuals that had a kidney transplant up to 
31st December 2013. HIV/KT individuals were enrolled into the study if they met 
the inclusion criteria.  
 
Inclusion criteria 
1. Patients that acquired HIV prior to kidney transplantation 
2. Patients ≥ 18 years of age 
3. Patients that received a kidney transplant in the United Kingdom 
 
Exclusion criteria 
1. HIV+ patients that received a kidney transplant abroad 
2. Patients with no available data 
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Data Collection 
A standardised case reporting form (CRF) was designed following discussions 
with the UK HIV/KT study steering committee (Appendix E). The CRF 
contained information summarised in Table 16 and Table 17. CRFs were 
completed by the Transplant and HIV centre. Since the CRF contained 
demographic data to include patient initials, date of birth, ethnicity and gender; it 
was possible to cross-check for duplication. Each record from each of the 
centres were checked for missing information and merged into one form. During 
the merging process where there was conflicting information or inaccuracies, 
centres were contacted to verify information. Ambiguous or missing information 
on the final version of the form were also verified by local clinicians. The final 
‘clean’ dataset was then transferred to an electronic database. Data were stored 
on STATA statistical software database for analyses. Data quality control 
processes using STATA commands were also performed to identify missing or 
conflicting data. For example, if the date of the last clinic preceded the date of 
transplant. Any records that contained ambiguous information were excluded 
from analysis. 
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Table 16: Baseline Data Collected in the UK HIV Kidney Transplant Study 




HIV Background Information Date of HIV diagnosis  
HIV risk of acquisition 
Baseline HIV viral load 
AIDS diagnoses prior to KT  
Date of AIDS diagnoses prior to KT 
CD4 T cell count nadir prior to KT 
CD4 T cell count at KT 
Antiretroviral drug therapy history prior to 
KT 
Antiretroviral drug therapy start date 
Renal Background Information Aetiology of kidney disease 
Methods used to confirm kidney disease 
(e.g. biopsy, radiology, or other) 
If applicable, dialysis history 






History of tumors/neoplasms/malignancy 
Hepatitis B surface antigen (HBV DNA if 
applicable) 
Hepatitis C antibody (HCV RNA if 
applicable) 
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Table 17: Post-transplant Data Collected in the UK HIV Kidney Transplant Study 
Donor Information Age (if known) 
CMV IgG serology (if known) 
HLA mismatch status 
Allograft type – cadaveric or living donor 
Cold ischaemic time (if known) 
Warm ischaemic time (if known) 
Calculated Reaction Frequency (CRF)  
Allograft Outcomes Date of transplant 
Delayed graft function (if applicable) 
Allograft rejection (if applicable) 
Date of allograft rejection episodes  (if applicable) 
Details of allograft rejection treatment 
Details of graft loss (if applicable)  




Serial CD4 T cell counts 
Serial HIV viral load counts 
Serial serum creatinine measurements 
Serial Immunosuppressant drugconcentrations 




cART regimen information 
Immunosuppressant drug therapy information including doses and dosing intervals 
Chemoprophylaxis medications 
Other concomitant medications 
Post-transplant 
Complications 
Opportunistic infections and management 
Malignancies / Tumours  
Recipient Information Weight at KT 
Height 
Details on previous transplants (if applicable) 
Details of simultaneous transplants (e.g. SPK or SLK) 
Outcome at last visit (dead/alive/lost to follow-up/transfer of care) 
Cause of death (if applicable) 
 
The UK experience of the first 35 HIV/KT cases identified that had been transplanted up to 31/12/2011 has been 
published, (see Appendix A). Data analyses of the final dataset are represented in this chapter.
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Definitions 
Delayed graft function 
Delayed graft function was defined as the need for dialysis in the first week 
post-KT and whose grafts functioned thereafter. 
Primary non-graft function 
Patients whose grafts never functioned and required maintenance dialysis 
within 6 months of KT were considered to have primary allograft failure. 
Acute rejection 
Acute allograft rejection was defined as confirmed histopathological features of 
rejection requiring the use of enhanced immunosuppression to counter acute 
deteriorations in graft function within the first year post-KT. This was then 
referred to as ‘biopsy proven acute rejection’ (BPAR). Grading of the severity 
of acute rejection (e.g. Banff classification (Jennette, 2007)) was not evaluated 
due to non-standardised grading criteria between centres. Interpretation of the 
allograft rejection type was derived from histopathology reports as summarised 
in Table 18.  
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Table 18: Types of Allograft rejection 
Hyperacute allograft 
rejection 
Occurs within minutes or hours post-transplant in 
pre-sensitised recipients with circulating HLA, ABO 
or other alloantibody-to-donor endothelial surface 




Develops in the first few weeks post-transplant and 
declines after the first 3 months. Although, it can 
still occur at any time when immunosuppressive 
treatment is inadequate. ACR is T cell mediated 
usually due to reduced or stopping 
immunosuppression. ACR is classified into two 
types. Type I cellular rejection is histologically 
characterised by at least 25% of interstitial 
inflammation accompanied with moderate tubulitis. 
Type II is vascular in nature and is defined by the 
presence of mononuclear cells beneath the 
vascular endothelium (McKay and Steinberg, 2010). 
Antibody mediated 
rejection (also referred 
to as acute humoral 
rejection (Mauiyyedi et 
al., 2002)) 
 
Occurs at any time (days to years) post-transplant. 
Acute ABMR is defined by four criteria (Racusen et 
al., 2003, Takemoto et al., 2004, Colvin and Smith, 
2005):  
(i) Clinical evidence of acute graft dysfunction  
(ii) Histological evidence of acute tissue injury  
(iii) Immunopathological evidence for the action of 
antibodies i.e. positive staining for complement 
component 4d (C4d) deposited in peritubular 
capillaries or antibodies or C3 in arteries  
(iv) Serological evidence of HLA-specific antibodies 
or other donor-specific antibodies at the time of 
biopsy.  
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 Chronic rejection Chronic rejection is characterised by a chronic 
allograft dysfunction with a slow loss of function 
accompanied by proteinuria and hypertension. 
Histopathological findings are defined by 
fibrointimal thickening of arteries, interstitial fibrosis, 
tubular atrophy and lesions characteristic for 
chronic allograft nephropathy (CAN) (Joosten et al., 
2005). 
 
Inconclusive reports or reports of subclinical rejection were referred to local 
histopathologists and clinicians for interpretation. Information on the presence 
of polyomavirus (e.g. BK virus) or cytomegalovirus induced nephritis was also 
collected.  Calcineurin inhibitor nephrotoxicity was excluded due to lack of 
strong evidence to associate systemic blood concentrations of ciclosporin or 
tacrolimus to CNI induced nephrotoxicity (Naesens et al., 2009).   
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Steroid resistant rejection 
This is defined in literature as rejection that does not result in a decline in 
creatinine levels within 20% of baseline within 3 to 5 days after the last dose of 
intravenous methylprednisolone (Shinn et al., 1999, Bock, 2001). In another 
definition, steroid resistant rejection was considered if alternative treatment 
(e.g. antithymocyte globulin, IVIG, etc) was used  (Bock, 2001). In this study, 
steroid resistant rejection was defined as rejection that required more than one 
treatment course of high dose IVMP for the same rejection episode and/or 
resulted in the use of alternative immunosuppressive therapies (e.g. IVIG or 
ATG).  
Allograft function 
Allograft function was expressed as estimated glomerular filtration rate (eGFR) 
using IDMS-adjusted serum creatinine measurements and chronic kidney 
disease epidemiological collaboration (CKD-EPI) equations (Pugliese et al., 
2011).  
New onset of diabetes mellitus (NODAT) 
New onset of diabetes mellitus after transplant (NODAT) was defined as 
impaired glucose tolerance post-transplant requiring treatment with oral 
hypoglycaemic agents and/or insulin.  
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Cytomegalovirus reactivation 
The management and prevention of cytomegalovirus (CMV) infection varied 
between centres with valganciclovir prophylaxis administered for three months 
post-transplantation irrespective of donor/recipient CMV IgG status at some 
centres, while others prescribed CMV prophylaxis to those with mismatched 
CMV IgG serology i.e. CMV IgG negative recipient receiving an allograft from 
CMV IgG positive donors. Post-transplant CMV surveillance was routine for all 
patients with preemptive valganciclovir treatment if the CMV viral load 
exceeded 3-4000 copies/mL. 
HIV Disease Progression 
HIV disease progression was defined as persistent loss of virological control (> 
50 copies/ml) at any point post-transplantation with an accompanying AIDS 
defining illness (Schneider E, 2008, BHIVA et al., 2014). The CD4 T cell count 
was not taken into account as post-transplant immunosuppressant drug 
management included agents known to cause lymphocyte depletion.  
HIV Viral Load Blips 
A virological blip was defined as a detectable VL between 50 - 400 copies/mL, 
which is preceded and followed by an undetectable result (<50 copies/mL) 
without any change of antiretroviral therapy (BHIVA et al., 2014). 
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Statistical analysis 
All analyses were performed using Stata (version 12.1 StataCorp, Texas, 
USA). Baseline parameters were expressed as n (%), mean (SD) or median 
(IQR). Wilcoxon-ranksum test was used to compare medians; Z-tests were 
used to compare means; and two-sided chi-squared (X2) or Fisher’s exact test 
to compare proportions. Patient survival and graft survival were calculated 
using Kaplan-Meier estimates.  Cumulative hazard of first allograft rejection 
was calculated using Nelson-Aalen estimates. Cox proportional hazard 
analysis was performed to identify recipient/donor factors associated with 
allograft rejection.  
In order to account for the correlation of between repeated measures data, a 
multi-level mixed effect linear regression model was performed. The repeated 
measures data analysed included renal graft function measured at weeks 1, 2, 
4, 6, 8, 12, 24, 36, 52 and at last clinic visit. This mixed effect model was 
performed using unstructured within-subject covariance to examine whether 
there was a significant difference (p <0.05) in change of graft function from 
baseline to week 52 and last visit for patients that experienced allograft 
rejection compared to those that remained rejection free post-transplant. The 
association of allograft rejection and the slopes of graft function versus time 
post-transplant were also examined using mixed-effect models allowing for a 
random intercept and slope. Graft function was expressed as eGFR calculated 
using the CKDEPI equation. The analysis was performed using the xtmixed 
command in STATA (version 12.0). 
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3.3. Results 
Patient and donor characteristics 
97 HIV positive KT recipients were identified; 93 were transplanted in the UK 
up to 31st December 2013, the remaining four patients had received renal 
allografts in the USA and Sweden prior to 2005, Belgium and India (see 
Figure 14 for full patient disposition). Since 2005, there was a yearly increase 








Primary non-graft failure, 
N=4 
UK HIV/KT Cohort  
N=97 
Excluded  
HIV/KT Recipient ≤ 18 years, N=1 
HIV negative at KT, N=3 
Transplanted abroad, N=4 
No data, N=6 




Final dataset,  
N=78 
Figure 14: Patient disposition for UK HIV/KT cases transplanted up 
to 2013 
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Figure 15: UK HIV/KT by Transplant Year 
 
Graph represents number of HIV kidney transplant recipients stratified by year for period 
covering up to 2013. 
 
There were 14 patients that did not meet the study criteria and were therefore 
excluded from further analyses. Of those excluded, there was one child (11 
years of age), three adults that acquired HIV post-transplantation, four were 
transplanted abroad (India, Belgium, USA and Berlin) and the remaining six 
patients had no data available. The six patients were transplanted at Oxford 
Radcliffe hospital (n=4), Birmingham (n=1) and Manchester (n=1). All were 
referrals from external HIV centers (unknown) and received post-transplant 
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Of those that met the study inclusion criteria (n=83), one patient experienced a 
fatal cardiac arrest immediately post-KT and 4 had primary non-graft function. 
In the final dataset (n=78), majority were male (67%) and of black ethnicity 
(74%) with a history of severe immunodeficiency (Table 19). At KT all but one 
patient had fully suppressed HIV RNA levels. This patient at KT listing, 8 
months prior, had a wild type virus being managed with a dual cART regimen 
(DRV/r plus ETV) and undetectable HIV RNA levels (<40 cps/mL). Clinicians 
suspected non-adherence as the cause of virological failure (3544 copies/mL). 
Virological control was achieved post-KT on resuming regular cART regimen. 
The median nadir CD4 cell count pre-KT was 90 (40, 171) cells/mm3, and 44% 
of patients had experienced at least one AIDS defining illness. Of note, two 
patients had visceral Kaposi sarcoma prior to KT and one patient had active 
hepatitis C co-infection at the time of KT. HIVAN was the commonest kidney 
diagnosis (52%), other diagnoses are summarized in Table 19. All patients 
were stable on cART at KT. The median (IQR) CD4 cell count at KT was 366 
(277, 516) cells/mm3; 6 patients (8%) had median (IQR) CD4 cell counts <200 
(median 131, range 76-194) cells/mm3. None of the patients interrupted cART 
in the peri-operative period; 22 (29%) received a pre-transplant trial of 
immunosuppressive therapy with concomitant monitoring of calcineurin 
inhibitor drug concentrations to guide post-KT dosing. The median (IQR) age 
of the donors was 45 (35, 56) years, 44% of allografts were HLA-DR matched, 
27 donors (35%) had a known positive CMV IgG serology and 26 patients 
(34%) received a kidney from a live donor (Table 20). All patients were first 
time kidney transplant recipients, none were re-transplants,    
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Table 19: Baseline HIV Kidney Transplant Recipient Characteristics  
Data available for *n=72; **n=76; ₺n=77; ‡n=75; †n=74; ¶n=71 
Abbreviations: MSM, men who have sex with men; HBsAg, hepatitis B surface antigen; 
HCV Ab, hepatitis C antibody; CDC-C, CDC classification system for HIV-infected adults and adolescents stage C;  




Table 20: HIV Kidney Transplant - Donor characteristics 
 N=78 
  
Donor age (years), median (IQR)* 45 (35, 56) 














HLA mismatch, median (IQR) * 3 (2, 3) 
HLA-DR matched 27 (44) 
Recipient/Donor/CMV IgG status  
      CMV mismatch (R-D+), N (%)  4 (5) 
      CMV mismatch (R-Du), N (%)  2 (3) 
  
Abbreviations: HLA, human leucocyte antigen; CMV, cytomegalovirus; IgG, immunoglobulin 
G; R-D+, recipient negative, donor positive; R-Du, recipient negative, donor unknown status;  
ABOi, ABO incompatible. 
* Data available for *n=56; **n=77; ₺n=63 
Characteristic N=78 
  
Age (years), median (IQR) 45 (38, 51) 
Male, N (%) 52 (67) 
Black ethnicity, N (%) 57 (74) 
Risk HIV acquisition, N (%)*  
     Heterosexual 54 (75) 
     MSM 17 (24) 
Time since HIV diagnosis (years), median (IQR)** 8 (7, 11) 
AIDS (CDC-C), N (%)₺  
     Mycobacterial infection 15 (19) 
     Cytomegalovirus (end-organ) 8 (10) 
     Kaposi sarcoma 3 (4) 
CD4 cell count (cells/mm3), median (IQR)  
     At KT₺ 365 (277, 516) 
     Nadir pre-KT† 91 (39, 169) 
HIV RNA <50 (copies/ml), N (%) 77 (99) 
Viral Hepatitis, N (%)  
     HBsAg positive₺ 10 (13) 
     HCV Ab / HCV RNA positive‡ 4 (5) 
Time on cART (years), median (IQR)† 7 (4, 10) 
Class of drugs in cART regimen, N (%)  
     PI-containing cART 30 (38) 
     PI-sparing cART 48 (62) 
Pre-KT Dialysis (HD, PD)¶ 65 (92) 
     Duration (years), median (IQR) 5 (3, 7) 
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Patient and graft survival 
The study participants were followed for a median (IQR) of 31 (19, 55) months, 
and vital status at 12 months was available for 70. Four additional patients 
died, three with functioning allografts and one with complete graft failure. 
Deaths were due to pneumonia seven months after receipt of anti-thymocyte 
globulin (ATG) as anti-rejection therapy, cardiac failure two years after re-
initiation of dialysis, liver failure secondary to hepatitis C and multi-organ 
failure, microvesicular hepatic steatosis and severe lactic acidosis suspected 
to be due to drug toxicity. Patient survival at 1, 3 and 5 years post-KT was 
97·4%, 94·9% and 90.1% respectively (see Figure 16a); the mortality rate was 
1.5 (95% CI 0.6, 4.0) per 100 person-years of follow up. Graft survival at 1, 3 
and 5 years was 97.4%, 90.2% and 82.3% respectively (see Figure 16b). 
 
Figure 16: Patient and Graft Survival after HIV Kidney Transplantation 
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(b) Patient Survival after HIV Kidney Transplantation by Donor Type 
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(d) Graft Survival after HIV Kidney Transplantation by Donor Type 
 
 
Graph represents Kaplan-Meier estimates of overall patient (a) and graft (d) 
survival; patient (c) and graft (b) survival stratified by donor type  of HIV kidney 
transplant recipients (n=78) transplanted up to 2013 with follow-up until 31st 
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Post-transplant Immunosuppression 
All patients received induction immunosuppressive therapy consisting of high 
dose corticosteroids (IVMP, intravenous methylprednisolone). Excluding 2 
patients that received IVMP only and one ABO incompatible transplant patient, 
75 (96%) received additional inductive IS therapies to include monoclonal 
antibodies – anti-CD25 (basiliximab/daclizumab), n=73 and anti-CD52 
(alemtuzumab), n=2. The ABOi transplant received pre-transplant conditioning 
with anti-CD20 (rituximab) plus plasma exchange. 76 (97%) patients received 
triple maintenance immunosuppressive therapy consisting of a calcineurin 
inhibitor, mycophenolate or azathioprine, and corticosteroid. The remaining two 
patients were managed with a CNI-minimisation protocol that included induction 
therapy with alemtuzumab followed by low dose tacrolimus monotherapy (target 
Tac concentrations 5 to 8 ng/mL). The CNI doses used in the first year post-KT, 
the CNI concentrations attained, and the relevant target ranges are displayed in 
Table 21.  
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 Ct (ng/ml) b Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml) c Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml)  Dose (mg/kg/day) 
1 375±497 496±610 1.3±1.7 184±96 9.6±4.5 9.8±9.1 19.2±13.0a 0.0194±0.0225 6.3±2.9a 0.13±0.09 
2 333±291 402±361 0.8±0.6 233±88 11.0±4.3 10.0±5.9 15.1±8.4a 0.0025±0.0017 8.2±3.3a 0.18±0.11 
4 245±93 237±76 0.7±0.5 259±119 10.6±4.5 12.3±11.2 19.5±21.3a 0.0024±0.0034 10.0±3.6a 0.24±0.11 
6 253±89 255±86 0.5±0.2 250±99 10.2±4.5 10.6±5.6 12.4±9.4a 0.0013±0.0006 10.0±3.5a 0.024±0.12 
8 236±69 224±75 0.4±0.1 260±53 11.6±4.1 9.2±3.2 8.7±4.1 0.0013±0.0010 9.4±2.9 0.22±0.11 
12 231±61 238±53 0.4±0.2 217±53 10.7±4.4 9.4±3.6 10.8±5.2 0.0016±0.0020 8.9±2.8 0.20±0.11 
24 180±45 186±30 0.4±0.2 171±64 6.6±2.5 9.7±4.1 8.9±4.4 0.0014±0.0013 10.0±4.0 0.18±0.09 
36 165±41 167±46 0.4±0.2 163±36 6.5±2.0 8.1±3.3 8.1±4.0 0.0015±0.0013 8.1±3.1 0.18±0.09 
52 129±36 142±42 0.4±0.2 119±32 6.4±2.0 9.2±4.4 7.0±1.6 0.0015±0.0015 9.9±4.8 0.14±0.10 
a P <0.05 (PI-containing cART vs. PI-sparing cART); b Target range: 200-350 ng/mL during weeks 1-12, 100 – 250 ng/mL thereafter; c Target range: 8-15 ng/mL during weeks 1-12, 5-10 ng/mL 
thereafter. 
 
Table 21: Mean (+/- SD) Calcineurin Inhibitor Doses & Mean (+/-SD) Whole Blood Concentrations in HIV Infected Kidney Transplant Recipients 
- 129 - 
Allograft rejection  
28 patients (36%) experienced allograft rejection within 12 months of KT. The 
cumulative hazard (95% CI) of AR in the first year post-KT was 43% (30%, 
64%) (see Figure 17). The median (IQR) interval between KT and the first AR 
episode was 2.6 (0.5, 5.9) months. The overall incidence rate of AR during the 
first year post-KT was 4.3 (95% CI 3.0, 6.2) episodes per 100 person-months, 
and was similar for patients who received PI-containing vs. PI-sparing cART 
(5.6 [95% CI 3.3, 9.7] vs. 3.5 [2.1, 5.9] per 100 person-months; p=0·10) and for 
those who received tacrolimus vs. ciclosporin-based maintenance 
immunosuppressive therapy at KT (2.2 [1.2, 4.1] vs. 9.1 [5.7, 14.4] per 100 
person-months; p=0·0001). Factors associated with the first AR episode in the 
first 12 months post-KT are described in Chapter 4.  24 patients received pulsed 
corticosteroids; other or additional treatment interventions to combat AR 
included intravenous immunoglobulin (IVIG, n=7), plasma exchange (n=6), anti-
thymocyte globulin (ATG, n=4), rituximab (n=1), switching CNI choice (n=11, 
CsA to Tac switch), and augmentation of baseline immunosuppression (n=8).  
 
  
- 130 - 
Figure 17: Allograft Rejection in HIV Kidney Transplant Recipients 
 
Graph representing Nelson-Aalen cumulative hazard of first acute allograft 
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Allograft function 
Primary non-graft function occurred in 4 patients (5%); 3 received an allograft 
from a deceased donor and 1 from a living donor. Delayed graft function was 
encountered in 16 patients (21%), all of whom had received a kidney from 
deceased donors. The overall median (IQR) EGFR estimated by CKD-EPI 
equation at 1 year and at last clinic visit was 51 (34, 73) and 46 (35, 63) ml/min 
per 1.73 m2 of body surface area. The overall median (IQR) change in eGFR at 
1 year and at last clinic visit compared to value at month 3 post-KT was -5.5 (-
16, 7.9) and -4 (-10.5, 9.8) ml/min/1.73m2 respectively, (p=0.35). There was a 
significant decline in graft function in those recipients that experienced acute 
allograft rejection in the first year post-KT compared to those that remained 
rejection free, (see Figure 18). At 1 year and at the last clinic visit respectively, 
the median (IQR) EGFR was 38 (27, 48) and 36 (21, 45) ml/min per 1.73 m2 of 
body surface area for the AR group and 60 (47, 83) and 54 (39, 66) ml/min per 
1.73 m2 of body surface area for those who remained rejection free, (AR vs No 
AR at 1 year p=0.0002; last clinic visit p=0.0004). At the last clinic visit, there 
was a significantly higher proportion of patients with an EGFR <30 ml/min per 
1.73 m2 (CKD Stage 4) and <15 ml/min per 1.73 m2 (CKD Stage 5) in the AR 
group compared to No AR group, (X2 36% (n=10) vs 8% (n=4) p=0.002; 14% 
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Figure 18: Graft Function Post-Transplantation Stratified By Acute 
Rejection at 1 Year 
 
Graph representing changes in graft function, according to acute allograft rejection status at 1 
year and at last clinic visit. This is restricted to first AR episode at 1 year. The median (IQR) 
CKD-EPI EGFR are plotted over time. The red lines represent the staging of chronic kidney 
disease (CKD). ) .  
In a multi-level mixed effects model, the eGFR was somewhat lower in those 
that experienced an allograft rejection over the first year post-transplant 
compared to those that remained rejection free (-8.3 (95CI -17.9, 1.26) 
ml/min/1.732 lower at baseline, p=0.09). The change in eGFR over the first year 
post-transplant was significantly different between groups (interaction p=0.003), 
Figure 19. A slight increase in graft function was observed from baseline to 1 
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whereas in the rejection free group there was a modest decline in eGFR over 
time (-0.06 (95CI -0.18, +0.07) ml/min/1.732). 
Figure 19: Predicted Slopes of estimated Graft Function (eGFR) stratified 
a priori by Allograft Rejection with 95% CIs  
 
Including eGFR at last clinic visit we similarly observed that At last clinic visit, 
eGFR was significantly lower in the AR group compared to baseline for those 
that experienced a rejection episode (-12.7 (95CI -21.8, -3.7) ml/min/1.732 lower 
at baseline, p=0.006). The slopes of eGFR versus time for AR vs AR free 
groups were similar (interaction p=0.20). Further, both groups demonstrated a 
somewhat modest decline in eGFR over time, (AR free -0.03 (95CI -0.06,  
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Post-transplant Complications 
HIV Virological Control 
Throughout the follow-up period post KT, HIV infection remained fully suppressed in all patients; with transient HIV 
viraemia (HIV RNA blips 50-139 copies/mL) observed in 6 participants, (See Table 22). At baseline, HIVAN was the 
most common cause of kidney disease (n=4); majority received allografts from deceased donors (n=4) and were 
taking a PI-containing cART regimen (n=5) and ciclosporin based IS therapy (n=5).  Only one recipient did not 
experience post-KT complications (rejection, infections or tumors/neoplasms). At last clinic visit, patient 1 (see Table 
22) had nephrotic syndrome which on biopsy showed focal segmental glomerulosclerosis (FSGS) suspected to be 
secondary to sirolimus, diabetic glomerulosclerosis (although had excellent diabetic control) or HIVAN. Chronic 
antibody mediated rejection with class 1 donor specific antibodies was suspected in this recipient. A switch to 
sirolimus had been made 4 years prior when a biopsy revealed chronic allograft nephropathy. All other recipients had 
an unremarkable review at last clinic visit. Antiretroviral resistance data were not available for any of the recipients.  
 
Table 22: Summary of HIV+ Patients that Experienced Viral Load Blips Post-Transplantation 
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1,249,515 288 453 (332) 
 
 












14,000 830 830 (720) ABC/3TC/LPV/RTV CsA Yes Yes 
(CMV 
Infection) 
AR, allograft rejection; CsA, ciclosporin; ABC, abacavir; 3TC, lamivudine; EFV, efavirenz; FTC, emtracitabine; TDF, tenofovir; LPV/RTV, ritonavir boosted lopinavir; DRV/RTV, 
ritonavir boosted ritonavir; RAL, Raltegravir; ATZ/RTV, ritonavir boosted atazanavir; AZT, zidovudine; U, unknown; HSV, Herpes simplex virus; CMV, cytomegalovirus; UTIs, 
urinary tract infections; VL, viral load; c/mL, copies/mL   
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During the follow-up period, there was overall good immunological status with 
43% (n=251) of all available CD4 T cell counts > 500 cells/mm3, (see Figure 
20). The overall median (IQR) CD4+ T cell count at 1 year after transplantation 
was 410 (225, 608) cells/mm3. The median change of the CD4+ T cell count 
from baseline to 1 year post-KT was significantly greater for those that received 
lymphocyte depleting inductive therapies (i.e. alemtuzumab) compared to non-
depleting agents (i.e. anti-CD25 monoclonal antibodies) (-296 and -18 
cells/mm3 respectively, p=0.05).  Post-transplant nadirs of >200, 100-199, 50-99 
and <50 cells/mm3 encountered in 63%, 16%, 7% and 11% of patients 
respectively (n=62). 
Figure 20: Post-Transplant CD4 T-Cell Counts 
  
Graph representing all available Post-HIV/KT CD4 T cell Counts from 62 recipients. Proportions 
represent counts from each category as follows: 43%, >500 cells/mm3; 20%, 350 – 500 
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Opportunistic Infection 
The occurrence of opportunistic infections was infrequent (41%, n=29). Post-
transplantation, all recipients received chemoprophylaxis against pneumocysitis 
jirovecii (PCP) and 45% (n=32) received CMV prophylaxis. CMV prophylaxis 
with valganciclovir was administered for 3 months post-KT to recipients with 
CMV donor/recipient mismatch or unknown IgG serology. All other recipients 
had CMV surveillance with preemptive therapy. PCP occurred in one patient 
and CMV in 20 patients (26%); none had extra-renal tissue-invasive CMV 
disease. Treatment of CMV viraemia included reduction of immunosuppressive 
therapy, discontinuing mycophenolate or treatment with valganciclovir when 
CMV PCR > 3000 copies/mL. BK viraemia occurred in 8 patients with 3 patients 
having histological evidence of BK nephropathy; all patients were managed with 
reductions in immunosuppressive therapy. Epstein-Barr virus (EBV) was 
detected in blood of 5 patients although; there was one case of 
immunodeficiency associated EBV positive lymphoproliferative disorder of 
diffuse large B-cell lymphoma (DLBCL) subtype confirmed on biopsy 4 years 
post-KT. This patient having waited 8 years on haemodialysis for a kidney 
transplant, experienced severe central nervous system CMV and HSV 
reactivation with associated encephalitis 8 months post-KT. This was resolved 
with valganciclovir treatment and switching the choice of calcineurin inhibitor 
from ciclosporin to tacrolimus and the addition of maraviroc to his antiretroviral 
therapy combination (abacavir, tenofovir, lopinavir/ritonavir). A further 3 years 
after, a biopsy histology of the colon showed features of immunodeficiency 
associated EBV positive lymphoproliferative disorder (DLBCL).  
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The patient’s DLBCL was managed with 4 cycles of R-CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone) and a few doses of 
rituximab monotherapy. At the last clinic visit (01/2016), the patient had lost his 
graft and returned to maintenance haemodialysis.  
 
Herpes simplex virus infection occurred in 5 patients; 4 had genital HSV treated 
with aciclovir. One case of HSV encephalitis that required critical care 
management, treatment with aciclovir and the addition of maraviroc to cART 
regimen (abacavir/tenofovir/lopinavir/ritonavir). One patient developed 
oesophageal candidosis treated with an antifungal. 
 
There were two cases of Kaposi Sarcoma (KS). The first case of cutaneous KS 
managed with docetaxel and a change in immunosuppressive therapy from 
tacrolimus to sirolimus, resulting in complete resolution. The second case was 
of KS lesions on the dorsal of left and right foot that was human herpesvirus 
type 8 (HHV8) positive; treatment included inclusion of sirolimus, active 
monitoring and consideration for radiotherapy if lesion was progressive.  
 
Tumors/Neoplasms 
Apart from the two cases of KS and the case of PLTD, there were four 
tumors/neoplasms reported. Two cases were of Bowen’s disease, one basal 
cell carcinoma and one lentiginous junctional melanoma. Treatment for all 
cases involved surgical excision of the affected areas.   
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Clinical course of patients who did not meet the 2005 criteria for kidney 
transplantation 
There were 6 patients with CD4 T cell count below 200 cells/mm3; 3 did not 
experience opportunistic infections or HIV disease progression; 3 developed 
AR, and all had functioning grafts with the most recent eGFR ranging between 
28 and 72 mL/min/1.73m2.  
There patient with a detectable HIV RNA viral load at KT (3544 copies/mL) did 
not experience any allograft rejection although developed renal artery stenosis, 
CMV viraemia and NODAT as a consequence of high tacrolimus 
concentrations. The patient was switched to a PI-sparing regimen 
(Etravirine/Raltegravir/lamivudine) and at last clinic visit eGFR was 64 
mL/min/1.73m2 and HIV RNA < 50copies/mL. 
The patient with a history of extra-cutaneous (pulmonary and hepatic) Kaposi 
sarcoma did not experience recurrent KS. Two of the four patients with hepatitis 
C were viraemic (HCV RNA > 700,000 IU/mL). One of the patients with with 
replicating HCV (genotype 1b) acquired HCV infection while awaiting 
transplantation; he was retrospectively diagnosed with HCV and had cirrhosis 
on liver biopsy 18 months post-KT. This patient died almost 3 years post-
transplant from liver failure; the HCV RNA viral load at the time was 1, 227, 842 
copies/mL.  
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Review at last clinic visit 
The median follow-up for the entire cohort was 2.6 (IQR 1.6, 4.6) years. At the 
last clinic visit, almost half of patients (n=37) were on triple immunosuppressant 
drug therapy agents; 46% (n=35) were on dual IS therapy and 63% (n=48) 
included corticosteroids. The overall median eGFR was 46 (35, 63) ml/min per 
1.73 m2 of body surface area (CKD Stage 3). Blood pressure control was 
slightly suboptimal with median systolic 138 (125, 147) and diastolic 84 (76, 90) 
mmHg (Reference systolic 130 and diastolic 80 mmHg (Baker et al., 2011)). 
Majority of patients 89% (n=69) were on a median of 2 anti-hypertensives. 
Antihypertensives included: calcium channel blockers (n=30); angiotensin 
converting enzyme inhibitors (n=18); angiotensin II receptor antagonist (n=20); 
betablockers (n=24); alphablockers (n=25); and diuretics (n=8). When stratified 
by CNI choice at last clinic visit, blood pressure control was good and similar 
between groups with patients on ciclosporin vs. tacrolimus achieving a median 
systolic blood pressure of 138 (123, 144) vs. 137 (127, 150) mmHg (p=0.85) 
and diastolic blood pressure of 80 (74, 85) vs. 85 (75,90) mmHg (p=0.17) 
respectively.  
 
New onset of diabetes after transplantation (NODAT) was reported in 4 patients 
all of whom were taking Tac based IS therapy and PI-sparing cART. Two 
female recipients had three successful pregnancies through natural conception; 
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One patient, 62 years of age developed a non ST-segment elevation myocardial 
infarction (NSTEMI) during plasma exchange therapy for antibody mediated 
rejection. This patient had a history of endocarditis at 12 years of age. The 
patient underwent percutaneous coronary intervention (PCI) however required a 
second PCI after 6 months for in-stent restenosis (ISR) despite dual antiplatelet 
therapy (aspirin plus clopidogrel).  
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3.4. Discussion 
This is the first study in the United Kingdom to substantiate the feasibility of 
kidney transplantation in HIV infected individuals with fully suppressed HIV RNA 
levels maintained on cART. Outcomes from this national observation cohort 
study reports favorable patient and graft survival, low incidence of post-
transplant complications albeit; with a high incidence of delayed graft function 
(21%) and acute allograft rejection with almost one third of first AR episodes 
occurring within the first 3 months post-KT. Findings from this carefully selected 
HIV+ cohort provide further support for the use of KT in HIV positive patients. 
 
Patient and Graft Survival 
In the UK general population (UKT), patient survival post-kidney transplantation 
at 1, 2, and 5 years is 95-99%, 93-98% and 86-95% respectively. Graft survival 
at 1, 2, and 5 years respectively is 91-97%, 90-95% and 85-92% (NHSBT, 
2015). These rates were similar to the UK HIV/KT cohort (at 1, 2, 5 years 
respectively, patient survival 97.4%, 97.4% and 90.1% vs graft survival 97.4%, 
97.4% and 82.3%). This accepts the first hypotheses (H0 1.1 and H0 1.2) that 
those kidney transplantation outcomes in HIV infection were comparable in 
terms of patient and graft survival compared to the general UK population. At 
baseline, the current cohort was typically young (median age 45 years), male 
(67%) and with one third having received an allograft from a living donor. 
Similarly, in the general UK KT population recipients are young (~30% aged 35-
49 years), male (~60%) with 34% of allografts from living donors (NHSBT, 
2015). There was a higher proportion of patients of black ethnicity in the UK 
HIV/KT cohort in comparison to the general population, 74% vs. 8% (NHSBT, 
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2015). This difference in ethnic proportions has been reflected in the transplant 
waiting times where HIV+ patients had longer waiting times (median 5 years) 
compared to the general population (median 2.7 years (NHSBT, 2015)). An 
analysis of KT recipients of black ethnicity alone, the median transplant waiting 
time for HIV+ patients was 6 years compared to 3.4 years in UKT population 
(NHSBT, 2015). Although, this is representative of the low ethnic minority donor 
pool (NHSBT, 2015). What was encouraging was the increasing uptake of 
kidney transplantation in the HIV infected population over the study period (see 
Figure 15). Although not ascertained in the present cohort, the long waiting 
times on permanent renal replacement therapy in the HIV+ population may 
have impacted the patient and graft survival as is suggested in the literature for 
HIV negative KT recipients (Meier-Kriesche et al., 2000, Meier-Kriesche and 
Kaplan, 2002). In a HIV negative KT study, the 5 year allograft survival of pre-
emptive transplantation observed was 85% compared to 75% in those who 
were on dialysis 3 to 4 years prior to transplantation (Meier-Kriesche et al., 
2000).    
 
The United States of America have reported similar outcomes in HIV/KT 
recipients. Patient and graft survival rates respectively were 94.6%, 90.4% at 1 
year and 88.2%, 73.7% at 3 years (n=150) (Stock et al., 2010a). The careful 
selection of HIV+ individuals for transplantation has been implicated in the 
favorable outcomes observed (Stock et al., 2001, Roland and Stock, 2003, 
Stock et al., 2003b, Stock and Roland, 2007, Stock et al., 2010a). Chapter 1 of 
this thesis discusses the early experience of kidney transplantation both in the 
pre-HAART and early HAART era. A review of the literature during this period 
(pre-2005) highlighted the association of HIV disease factors (i.e. CD4+ T cell 
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counts, HIV RNA levels and history AIDS defining illnesses) with adverse post-
KT outcomes (Roland and Stock, 2003). There was consensus from the early 
pilot studies(Stock et al., 2003a), US NIH study (Stock et al., 2010a) and UK 
guidelines (Bhagani et al., 2006) that HIV/ESKD selection criteria to include 
CD4+ T cell counts >200 cells/mm3, undetectable HIV RNA levels 
(<50copies/mL) and no prior history of opportunistic infections. Although, 
improvement with opportunistic infection prophylaxis and anecdotal evidence of 
ineligible HIV+ patients with histories of many opportunistic diseases having no 
recurrences post-KT (Roland, 2004); expanded the selection criteria. One report 
described 2 patients that were ineligible because of history of pneumocystis 
jiroveci pneumonia and CMV disease in one case and history of Kaposi’s 
sarcoma and CMV disease in another patient both with no recurrence of OI 
diseases (Roland, 2004). In the UK, emphasis was placed on AIDS defining 
illnesses following successful immune reconstitution with cART and history of 
neoplasms/infections that were considered high risk of re-activating with 
immunosuppression (Bhagani et al., 2006). In the current report, patients (n=6) 
were considered ineligible because of: CD4+ cell counts < 200cells/mm3, 
although with undetectable HIV RNA levels; detectable HIV (VL >3544 
copies/mL); and history of extra-cutaneous (pulmonary and hepatic) Kaposi 
sarcoma, had positive post-KT outcomes and maintained undetectable HIV 
RNA levels. However, severe/progressive hepatitis C co-infection resulted in a 
fatality in one patient. HCV infection, although not a contraindication in the HIV 
negative population, is associated with increased morbidity and mortality post-
KT (Baid-Agrawal et al., 2014). Outcomes from the US NIH study (Stock et al., 
2010a) were significantly worse for HCV/HIV co-infected KT recipients with 
patient/graft survival rates of 88.3%/88.6% at 1 year respectively compared to 
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HCV negative HIV/KT recipients, 96.1%/90.1% at 1 year. Furthermore, 
HCV/HIV co-infection was associated with significantly higher rates of serious 
infections (KM estimates per follow-up year 0.8 vs. 0.5, logrank P = 0.02). 
However, the emergence of newer anti-HCV therapies, direct acting antivirals 
(DAAs), that could potentially cure and completely eradicate HCV may possibly 
improve outcomes for HCV/HIV KT recipients. 
 
Allograft outcomes  
Allograft outcomes were complicated by the high rejection rates, almost double 
those noted in UK general population, 36% vs 12-24% at 1 year respectively 
(Summers et al., 2010, Summers et al., 2013). This rejects the third hypothesis 
(H0 1.3) that kidney transplantation in HIV-positive patients has associated 
allograft rejection rates comparable to the general UK population. When 
compared to the USA study of HIV/KT, our time to first AR rates at 1 year were 
similar, 36 vs 31% respectively (Stock et al., 2010a). The reason for this high 
incidence of rejection has not been fully elucidated however, what has been 
postulated is a combination of HIV associated immune reactivation and sub-
optimal immunosuppression (Trullas et al., 2005, Roland et al., 2008b, Stock et 
al., 2010b, Canaud et al., 2014). Analyses of the factors associated with AR in 
this cohort are presented and discussed extensively in Chapter 4.   
In the present analysis, there was no donor/recipient factor found to be 
associated with DGF development (data not shown). Mazuecos et al (2013) in 
an observational study that included HIV negative controls, observed a high 
incidence of DGF in the HIV+ population (52% vs. 21%, P < 0.001). The rate of 
DGF in the HIV/KT population has been variable; Stock et al (2010) observed a 
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rate of 46% (n=150), Roland et al (2008) 50% (n=18), Touzot et al (2010) 28% 
(n=27), Panarey (2015) 46% (n=39), Kershaw et al (2015) 52% (n=33), Kucirka 
et al (2015) 30-40% (n=315). A high rate of DGF among HIV/KT recipients 
could be multifactorial to include donor characteristics, quality of the allograft 
and recipient characteristics. Although multiple risk factors for developing DGF 
have not been accounted for in this present analysis such as cold ischaemic 
time (CIT), anastomosis time, donor age and deceased donor allograft type i.e. 
after cardiac or brain death, donor body mass index (Irish et al., 2010, Doshi et 
al., 2011, Weissenbacher et al., 2012, Marzouk et al., 2013, Mazuecos et al., 
2013), there are other plausible HIV independent risk contributing factors. 
Mazuecos et al (2013) multivariable analyses identified HIV infection, HCV co-
infection and CIT as predisposing factors to developing DGF in HIV/KT 
recipients. Prolonged duration of pre-transplant dialysis has also been 
suggested to predispose HIV/KT recipients to DGF (Schweitzer et al., 1998, 
Panel de expertos del Grupo de Estudio de Sida y del Plan Nacional sobre el, 
2010, Doshi et al., 2011, Weissenbacher et al., 2012). Vascular calcification 
frequently observed in patients on prolonged dialysis is thought to delay the 
anastomosis time thereby increasing the risk of developing DGF post-KT. 
Furthermore, persistent residual kidney function in patients on short term 
dialysis may promote early graft function (Schweitzer et al., 1998, Vercauteren 
et al., 2003).  Prolonged pre-transplant dialysis time is common among 
HIV/ESKD especially in those with co-infection (e.g. HCV) (Moutinho et al., 
2005, Fabrizi, 2013, Mazuecos et al., 2013). In the UK general population, 
differences in DGF rates by deceased donor type i.e. heart beating or non-heart 
beating donor has been observed; 24% compared to 48% in the latter group. 
Similarly, there was a low incidence of primary non-graft function (PGNF) 
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observed in the UK HIV/KT cohort. PGNF in the HIV negative kidney transplant 
population have been observed similar rates, 4.9 – 5.7% HIV- vs 5% in current 
HIV+ cohort (Weber et al., 2002b, BTS, 2005). 
Although the post-transplant course of allograft function was significantly 
worsened by experiencing allograft rejection. These findings were not dissimilar 
to the USA HIV/KT NIH study that reported eGFR at 1 year of (51.8 AR vs. 60.5 
no AR ml per minute per 1.73 m2, P=0.05) although, the AR group seemed to 
have significantly worse outcomes (Stock et al., 2010a). Outcomes were also 
comparable to the general population. In the PORT (Patient Outcomes in Renal 
Transplantation) study, a multinational global study (n=13,671), majority of 
patients (55 to 60%) had stage 3 CKD after 1 year post-transplant (Kasiske et 
al., 2011). Graft function was worsened by allograft rejection at 1 year. The rate 
of AR was 23% (n=3145), of whom 53% had an eGFR <44 ml per minute per 
1.73 m2 at 1 year. In a recent UK national kidney transplant trial (n=852) 
reported graft function at 6 months post-transplant of eGFR 49.8 – 50.1 ml per 




Opportunistic infections (OI) overall were uncommon in the present HIV/KT 
dataset (41%). CMV infection was the most common OI occurring in a quarter 
of the HIV/KT recipients. In solid organ transplantation, CMV infection can occur 
as a primary or latent viral infection. CMV disease is associated with increased 
morbidity and mortality owing to the detrimental effects to the allograft and other 
native organ (Rubin, 1989). CMV disease can occur in the retina, lung, 
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gastrointestinal tract, central nervous system, liver, biliary tract, heart and 
adrenal glands (Torres-Madriz and Boucher, 2008, Nelson et al., 2011). It is the 
most commonly occurring OI in the general solid organ transplant population 
with 8 - 39% overall and 8% among kidney transplant recipients expected to 
experience symptomatic CMV infection (Patel et al., 1996, BTS, 2011). The 
prevalence of kidney transplant recipients considered at risk of developing CMV 
disease has been estimated to be 30% in the UK (Newstead, 1995). Although, 
this rate is influenced by the matching of the donor/recipient CMV IgG serology 
and the multiple strains of CMV (Grundy et al., 1988) (BTS, 2011). CMV 
seroprevalence among the general adult population is approximately 70 to 90% 
(Kasiske et al., 2010, Kuo et al., 2010, Requiao-Moura et al., 2015). The 
distribution of donor/recipient CMV IgG serology matching in the general KT 
population has been reported as follows: D+/R+, 47.7%, D-/R+, 24.1%, D+/R-, 
18.2%, and D-/R-, 10.3% (Kuo et al., 2010, Requiao-Moura et al., 2015). CMV 
infection among HIV positive individuals in the pre-HAART era was one of the 
leading causes of HIV disease progression often associated with 
immunodeficiency (Nelson et al., 2011). Antiretroviral drugs have significantly 
improved the occurrence of CMV disease to an estimated 4% (Kim et al., 2006) 
from 20 – 40% previously (Nelson et al., 2011). However, there is a high CMV 
seroprevalence among HIV positive patients which is in excess of 90% (Kim et 
al., 2006, Asboe et al., 2012). Furthermore, detectable CMV viraemia has been 
reported in 20 to 60% of HIV positive patients on HAART and with CD4 T-cell 
counts < 100 cells/mm3 (Bowen et al., 1997, Spector et al., 1998, Wohl et al., 
2009). The use of primary chemoprophylaxis by HIV positive individuals has not 
been proven to be effective in the prevention of CMV disease. Consequently, 
CMV DNA is therefore not routinely monitored and use of primary CMV 
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prophylaxis is restricted to HIV+ individuals with a CD4 T count < 50 cells/µL, 
persistent CMV viraemia and no HIV treatment options. Secondary prophylaxis 
is also not routinely recommended except for relapse of CMV pneumonia or 
CMV oesophagitis with concomitant ophthalmological disease (Asboe et al., 
2012).  
In the general KT population, the use of primary prophylaxis is much debated. 
There are two approaches that are utilized in the prevention of CMV disease in 
KT recipients. Briefly, universal prophylaxis involves the administration of low 
dose antivirals for a prolonged period post-transplantation. Administration of low 
dose valganciclovir for 100 days reduced rate of CMV disease to 5% in all 
patients and to 15% among those at risk of primary CMV infection (Gane et al., 
1997, Singh, 2001). This approach, however, has cost implications, increased 
risk of drug resistance, and drug toxicity. Preemptive therapy involves initiating 
prophylaxis in select high-risk transplant recipients (D+/R-) with asymptomatic 
CMV viraemia (Gane et al., 1997, Fischer et al., 2013). CMV infection is low 
among D+/R+ and D-/R+ among solid organ transplant recipients (BTS, 2011) 
which supports the use of preemptive therapy. However, this approach is limited 
by the cost and practicalities of CMV surveillance and the reliability of the 
diagnostic tests (Winston, 1995, Fischer and Masur, 1997, Singh, 2001). 
Furthermore, antivirals used during periods of high viral burden can be 
ineffective and promote emergence of CMV resistance (Drew et al., 1991, 
Rosen et al., 1997, Singh, 2001). This has also been observed in the HIV 
positive non-transplant patients where preemptive anti-CMV therapy proved 
ineffective in preventing CMV end-organ disease (Wohl et al., 2009). In the 
United States, KDIGO guidelines recommend universal CMV chemoprophylaxis 
for at least 3 months except where both donor and recipient have negative 
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serology (Kasiske et al., 2010).  A recent national study (n=315) reported an 
overall < 10% proportion of HIV kidney transplant recipients that developed 
infections in the first year post-transplant (Kucirka, 2015). Although it has been 
argued that the use of antithymocyte globulin induction therapy increases the 
risk of CMV infection in HIV/KT recipients, Kurcika et al (2015) found ATG to 
have a lower risk compared to other groups (3.8% ATG, 8.7% anti-CD25 and 
7.9% with no induction). In the present study, more than a quarter of patients 
developed CMV infection 5 of whom had received chemoprophylaxis. These 
results may suggest that universal prophylaxis may be protective in HIV/KT 
recipients although, further study in a larger cohort is warranted. 
Other viral infections such as BK virus and Epstein-Barr virus can also 
adversely affect kidney transplant outcomes. In the present study there was a 
low occurrence of BKV and EBV infections with 3 cases of BKV neprophathy 
(BKVN) and 1 case of PTLD. Results from a sub-study of the US NIH HIV/KT 
multisite trial, BKV viraemia occurred in 25% (n=137), biopsy proven BK 
associated nephropathy in 9 (7%) patients (Hirsch, 2013) and there were no 
cases of PTLD (Stock et al., 2010a). In the multivariable analyses, acute 
rejection was the only factor that was marginally associated with risk of 
developing BK viraemia (AR (HR: 2.0; 95% CI: 0.9-4.0; p=0.07)). Outcomes for 
both US NIH and present study were similar to the HIV negative KT population. 
The BKV seroprevalence in the general adult population is estimated at 60 to 
80%. BKV reactivation from the allograft is suggested to be the cause of 
viraemia and viruria in the general KT population. BKVN might further develop 
in 1 to 10% of the general KT population which may result in graft loss in 10 to 
80% (Comoli and Ginevri, 2012, Comoli et al., 2013, Mutlu et al., 2015). PTLD 
in the general KT population is uncommon (1 to 3%) but if acquired is 
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associated with a high risk of mortality. Approximately 90% of the adult 
population by age 40 is reported to have developed antibodies to EBV. There 
are no antiviral drug therapies available to treat or prevent BKV or EBV; 
management includes reduction in immunosuppression (Cockfield et al., 1993, 
Weikert and Blumberg, 2008).   
Malignancy  
Tumors and neoplasia were infrequent in the present study (8%, n=6). Findings 
were similar to the US NIH trial that reported 14 (8.7%) malignancies (skin 
cancer (n=5), cutaneous Kaposi’s sarcoma (n=3), penile squamous cell cancer 
(n=1), head and neck cancer (n=3) and renal cell cancer (n=2)) over a 3.5 year 
follow-up period (Nissen et al., 2012). Both in the current and US studies, the 
KS cases responded to treatment with sirolimus. These results are not 
dissimilar to the HIV negative kidney recipients. The incidence of malignancy in 
the HIV negative KT population is reported to be 3 to 5 times higher than the 
general population (Birkeland et al., 2000, Zeier et al., 2002, Morath et al., 
2004). Immunodeficiency is thought to be the causal factor that increases the 
risk of cancer in both the transplant and HIV/AIDS populations (Grulich et al., 
2007). 
An epidemiological study that compared HIV negative kidney transplant 
recipients to the general population observed a 13.8 fold increased risk of 
cancer in the former group (Yang et al., 1998). In the non-transplant HIV 
population, there is a substantially increased risk of cancer compared to the 
general population particularly for the AIDS defining cancers. In a meta-analysis 
that examined the incidence of cancer in the HIV/AIDS (7 studies, n=444 172) 
and transplant (5 studies, n=31 977) populations reported significantly higher 
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incidences of cancer compared to the general population. For three main types 
of AIDS defining cancers, all HPV related cancers and Hodgkin’s lymphoma the 
SIR (95 CI) was HIV/AIDS 11·03 (8·43–14·4); transplant 3·89 (2·42–6·26. In 
this study, HIV infected individuals were 70 times, 25 times and 5 times more 
likely to be diagnosed with Hodgkins lymphoma, anal and cervical cancers 
respectively than the general population  (Grulich et al., 2007). In a recent 
registry study over a 14 year period (1996 – 2010), the proportion of cancers 
reported were similar for HIV positive individuals and transplant recipients 
0.02% (n=4.7million) and 0.01% (9.7million) respectively (Shiels MS, 2014). 
However, no association has been found on whether solid organ transplantation 
further increases the risk of developing cancer in the HIV infected population 
(Nissen et al., 2012). Although, the authors observed an increased risk of 
progression of human papilloma virus (HPV)-associated neoplasia to high grade 
squamous intraepithelial lesions in 89 HIV/KT recipients whom were followed 
for anal cytology. This highlights the importance of anal and cervical 
surveillance in the HIV/KT population. In the present study, data were sparse on 
anal and cervical cytology therefore not reported. 
 
HIV virological control and disease progression 
In the current cohort, there was no evidence of accelerated HIV disease 
progression. Likewise, in the USA NIH study there was no evidence of 
advanced HIV disease. However, there were two cases of HIV associated 
nephropathy that recurred post-transplant in the USA cohort despite having 
undetectable HIV viral load (<50cps/ml) (Stock et al., 2010b). Although, FSGS 
may have been the differential diagnosis as it is the predominant (~30%) kidney 
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disease that reccurs post-KT in the general population (Ponticelli and Glassock, 
2010).   
In both cohorts, there were two cases each of Kaposi Sarcoma; and only one 
case of PTLD in the UK cohort. In the general KT population, the prevalence of 
Kaposi Sarcoma varies between geographical regions. The prevalence of 
Kaposi Sarcoma in Europe is estimated at 1.6%; Australia and USA by 
comparison is 24% and 1.6% respectively (Tan and Goh, 2006, Raeisi et al., 
2013). Kaposi Sarcoma in general KT population approximately 82% of all 
cases occur within 2 years of receiving an allograft (Bouwes Bavinck et al., 
1996, Mbulaiteye and Engels, 2006). Kaposi Sarcoma is associated with HHV-8 
reactivation that may be induced by immunosuppressive treatment.  
There was no loss in HIV virological control with the use of immunosuppressive 
therapies or with the associated decline in CD4 T cell counts. However, there 
were cases of transient low level HIV viraemia in both cohorts. HIV viral load 
blips are common in the general HIV population on cART (Asboe et al., 2012, 
Young et al., 2015). HIV VL blips have been suggested to be due to reduced 
antiretroviral drug concentrations (Kieffer et al., 2004, Persaud et al., 2004, 
Nettles et al., 2005, Dinoso et al., 2009, Asboe et al., 2012).This was not 
ascertained in both the current dataset or the USA NIH study. However, 
concerns of HIV viral rebound are considered when HIV VL > 500 copies/mL 
(Martinez et al., 2005, Grennan et al., 2012, Young et al., 2015). It is therefore 
not a reason to alter antiretroviral drug therapy (Asboe et al., 2012). It has been 
suggested the variation in HIV RNA testing and non-adherence could be 
contributory factors (Asboe et al., 2012, Garrett et al., 2012). Another theory is 
the possible HIV reservoir replenishment brought about antigen stimulation of 
latently infected cells (Jones and Perelson, 2007). This could explain the 
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observation made by Canaud et al (2014) where they found HIV-1 had infected 
the kidney allograft after transplantation despite undetectable HIV viraemia. 
In the pre-HAART era, there were concerns that use of immunosuppressive 
agents may enhance HIV disease progression. However, through various 
mechanisms immunosuppressant drugs have demonstrated anti-HIV properties 
(Roland, 2004). While there were cases in the present cohort of Kaposi 
Sarcoma, an AIDS defining illness, the rate was not dissimilar to the general KT 
population (Shiels MS, 2014).  All Kaposi Sarcoma patients were successfully 
treated with sirolimus. In early HIV/KT studies, there were concerns of 
acceleration of AIDS defining illnesses particularly with the use of immune 
depleting agents (Stock et al., 2001). This has not been observed in both the 
USA NIH study and the current dataset (Stock et al., 2010a).  
Other post-transplant complications were few. New onset of diabetes after 
transplantation occurred in only 4 (5%) patients on tacrolimus based therapy. 
The prevalence of NODAT in general KT population varies between 2 to 53% 
(Balla and Chobanian, 2009, Sarno et al., 2012, Palepu and Prasad, 2015). 
Between the calcineurin inhibitor agents, tacrolimus is 50% more likely to 
induce diabetes than ciclosporin (Kasiske et al., 2003, Woodward et al., 2003, 
Palepu and Prasad, 2015).  
There was no increased risk of developing cardiovascular disease (CVD) 
although; a longer follow-up is necessary to draw this inference. The one case 
of non-ST segment elevation myocardial infarction was precipitated by plasma 
exchange. This patient had no prior history of cardiovascular disease. CVD is 
associated with increased morbidity and mortality among kidney transplant 
recipients. The annual rate (fatal/non-fatal) of CVD events in the general KT 
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population is 3.5 to 5.0% which is 50 fold greater than the wider general 
population (Fishbane, 2005, Kidney Disease: Improving Global Outcomes 
Transplant Work, 2009). Other additional factors such as obesity, diabetes, 
hypertension, and proteinuria can further contribute to CVD risk in the KT 
population (Metcalf et al., 1992, Fernandez-Fresnedo et al., 2002, Fishbane, 
2005, Jeon et al., 2015). Furthermore, HIV infection is an independent risk 
factor for developing CVD (Triant, 2012). Some antiretroviral medication use 
(e.g. abacavir) has also been associated with increased risk of CVD 
(D.A.D.StudyGroup et al., 2008, Friis-Moller et al., 2015). Preventative 
measures and close monitoring is therefore warranted in the HIV/KT cohort in 
order to mitigate CVD. Post-transplant blood pressure control is one example. 
In the current cohort, at the last clinic visit blood pressure control was good with 
median systolic 138 (125, 147) and diastolic 84 (76, 90) mmHg with almost 90% 
of patients being maintained on 2 blood pressure control medication. The 
KDIGO guidelines suggest that post-KT blood pressure should be maintained at 
<130/80mmHg (Kidney Disease: Improving Global Outcomes Transplant Work, 
2009). 
The strength of the current study is its size and duration of follow-up. This study 
is the largest HIV/KT cohort in Europe (Trullas et al., 2010) and comparable to 
the USA NIH Study. With the exception of three patients, the remaining patients 
had a minimum of one year of follow-up and the median follow-up was nearing 
3 years. Nonetheless, the study had some limitations. First, as the observational 
cohort study design where multiple data sources were used may have 
introduced information bias but also prevented standardization (Vandenbroucke 
et al., 2014). The evolution of HIV and renal care over the long study period 
also contributed to non-standardised management. For example, an 
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independent blinded biopsy review including protocol biopsies may have 
strengthened allograft rejection findings. Information was lacking that may have 
introduced confounding e.g. sensitization (from blood transfusions, pre-
transplant pregnancies, etc), calculated reaction frequency, cold ischaemic 
times, proteinuria and donor specific antibodies. The high proportion of patients 
of black ethnicity may have also been a confounding factor. Cytochrome P450 
3A5 expressers, that have significantly higher dose requirements of certain 
immunosuppressant drugs (e.g. tacrolimus), are more prevalent in black ethnic 
KT recipients compared to other ethnicities (Macphee et al., 2002, MacPhee et 
al., 2004, Macphee et al., 2005, Moreton et al., 2005, Vadivel et al., 2007, 
Spierings et al., 2013). Variation in human leukocyte antigen polymorphisms 
and having a stronger immune response are some of the explanations offered 
for the disparity of immunological responses between ethnic groups (Milford et 
al., 1987, Opelz et al., 1989, Gordon et al., 2010).  
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3.5. Conclusion 
The analysis confirms the feasibility of kidney transplantation in carefully 
selected HIV infected individuals. Favourable outcomes may have been 
attributable to the stringent selection criteria including fully suppressed HIV, 
being maintained on cART and with a somewhat recovered immune status. The 
safety of post-transplant immunosuppression was demonstrated by lacking 
evidence of HIV disease progression, AIDS defining illnesses or 
tumours/neoplasms. Allograft rejection complicated post-transplant outcomes. 
The complex immunosuppressant and antiretroviral drug interactions are 
suggested to have contributed to suboptimal immunosuppression. This 
hypothesis has been explored in Chapter 5. Strategies that could be explored to 
improve post-allograft outcomes include the use of more potent induction 
immununosuppressive therapies and integrase inhibitor based antiretroviral 
drug regimens to avoid drug interactions. Although not explored in the present 
analysis, having defined donor selection criteria may also contribute to having 
optimal allograft outcomes. Finally, the current cohort requires longer follow-up 
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Chapter 4. Calcineurin Inhibitors and Rejection in HIV/KT  
4.1. Introduction 
The success of kidney transplantation is attributable to the immunosuppressive 
therapies that target various pathways involved in the native and adaptive 
alloimmune responses to the allograft (Wolfe et al., 1999, Halloran, 2004, 
Kaplan and Meier-Kriesche, 2004, Sayegh and Carpenter, 2004). Over the past 
50 years, the use of immunosuppressive agents have vastly improved patient 
and graft survival rates post-kidney transplantation (Sayegh and Carpenter, 
2004). However, there were long term risks of developing adverse events with 
life-long immunosuppression (Kaplan and Meier-Kriesche, 2004). Subsequently, 
there has been progressive development in the optimisation of 
immunosuppressive therapy by combining the different agents and 
personalising therapies to meet individual patient’s needs (Sayegh and 
Carpenter, 2004, Azzi et al., 2013). However, achieving immune tolerance still 
remains the ultimate dream of clinicians (Ruiz et al., 2013).      
There are three main pathways that achieve immunosuppression including: (i) 
lymphocyte depletion, (ii) blockade of lymphocyte responses, or (iii) diverting 
lymphocyte traffic (Halloran, 2004) as shown in Figure 21. 
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Figure 21: Diagram of T-cell Mediated Rejection and the different mechanisms of action of 





Steroids – Cytokine 
mRNA e.g. IL-2 
Figure adapted from “Immunosuppressive Drugs for Kidney Transplantation.”by Philip F. Halloran, M.D., 
Ph.D. 2004, New England Journal of Medicine; 351:2715-2729.  
 
When kidney allograft is inserted into the recipient, there are three distinct signalling pathways that are 
activated in the process of rejecting the transplanted organ. Signal 1 occurs when the antigen presenting 
cells (APCs) initially migrate to T cell areas of secondary lymphoid organs to present the donor antigens to 
the naïve and central memory T cells (TCEM). When the APCs present the donor cells and activate the T 
cells through the T-cell receptor (TCR), the naïve T cells start to modulate expression of surface molecules 
that are associated with activation, costimulation and adhesion (Expansion of activated human naïve T-cells 
precedes effector function (Brenchley et al., 2002). Signal 2 then occurs when CD80 receptor expressed on 
the APC engages the CD28 receptor expressed on the surface of the T cell. The resulting costimulation 
response activates 3 signal transduction pathways (a) calcineurin pathway (b) mitogen activated protein 
(MAP) kinase C-nuclear factor-KB (NF-KB) pathway which activates transcription factors – nuclear factor of 
activated T cells (NFAT), NF-KB and activating protein-1 (AP-1). This up-regulates expression of CD154, 
CD25 and releasing interleukin-2 (IL-2) cytokine. Subsequently, several cytokines are released that deliver 
growth signals thus initiating the cell cycle (Signal 3). This includes the molecular target of rapamycin 
(mTOR) pathway. Further, to complete the cell cycle and for lymphocyte replication to occur, synthesis of 
purine and pyrimidine nucleotides are required. Both proteins are regulated by inosine monophosphate 
dehydrogenase (IMPDH) and dihydroorotate dehydrogenase (DHODH), respectively. The T cells exposed to 
the donor antigen then migrate to and penetrate the allograft to destroy it. This process leads to the 
development of lesions such as tubulitis and endothelial arteritis. To deter this rejection process, 
immunosuppressive drugs target the different signalling pathways as depicted in the figure.  
 
Key: CsA, Ciclosporin; Tac, Tacrolimus; Aza, Azathioprine; MMF, Mycophenolate; SrL, Sirolimus; EVL, Everolimus; IL-2R Ab, Interleukin-2 
receptor α chain (anti-CD25, basiliximab); anti-CD52, Campth-1H; JAK3, Janus kinase 3; IKK, denotes inhibitor of nuclear factor-KB kinase; PI-
3K, Phosphoinositide-3-kinase pathway; S-1-P, Sphingosine-1-phosphate receptors; MHC, Major histocompatibility complex; CTLA-4-Ig, 
Cytotoxic T lymphocyte-associated molecule-4 (belatacept).      
  
 
- 159 - 
Lymphocyte depletion includes immunosuppressive agents that aim to destroy 
T cells, B cells or both. Examples of such agents include: polyclonal antibodies 
derived from horse or rabbit, anti-lymphocyte globulin (ALG) and anti-thymocyte 
globulin (ATG) respectively; mouse monoclonal anti-CD3 antibody (withdrawn 
from market); humanised monoclonal anti-CD52 antibody (alemtuzumab); and 
B-cell depleting monoclonal anti-CD20 antibody (rituximab) (Halloran, 2004). 
Non-depleting antibodies include: monoclonal anti-CD25 (Salis et al., 2008); 
and T cell costimulation (CD28/CD80) blockade agent (belatacept) (Vincenti et 
al., 2016).  There are other antibody targets that have been trialled or under 
development for example, anti-CD154 which was withdrawn due to 
thromboembolic complications (Koyama et al., 2004); and anti-CD2 – multiple 
agents have been trialled but failed to demonstrate superior allograft outcomes 
(Squifflet et al., 1997, Rostaing et al., 2013). 
In the early 1960s, the development of mercaptopurine-6 and azathioprine led 
to the use of immunosuppression as standard of care post-transplantation 
(Elion, 1993). Although, early experience with the nonselective cytotoxic agents 
was associated with undesired toxicity attributed to the suppression of other 
rapidly proliferating cells in the bone marrow and gastrointestinal tract 
(Hardman et al., 1996a). The discovery of more selective immunosuppressive 
agents (e.g. calcineurin inhibitors) revolutionised the management of allograft 
recipients, as they dramatically improved both host and graft outcomes (Azzi et 
al., 2013). Calcineurin inhibitors are the mainstay IS agents that have been in 
use since the 1980s (Azzi et al., 2013). Other agents that target different 
lymphocyte reponses include: T- and B-cell antiproliferative mycophenolate 
(Remuzzi et al., 2004); mechanistic target of rapamycin (mTOR) inhibitors 
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sirolimus (Morath et al., 2007) and everolimus (Pascual, 2009); and Janus 
kinase (JAK) 3 inhibitor tofacitinib (Wojciechowski and Vincenti, 2011). 
Discovery & Pharmacology of Calcineurin Inhibitors 
Calcineurin, a calcium dependent protein phosphatase, is triggered during T-cell 
antigen receptor (TCR) mediated activation which in turn dephosphorylates 
nuclear transcription factors (NF-AT, nuclear factor of activated T-cells) that 
mediate cell survival and expression of cytokines. This process produces 
proinflammatory responses that results in allograft rejection. By binding to 
specific endogenous cytosolic proteins, immunophilins, results in calcineurin 
inhibition. Calcineurin inhibitors interfere with these alloimmune reponses to 
prevent rejection (Peakman and Vergani, 2009, Sanchez-Fueyo and Strom, 
2011). Both ciclosporin and tacrolimus have similar pharmacodynamics 
properties by inhibiting calcineurin (Azzi et al., 2013).   
 
Ciclosporin 
Ciclosporin was the first calcineurin inhibitor discovered in the early 1980s by 
Dr. Sandor Lazary and Dr. Jean-Francois Borel at the Sandoz Company in 
Basel, Switzerland. Ciclosporin is a cyclic polypeptide isolated from a fungus 
Tolypocladium inflatum Gams which binds to cyclophilin and the resulting 
complex inhibits calcineurin (Hardman et al., 1996b, Rang and Dale, 2012).  
 
Tacrolimus 
Tacrolimus like ciclosporin is derived from fungus in particular Streptomyces 
tsukubaensis. It inhibits calcineurin by binding to FKBP-12 protein, an 
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immunophilin that plays an important role in the T-cell activation process 
(Hardman et al., 1996b, Rang and Dale, 2012). Unlike cyclophilin which is 
widely abundant in the body (Wang and Heitman, 2005), FKBP proteins are 
present in FKBP-expressing cells found in the cellular component of whole 
blood. Lymphocytes in particular, highly express FKBP proteins (Baughman et 
al., 1997, Yura et al., 1999, Galat, 2003).  
 
Early Calcineurin Inhibitor Clinical Studies in HIV negative KT recipients 
Although calcineurin inhibitors are potent immunosuppressive agents, the 
complexities of the immune activation responses following kidney 
transplantation require for the combined use of multiple immunosuppressant 
drugs for the prevention of allograft rejection. The first human clinical trial used 
ciclosporin monotherapy for deceased donor kidney transplantation in seven 
patients on dialysis. Initial results showed no signs of rejection however; six 
patients required the addition of a cyclophosphamide analogue to manage 
interstitial inflammation associated with mononuclear infiltration, one 
experienced graft loss due to pyelonephritis and one died with disseminated 
aspergillosis (Calne et al., 1978). A follow-up study by Calne et al (1979) using 
ciclosporin monotherapy in 34 transplant patients (32 kidney, 2 pancreas, 1 
liver) showed promising results with 82% overall patient 1-year survival and 
81% kidney graft survival at 1 year; 19% (n=6) rejection rate. Although, in 20 
patients the addition of a cyclophosphamide analogue was required and a 
further six additional steroids to optimise the immunosuppressive therapy. The 
intensification of the immunosuppression resulted in severe infectious and 
malignant complications (Calne et al., 1979). Very soon after, a large 
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multicentre European trial was conducted in 232 deceased donor kidney 
transplants randomised into ciclosporin monotherapy (n=117) vs azathioprine 
(n=115) plus steroids groups. The results at 1 year showed excellent results in 
favour of ciclosporin compared to the control group respectively, 99% vs 92% 
patient survival, 72% vs 52% graft survival and 19% vs 9% acute rejection rate. 
However, in the ciclosporin group 24 out of 84 with remaining functioning grafts 
at 1-year were switched to azathioprine plus steroids for the treatment of 
allograft rejection (n=18) and to avoid CNI related adverse events (n=6); 1 had 
additional steroids and 59 remained on CsA monotherapy. No differences were 
noted in the rates of infection although, it was noted that those in the ciclosporin 
arm had worse renal function. It was soon discovered that the poor renal 
function was due to the nephrotoxic properties of ciclosporin 
(EuropeanMulticentreTrialGroup, 1983). Interestingly, graft survival was better 
in the ciclosporin group despite having more frequent rejection episodes and 
despite using higher doses than we currently use today (17mg/kg/day vs 
10mg/kg/day (NovartisPharmaceuticals, 2014), respectively) 
(EuropeanMulticentreTrialGroup, 1983). Further evidence emerged that 
suggested the use of ciclosporin monotherapy was effective for preventing 
allograft rejection however; adverse events such as nephrotoxicity also became 
evident (Azzi et al., 2013). 
 
A Canadian multicentre, randomised trial that included 209 deceased donor 
kidney transplant recipients was among the first studies that looked at 
combining ciclosporin plus steroids to ascertain if it would improve outcomes. 
Their results were somewhat better than the European trial with 97% vs 86% 1-
year patient survival and 80% vs 64% 1-year graft survival in those taking CsA 
- 163 - 
plus steroid compared to Aza plus steroid. There were 159 treated rejection 
episodes in the ciclosporin group compared to 157 in the control group. This 
study also used much higher ciclosporin doses (20mg/kg loading dose) but 
aimed for similar Ctrough whole blood concentrations to what we use today (100-
400ng/ml) (CanadianMulticentreTrial, 1983). What established CNIs being used 
as the main agent for immunosuppressant drug therapy in solid organ 
transplantation, was a collaborative study from 200 European transplant centres 
that showed 10 – 15% superiority in graft survival in patients taking ciclosporin 
based therapy (CsA (n=2,965) vs other (n=6,915) respectively, 78% vs 67% at 
1 year p<0.0001) (Opelz, 1986). It wasn’t until 1997, 20 years after using 
ciclosporin that tacrolimus was discovered (Tanaka et al., 1997). Due to the 
difference in mechanism of action, it was hoped that tacrolimus would have 
fewer adverse effects including nephrotoxicity however, there was no evidence 
of this (Williams and Haragsim, 2006).  
Early studies that compared tacrolimus with ciclosporin reported dramatic 
reductions in acute rejection (Tac vs CsA respectively, 25.9% vs. 45.7% 
P<0.001, n=448 (Mayer et al., 1997); 30.7% vs. 46.4% P=0.001, n=412 (Pirsch 
et al., 1997)) albeit with no differences in patient or graft survival rates (Tac vs 
CsA respectively, 1-year patient 93.0% vs. 96.5% P=0.140 and graft survival 
rates 82.5% vs. 86.2%; P=0.380 (Mayer et al., 1997); 1-year patient 95.6% vs. 
96.6% P=0.58. and graft survival rates 91.2% vs. 87.9%; P=0.29 (Pirsch et al., 
1997)). 
Aside from nephrotoxicity, CNIs were associated with other adverse effects 
such as hypertension, diabetes, neurotoxicity and dyslipidaemia. This led to 
looking for strategies to optimise immunosuppressive therapy by minimising or 
avoiding CNIs to evade related toxicity whilst achieving/maintaining efficacy 
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(Azzi et al., 2013). The addition of mycophenolate, a potent immunosuppressive 
agent that selectively inhibits T- and B-cell proliferation, to ciclosporin plus 
steroids (triple therapy) saw kidney rejection rates as low as 17% (pooled 
efficacy analysis of three clinical trials n=1493) in the first 6 months post-KT 
(Halloran et al., 1997). However, early trials observed patients suffering from 
adverse reactions attributed to mycophenolate to include gastrointestinal 
reactions, leukopenia and increased opportunistic infections (1995, Sollinger, 
1995, Browne, 1996, Halloran et al., 1997). Despite using dual and triple 
immunosuppressant drug combinations, allograft rejection continued to be 
problematic and was associated with poorer long-term graft function (Pelletier et 
al., 1998). This led to the development of more intensive immunosuppressive 
therapy such as the poly/monoclonal antibodies and lymphocyte depleting 
agents (Nashan, 2005). One study explored ‘quadruple immunotherapy’ in 
kidney transplant patients (n=499), comparing ciclosporin plus mycophenolate 
plus steroid to Aza plus mycophenolate plus steroids with the inclusion of 
mono/polyclonal antibodies (antithymocyte globulin, ATG; antilymphocyte 
globulin, ALG; muromonab, OKT3) in both groups. The authors reported first 
biopsy-proven rejection rates at 6 months of 38% in azathioprine group vs 18% 
in ciclosporin group (Sollinger, 1995).  
The choice of immunosuppressive drug regimen was not the only focus of 
managing kidney transplant recipients, determining the optimal CNI drug 
exposure associated with CNI efficacy also became paramount (Grevel et al., 
1991, Min et al., 1998, Staatz et al., 2001, Borobia et al., 2009). CNI therapeutic 
drug monitoring initially used total exposure, AUC, to determine efficacy but this 
was not practical in clinical practice. Subsequent PK studies aimed to determine 
the optimal single time point that correlated with total exposure. Some evidence 
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suggested that peak concentrations (Cmax) had better correlation to total 
exposure (AUC) than pre-dose (Ctrough) concentrations and therefore, were 
better predictors of allograft outcome (e.g. rejection) (Jorgensen et al., 2002, 
Felipe et al., 2003, Aoyama et al., 2005, Mardigyan et al., 2005a, Mardigyan et 
al., 2005b, Takeuchi et al., 2008). However, this was also impractical in the 
clinical setting. Ctrough/pre-dose whole blood concentrations soon became the most 
commonly used for CNI therapeutic drug monitoring (TDM) (Schiff et al., 2007).  
However, the wide inter- and intra-patient variability due to multiple influential 
factors (e.g. food interactions, drug interactions, pharmacogenetics, gender, 
patient adherence, drug formulation or ethnicity) meant that Ctrough/pre-dose drug 
concentrations did not accurately correlate to total drug exposure (Min et al., 
2000, Macphee et al., 2002, MacPhee et al., 2004, Macphee et al., 2005, Acott 
et al., 2006, Connor et al., 2012, Ro et al., 2012, Spierings et al., 2013); refer to 
Chapter 5 for further details on CNI drug exposure.   
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Purpose of study 
The main purpose of this chapter is to investigate whether calcineurin inhibitor 
choice (ciclosporin versus tacrolimus) has an impact on allograft outcomes, 
specifically allograft rejection in the first year post-kidney transplantation of HIV 
positive patients. Secondary outcomes include identifying factors associated 
with allograft rejection in the UK HIV/KT cohort by using univariate and 
multivariate analyses. Finally, a descriptive analysis of the adverse events 
mainly reactivation of latent viral infections stratified a priori by CNI choice.   
 
Hypothesis 
The main hypothesis of this chapter is 
 
H0: There will be no differences in allograft rejection rates in HIV positive 
kidney transplant recipients taking either ciclosporin or tacrolimus based 
immunosuppression therapy.  
- 167 - 
4.2. Method 
Study Design 
This was a national observational cohort study including 40 Transplant and 
referring HIV centres. The full details of the study methods have been described 
previously in Chapter 3 page 109 - 113.  
 
Ethics Approval 
This was a multicentre research ethics committee (MREC) approved study. The 
full details of the ethics and local R&D approvals have been previously 
described (see Chapter 3 page 109).  
 
Patient Enrolment 
Case ascertainment was established by clinicians at the local centres. Data 
were used from HIV positive individuals over 18 years of age that had a kidney 
transplant up to 31st December 2013. Enrolled patients were stratified a priori by 
CNI choice at the point of transplantation, ciclosporin (CsA) or tacrolimus (Tac).  
 
Inclusion criteria 
1) Patients that acquired HIV prior to kidney transplantation 
2) Patients ≥ 18 years of age 
3) Patients that took calcineurin inhibitors (CsA or Tac) as part of 
immunosuppressant drug therapy management in the first year post-
transplant 
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Exclusion criteria 
1) Patients that acquired HIV post-kidney transplantation 
2) Patients under 18 years of age.  
3) Patients that took other non-calcineurin inhibitor based therapy at 
transplantation for example, mammalian target of rapamycin (mTOR) 
inhibitors (e.g sirolimus).  
4) Patients that had primary graft non-function within 6 months of being 
transplanted 
5) Patients with insufficient/missing/no data 
 
Data Collection 
The full study design, case ascertainment and data collection have been 
previously described in Chapter 3 page 109 - 113. For the purposes of this 
chapter, the data used included baseline recipient/donor characteristics, HIV 
management with antiretroviral therapy, immunosuppressant drug therapy 
management during first year post-KT, patient/graft outcomes and CNI related 
adverse events as outlined below. 
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Recipient and Allograft Characteristics 
Baseline recipient characteristics include: demographics - age, gender and 
ethnicity; renal disease background and history of management – renal disease 
aetiology and date of permanent replacement therapy initiation if applicable; 
HIV disease background and management – date of HIV diagnosis, HIV risk, 
antiretroviral therapy at KT; CD4 nadir prior to KT and CD4 count at KT; co-
morbidities – hepatitis B or C co-infection, hypertension or diabetes; and for 
those co-infected, hepatitis B or C viral load.   
Allograft characteristics include donor type, HLA mismatch status and 
donor/recipient CMV mismatch status.  
 
Host/Graft Outcomes 
Recipient survival was defined as the time from transplantation censored at last 
clinic visit. Graft survival was defined as the time from transplantation to the 
date reported by clinician as return to dialysis or death censored (to include 
those that died with a functioning graft). The analyses were limited to the first 12 
months post-transplant. Primary allograft failure was defined as the need for 
maintenance dialysis within 6 months post-KT without the graft functioning 
sufficiently to sustain the recipient’s life. 
Serum creatinine values at weeks 1, 2, 4, 6, 8, 12, 24, 36 and 52 post-KT were 
used to determine graft function. Graft function was calculated by the estimating 
the glomerular filtration rate (eGFR) using the Chronic Kidney Disease 
Epidemiology Collaboration formula (Malyszko et al., 2010).  
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Analyses of acute allograft rejection were restricted to biopsy-confirmed 
episodes (BPAR). Biopsies that were inconclusive were reviewed by the 
clinician for a confirmed diagnosis. Acute allograft rejection was limited to the 
first episode that occurred within 12 months post-transplant. Patients with less 
than 12 months of follow-up were included in the AR analyses up to the date of 
last clinic visit taken.   
 
Adverse Events 
Adverse events (ADEs) were restricted to immunosuppression related events 
that occurred in the first 12 months post-KT stratified a priori by CNI choice an 
reported by clinicians. ADEs include: latent viral reactivations – cytomegalovirus 
(CMV), BK virus, Epstein-Barr virus, herpes simplex virus; opportunistic 
infections – bacterial/fungal/protozoal/viral infections; HIV virological control; 
tumors/malignancies; post-transplant lymphoproliferative disorder (PTLD); new 
onset of diabetes (NODAT); and drug induced cytopenias. CMV prophylaxis 
with an antiviral agent (e.g. valganciclovir) was noted. 
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Analyses of CNI Efficacy  
Patients were a priori stratified by the type of calcineurin inhibitor (ciclosporin or 
tacrolimus) received immediately post-KT and, for pharmacokinetic analyses, by 
their antiretroviral regimen (protease inhibitor [PI] containing vs. PI sparing). 
Clinical characteristics at the time of KT were described. The CNI doses were 
recorded for each patient and expressed relative to total body mass (in 
mg/kg/day). 
 
CNI Ctrough concentration analyses were carried out at the following a priori 
selected time points: 1, 2, 4, 6, 8, 12, 24, 36 and 52 weeks post-KT. CNI Ctrough 
doses and concentrations were censored at: date of clinical event (BPAR); date 
CNI drug was discontinued or switched; date of death or date of last clinic visit 
up to 1 year post-KT.  
 
Calcineurin inhibitor Ctrough concentrations were taken as the concentration 
taken at 12- or 24-hours post-dose for twice and once daily regimens 
respectively. Where patients were taking extended interval CNI dosing (i.e. 
once every 2, 3, 7 days), the pre-dose concentration was considered the Ctrough. 
CNI concentrations not taken pre-dose for extended interval dosing regimens 
were excluded from the analyses.  
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The first CNI Ctrough concentration measured after initiating a dose post-KT was 
considered when no dose change prior to first measurement available up to 7 
days post-KT. For the subsequent selected time points, the CNI Ctrough 
concentration within 10 days (either side) of the specified dates was chosen for 
analyses. Where two or more concentrations were available, the first available 
result following the specified date was used (Oo et al., 2008). 
 
All available CNI whole blood concentrations were downloaded from their 
electronic patient records; these measurements were assumed to be taken at 
12- or 24-hours post-dose for twice and once daily dosed drugs, respectively, 
and thus representing Ctrough concentrations. Where patients had been taking 
extended interval CNI dosing (i.e. once every 2, 3, 7 days), the pre-dose 
concentration was considered the Ctrough. For these patients, the daily dose was 
calculated by dividing the single dose taken by the number of days preceding 
the Ctrough concentration reported. Analysis of CNI doses and Ctrough 
concentrations used the following time points: weeks 1, 2, 4, 6, 8, 12, 24, 36 
and 52 post-KT. If no concentration was available for these time points, Ctrough 
concentrations were carried forward for a maximum of 7 days in the first 3 
months post-KT, and for a maximum of 21 days thereafter. 
 
All available CD+ T cell counts were assessed for immunological response 
stratified a priori by CNI choice at KT. Further analyses comparing cART 
choice, induction therapy choice and experiencing BPAR at 1 year were also 
carried out. Analysis was performed at baseline, month 1, 2, 4, 6, and 12 post-
KT. The measurement closest to these time points were used. 
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Statistical Analyses 
Baseline characteristics were compared using Z-test (proportions), Wilcoxon 
ranksum test (medians) or T-tests (means). Overall patient and graft survival 
and cumulative incidence/hazard were estimated using Kaplan-Meier methods.  
In this analysis, patients were censored at the first episode of acute graft 
rejection or at the time of CNI switch, whichever came first. The logrank test 
was used to compare groups. Risk factors for the allograft rejection episode 
occurring in the first 12 months post-KT were identified with Cox proportional 
hazard regression analysis. Analyses of CNI doses and concentrations were 
censored at CNI and/or cART switch. 
 
A multi-level mixed effect linear regression model was used to analyse repeated 
measures data, i.e renal graft function measured at weeks 1, 2, 4, 6, 8, 12, 24, 
36, 52. This mixed effect model was performed to examine whether there was a 
significant difference (p <0.05) in change of graft function from baseline to week 
52 for patients taking ciclosporin compared to those taking tacrolimus. The 
association of CNI choice and the slopes of graft function versus time post-
transplant were also examined using mixed-effect models allowing for a random 
intercept and slope. The analyses were performed using the xtmixed command 
in STATA (version 12.0). Graft function was expressed as eGFR calculated 
using the CKDEPI equation. 
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Study Assumptions and Confounding factors 
Continued adherence to both immunosuppressant and antiretroviral drugs was 
assumed for this chapter’s analyses. 
As this was an observational study, the confounding factors listed below were 
identified.  
1. CNI switch in the first year post-transplant 
2. Induction therapy choice (monoclonal, polyclonal or high dose steroids 
only) 
3. Variability in centre biopsy protocols and histopathology/clinician 
interpretation of biopsy results 
4. Variability in the immunoassays used for CNI whole blood concentration 
monitoring 
5. Variation in immunosuppressant drug maintenance therapy to include 
a. Steroid withdrawal post-KT (i.e. withdrawal at 1, 3 or 3+ months 
post-KT) 
b. Maintenance with mono, dual or triple immunosuppression 
therapy 
c. Withdrawal of mycophenolate or azathioprine as the second IS 
agent  
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6. Variation in therapeutic target CNI drug concentrations. To standardise 
the analyses, the following target ranges were used 
a. Ciclosporin: weeks 1 – 12, 200 – 350ng/ml; weeks 13 – 52, 100 – 
250ng/ml 
b. Tacrolimus: weeks 1 – 12, 8 – 15ng/ml; weeks 13 – 52, 5 – 
10ng/ml 
These target ranges were guided by taking the lower and upper values used of 
the local protocols for kidney recipients considered of high immunological risk.  
 
To control for confounding in the study design 1) patient characteristics at 
baseline in both CNI groups were tested for matching using paired statistical 
tests (e.g. t test or z-tests) (Austin, 2011), 2) patients were censored at CNI 
switch for time-to-event analyses (Velentgas, 2013). Other factors were not 
controlled for due to the study population size and intra- and inter-centre 
variability in IS protocols and immunoassays over the study period. 
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4.3. Results 
Patient Disposition 
There were 97 HIV positive adults that underwent kidney transplantation up until 
31st December 2013 at the participating centres. Those that did not meet the 
study inclusion criteria (N=14) included: one patient less than 18 years of age; 
four transplanted abroad (India, Belgium, Berlin and USA); three that acquired 
HIV post-transplantation; one patient who died during KT and six that had no 
data. The six patients were transplanted at Oxford Radcliffe hospital (n=4), 
Birmingham (n=1) and Manchester (n=1). All were referrals from external HIV 
centers (unknown) and received post-transplant follow-up at their base 












Figure 22: Patient Disposition for UK HIV/KT Cases Stratified By Those 
on Ciclosporin and Tacrolimus Based Immunosuppression Therapy 






UK HIV/KT Cohort  
N=97 
Excluded  
HIV/KT Recipient ≤ 18 years, N=1 
HIV negative at KT, N=3 
Transplanted abroad, N=4 
No data, N=6 
 
Excluded 
Died on allograft insertion, N=1 
Primary graft non-function, N=4 
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Of the remaining 83 patients, 5 patients were further excluded one had died 
during allograft insertion and 4 experienced primary non-graft failure. The 
remaining 78 patients were included in the analyses, (see Figure 22). 
 
Patient Characteristics 
At KT, all recipient characteristics were well matched except for age, (see Table 
23). The overall median (IQR) age of the patients was 44.6 (38.5, 51.4) years 
with those who received tacrolimus being older (median age 46.2 vs. 39.6 
years, p=0.01) than those who received ciclosporin. The majority were male 
(67%) and of black ethnicity (74%) with a median (IQR) CD4 cell count of 366 
(277, 516) cells/mm3 and well controlled HIV replication. Twenty-six patients 
(34%) received a kidney from a live donor, six (8%) were transplanted pre-
emptively, one had received a previous kidney allograft 14 years earlier, one 
underwent simultaneous kidney-pancreas transplantation, one received an ABO 
incompatible graft, and one HCV co-infected recipient received two kidneys 
from an HCV positive donor. All of the patients were first time kidney transplant 
recipients; none were re-transplants. Hepatitis B and C co-infection was present 
in 13% and 5% respectively; hepatitis B DNA was undetectable in all hepatitis B 
positive patients while 2 of the 4 hepatitis C co-infected patients were viraemic 
(HCV RNA >700,000 IU/mL). Diabetes was present in 15% and hypertension in 
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Table 23: Baseline Patient Characteristics at Kidney Transplantation Stratified According to CNI 
Immunosuppression Therapy 
 
*Comparing medians, Wilcoxon rank-sum (Mann-Whitney) test; comparing proportions (%), two-sided chi-squared test and two-sample test of proportions. 
Statistically significant (p < 0.05); Missing values  -  **n=1, ¶ n=3, †n=5, Ψ n=6, ǂ n=7, ₺n=15,  b Tacrolimus n=8. 
Key:  IS – immunosuppression, CNI – calcineurin inhibitor, HTS - heterosexual; aCalcineurin inhibitor + Mycophenolate or Azathioprine + corticosteroids 
  All patients 
N=78 
Ciclosporin 
N = 31 
Tacrolimus 
N = 47 
P value* 
Recipient characteristics      







Gender, n (%) Male 52 (67) 24 (77) 28 (60) 0.10 
Ethnicity, n (%) Black 58 (74) 24 (77) 34 (72) 0.62 
Cause of ESKD, n (%) ** HIVAN 40 (52) 18 (58) 22 (48) 0.38 
Duration of pRRT, median(IQR) ǂ Years 4.9 (2.6, 7.1) 4.5 (2.2, 6.4) 6.1 (3.3,7.3) 0.27 
 
HIV parameters, median(IQR) 
     
Mode of acquisitionΨ, n(%) HTS 54 (75) 22 (71) 32 (78) 0.46 
Pre-KT nadir CD4 count† Cells/mm3 92 (40, 171) 92 (38, 160) 95 (41, 179) 0.93 
CD4 count at KT** Cells/mm3 366 (277, 516) 398 (277, 601) 344 (276, 504) 0.28 
Viral load log10 
copies/ml 
1.7 (1.6, 1.7) 1.7 (1.6, 1.7) 1.6 (1.6, 1.7) 0.07 
 
Co-morbidities, n (%) 
     
Diabetes  12 (15) 4 (13) 8 (17) 0.62 
Hypertension  70 (91) 29 (94) 41 (87) 0.37 
Hepatitis B co-infection, n (%)**  10 (13) 5 (16) 5 (11) 0.50 
Hepatitis C co-infection, n (%)¶  4 (5) 3 (10) 1 (2) 0.16 
 
Graft characteristics 
     
Allograft type, n (%)** Cadaveric 51 (66) 18 (58) 33 (72) 0.21 
HLA mismatch, median(IQR) ₺  3 (2, 3) 3 (2, 3) 3 (2, 4) 0.59 
Donor/Recipient CMV mismatch 
status, n (%) 
     
D+/R- 4 (5) 2 (6) 2 (4) 0.67 
 
Antiretroviral drug therapy, n (%) 







Integrase inhibitor containing 
Raltegravir 

































Immunosuppressive therapy, n 
(%) 
     
Induction therapyb      
       Basiliximab or Daclizumab  73 (94) 29 (94) 36 (92) 0.90 
Alemtuzumab  2 (3) 0 (0) 2 (5)  
Rituximab+plasma exchange  1 (1) 0 (0) 1 (3)  
Pulsed corticosteroids only  2 (3) 2 (6) 0 (0)  
Triple IS regimena  76 (97) 31 (100) 45 (96) 0.26 
Tacrolimus monotherapy  2 (3) - 2 (4)  
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Antiretroviral Therapy 
Overall at KT, 62% were being managed on a PI sparing cART regimen; 52% 
received a non-nucleoside reverse transcriptase inhibitor (NNRTI). In those on a 
PI containing cART regimen (38%) all took ritonavir boosted protease inhibitor 
(PI/r) containing ART. There were six patients that took a combination of NNRTI 
and PI/r containing ART regimens. Of those taking integrase inhibitor containing 
ART (n=23), only 10 patients took ART regimens that did not contain NNRTI or 
PI/r antiretroviral drugs.     
 
Immunosuppressant Treatment Regimens 
All patients received induction IS therapy with pulsed corticosteroids plus 
monoclonal antibodies (anti-CD25 [basiliximab or daclizumab, n=73], anti-CD52 
[alemtuzumab, n=2], or anti-CD20 [rituximab, plus plasma exchange pre-
conditioning for ABO-incompatibility, n=1]), or pulsed corticosteroids only (n=2). 
None of the patients received polyclonal anti-thymocyte globulin (ATG) as part 
of their induction regimen; 4 patients received ATG for anti-rejection treatment. 
All patients received a CNI as part of their initial post-KT immunosuppressive 
therapy; the initial CNI was ciclosporin in 31 and tacrolimus in 47 patients.  
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The majority of patients received triple immunosuppressive therapy with the CNI 
administered concurrently with mycophenolate (97%) and prednisolone (100%). 
There was between and within centre variability in corticosteroid withdrawal 
during the first 12 months post-KT (data not shown). During the first year post-
KT, 16 patients (50%) discontinued ciclosporin (n=14 switched to tacrolimus, 
n=2 to sirolimus) after a median of 19.4 (IQR 11.4, 35.8) weeks, with reported 
reasons acute allograft rejection (n=11), incident Kaposi sarcoma (n=1), nausea 
(n=1), failing graft (n=1), CNI toxicity (n=1) and physician choice (n=1). Of those 
who initiated tacrolimus, one patient switched to sirolimus within 6 days post-KT 
due to CNI toxicity.  
Calcineurin inhibitor doses and drug concentrations achieved are described in 
Chapter 5 (see page 222). 
 
Allograft Outcomes 
Delayed Graft Function 
Delayed graft function occurred in 16 patients (21%; ciclosporin 7, tacrolimus 9) 
all of whom received an allograft from a deceased donor.In the first year post-
KT, 2 patients died with a functioning graft, and 2 experienced complete graft 
failure due to AR. The overall 1 year patient and graft survival rates were 96.8% 
and 95.3% respectively. 
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Allograft Rejection 
Acute allograft rejection was diagnosed in 28 (36%) patients. The median time 
to AR was 2.6 (0.5, 5.9) months from allograft insertion. Acute rejection was 
significantly more common among patients who started ciclosporin (n=18, 58%) 
compared with tacrolimus (n=10, 21%). At 1-year post KT, the cumulative 
incidence of acute rejection was 60% in the ciclosporin group compared with 
20% in the tacrolimus group (p=0.0003, (see Figure 23). Nearly half of all AR 
episodes with tacrolimus occurred within 14 days of KT. By contrast, AR 
episodes with ciclosporin were common throughout the first 9 months post-KT.  
Figure 23: Cumulative incidence of acute allograft rejection 
 










47 41 40 38 34 31 Tacrolimus 
31 23 18 13 10 10 Ciclosporin 
Number at risk 
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Graft Function 
The median eGFR at 52 weeks was 41 (IQR 31, 62) and 55 (IQR 40, 78) mL/min/1.73 m2 for patients who initially 
received ciclosporin and tacrolimus, respectively, (see Figure 24).  In a multi-level mixed effects model, eGFR at 
baseline was similar for both CNI groups with ciclosporin somewhat lower than tacrolimus (overall difference -2.92 
(95CI -12.9, 7.1) ml/min/1.732, p=0.57). The rate of change in eGFR over the first year was significantly different in 
both groups (interaction p=0.000), with moderate decline observed in the Tac group (-0.09 (-0.20, 0.03)) and small 
increase in the ciclosporin group (0.25 (0.14, 0.36)). Findings were similar when last clinic visit was factored into the 
model with the rate of change in eGFR remaining significantly different between groups (interaction p=0.03). For 
patients that were taking tacrolimus, there was a modest decline of eGFR to last clinic visit (-0.03 (-0.055, -0.006) 
when compared to ciclosporin (0.01 (-0.02, 0.04)). 
 
 
Figure 24: Post-Transplant Allograft Function 
 
Graph showing graft function over the first year post-kidney transplant stratified by CNI choice. Graft 
function was defined by estimate glomerular filtration rate (eGFR) calculated using CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration) formula (Levey et al., 2009). Bars represented median eGFR 




































- 183 - 
Immunological Responses 
At baseline, there were no differences in the mean CD4 T cell counts in both 
tacrolimus and ciclosporin groups. Throughout the study period both groups 
maintained a CD4 T cell count > 200 cells/mm3. In the ciclosporin group, 
recipients saw an increase and overall had higher CD4 T cell counts when 
compared to those on tacrolimus (see Figure 25A). The largest difference 
between the groups in CD4 T cell count was at month 4 and 6 although not 
significant p=0.05, p=0.11 respectively. When stratified by cART choice, no 
differences in CD4 T cell counts were found (see Figure 25B). When looking at 
choice of induction therapy, two patients on alemtuzumab (anti-CD52) showed 
significant persistent CD4 T cell depletion throughout 12 months of follow-up 
(see Figure 25C). Those that experienced AR seemed to have somewhat 
difference in CD4 T cell counts at 2 months post-KT compared to those that 
remained rejection free (see Figure 25D). Those on anti-CD25 therapies, 
basiliximab and daclizumab, maintained CD4 T cell counts >300 cells/mm3 
throughout the first year post-KT. 
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Immunological Responses Post-KT 
Figure 25: Changes in CD4+ T Cell Count Post-KT stratified by CNI choice 
A. CNI choice at KT           B. cART choice at KT 
     
C. Induction Therapy Choice            D. Allograft Rejection  
    
Graph of mean (SD) CD4+ T Cell Count change over time post-transplantation stratified by CNI choice (A), cART choice (B),choice of induction therapy (C) and allograft rejection (D). At baseline, patients on a non-PI had 
significantly higher CD4+ T Cell counts (ranksum p=0.02) although over time no differences were found between the two groups. Patients that received basiliximab and daclizumab, both antiCD25 monoclonal antibodies, had 
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CNI-associated Adverse Events 
Reactivation of latent viral infections was more commonly observed in those taking ciclosporin compared 
to tacrolimus (overall n=22 vs. n=12 p=0.0002; cytomegalovirus (CMV) n=13 vs. n=7; herpes simplex 
(HSV) n=4 vs. n=2; Epstein-Barr Virus (EBV) n=0 vs. n=2; BK viraemia/nephropathy n=5 vs. n=1). 
However, primary CMV prophylaxis was less frequently prescribed in those who received ciclosporin 
(n=9) compared to tacrolimus (n=23) (p=0.02); (see    Figure 26). CMV reactivation preceded AR in 9 of 
12 patients, i.e. this was generally not precipitated by anti-AR therapy. HIV viral load blips <200 copies/ml 
occurred in four patients all taking CsA at KT, of whom three had latent viral reactivations. Those that had 
HIV viral load blips, three were on PI/r all of whom experienced an AR episode; the remaining patient on 
PI-sparing did not reject. There was no difference in the incidence of drug induced cytopenias (n=7 in 
each group). Two malignancies emerged (Kaposi sarcoma and lentiginous junctional melanoma, n=1 
each), both patients on ciclosporin, and 2 cases of new onset of diabetes post-transplantation (NODAT), 
both in patients taking tacrolimus. One patient developed thrombotic microangiopathy while receiving 
tacrolimus. 
 
   Figure 26: Post-Transplant CMV Infection Stratified by CNI Choice at KT 
 
Graph showing cumulative incidence of first CMV infection by 
















CMV Infection by CNI Choice at KT
CMV Prophylaxis  
Ciclosporin n=9 
Tacrolimus n=23 
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Factors Associated with Acute Rejection 
Factors associated with rejection were analysed using Cox proportional hazard 
regression. Univariable analysis only identified one factor significantly 
associated with AR, the choice of initial CNI (hazard ratio [HR] for tacrolimus vs 
ciclosporin 0.25 [95% CI 0.11, 0.57], p=0.001). Recipient age, gender, ethnicity, 
deceased donor graft, year of KT, nadir or current CD4 cell count, and viral 
hepatitis status were not associated with AR, (see Table 24).  
 
Six patients experienced allograft rejection within the first 2 weeks post-KT. 
These included antibody mediated rejection (n=4) and severe hyperacute 
rejection (n=2) episodes that would have occurred independent of CNI choice. 
Therefore, I performed a sensitivity analysis which included follow up from week 
3 onwards, use of tacrolimus (HR 0.16 [95% CI 0.06, 0.43]) and abacavir (0.39 
[95% CI 0.16, 0.94]) were protective whereas use of protease inhibitors (HR 
2.63 [95% CI 1.08, 6.44]) was associated with an increased risk of AR. HLA-DR 
was the only immunological parameter assessed for the risk of developing 
rejection although, there was a proportion of patients with missing data (18%, 
n=14). Other immunological factors such as calculated reaction frequency 
(CRF) and re-transplantation were not tested in this cohort. Reasons for this 
include: changing clinical practice over the study changed from measuring 
panel reactive antibody (PRA) to CRF that prevented standardisation of the 
analyses; and, no patients had been re-transplanted, all were first time 
transplant recipients. Of these factors, only the use of tacrolimus (HR 0.19 [95% 
CI 0.06, 0.57]) remained significantly associated with a reduced risk of AR in 
multivariable analysis. Use of tacrolimus was not associated with AR in the first 
2 weeks post KT (HR 0.88 [95% CI 0.20, 3.92]).  
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Table 24: Factors Associated with Allograft Rejection in the First Year Post-KT  
Characteristics Entire follow up (n=78) Excludes follow up during the first 2 weeks post-
KT (n=72) 
 Univariable Univariable Multivariable 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 














































Transplant year 1.04 (0.89, 1.21) 0.59 1.00 (0.84, 1.18) 0.97   
CD4 count at KT**  
(per 50 cell increase) 
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0.99 (0.433, 2.56) 
1.36 (0.30, 6.20) 








0.94 (0.37, 2.39) 
1.75 (0.37, 8.25) 








1.26 (0.48, 3.28) 
1.46 (0.30, 7.11) 









































































































HR=Hazard ratio estimated from Cox proportional hazard regression model with 95CI of the estimated HR. Model 
adjusted for CNI switch; CI=Confidence Interval; P=p-value;  
 Missing values  -  **n=1, ¶ n=3, Ψ n=6,  b Tacrolimus n=8 
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4.4. Discussion 
In this national observational cohort study of KT in HIV positive patients, acute 
allograft rejection was a frequent complication almost twice the rate seen in the 
general population (36% vs 12-24% respectively (Summers et al., 2010, 
Summers et al., 2013)). Overall, there was a significantly higher incidence of AR 
observed in the ciclosporin group compared to those that received tacrolimus 
(60% vs 20% at 1 year, p=0.0003). This rejects the null hypothesis. This was 
also proven in the multivariable analyses (Tacrolimus vs Ciclosporin HR 95CI: 
0.27 (0.12, 0.61), p=0.002). 
CNI Choice  
In our cohort except for age, both CNI groups were well matched at KT; this 
included the choice of induction therapy which mainly consisted of anti-CD25 
monoclonal antibodies plus pulsed corticosteroids. Maintenance therapy 
included a choice of CNI plus mycophenolate or azathioprine plus 
corticosteroids. This allowed for a comparison of ciclosporin versus tacrolimus 
based IS therapy in the management of HIV/KT. Results revealed a two-fold 
greater incidence of AR was observed with ciclosporin. This is consistent with 
data from the USA HIV/KT NIH study where the use of ciclosporin was 
associated with 2.1 (95% CI 1.1-3.9) fold increased risk of AR (Stock et al., 
2010a). Although in their analysis, there was a proportion of patients not taking 
calcineurin inhibitor based IS therapy; of 150 HIV/KT patients in the study, 99 
were on CsA, 33 on Tac and 18 on other immunosuppression therapy. 
Inferences could not be drawn from other HIV/KT cohorts as majority were 
small case series. In a small American cohort (N=40), all patients received 
ciclosporin plus sirolimus; allograft rejection occurred in 9 (22%) of recipients 
(Kumar et al., 2005). In a small Spanish case series (N=7), all patients were 
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taking tacrolimus based IS therapy of whom 40% (2/5) experienced allograft 
rejection; excluding 2 that lost their grafts within first week post-KT (Gomez et 
al., 2013). Another case series including 13 HIV/KT recipients in Italy observed 
63% (5/8) AR rate in the CsA group and 60% (3/5) in the Tac group (Bossini et 
al., 2014). However in the Italian cohort, all recipients were on a steroid free IS 
regimen. The Parisian experience of HIV/KT (n=27; CsA n=11, Tac n=16) 
observed overall low rejection rate of 15% (n=4) (Touzot et al., 2010). The 
authors did not report which regimen the patients were taking but did conclude 
that the low rejection rate observed was due to the predominant use of Tac. In a 
recent report on the Portuguese experience of HIV/KT (n=17), all recipients 
were taking Tac and five experienced allograft rejection (Querido et al., 2015). 
In the general population, tacrolimus has demonstrated more favourable 
outcomes post-kidney transplantation when compared to ciclosporin. A meta-
analysis and meta-regression of early clinical trials between 1966 to 2003 
identified 123 reports including 30 RCTs that examined the use of Tac 
compared to CsA for the post-transplant management of KT recipients (Webster 
et al., 2005). This analysis included a combined total of 4102 randomised 
kidney transplant participants from 30 RCTs. All primary post-KT outcomes 
favoured Tac over CsA. There was a significant reduction in allograft rejection 
by Tac at any time point post-KT especially at 6 months where there was a 55% 
marked reduction in AR by Tac compared to CsA, RR 0.45, 95%CI 0.33 to 0.60. 
Authors concluded that when Tac was selected over CsA, allograft rejection 
was avoided in 12 patients for every 100 kidney transplants performed.  
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In the past decade, studies have continued to resonate Tac being the more 
preferred CNI choice in kidney transplantation. The Symphony trial was such an 
example that demonstrated that low dose Tac to be highly efficacious compared 
to standard dose ciclosporin, low dose ciclosporin, and low dose sirolimus 
observed respectively a 12% (30/249), 26 % (61/233), 24% (60/248), and 37% 
(84/228) rejection rate at 1 year (Ekberg et al., 2009a). Although this was a 
pivotal study that instigated the use of low dose CNIs, the study outcomes were 
not generalizable to recipients with immunological high risk of allograft rejection. 
Clinical trials that examined the choice of CNI for patients at high risk of allograft 
rejection also found tacrolimus to be superior to ciclosporin. Especially in 
patients with steroid resistant allograft rejection or rejection that was recalcitrant 
to conventional therapy; Tac was more potent compared to CsA with 
reversibility of AR observed in > 70% of cases (Jordan et al., 1994, Eberhard et 
al., 1996, Woodle et al., 1996, Mayer et al., 1997, Hauser and Neumayer, 1998, 
Manu et al., 1999).   
CNI Exposure & Allograft Rejection 
It is possible that subtherapeutic CNI exposure contributed to the high rate of 
AR, refer to Chapter 5 for further analyses of CNI drug concentrations. Although 
Ctrough concentrations are routinely used in clinical practice to guide CNI dosing, 
it is unclear how well Ctrough concentrations correlate with total exposure (area 
under the concentration time curve [AUC]) in the HIV/KT population. Frassetto 
et al. recently reported that tacrolimus AUC correlated best with Ctrough 
concentrations but that ciclosporin AUC showed better correlation with 
concentrations obtained at 4 hours post-dose (C4 concentrations) (Frassetto et 
al., 2014). Interestingly, despite achieving higher proportions of 
therapeutic/supratherapeutic Ctrough concentrations in the early period post-KT 
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we observed a higher proportion of AR episodes in the CsA/PI group compared 
to the CsA/PI-sparing group. This was not the case for those on tacrolimus 
where majority of those that had an AR episode were on PI-sparing regimens. 
Although not significant, there was somewhat higher proportion of patients that 
experienced an AR episode in the supratherapeutic group compared to the 
other groups (therapeutic and subtherapeutic).  
When we analysed if the Ctrough concentrations achieved at week 2 post-KT had 
an influence on AR, we found that having a supratherapeutic concentrations 
had a somewhat increased risk of AR compared to therapeutic or 
subtherapeutic concentrations (see Figure 23). Perhaps CNI overexposure 
causing nephrotoxicity could offer for a differential diagnosis. In the HIV 
negative population, clinical-pathological correlations have been sought to 
ensure correct diagnosis between CNI-induced nephrotoxicity and acute 
rejection (Liptak and Ivanyi, 2006). Exposure to high CNI concentrations may 
cause acute tubular necrosis (ATN), toxic tubulopathy or vascular toxicity while 
some forms of allograft rejection are also known to cause ATN type tubular 
damage (Liptak and Ivanyi, 2006).  
Although, CNI concentrations have not been found to correlate well with kidney 
damage caused (Liptak and Ivanyi, 2006). Also irrespective of CNI 
concentrations, CNI metabolites have been known to cause nephrotoxicity. 
Frassetto et al (2013) performed pharmacokinetic studies of both ciclosporin 
and tacrolimus metabolites post-HIV/KT and found that patients on antiretroviral 
therapy with CYP enzyme inducing properties (e.g. NNRTIs, efavirenz or 
nevirapine), caused a profound increase in certain metabolites known to cause 
nephrotoxicity. By contrast, in the HIV negative population, low levels of certain 
metabolites e.g. AM1 and AM9 ciclosporin metabolites have been associated 
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with increased risk of allograft rejection (Bauer et al, 2003). Patients taking CYP 
enzyme inhibitor agents (e.g. protease inhibitors) although would increase the 
CsA drug concentrations, they have been found to reduce AM1 and AM9 
(Frassetto, 2013) thus may increase risk of allograft rejection in this patient 
group. 
When considering co-medication of antiretroviral drugs with CNIs, drugs such 
as tenofovir and atazanavir have nephrotoxic potential while others such as 
ritonavir- or cobicistat-boosted PI/integrase inhibitors may give rise to 
challenging drug-drug interactions (Yombi et al., 2014). In our analyses we see 
that the use of INI, raltegravir, to avoid drug interactions may be protective 
against allograft rejection. This was also observed in a French HIV/KT cohort 
that used raltegravir based cART (n=13) (Tricot et al., 2009a). 
Other Factors Associated with Acute Rejection 
In univariable analysis restricted to AR events that occurred 3-52 weeks post-
KT, use of PI was associated with an increased risk of AR and use of abacavir 
with a reduced risk of AR. Ritonavir-boosted PI, through P-glycoprotein and 
CYP3A inhibition (Perloff et al., 2001, Kageyama et al., 2005), increase CNI 
exposure (2-4 fold for ciclosporin, 10 fold for tacrolimus) (Frassetto et al., 2013). 
Tacrolimus is particularly challenging to dose in patients receiving PI who 
required an approximately 100-fold dose reduction.  
Abacavir is a guanosine analogue which may act synergistically with 
mycophenolate mofetil, a drug that blocks the formation of guanosine 
monophosphate, thus depleting the endogenous deoxyguanosine triphosphate 
(dGTP) pool (Margolis et al., 1999). Abacavir is phosphorylated to its active 
form carbovir triphosphate (CBVTP) which competes with endogenous dGTP 
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for incorporation into HIV viral DNA (Sankatsing et al., 2004a); mycophenolate 
may thus increase the antiviral efficacy of abacavir (Margolis et al., 1999). It is 
unknown whether abacavir enhances the immunosuppressive effects of 
mycophenolate. In multivariate analysis, however, the use of PI or abacavir was 
no longer associated with AR. 
In univariable and multivariable analyses no association of CD4+ T cell count 
with allograft rejection was found. In the USA cohort, a higher CD4 T cell count 
was found to be marginally protective (hazard ratio per increase of 50 cells per 
cubic millimeter, 0.9; 95% CI, 0.9 to 1.0; P = 0.07) (Stock et al., 2010b).  
 
Possible mechanisms of rejection in HIV/KT population 
HIV/Ciclosporin Competitiveness for Cyclophillin 
There are studies to demonstrate that HIV competes with ciclosporin for 
cyclophilin although the HIV/cyclophilin complex does not result in calcineurin 
inhibition as seen with ciclosporin (Luban et al., 1993). Some researchers 
suggest that calcineurin induces the activation of nuclear factor-kappa B (NFĸB) 
which in turn stimulates the latent HIV long terminal repeat (LTR) (Chan et al., 
2013). However, the inhibitory effect of CNIs is reversible and calcineurin 
recovery has been noted as early as 2 hours post-dose (Sommerer et al., 
2009). Calcineurin recovery rates have noted to be quicker for ciclosporin 
compared to tacrolimus (Fukudo et al., 2005). Also, some research has shown 
that 50% of lymphocyte activity persists with ciclosporin permitting strong 
cytokine expression (Batiuk et al., 1995b). Furthermore, inhibition of p-
glycoprotein transporters (responsible for the drug efflux), by protease inhibitors 
for example, that one would expect to result in increased intracellular ciclosporin 
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drug concentrations did not prevent the recovery of calcineurin activity in 
leukocytes (Batiuk et al., 1995b). This may provide some explanation for the AR 
episodes seen in the CsA/PI containing group of our study.  
 
Enhanced Intracellular Efficacy of Tacrolimus 
The advantage of using tacrolimus is that it binds to a different immunophilin, 
FKBP-12, that is highly expressed in lymphocytes (Marinec et al., 2008) unlike 
cyclophilin that is found in all cells (Wang and Heitman, 2005). This affinity for 
lymphocytes that have low levels of CYP3A4 enzymes provides for the 
prolonged half-life of Tac (Batiuk et al., 1995a). This effect has been explored to 
improve drug targeting and efficacy of protease inhibitors e.g. appending FKBP-
binding portion of FK506 (tacrolimus) to amprenavir that resulted in a 20-fold 
improved half-life in mice (Marinec et al., 2008). This effect is probably what 
offers Tac a more efficacious profile compared to ciclosporin thus have fewer 
AR episodes.  
 
HIV-driven Immunological Responses 
Another explanation could be due to the immunological profile of HIV+ patients 
which differs to HIV negative patients. It has been noted that when HIV+ 
patients initiate antiretroviral therapy and CD4 T cell counts increase, the 
majority of these are memory T cells. It has been suggested that if these 
expanded T cells have cross-reactivity with alloantigens from the donor 
allograft; these cells may cause rejection (Stock et al., 2003b). Although this 
has yet to be elucidated in the HIV+ kidney transplant population.  
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There is also the possible B cell involvement where HIV+ patients are known to 
have HIV-associated B cell fatigue causing proinflammatory cytokine release 
that might prime antigen-presenting cells. This has been hypothesised in the 
HIV negative population where rituximab (antiCD20) monoclonal antibodies 
used for induction therapy causing B cell depletion that could be likened to B 
cell associated fatigue. This trial was stopped early due to the high rate of 
rejection, 83% vs 14% in the control group (n=13) (Clatworthy et al., 2009). 
Acute cellular rejection (ACR) was most commonly observed in this trial which 
has also been noted in HIV/KT recipients; 28% at 1 month and 55% at 12 
months post-KT (Malat et al., 2012). 
 
There is also the possibility of latent viral reactivations that infect the graft. In 
our cohort, we observed only 3 cases of BK nephropathy and no other viral 
caused nephropathies. In a French cohort that examined protocol biopsies post-
HIV/KT found HIV infected the transplanted allograft in 68% of patients (n=19) 
despite well controlled HIV (undetectable HIV RNA in plasma < 50cps/ml). HIV 
was predominantly detected in the podocytes that resulted in a rapid decline in 
allograft function compared to those with tubular cell infection (Canaud et al., 
2014).  
 
The strength of this study is near complete sample that was well matched 
allowing for controlling of confouding factors. Also, detailed data were available 
on HIV treatment, IS management (including drug concentrations), CD4 cell 
counts and HIV viral loads. Nonetheless, the study has several limitations 
including its observational nature, the non-standardised KT protocols employed 
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at the participating centres with evolution over the 8 year study period, the 
relatively small number of patients, retrospective case identification, and some 
missing data. Whilst we assumed available drug concentrations to reflect Ctrough 
concentrations, we were unable to ascertain which of those reported drug 
concentrations were true Ctrough concentrations. Chapter 5 contains further 
analyses of CNI drug concentrations. There were clinical parameters not 
measured in this study that may have useful in the analyses of allograft 
rejection including pre-transplant calculated reaction frequency (CRF)and post-
transplant donor specific antibodies. These parameters may have enabled in 
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4.5. Conclusion 
The results support the hypothesis that HIV positive kidney transplant recipients 
receiving ciclosporin based immunosuppression therapy have higher allograft 
rejection rates in the first year post year post-transplant compared to tacrolimus 
based IS therapy. This suggests that tacrolimus may be the preferred choice for 
the management of HIV kidney transplant recipients. This finding is consistent 
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Chapter 5. Achieving Therapeutic Drug Concentrations in 
HIV+ Kidney Transplant Recipients  
5.1. Introduction 
Calcineurin inhibitors, ciclosporin and tacrolimus, have a narrow therapeutic 
index which requires close therapeutic drug monitoring (Schiff et al., 2007). 
This makes CNI dosing and achieving therapeutic drug concentrations quite 
challenging particularly during the early period post-transplant when 
immunosuppression drug management is critical (Perico et al., 2004). Not 
achieving and maintaining therapeutic drug concentrations throughout the 
life of the host/graft is detrimental for short and long-term transplant 
outcomes (Perico et al., 2004, Gotti et al., 2005, O'Seaghdha et al., 2009). 
Although there are many factors that cause variations in CNI drug exposure 
to include: drug formulation (Hibberd et al., 2006, Qazi et al., 2006, Sharma 
et al., 2006); food (Takeda et al., 2007) or drug interactions (van 
Maarseveen et al., 2012); gender (Min et al., 2000); pharmacogenetics 
(Macphee et al., 2002, MacPhee, 2012); or patient adherence (Borra et al., 
2010a). Furthermore, haemodynamic changes in the patient post-
transplantation may also contribute to the changes in CNI drug exposure 
(Capela et al., 2014). The resulting inter- and intra-patient variability CNI 
drug concentrations have been known to put kidney transplant recipients at 
risk of allograft rejection and subsequently reduced graft survival (Borra et 
al., 2010a). By contrast, CNI over-exposure puts kidney transplant 
recipients at risk of adverse drug reactions to include nephrotoxicity 
(Scholten et al., 2005).  
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Within the HIV positive population achieving the optimum 
immunosuppression is vital, not only for the prevention of allograft rejection 
but also, for the prevention of morbidity and mortality which includes 
reactivation of latent viral infections (Palefsky and Holly, 2003). 
Opportunistic infections can accelerate the progression of HIV disease 
(Nelson et al., 2011) therefore, preventing latent viral reactivation in 
immunocompromised patients through achieving the right balance of 
immunosuppression is crucial. Furthermore, HIV positive patients take 
antiretroviral drugs that share the same metabolic and transporter pathways 
as calcineurin inhibitor immunosuppressant drugs resulting in profound 
drug-drug interactions (van Maarseveen and van Zuilen, 2013). These drug 
interactions make achieving and maintaining the ‘therapeutic’ window of the 
calcineurin inhibitor drugs challenging in clinical practice.  
 
Metabolism of Calcineurin Inhibitors 
Ciclosporin 
Ciclosporin is highly lipophilic which results in variation in the oral 
bioavailability of between 1 to 89%. The first formulation of CsA, 
Sandimmune ®, was oil based which limited aqueous solubility resulting in 
poor oral absorption. Neoral ® was later introduced using a new formulation 
where a microemulsion formed on contact with water. This somewhat 
improved oral absorption, particularly via the small intestine, however, there 
was still a wide inter- and intra-patient variability (Knops et al., 2013). 
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Once ciclosporin is absorbed, almost half is metabolised in the intestine and 
8% is lost to first pass hepatic metabolism. The remainder is distributed to 
the plasma (33 to 47%), lymphocytes (4 to 9%), granulocytes (4 to 12%) 
and erythrocytes (41 to 58%). The percentage available in the plasma is 
highly protein bound (98%). Ciclosporin is a substrate for the multidrug 
resistance protein (MRP) p-glycoprotein transporter and is primarily 
metabolised by cytochrome P450 3A4 isoenzymes (Table 25)(Knops et al., 
2013). This metabolic pathway subjects CsA to multiple drug interactions. 
The biotransformation of CsA produces 30 metabolites which have different 
activity. For example, AM1 metabolite can inhibit T cell function (Ozbay et 
al., 2007). 
 
Table 25: Summary of Metabolism and Transporter Mechanisms of 
Commonly Used Immunosuppressant Drugs in Kidney 
Transplantation 
Immunosuppressant Drug Metabolism (ASHP, 2015, PharmGKB, 2015) 
 Metabolised by Transported by 
Calcineurin Inhibitors 
Ciclosporin CYP3A4, CYP3A5 P-gp, MRP-1 
Tacrolimus CYP 3A4, CYP 3A5 P-gp 
mTOR Inhibitors 
Sirolimus CYP3A4, CYP3A5, UGT1A8 P-gp 
Everolimus CYP3A4, CYP3A5, 2C8 P-gp 
Antiproliferative/Corticosteroids 
Azathioprine TPMT, HGPRT - 
Mycophenolate UGT MRP-2 
Prednisolone CYP3A4 P-gp, MRP-1 
Key: 
CYP, cytochrome P450; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; MRP, 
multi-drug resistance protein; P-gp, P-glycoprotein; TPMT, Thiopurine-S-methyltransferase; 
UGT, UDP-glucuronosyltransferase 
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Tacrolimus 
Similarly to ciclosporin, tacrolimus exhibits poor oral bioavailability which is 
further reduced by the ingestion of fatty meals with only approximately 20% 
reaches the systemic circulation after oral administration. This results in a 
wide intra-patient variability ranging from 4 to 93% (Knops et al., 2013). 
Alterations in gut motility and the presence of loose stool have been found 
to influence the absorption of tacrolimus (Hochleitner et al., 2001, 
Nakamura et al., 2014). Furthermore, HIV associated enteropathy, involving 
damage to the gastrointestinal epithelial layer, villous atrophy, crypt 
hyperplasia and villous blunting; may reduce enzymatic activity in the small 
intestine thus influencing plasma concentrations (Mittal et al., 2001, 
Brenchley and Douek, 2008). Once tacrolimus reaches the circulation, only 
5% is distributed into the plasma compartment, the majority being bound in 
erythrocytes (Knops et al., 2013). 
Tacrolimus is a substrate for p-glycoprotein and is primarily metabolised by 
cytochrome P450 3A4 and 3A5 isoenzymes (refer to Table 25). Nine 
metabolites have been identified to date and 4 have been found to have 
potent immunosuppressant activity. CYP3A5 is more influential in the 
metabolism of tacrolimus and genetic polymorphisms have been 
demonstrated to guide the dose requirements in particular patient groups. 
For example, patients of black ethnicity possessing the CYP3AP1 G allele 
are known to be high expressers of 3A5 and therefore require higher 
tacrolimus doses compared to other ethnic groups (Macphee et al., 2002, 
MacPhee, 2012). In addition, physiological changes that occur post-
transplant may alter the requirements of tacrolimus. For example, the use of 
anaesthesia and accompanied dehydration post-KT could result in 
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decreased intestinal motility which may in turn increase metabolism and/or 
tacrolimus absorption in the small intestine. This is important to consider as 
some of the antiretroviral drugs are known to cause diarrhoea (MacArthur 
and DuPont, 2012) that could affect the absorption of tacrolimus. Alterations 
to P-gp and CYP3A4 activity post-transplantation associated with changes 
to gut microbiota following the use of antibiotics, gastric acid suppressants 
and corticosteroid tapering, could also influence the tacrolimus dosing 
regimen (Lemahieu et al., 2005a, Lemahieu et al., 2005b, Lee et al., 2015). 
CNI and Antiretroviral Drug Interactions 
Antiretroviral drugs that share transporter and metabolic pathways with 
calcineurin inhibitors are subject to drug-drug interactions. Transporter 
proteins and metabolic enzymes responsible for the handling of 
antiretroviral drugs currently available in the UK are summarised in Table 
26. Overall, there are two major classes of ARVs that demonstrate clinically 
significant pharmacokinetic drug interactions, non-nucleoside reverse 
transcriptase inhibitors, which are inducers of p-glycoprotein and 
cytochrome P450 enzymes, and protease inhibitors which are potent P-gp 
and CYP enzyme inhibitors. The use of P-gp or CYP3A4 inhibitors would 
extend the elimination half-life of immunosuppressants thus alter the time it 
takes to achieve steady state and, depending on dosing frequency, the 
maximum whole blood concentration (Cmax) and total exposure (AUC) 
achieved (Venkataramanan et al., 1995). Additionally, depending on drug 
concentrations, the kinetic order could change from first order to zero order 
kinetics (Rowland et al., 2011).  
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There are several approaches to managing the extension of the drug 
elimination half-life, such as:  
a. Administer a loading dose  
b. Extend the dosing interval 
c. Reduce the dose given  
When managing pharmacokinetic drug interactions several strategies could 
be utilised pre-emptively in order to avoid sub- or supra-therapeutic drug 
concentrations. There are multiple influential factors to consider e.g. drug 
half-life, liver/renal impairment, absorption, enterohepatic recycling, 
distribution, metabolism, excretion, protein binding. Both ciclosporin and 
tacrolimus are highly protein bound, 90 to 98% respectively, and when 
absorbed less than 1% is excreted in the urine. With so little excreted via 
the kidneys, no dose adjustment is required in renal impairment (Ashley and 
Dunleavy, 2014). The half-life of both CsA and Tac ranges from 5 to 20 
hours and 12 to 16 hours respectively. Therefore, it could take between 1 to 
4 days for CsA/Tac to reach steady state whole blood concentrations. 
However, this does not take into account that the drug half-life could be 
further altered by drug interactions as well as haemodynamic or metabolic 
changes that occur post-transplantation (Venkataramanan et al., 1995, 
Schiff et al., 2007, Frassetto et al., 2013).  
Co-administration of ciclosporin or tacrolimus with either NNRTIs or PIs 
would require a CNI dose increase and decrease respectively (see Table 
27). Other antiretroviral drug classes are unlikely to interact therefore, 
minimal or no CNI dose adjustments would be expected (van Maarseveen 
et al., 2012, LHPG, 2015).   
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CNI Therapeutic Drug Monitoring 
Ciclosporin and tacrolimus both possess narrow therapeutic indices that 
require routine therapeutic drug monitoring (TDM) which determine drug 
efficacy and toxicity. Total drug exposure, determined by the area under the 
whole blood concentration-time curve (AUC), would be the ideal parameter 
to use for TDM however; it is not practical in clinical practice. For these 
reasons, limited sampling strategies have been found more attractive in 
routine clinical care. However, there is conflicting evidence of the optimal 
time point for CNI TDM. Early studies on ciclosporin TDM demonstrated 
better correlation of the maximum concentration (Cmax) and AUC with 
allograft rejection compared to the pre-dose concentrations (Ctrough) 
(Kasiske et al., 1988, Schiff et al., 2007). Although, monitoring Cmax and 
AUC in routine clinical care was also not feasible due to the inaccuracies of 
sampling times. Monitoring both Ctrough and Cmax at 2 hours post-dose (C2) 
was later found to best correlate with total CsA exposure (AUC) to avoid 
allograft rejection (Keown et al., 1996, Levy et al., 2002, Schiff et al., 2007). 
It was the Concert research group (Levy et al., 2002) that reiterated that C2 
monitoring was the optimal time point for CsA TDM and that Ctrough poorly 
predicted clinical events. However, the Concert group also noted that there 
were patients that were poor or slow absorbers of CsA which meant that C2 
was not representative of Cmax for all patients. It was also argued, that the 
use of adjunctive immunosuppressant drug therapy, such as 
mycophenolate, or induction therapy would reduce the need to monitor C2 
concentrationsalthough there wasn’t strong evidence to support this 
(Hardinger et al., 2004c, Remuzzi et al., 2004). Consequently, single point 
monitoring of Ctrough became routine clinical practice.  
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Aside from the sampling time, achieving therapeutic concentrations in the 
immediate period post-transplant was crucial. In the general population, 
there were studies that demonstrated achieving either therapeutic C2 or 
Cmax CsA concentrations early, in the first 2 weeks post-transplantation, 
were a strong predictor of allograft rejection (Clase et al., 2002, Internation 
Neoral Renal Transplantation Study, 2002, Levy et al., 2002, Gotti et al., 
2005, Schiff et al., 2007). However, there are other competing factors 
during this time period that could deter from achieving therapeutic 
concentrations such as delayed graft function and/or induction therapy 
choice (Clase et al., 2002, Hardinger et al., 2004c, Schiff et al., 2007).  
By contrast, several studies showed that tacrolimus AUC best correlated 
with Ctrough concentrations (Balbontin et al., 2003, Undre, 2003, Scholten et 
al., 2005, Schiff et al., 2007). However, some studies demonstrated that 
Tac whole blood concentrations drawn 4 hrs post dose were a better 
predictor of clinical events compared to Ctrough concentrations (Wong et al., 
2000, Armendariz et al., 2005, Schiff et al., 2007).  Due to practical and 
cost-effective reasons as discussed previously, Ctrough Tac monitoring has 
become the norm in clinical practice.  
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Table 26: Summary of Metabolism and Transporter Mechanisms of Antiretroviral Drugs  
Antiretroviral Drug Metabolism (van Maarseveen et al., 2012, ASHP, 2015, LHPG, 2015) 
 Metabolised by* Transported by Enzyme/Transporter Induction or Inhibition 
Effect 
Protease inhibitors (PI) 
Atazanavir 3A4 P-gp, MRPs, 
BCRP 
Inducer of P-gp, MRP1 
Inhibitor of 3A4, 2C8 UGT1A1, BCRP, P-gp, 
MRPs, OATP  
Darunavir 3A4 P-gp Inducer of 2C9, 2C19, 2C8 Inhibitor of  3A4, 2D6, 
P-gp, OATP 
Fosamprenavir 3A4 P-gp Inducer possibly 3A4 with ritonavir 
Inhibitor of  3A4, BCRP, P-gp, MRP1, OATP 
Indinavir 3A4 P-gp, MRP1, 
MRP2, OATP 
Inhibitor of  3A4, P-gp, MRP1, OATP-C 
Lopinavir  3A P-gp Inhibitor of  3A, BCRP 
Nelfinavir 3A, 2C19, 2C9, 2D6 P-gp, MRP1&2 Inhibitor of 3A, MRP1, BCRP, OATP-C 
Ritonavir 3A, 2D6 P-gp, MRP1 Inhibitor of 3A, 2D6, P-gp, MRP1, OATP-C, BRCP 
Inducer of 1A2, 2C8/9/19 & MRP1. 
Saquinavir 3A4 P-gp, MRP1&2, 
OATCP 
Inhibitor of  P-gp, MRP1, BCRP, OATP-C 
Tipranavir 3A4 P-gp Inhibitor of 3A4/5, 2D6, P-gp, BCRP. 
Inducer of 3A, P-gp, 2C19 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Delavirdine 3A4, 2C9, 2D6, 2C19 BCRP, MRPs Unknown 
Efavirenz 3A4, 2B6 P-gp Inducer of 3A4, 5, 7 
Inhibitor of  2C9, 2C19&3A4 
Etravirine 3A4, 2C9, 2C19 
UGT 
P-gp Weak Inducer of  3A4 
Weak inhibitor of 2C9, 2C19, P-gp 
Nevirapine 3A4, 2B6 P-gp Inducer of 3A4, 5, 7 
Rilpivirine 3A, potential 2A19 Not significantly 
transported by P-gp 
P-gp inhibitor; unlikely to induce or inhibit CYP 
enzymes at dose of 25mg daily 
Integrase/Entry Inhibitors  




BCRP and P-gp Does not inhibit or induce CYP enzymes or 
transporters 
Elvitegravir/cobicistat Elvitegravir – 3A and 
UGT1A1 and 
UGT1A3; Cobicistat 
– 3A, 2D6 (minor) 
P-gp primarily Elvitegravir inducer of 2C9 and UGT (modest); 
Cobicistat inhibitor of 3A, 2D6, P-gp, BCRP, 
OATP1B1, OATP1B3 
Maraviroc 3A4 P-gp Unlikely to induce or inhibit at clinically relevant 
concentrations 
Raltegravir UGT1A1; no 
CYP450 involvement 
Unknown No CYP450 or P-gp inhibition or induction 
*CYP450 enzyme unless indicated.  
Key:  BCRP, = breast cancer resistance protein; CYP, =cytochrome P450; MRP =multi-drug resistanceprotein; OATP= Organic anion-transporting 
polypeptide; P-gp = P-glycoprotein; UGT =UDP-glucuronosyltransferase 
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Table 27: Calcineurin Inhibitor and Antiretroviral Drug-Drug Interaction 
Table  
Drug Interactions between CNIs and Antiretroviral Drugs (Buncherd et al., 2012) 
 NRTI NNRTI PI INI MVC 
Calcineurin Inhibitors 
Ciclosporin -   - - 
Tacrolimus -   - - 
mTOR Inhibitors 
Sirolimus -   - - 
Everolimus -   - - 
Antimetabolite/Corticosteroids 
Azathioprine - - - - - 
Mycophenolate * - - - - 
Prednisolone -   - - 
Key: (-), No interaction in literature or unexpected from theoretical metabolism/transporter 
mechanisms; , increase in drug concentrations; , decrease in drug concentrations; Number of 
arrows represents the degree of the interaction expected; *, in vitro evidence of increase 
intracellular drug concentrations. 
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Summary of Published Evidence of DDIs between CNIs and ART Post-
HIV/KT 
Co-administration of calcineurin inhibitors with antiretroviral drugs particularly 
those with P-gp/CYP inhibition or induction properties makes achieving the 
optimal CNI dose post-kidney transplantation challenging. Reports in the 
literature, have described the need for CNI dose adjustments required in order 
to achieve therapeutic CNI drug concentrations in patients co-administered 
antiretroviral therapy. In summary, the co-administration of tacrolimus with P-
gp/CYP inhibitors – ‘PI containing cART’ then a dose reduction up to 140 fold 
may be required (see Table 28). Ciclosporin dose reduction is also required 
when co-administered with PI-containing cART although to a lesser extent 
compared to Tac, ~20 fold. Modest dose adjustments are required when both 
Tac and CsA are co-administered with PI-sparing cART (see Table 29).  
Although the literature summarises the CNI doses used when co-administered 
with cART, clinical studies have not been conducted to describe in clinical 
practice the following:  
i. Distribution of Ctrough concentrations throughout the first 12 months post-
HIV/KT with proportion that achieved sub-, supra- and therapeutic Ctrough 
concentrations 
ii. Relationship of CNI dose and Ctrough concentration achieved 
iii. Time to achieve therapeutic CNI Ctrough concentrations in the early period 
post-HIV/KT  
iv. CNI doses used to achieve therapeutic CNI Ctrough concentrations in the 
early period post-HIV/KT 
v. Inter/Intrapatient variability of Ctrough concentrations determined during 
periods of stability (6 to 12 months) post-transplant 
vi. Factors associated with CNI Ctrough concentration achieved and clinical 
end-points such as allograft rejection, graft function or graft loss
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Table 28: Summary of Evidence (case studies, case series, prospective studies) of CNI and Drug Interactions with 
PI-Containing Antiretroviral Drug Therapy 
  
PI Containing ART 
Publication Organ N ART Regimen Effect on Dose Effect on Pharmacokinetic parameters 
Ciclosporin 
(Brinkman et al., 1998) KT 1  SQV 50% dose reduction 300% higher CsA AUC concentrations; SQV 
AUC 500% higher than 5 controls not taking 
CsA. 
(Gruber et al., 2008a) KT 8 PI/r Not specified Dose ranges:  
• 25mg q 24h, q 48h 
• 50mg to 75mg q 12h 
• 75 q 72h 
• 125mg q 48h 
• 175mg q 72h 
Ctrough concentrations not reported; doses 
aimed at achieving Ctrough concentrations of 
225 to 300 ng/ml. 
(Gregoor et al., 1999) KT 1 SQV/r 50mg q 12h Drug concentrations over 1000 ng/mL 
Tacrolimus 
(Hardy et al., 2004) KT 1 SQV/r 0.5mg once a week; 140- 
fold dose reduction 
Drug concentrations over 175 ng/mL 
(Tan et al., 2004a) KT 3  Not specified Case 1: 0.1mg q 96h 
Case 2: 4mg q 24h 
Ctrough concentrations:- 
Case 1: 3.7ng/ml 
Case2: 7.0ng/ml; Renal toxicity noted on 
biopsy. 
(Frassetto et al., 2007) KT & OLT 35  
(20 KT, 15 
OLT) 
Not specified 80% dose reduction & 7 fold 
increase in dosing interval 
Similar drug concentrations achieved to 
patients not on ART after dose adjustment. 
(Sheikh et al., 1999) KT 1 NFV Dose ranged from 0.5mg q 
24h to 4mg q 12h 
Ctrough concentrations ranged from 23.7 to > 
120 ng/ml; Neurological toxicity 
(Jain et al., 2003) OLT & SLK 3 LPV/r 1 mg once a week Ctrough concentrations 2.9 to 5.4 ng/ml 
(Mertz et al., 2009) SPK 1 DRV/r Dose reduction to 3.5% of 
normal dose 
Drug concentrations over 100 ng/mL 
(Morelle et al., 2010) KT 1 LPV/r 0.5mg once a week; 140-fold 
dose reduction 
Drug concentrations over 30 ng/mL for 15 
days 
(Cousins et al., 2011) KT 1 ATZ/r 1.5mg twice daily TAC resulted 
in high concentrations 
Drug concentrations as high as 160 ng/mL 
were reported 
(Akhtar et al., 2011) SPK 1 DRV/r; ETV; RAL 1mg every week Ctrough concentrations 8 to 15 ng/ml 
(van Maarseveen and van 
Zuilen, 2013) 
KT 4 LPV/r; DRV/r;  
+/-ETV, EFV, NVP 
2, 1.5, 2, and 2 mg loading 
dose (0.01 to 0.1mg/kg) 
Median Ctrough concentrations 17.8 ng/mL;  
pre-KT CNI trial 12h AUC showed no peaks 
Key:       KT, kidney transplant; OLT, orthotopic liver transplant; SLK, simultaneous liver-kidney transplantation; SPK, simultaneous kidney–pancreas 
transplantation; q, every; h, hours; CsA, cicloposrin; Tac, tacrolimus; ATZ, atazanavir; DRV, darunavir; EFV, Efavirenz; ETV, etravirine; LPV, lopinavir; NVP, 
Nevirapine; NFV, nelfinavir; SQV, saquinavir; /r, ritonavir boosted 
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Table 29: Summary of Evidence (case studies, case series, prospective studies) of CNI and Drug Interactions with PI-
Containing Antiretroviral Drug Therapy 
PI Sparing ART 
Publication Organ N ART 
Regimen 
Effect on Dose administered Effect on whole blood concentrations 
Ciclosporin 
(Frassetto et al., 
2007) 
KT & OLT 35  
(20 KT, 15 
OLT) 
EFV, NVP  EFV – ~50% dose increments 
NVP - Minimal dose adjustments 
30% lower Ctrough concentrations reported with EFV despite 
dose adjustments. The trough/dose ratio for EFV is less 
than half that of NVP. 
(Gruber et al., 
2008a) 
KT 8 NVP  50 to 150mg q 12h vs 175 to 
200mg q 12h in NRTI only cART 
Ctrough concentrations not reported; doses aimed at 
achieving Ctrough concentrations of 225 to 300 ng/ml. 
(Tricot et al., 
2009b) 
KT & OLT 13 RAL KT: 10 mg q 24h 
OLT: 175 to 250 mg q 24h 
KT: C2 400 ng/ml 
OLT: C0135 to 218 ng/ml 
Tacrolimus 
(Tan et al., 2004a) KT 3 Not specified 16mg every other day 3.0ng/ml Ctrough concentrations 
(Frassetto et al., 
2007) 
KT & OLT 35  
(20 KT, 15 
OLT) 
EFV, NVP 3.1 ± 1.4mg every 12h vs 7 to 
9mg every 12h in ARV naïve 
patients. 
Ctrough concentrations achieved 6.4 ± 2.9ng/ml vs 3 to 
30ng/ml in ARV naïve patients. 
(Tricot et al., 
2009b) 
KT & OLT 13 RAL  
KT: 7 to 24 mg q 24h 
OLT: 0.5 to 10 mg q 24h 
Ctrough concentrations:- 
KT: 7.1 to 10.5 ng/ml 
OLT: 3.4 to 9.2 ng/ml 
(Miro et al., 2010) SPK 1 RAL 1.8 to 4.1 mg q 24h Ctrough concentrations 5.7 to 19.2 ng/ml 
 Key: KT, kidney transplant; OLT, orthotopic liver transplant; CsA, cicloposrin; EFV, Efavirenz; h, hour; NVP, Nevirapine; NRTI, nucleoside/tide reverse 
transcriptase inhibitor; SQV, saquinavir; cART, combination antiretroviral drug therapy; C0, Ctrough concentrations. 
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Purpose of study 
The main aim of this study was to describe the calcineurin whole blood 
concentrations attained in clinical practice for HIV positive kidney transplant 
recipients in the first year post-transplantation. In particular, to determine the 
extent target range CNI whole blood concentrations were achieved and 
maintained during the first 12 month post-HIV/KT.  
Primary aims 
Aim 1: To describe CNI trough whole blood concentrations achieved and 
associated doses during the first 12 months post-transplant. 
Aim 1A: To describe the time and dose to achieve the first therapeutic trough 
whole blood concentration during the first 14 days post-transplant. 
Aim 1B: To describe the proportion of therapeutic trough whole blood 
concentrations achieved and associated doses in the ‘early’ (0 to 12 weeks) 
phase post-transplant. 
Aim 1C: To describe maintenance trough whole blood concentrations and 
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5.2. Method 
Patient Enrolment 
For this chapter, data were used for all enrolled HIV+ study subjects. Enrolled 
patients were stratified into two groups, those on ciclosporin (CsA) and 
tacrolimus (Tac) based CNI therapy at the point of transplantation. All patients 
were included in chapter analyses unless they met any exclusion criteria. 
Exclusion criteria 
1. Patients that took other non-calcineurin inhibitor based therapy at 
transplantation for example, mammalian target of rapamycin (mTOR) 
inhibitors (e.g sirolimus).  
2. Post-dose CNI concentrations were excluded. 
3. Patients with incomplete data on CNI dosing and Ctrough drug 
concentrations (fewer than 3 drug concentration measurements).  
4. Patients that received non-oral CNI formulations (e.g. intravenous 
infusions).  
5. Patients that did not start CNI therapy immediately post-transplantation. 
6. Patients that had an ABO incompatible transplant and those that 
received alemtuzumab for induction therapy. 
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CNI Drug Concentration Analyses 
Calcineurin inhibitor whole blood concentrations were all assumed to represent 
trough values, defined as the concentration prior to the next dose, irrespective 
of dosing interval i.e. 12 or 24 hourly. Any CNI concentrations not taken pre-
dose, e.g. in the case of extended interval dosing regimens, were excluded from 
the analyses. Data were analysed for specific time points post -transplant i.e. 1, 
2, 4, 6, 8, 12, 24, 36 and 52 weeks post-KT. Patients were censored at date of 
clinic event (allograft rejection), date CNI drug is discontinued or switched or, 
date of last clinic visit up to 1 year post-KT. Whole blood concentrations were 
included for analysis where they fell within 14 days of the specific time point and 
steady state conditions were likely (Oo et al., 2008).  
Target Ctrough CNI drug concentrations for the first year post-transplantation 
varied between centres and also over the study period where practices 
changed. Target ranges were also guided by clinic events e.g. acute rejection or 
suspected CNI toxicity. There was also variability in target ranges throughout 
the first year post-transplant with consideration for high immunological risk 
group of patients. For these reasons, analyses was standardised as follows 
• Ciclosporin Ctrough target range: 200-350 ng/mL during weeks 1-12, 100 – 
250 ng/mL thereafter;  
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Initiating doses were as per local protocol except when the pre-transplant CNI 
trial dosing strategy (Bhagani et al., 2006) was utilised. Total daily CNI doses 
were calculated by multiplying the single dose by dose frequency [units 
expressed as mg/day]; for weight adjusted doses this was calculated by dividing 
the CNI dose by the weight in kilograms [units expressed as mg/kg]; and dose 
adjusted Ctrough concentrations were calculated by dividing the drug 
concentration by the dose [units expressed as ng/ml per mg or mg/kg for weight 
adjusted doses].   
 
Assumptions 
All CNI drug concentrations reported were assumed to be true trough values, 
assayed using validated approaches.  All patients were assumed to be 100% 
adherent with their medicines. 
 
 
Statistical analysis  
Descriptive statistical tests were used for analyses in this chapter. Univariate 
analyses of baseline recipient characteristics stratified a priori by CNI choice at 
transplantation i.e. ciclosporin vs tacrolimus were tested for statistical 
significance using Fisher’s exact test (2-sided) where values were < 5 and chi-
squared test (2-sided) where values were >5  (considered statistically significant 
if p <0.05); Wilcoxon rank-sum for medians or T-tests for means. Z-tests were 
used to compare proportions.  
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5.3. Results 
Patient Disposition 
There were 97 HIV Kidney Transplant (KT) recipients identified that were 
transplanted up to 31st December 2013. Those that did not meet the study 
inclusion criteria (N=19) included: one patient less than 18 years of age; four 
transplanted abroad (India, Belgium, Berlin and USA); three that acquired HIV 
post-transplantation; one patient who died during KT, four with primary non-graft 
function and six that had no data. The six patients were transplanted at Oxford 
Radcliffe hospital (n=4), Birmingham (n=1) and Manchester (n=1). All were 
referrals from external HIV centres (unknown) and received post-transplant 
follow-up at their base hospitals. Of the remaining 78 patients, 31 patients were 
taking ciclosporin and 47 tacrolimus based IS therapy. In the CsA group, the 
excluded patients included 6 patients without any drug concentrations reported 
and 2 patients with < 3 available drug concentrations. Of the 8 patients that 
were excluded, 5 were transplanted at GSTT, one at St Barts Hospital and two 
at the Royal Free hospital. The reasons for missing drug concentrations were 
as follows: switching therapy to Tac in the early period post-transplant (n=5) 
and loss to follow-up (n=3). In the Tac group, there were 11 patients with no 
drug concentration values reported and 3 with < 3 drug concentrations 
available. Of the 14 patients excluded from the analyses the participating 
centres were St Helier hospital (n=1), Luton & Dunstable hospital (n=1), 
Edinburgh (n=1), Manchester (n=6), Birmingham (n=1) and Imperial (n=3). The 
reasons for missing drug concentrations were as follows: lost medical notes; 
implementation of new electronic medical records; lost to follow-up; 
inaccessibility due to geographical location (Glasgow & Edinburgh); and unable 
to access follow-up data from the referring base hospitals.  









Figure 27: Patient disposition for UK HIV/KT cases stratified by 
those on Ciclosporin and Tacrolimus based Immunosuppression 
Therapy 
Ctrough concentrations 
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Patient Characteristics  
56 patients met the inclusion criteria and allowed in-depth analysis of their CNI 
drug concentrations (see Figure 27). Twenty three of these received ciclosporin 
and 33 tacrolimus based IS therapy. The ciclosporin (CsA) and tacrolimus (Tac) 
groups were well matched for baseline characteristics except for antiretroviral 
drug choice at KT where a higher proportion of PI-containing ART regimen was 
used in the CsA group compared to the Tac group (p<0.05). Patients in the CsA 
group were more likely to have taken part in a pre-KT CNI dosing trial (p<0.01), 
refer to Table 30 and Table 31. The median (IQR) age at KT of the recipients 
was 44 (38, 50) years with a slightly younger cohort constituting the CsA group 
39 (37, 49) vs 46 (40, 51) years. 
The 56 patients yielded a total of 2524 whole blood drug concentrations for 
analyses; 42% (1067 samples) in the CsA group and 58% (1457) in the Tac 
group. The median (IQR) number of samples per patient were 43 (39, 58) for 
the CsA group 36 (29, 43) for the Tac group.  
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Table 30: Baseline patient characteristics at kidney 
transplantation according to CNI immunosuppression therapy 
n (%) 
 Ciclosporin 
N = 23 
Tacrolimus 
N = 33 
P value* 
Age, median(IQR) Years 39 (37, 49) 46 (40, 51) 0.06 
Gender, n (%) Male 18 (78) 20 (60) 0.16 
Ethnicity, n (%) Black 17 (74) 27 (82) 0.48 
Cause of ESKD, n (%)  HIVAN 14 (61) 16 (48) 0.54 
Duration of pRRT, 
median(IQR) ǂ 
Years 4 (2, 6) 7 (4, 7) 0.07 
HIV parameters, median(IQR)     
CD4 count at KT Cells/mm3 377 (271, 
566) 
350 (273, 504) 0.66 
Co-morbidities, n (%)     
Diabetes  4 (17) 4 (12) 0.58 
Hypertension  22 (96) 31 (94) 0.78 
Hepatitis B co-infection, n (%)  5 (22) 4 (12) 0.34 
Hepatitis C co-infection, n 
(%)** 
 3 (13) 1 (3) 0.17 
Graft characteristics     
Allograft type, n (%) Cadaveric 12 (52) 24 (73) 0.11 
HLA mismatch, 
median(IQR) ₺ 
 3 (1, 4) 3 (2, 4) 0.41 
Donor/Recipient CMV 
mismatch status, n (%) 
    
D+/R- 1 (4) 1 (3) 0.79 
Antiretroviral drug therapy 
(ART) choice, n (%) 
    
PI-containing ART  14 (61) 9 (27) 0.01 
*Comparing medians, Wilcoxon rank-sum (Mann-Whitney) test; comparing proportions (%), chi-squared test 
(2-sided). Statistically significant (p < 0.05); Missing values - **n=2, ǂ n=6, ₺n=7. 
 
Table 31: Immunosuppression drug therapy 









Induction therapyb    
AntiCD25 monoclonal 
antibody 
21 (91) 32 (97) 0.35 
Other 2 (9) 1 (3)  
Triple IS regimena 23 (100) 33 (100) NS 
CNI treatment crossover 16 (50) 1 (3) 0.36 
Ciclosporin - -  
Tacrolimus 9 (39) -  
Sirolimus 1 (4) -  
Reason for CNI 
crossover 
   
Acute rejection 7  -  
CNI toxicity 1  -   
Other 2 -  
Pre-transplant CNI dose 
finding trial 
13 (57) 4 (12) 0.00 
Key:  IS – immunosuppression, CNI – calcineurin inhibitor; aCalcineurin inhibitor + 
Mycophenolate or Azathioprine + corticosteroids; Comparing proportions (%), chi-
squared test (2-sided); statistically significant (p < 0.05). 
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Overall distribution of CNI Ctrough drug concentrations 
The overall distribution of Ctrough concentrations throughout the first year post-transplantation of the UK HIV kidney 
transplant recipients (n=56) are shown in Figure 28 and Figure 29 for tacrolimus and ciclosporin patients 
respectively. In the CsA group, majority of the Ctrough drug concentrations were within the target range were 52% at 
weeks 0 to 12 and 79% at months 6 to 12. However, in the Tac group there were lower target concentrations 
observed in the early period post-KT, week 0 to 12 (44%), compared to the late period post-KT, month 6 to 12 
(64%). The proportions of Ctrough concentrations in the early period post-KT was significantly different when CsA 
was compared to Tac, (respectively 52% vs 44%, p=0.002). Likewise, in the late period post-KT the proportion of 
target Ctrough concentrations were significantly higher in the CsA compared to Tac, (respectively 79% vs 64%, 
p=0.0000). Ctrough drug concentrations for both groups were positively skewed (not normally distributed) with an 
overall mean of 218 (163, 282) ng/ml and 8 (6, 10) ng/ml for Tac and CsA groups respectively.  
 
 
Figure 28: Overall Distribution of Tacrolimus Ctrough Concentrations in the First Year Post-HIV/KT 
A. Scatter plot of all Tac Ctrough concentrations available                  B. Histogram of all Tac Ctrough concentrations available 
          
Figure 29: Overall Distribution of Ciclosporin Ctrough Concentrations in the First Year Post-HIV/KT 
A. Scatter plot of all CsA Ctrough concentrations available                  B. Histogram of all CsA Ctrough concentrations available 
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Overall, there were similarities in the time to achieve therapeutic Ctrough drug 
concentrations between CNI groups, median (IQR) were 3 days (1, 20) for Tac 
and 4 days (2, 12) for CsA post-KT. Throughout the follow-up period, 
fluctuations in the Ctrough concentrations were observed in both CNI groups; 
however, this seemed to stabilise in the late period (6 to 12 months) post-
transplant (see Figure 28). By week 4 post-transplant, more than half of the 
patients in both CNI groups had achieved therapeutic concentrations i.e. 50% 
Tac (n=33) vs 57% for CsA (n=23). Analyses stratified by cART choice 
observed significant differences in Ctrough drug concentrations for both CsA and 
Tac groups in the early period post-transplant. The mean ± SD Tac Ctrough 
concentrations at week 1 post-KT for those taking PI-containing vs PI-sparing 
cART were significantly different, respectively 19.2±13.0 vs. 6.3±2.9, p=0.002 
(see Figure 28B and Table 32). Thereafter, the mean Ctrough concentrations 
post-KT were similar. There were similar findings in the CsA group where week 
1 post-KT Ctrough concentrations were significantly higher in those taking PI-
containing cART compared to PI-sparing cART respectively, 496±610 vs 
184±96, p=0.01. From week 2 post-KT onwards, there were no statistical 
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CNI Doses required to Achieve Therapeutic Ctrough Concentrations  
When considering CNI doses used to achieve therapeutic  Ctrough 
concentrations, in the CsA group those on PI-containing cART dosing required 
a 10 fold dose reduction on average 1mg/kg/day (standard dose 10 to 
15mg/kg/day (NovartisLtd, 2014)) which remained consistent throughout the 12 
months of follow-up (see Figure 28A). By contrast, CsA doses in the PI-sparing 
regimen group were similar to standard doses although, required progressive 
dose reductions with lower maintenance doses used in the later months post-
KT (see Figure 28B). This was in line with local protocols to minimise CNI 
exposure.  
 
In those taking tacrolimus, a profound dose reduction approximately 100 fold 
(standard dosing 0.10-0.20 mg/kg/day (SandozLtd, 2013)) was required when 
co-administered with PI-containing cART (see Table 32 and Figure 28C). 
There were very few dosing alterations made throughout the study period. 
However, in the PI-sparing group somewhat higher Tac doses were used 
compared to standard dosing in the early period post-KT (see Figure 28D). For 
the remaining follow-up period doses were maintained at <0.2mg/kg/day. 
Ethnicity did not impact the CNI doses and whole blood concentrations 
achieved when stratified a priori by cART choice (see Table 32A and Table 
32B) although; the patients numbers in the sub-groups were low.  
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Table 32: Mean (±SD) calcineurin doses & Mean (±SD) whole blood concentrations in HIV positive kidney transplant recipients 
 
 




Table 32B: Mean (±SD) Tacrolimus doses & Mean (±SD) whole blood concentrations in HIV positive kidney transplant recipients stratified by 
Ethnicity 
  















 Ct (ng/ml) b Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml) c Ct (ng/ml)  Dose (mg/kg/day) Ct (ng/ml)  Dose (mg/kg/day) 
1 375±497 496±610 1.3±1.7 184±96 9.6±4.5 9.8±9.1 19.2±13.0a 0.0194±0.0225 6.3±2.9a 0.13±0.09 
2 333±291 402±361 0.8±0.6 233±88 11.0±4.3 10.0±5.9 15.1±8.4a 0.0025±0.0017 8.2±3.3a 0.18±0.11 
4 245±93 237±76 0.7±0.5 259±119 10.6±4.5 12.3±11.2 19.5±21.3a 0.0024±0.0034 10.0±3.6a 0.24±0.11 
6 253±89 255±86 0.5±0.2 250±99 10.2±4.5 10.6±5.6 12.4±9.4a 0.0013±0.0006 10.0±3.5a 0.24±0.12 
8 236±69 224±75 0.4±0.1 260±53 11.6±4.1 9.2±3.2 8.7±4.1 0.0013±0.0010 9.4±2.9 0.22±0.11 
12 231±61 238±53 0.4±0.2 217±53 10.7±4.4 9.4±3.6 10.8±5.2 0.0016±0.0020 8.9±2.8 0.20±0.11 
24 180±45 186±30 0.4±0.2 171±64 6.6±2.5 9.7±4.1 8.9±4.4 0.0014±0.0013 10.0±4.0 0.18±0.09 
36 165±41 167±46 0.4±0.2 163±36 6.5±2.0 8.1±3.3 8.1±4.0 0.0015±0.0013 8.1±3.1 0.18±0.09 
52 129±36 142±42 0.4±0.2 119±32 6.4±2.0 9.2±4.4 7.0±1.6 0.0015±0.0015 9.9±4.8 0.14±0.10 
Comparing means t-test, statistically significant P<0.05. a P <0.05 (PI-containing cART vs. PI-sparing cART); b Target range: 200-350 ng/mL during weeks 1-12, 100 – 250 ng/mL thereafter; c Target 
















 Ct (ng/ml) b Ct (ng/ml)b   Dose (mg/kg/day) Ct (ng/ml)  b Dose (mg/kg/day) Ct (ng/ml)  b Dose (mg/kg/day) Ct (ng/ml) b   Dose (mg/kg/day) 
1 375±497 543±670 1.4±1.9 285±122 0.7±0.08 176±39 11.6±3.3a 205±221 4.6±2.4a 
2 333±291 315±144 0.8±0.6 695±721 0.8±0.1 235±111 12.8±2.7 229±23 7.5±5.4 
4 245±93 238±85 0.7±0.6 232±38 0.5±0.2 305±114 12.4±3.2 167±73 7.1±5.2 
6 253±89 266±91 0.5±0.2 218±66 0.4±0.2 252±100 11.8±3.6 245±118 7.1±5.2 
8 236±69 232±76 0.4±0.1 192±76 0.4±0.2 240±48 12.8±3.2 312±21 8.7±6.0 
12 231±61 223±63 0.4±0.2 285±58 0.5±0.1 232±52 12.3±3.6 188±57 7.5±5.3 
24 180±45 184±32 0.4±0.2 200c 0.37c 190±42 8.4±0.6 153±86 4.8±2.6 
36 165±41 167±46 0.4±0.2 -d -d 161±33 4.9±2.9 166±54 7.5±0.4 
52 129±36 142±42 0.4±0.2 -d -d 135±22 7.5±0.4 96±36 4.9±2.9 
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 Ct (ng/ml)b   Dose (mg/kg/day) Ct (ng/ml)  b Dose (mg/kg/day) Ct (ng/ml)  b Dose (mg/kg/day) Ct (ng/ml) b   Dose (mg/kg/day) 
1 9.8±9.1 21.2±14.6 0.02±0.02 12.9±4.6 0.009±0.008 6.2±2.9 0.17±0.07 5.8±2.7 0.12±0.06 
2 10.0±5.9 16.7±9.1 0.003±0.002 10.7±4.6 0.002c 8.0±3.4 0.21±0.10 8.2±4.0 0.15±0.03 
4 12.3±11.2 24±23 0.003±0.004 6.1±0.07 0.001±0.0001 9.8±3.4 0.25±0.12 11.6±4.9 0.17±0.04 
6 10.6±5.6 12.9±10.4 0.001±0.001 10.6±6.8 0.002±0.0004 10.1±3.5 0.25±0.12 11.0±2.5 0.17±0.04 
8 9.2±3.2 9.2±4.0 0.001±0.001 7.0±5.6 0.001±0.0001 9.5±3.01 0.25±0.11 9±2.8 0.17±0.04 
12 9.4±3.6 11.2±5.8 0.002±0.002 9.5±3.5 0.001±0.001 8.9±2.8 0.22±0.10 8.3±3. 0.16±0.06 
24 9.7±4.1 9.5±4.8 0.001±0.001 7.0±1.5 0.001±0.001 9.7±3.7 0.20±0.07 12.1±5.4 0.15±0.05 
36 8.1±3.3 8.7±3.8 0.001±0.002 6.3±5.7 0.002±0.0003 7.5±2.3 0.20±0.08 11.6±5.09 0.17±0.03 
52 9.2±4.4 6.5±1.4 0.001±0.002 9.1c 0.002c 8.9±4.1a 0.19±0.07 15.5±5.8a 0.17±0.03 
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Figure 30: Tacrolimus and Ciclosporin Dosing and Ctrough Concentrations Stratified by cART Choice 
A            B 
   


















value 0.002 0.08 0.96 0.77 0.70 0.57 0.21 0.64 0.12 
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P-value 0.01 0.13 0.90 0.71 0.23 0.43 0.64 0.68 0.33 
 
Graph showing CNI dosing and mean Ctrough concentrations over the first year post-KT stratified by cART choice. A comparison to standardised CNI dosing 
is depicted in the graph. (A) Tacrolimus dosing (B) Tacrolimus Ctrough concentrations (C) Ciclosporin dosing (D) Ciclosporin Ctrough concentrations. P-values 
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Further analyses of the proportions of CNI Ctrough concentrations, found that irrespective of CNI choice one third of patients observed sub-therapeutic CNI Ctrough concentrations 
throughout the first 12 weeks post-KT (see Figure 31). When comparing proportions of supratherapeutic vs subtherapeutic Ctrough concentrations achieved, there were significant 
differences between PI-containing and PI-sparing cART respectively, 19% vs 41%, p=0.01 at week 1 and 12% vs 42%, p=0.0005 at week 2 and 18% vs 39%, p=0.002 at weeks 6, 8, 12 
for those taking Tac. There were no significant differences found at weeks 4, 24, 36 and 52. In the CsA group, significant differences PI-containing and PI-sparing cART were observed 
at weeks 1 (17% vs 39%, p=0.005), week 2 (26% vs 9%, p=0.004), week 24 (22% vs 4%, p=0.000) and week 52 (43% vs 4%, p=0.000) respectively. Comparisons made at weeks 4, 6, 
8, 12, and 36 were not statistically significant.  
 
Figure 31: Trough drug concentrations (Ctrough) in the first year following KT in HIV positive patients 
  
Proportion of patients with whole blood concentrations above, within, and below the target range. Ciclosporin target range: 200-350 ng/mL during weeks 1-12, 100 – 250 ng/mL thereafter; Tacrolimus target range: 8-15 
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5.4. Discussion 
Post-transplant management of HIV infected kidney transplant recipients is 
complicated by the significant drug interactions between calcineurin inhibitors 
and antiretroviral drugs. There are clinical pharmacokinetic studies reported in 
the literature for various CNI and cART combinations albeit with limited 
information reported on achieving and maintaining CNI drug concentrations in 
clinical practice. Analyses in this chapter have demonstrated (1) the challenges 
of achieving protocol guided target concentrations especially in those taking PI-
containing cART regimens. Supratherapeutic concentrations were frequent in 
the PI-containing cART group particularly in the first four weeks post-KT where 
concentrations were up to 3 times higher compared to the PI-sparing group. (2) 
significant dose adjustments were required to achieve target CNI concentrations 
for those on PI-containing cART; dose reductions up to 100 fold for Tac and 10 
fold for CsA. Minimal dose adjustments were required for those taking PI-
sparing cART. (3) challenges in maintaining target concentrations with frequent 
sub-therapeutic concentrations throughout the follow-up period mostly for those 
taking PI-sparing cART. In the first 3 months post-KT, almost one third of CNI 
concentrations were sub-therapeutic. (4) Ethnicity did not impact the CNI doses 
and whole blood concentrations achieved when stratified a priori by cART 
choice although; the patient numbers in the sub-groups were low.    
  
 - 226 - 
Early period post-KT 
At KT, both CNI groups were well matched with the exception of cART choice 
where those in the ciclosporin group had a higher proportion of those taking PI-
containing cART compared to those taking tacrolimus (61% vs 27%, p=0.01). 
This is not surprising as dosing of CsA with PI-containing drugs required 
approximately 10 fold dose reduction which allowed for a less complicated and 
shorter dosing interval (24h vs 168h) compared to Tac that required ~100 fold 
dose reduction.  
Dosing of CNIs in this early period can be complicated by multiple factors apart 
from drug interactions. Briefly, the haemodynamic changes post-KT (Williams 
and Lake, 1992, Kostopanagiotou et al., 1999), use of gastric acid suppressants 
that alter gut pH (Lemahieu et al., 2005b), corticosteroid withdrawal (Anglicheau 
et al., 2003), pharmacogenomics (Macphee et al., 2002, MacPhee, 2012), gut 
motility (Hochleitner et al., 2001, Lemahieu et al., 2005b)  or use of antibiotics 
that may affect gut flora (Lee et al., 2015) are all factors that could influence 
CNI exposure during this early period post-KT. When managing drug 
interactions, the time it takes for metabolic enzyme or transporter 
inhibition/induction should also be considered (Reitman et al., 2011). However, 
in our patient cohort it was recommended that recipients be stable on cART for 
at least 6 months prior to transplantation (Bhagani et al., 2006). Therefore, pre-
emptive DDI management was essential as it was assumed that the 
metabolic/transporter inhibition/induction processes were well established by 
transplantation.    
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Both CNI groups observed a large interpatient variability in the distribution of 
CNI Ctrough concentrations over the first 12 weeks post-KT. This meant multiple 
alterations in CNI dosing to achieve target CNI Ctrough concentrations. For both 
CNI groups taking PI-sparing cART, therapeutic doses used were comparable 
to those used in the general population (CsA ~10 vs 10-15 and Tac ~0.2 vs 0.1-
0.2 mg/kg/day respectively). Similar interpatient variations have been observed 
in the general population for both CNI drugs. In the Symphony study (Ekberg et 
al., 2009b), a large multicentre clinical trial on immunosuppressive regimens, 
reported approximately 50% of patients (n=1589) achieved CNI concentrations 
within target range (Tac 3-7 ng/mL; CsA 50-100 ng/mL) over the first year post-
KT. An evaluation of the CNI Ctrough concentrations achieved in the first week 
post-KT, in our cohort ~43% (58% CsA vs 30% Tac) of patients achieved target 
concentrations compared to the Symphony study that reported between 43% for 
low dose CsA (2 - 4mg/kg/day) and 51% or low dose Tac (0.1mg/kg/day). There 
are a few possible explanations for this first; clinicians may have taken a more 
cautious approach particularly when dosing Tac that required extended dosing 
interval when co-administered with PI-containing cART. Secondly, there was a 
significantly higher proportion of patients taking PI-containing cART (P-gp/CYP 
inhibitors) in the CsA group compared to the Tac group allowing for target 
steady state Ctrough concentrations to be achieved much quicker. Finally, 
evidence suggests a strong relationship between Tac bioavailability and 
intestinal abnormalities while CsA bioavailability remains unaffected (Maes et 
al., 2002).  
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By week 2 in our study, those that achieved target CNI Ctrough concentrations 
showed more stability over subsequent weeks. Similar to the Symphony study, 
those that achieved supratherapeutic CNI Ctrough concentrations by week 2 took 
longer to achieve target concentrations (up to 8 weeks in both groups).  
Although it is noteworthy, the Symphony study used much lower CNI doses and 
much lower target concentrations as KT recipients were considered at low risk 
of rejection unlike our cohort who considered high risk (Stock et al., 2010a, 
Locke et al., 2014). 
Late period post-KT 
In the late period post-transplant, months 6 to 12, CNI drug concentrations are 
expected to have stabilised and achieved steady state. Often in this period, 
clinicians make dose reductions to minimise CNI exposure to avoid 
nephrotoxicity (Schiff et al., 2007). The local protocols used for the current 
analyses followed a similar approach, Tac target concentrations reduced to 5 - 
10 ng/mL and CsA to 100 – 250 ng/mL for months 6 to 12 post-KT. Throughout 
the follow-up period, up to one third of the overall Tac concentrations were 
subtherapeutic compared to one fifth of CsA concentrations. High intrapatient 
variability in the later period post-KT can adversely impact the allograft (Borra et 
al., 2010b, Stevenson et al., 2011). Borra et al (2010) performed analyses of 
Tac drug concentrations drawn from months 6 to 12 in an outpatient setting. 
The authors found in multivariable analyses that within patient variability of Tac 
clearance was strongly associated with allograft failure (high intrapatient 
variability with no graft failure (n=263) 47.5% vs those with graft failure (n=34) 
70.6%, p=0.003). In another study, high intrapatient variability throughout the 
first year post-KT resulted in a higher allograft rejection rate compared to those 
with low intrapatient variability (19.4% vs 8.2% respectively, p=0.02). In the 
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current dataset, it was challenging to ascertain the impact of allograft rejection 
due to the sample size when stratified into three sub-groups (CNI choice, cART 
regimen and allograft rejection). However, in Chapter 4 more than half of 
allograft rejection episodes occurred in the first 14 days post-KT in the Tac 
group (AR rate at 1 year 21%) compared to CsA that occurred in the over the 
first 9 months post-KT (AR at 1 year 58%). It was therefore probable that the 
variability of the drug concentrations may have been skewed by the differences 
between CNI groups in AR rates and the timing of AR.          
 
Nevertheless, the analysis of CNI Ctrough concentrations only provides partial 
information on drug exposure. For example, the extended dosing interval with 
Tac and PI-containing cART has demonstrated a significant change in the total 
drug exposure (AUC) of Tac.  A pharmacokinetic study performed in 8 HIV+ 
transplant patients on PI-containing cART observed an AUC that was almost 12 
times greater than AUC of non-HIV transplant recipients (median [IQR] 
respectively, 24996 [18205–41601] vs 2000–5000 ng*hr/mL/mg/kg at weeks 2 
to 12 post-KT). By contrast, CsA AUC was lower in HIV+ transplant recipients 
(n=34) (median [IQR] respectively, 5759 [3325–8045] vs 7000–9000 
ng*hr/mL/mg/kg at weeks 2 to 12 post-KT) (Frassetto et al., 2013). In some 
instances ritonavir has altered Tac AUC from the typical ‘bell shaped curve’ to a 
plateau with a significant reduction in the maximal concentration (Cmax) (van 
Maarseveen and van Zuilen, 2013). This phenomenon is not observed in those 
taking PI-sparing cART where total exposure for both CNIs is lower than AUCs 
observed in the general population (median [IQR] respectively, CsA 862 [744–
1131] vs 7000–9000 and Tac 2170 [936–3261] vs 2000–5000 ng*hr/mL/mg/kg 
at weeks 2 to 12 post-KT)  (Frassetto et al., 2013). In our cohort 
 - 230 - 
pharmacokinetic studies were performed in 6 patients taking Tac and PI-sparing 
cART (Appendix G - not included in data analyses), we observed somewhat 
similar AUCs compared to those reported by Frassetto et al (2014).   
By contrast to the increased total exposure AUC, time to maximal concentration 
(Tmax) of Tac was delayed in those taking PI-containing cART compared to 
those on PI-sparing cART specifically NNRTIs (6 vs 2 to 3 hours). In those 
taking CsA, Tmax was similar for both cART groups (2 to 3 hours) (Frassetto et 
al., 2014). In the general population Tmax for both CNIs is 2 to 3 hours (Schiff et 
al., 2007). The delay in Tmax for those taking Tac/PI-containing cART suggests a 
slower rate of absorption (Kuypers et al., 2004). Additionally, the extension of 
Tac half-life by PIs in turn prolongs the time to achieve steady state 
concentration (Tss). The administration of a loading dose may assist in 
achieving Tss quicker provided the kinetics remains linear. In a small PK study to 
determine an optimal loading dose for Tac when co-administered with PI-
containing cART observed wide interpatient variability for doses ranging from 1 
to 7 mg (van Maarseveen and van Zuilen, 2013). The PK studies performed 
with 1mg loading dose in three patients demonstrated some peak 
concentrations that were within therapeutic range (8 to 15ng/ml) though after 96 
hours concentrations were subtherapeutic. The 2mg loading dose demonstrated 
much higher peaks similar to those observed in the HIV negative population 
(~20 to 25ng/ml) (Hardinger et al., 2004b)). However, subsequent 
concentrations achieved were not reported therefore unable to ascertain if 
target concentrations were sustained at a dosing interval of 168 hourly. The 
much higher doses of 6.5 to 7mg resulted in significantly high peaks that were 
sustained 96 hours post-dose.  This was also the case in our cohort where 
supratherapeutic concentrations were sustained in some instances up to one 
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month post-dose even with Tac discontinuation (data not shown). Though the 
van Maarseveen (2013) study was conducted in the pre-transplant setting which 
limited inferences drawn from their conclusions. Furthermore, their patients 
were taking combined PI/r and NNRTI cART regimens which results in large 
variances in total drug exposure (Frassetto et al., 2014). In addition, single oral 
dose pharmacokinetic studies differ from multiple oral dosing due to the 
cumulative drug absorption (Rowland et al., 2011). 
 
Besides total drug exposure, it is uncertain whether Ctrough is the best time point 
for optimal therapeutic drug monitoring. The Frassetto et al (2014) study 
suggests that over the course of time post-transplantation Ctrough correlates with 
AUC in those taking Tac and C4 correlates better with AUC than C0 or C2 in 
those taking CsA.  
 
Perhaps for the HIV/KT population employing more stringent monitoring 
strategies may alleviate the high allograft rejection rates. In support of this 
notion and to complicate matters further, time dependent changes to the 
clearance and oral bioavailability have been observed for both CsA and Tac 
when co-administered with various cART (Frassetto et al., 2013). For example, 
in subjects taking CsA and efavirenz antiretroviral drug observed ~30% 
increases in apparent oral bioavailability and decreased apparent oral clearance 
over time. On the contrary, those taking Tac/EFV observed an increase in both 
apparent bioavailability and clearance over time requiring a Tac dose reduction 
over time to maintain therapeutic concentrations. Subjects taking nevirapine did 
not exhibit the same decline in CsA oral clearance over time (Frassetto et al., 
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2013). Interestingly, the same authors observed increases in oral CsA 
bioavailability over time in those subjects taking PI-containing cART in one 
study (Frassetto et al., 2003) and no time-dependent alterations to the 
bioavailability in a subsequent study (Frassetto et al., 2013). This reiterates the 
unpredictability of changes to the pharmacokinetic parameters of CNIs 
irrespective of ART choice.   
The strength of this study is near complete sample that was well matched 
except for cART choice. The descriptive nature of this study provides some 
insight into the challenges of achieving and maintaining CNI drug 
concentrations in clinical practice when managing HIV/KT patients. The 
representation of the proportions of CNI drug concentrations that are above, 
below or within target range provides a more complete picture of the actual 
concentrations achieved compared to mean (SD) represented in the previously 
reported HIV/KT studies (Frassetto et al., 2005, Stock et al., 2010a, Frassetto et 
al., 2013, Frassetto et al., 2014). The variability observed may explain the poor 
allograft outcomes observed in this population. A further limitation is the 
possible use of different CNI formulations both between patients and within 
individuals over the study period. The utilisation of the pre-KT CNI trial as a 
dose finding strategy may have resulted in certain patient groups post-KT 
achieving target concentrations much quicker. Futhermore in the early years of 
HIV/KT circa 2005, there may have been an unawareness of CNI and cART 
drug interactions therefore extremely supratherapeutic concentrations may have 
skewed results. Finally, the effect of other covariates gender (Min et al., 2000) 
that may have caused variations in CNI drug exposure.   
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5.5. Conclusion 
This study describes the challenges of achieving and maintaining therapeutic 
CNI Ctrough in clinical practice over the first year post-transplant in HIV kidney 
transplant recipients. The co-administration of antiretroviral drugs with 
calcineurin inhibitors results in unpredictable drug exposure which is 
multifactorial but also highlights the challenges of managing these drug 
interactions. Use of integrase inhibitors to avoid the CNI and antiretroviral drug 
interactions is one way for optimal CNI exposure. However, where use of INI 
based cART is not possible, there are a few approaches to determining the 
optimal CNI dose when co-medicated with PI-containing cART especially. One 
approach is the use of a pre-transplant CNI trial. The current dataset was not 
robust to test this approach especially for those on tacrolimus and PI-containing 
cART combination.Another approach, if calcineurin inhibitors exhibit linear 
kinetics when combined with PI-containing cART, is the use of standardised 
dosing to limit superexposure e.g. 0.5 to 1mg/week of tacrolimus initiating dose 
with close therapeutic drug monitoring. However, with extended dosing intervals 
it may take longer to reach steadystate. One way to overcome the extended 
time to steadystate is by use of a loading dose. van Maarseveen (2013) data 
suggests a dose between 1 to 2mg would be required to achieve peak 
tacrolimus concentrations between 10 to 30ng/mL. The availability of liquid 
tacrolimus formulations (e.g. Modigraf® (AstellasPharma, 2015)) may also offer 
the advantage of administering smaller doses more frequently. However, a 
prospective pharmacokinetic study to determine an optimal approach of CNI 
dosing with PI-containing cART is warranted to corroborate these findings.   
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Chapter 6. Mycophenolate Therapeutic Drug Monitoring (TDM) 
in HIV-Positive Kidney Transplant Recipients  
6.1. Introduction 
Mycophenolate pharmacology 
Mycophenolate (MMF) was originally discovered in the late 19th century from 
Penicillium brevicompactum (Franklin and Cook, 1969, Eugui et al., 1991, 
Jeong and Kaplan, 2007). MMF is a potent and reversible inhibitor of inosine 
monophosphate dehydrogenase (IMDH), an enzyme that is involved in purine 
DNA synthesis.  This mode of action prevents the proliferation of T cell 
lymphocytes and antibody formation by B cells. It also inhibits the recruitment of 
leukocytes to inflammatory sites (Hardman et al., 1996a). These 
immunosuppressive and anti-inflammatory processes are necessary for the 
prevention of allograft rejection in kidney transplantation. Mycophenolate proved 
ineffective as a single immunosuppressive agent rather as complementary drug 
to the combined use of calcineurin inhibitors and prednisolone for the 
prevention of allograft rejection (Jeong and Kaplan, 2007).  
Mycophenolate is available in two salt forms, mycophenolate mofetil and 
mycophenolate sodium, chemical structures shown in Figure 32 (chemistry, 
2014). Both forms when hydrolysed form the active metabolite, mycophenolic 
acid (MPA). Mycophenolate therapeutic drug monitoring involves measuring 
MPA concentrations in plasma (Staatz and Tett, 2007).  
Figure 32: Mycophenolate Chemical Structure 
    
Mycophenolate mofetil  
Molecular Formula: C23H31NO7 
Mycophenolate sodium  
Molecular Formula: C17H19NaO6 
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Mycophenolate drug disposition in kidney transplant recipients 
Mycophenolate is extensively absorbed in the gastrointestinal tract with 72% to 
94% oral bioavailability (Staatz and Tett, 2007). MMF then undergoes 
glucoronidation by UDP-glucuronosyltransferase enzymes in the 
gastrointestinal tract, liver and possibly kidney before being excreted primarily 
into the urine and bile in its inactive form (mycophenolic acid glucoronide 
(MPAG))(Sweetman, 2011, [PharmGKB], 2014) (Moreno et al., 2008, 
Sweetman, 2011, [PharmGKB], 2014). MPAG in the bile undergoes de-
glucoronidation by bacterial enzymes back into MPA in the gastrointestinal tract 
before being reabsorbed. This enterohepatic recycling process is demonstrated 
in the delayed peak 6 to 12 hours after oral administration (see Figure 33) 
(Bullingham et al., 1998, Jeong and Kaplan, 2007). However, mycophenolate 
drug interactions have been known to interfere with the enterohepatic recycling 
process. There is evidence to suggest that ciclosporin inhibits enterohepatic 
recycling of MPAG thereby increasing mycophenolate dosing requirements in 
order to achieve adequate therapeutic MPA plasma concentrations (Cremers et 
al., 2005). 
Figure 33: Mycophenolic Acid Plasma Concentration Time Profile 
 
Graph showing mycophenolic acid plasma concentration 
time profile demonstrating enterohepatic recirculating seen 
following oral mycophenolate mofetil administration (Staatz 
and Tett, 2007). 
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There is large inter- and intra-patient variability of exposure to MPA in transplant 
recipients that is not entirely understood, and many factors may also contribute, 
including food, race, renal function, albumin level, delayed graft function, 
concomitantly administered interacting drugs and polymorphisms of metabolic 
enzymes and multidrug resistance proteins (Staatz and Tett, 2007, Grinyo et al., 
2009). 
 
Mycophenolate Therapeutic Drug Monitoring 
Over recent years, there has been much debate on the utility of mycophenolate 
therapeutic drug monitoring in solid organ transplantation. Therapeutic drug 
monitoring aims to optimise therapy by individualised dosing and avoid drug 
toxicity. In solid organ transplantation, not achieving therapeutic mycophenolate 
dosing can be detrimental to the allograft in preventing rejection. However, 
emerging evidence deterred the benefits of MPA TDM on the basis of lack of 
cost-effectiveness and opted instead for dose adjustment guided by MMF-
associated haematological or gastrointestinal toxicity (Kuypers et al., 2010). 
Clinical reviews were performed to evaluate the scientific evidence on TDM of 
MPA in solid organ transplantation (Jeong and Kaplan, 2007, Knight and Morris, 
2008, Knight et al., 2009, Kuypers et al., 2010) and found that strong evidence 
was lacking to demonstrate 
i. relationship between MPA exposure and allograft rejection or graft loss 
(van Gelder et al., 2008, Gaston et al., 2009) 
ii. relationship between MPA exposure and MMF-associated toxicity (Le 
Meur et al., 2007, van Gelder et al., 2008, Gaston et al., 2009) 
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iii. defined target MPA concentrations, both 12-hour trough (Ctrough) and total 
exposure (AUC), that determined clinical efficacy and toxicity (Kuypers et 
al., 2010)  
iv. strategies to achieve therapeutic target MPA concentrations in clinical 
practice (Le Meur et al., 2007, Budde and Glander, 2008, Gourishankar 
et al., 2010) 
v. cost-effectiveness of monitoring patients when they achieve steady state 
therapeutic target MPA concentrations (Kuypers et al., 2010) 
 
Although in certain patient groups the role of MPA TDM was found beneficial 
particularly in view of the wide inter/intra-patient variability of MMF exposure 
(Kuypers et al., 2010). For example, patients with high immunological risk 
where achieving and maintaining therapeutic MPA concentrations is critical in 
preventing allograft rejection (Kuypers et al., 2009, van Gelder et al., 2010). van 
Gelder et al (2010) defined those of high immunological risk as those with 
delayed graft function, re-transplants, panel reactive antibodies >15%, four or 
more human leukocyte antigen mismatches, or those of black ethnicity. In their 
study, those with high immunological risk (n=549) that achieved therapeutic 
MPA AUC had a lower rate of allograft rejection compared to those that 
achieved lower MPA AUC concentrations in the first month post-KT (14.3% vs 
7.8%, p=0.025). In the low immunological risk group, no differences in allograft 
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HIV infected kidney transplant recipients are considered to be of high 
immunological risk due to a combination of factors discussed in previous 
chapters. To summarise these factors briefly: there is a high proportion of HIV 
infected KT recipients of black ethnicity (74%, n=35 (Gathogo et al., 2014); 
69%, n=150 (Stock et al., 2010a)); a high incidence of delayed graft function in 
HIV/KT recipients has been observed especially in those who receive allografts 
from deceased donors (52%, n=36 (Mazuecos et al., 2013); 46% for deceased 
donor recipients, n=150 (Stock et al., 2010b)); and high incidences of allograft 
rejection in the first year post-KT (44%, n=35 (Gathogo et al., 2014); 31%, 
n=150 (Stock et al., 2010b)). Furthermore, the delicate balance of 
immunosuppression in this cohort is crucial for the prevention of latent viral 
reactivation and HIV disease progression. Although cART have somewhat 
improved the incidence of certain opportunistic infections in HIV infection 
(Nelson et al., 2011), there is an increased risk of latent virus reactivation post-
KT with the use of immunosuppressive therapy. In addition, post-HIV/KT 
immunosuppression could be further complicated by the co-medication of cART 
with immunosuppressant drugs resulting in profound drug interactions. Co-
administration of mycophenolate and antiretroviral drugs that inhibit or induce 
glucuronidation, e.g. some protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors, could potentially alter MPA concentrations (LHPG, n.d). 
Although clinical evidence of these cART-MPA drug interactions is lacking. An 
in vivo study including indinavir did not demonstrate any alterations of MPA 
concentrations (Sankatsing et al., 2004b). In the same study, there was an 
incidental finding of increased nevirapine clearance (MMF (n=9) vs No MMF 
(n=8) clearance (CL/F (L/h)) 3.25 (2.88–3.70) vs. 2.83 (2.43–3.34), p=0.04) 
thought to be induced by MPA however; the mechanism is unknown. MPA can 
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also potentially increase the intracellular concentrations of abacavir by depleting 
intracellular deoxyguanosine triphosphate (dGTP). However, the intracellular 
concentrations of abacavir or its active form, carbovir triphosphate, have not 
been altered when co-administered with mycophenolate (Sankatsing et al., 
2004b). Mycophenolate has also been demonstrated to inhibit the renal 
transporters organic anion transport (OAT) - OAT1/OAT3 which may reduce 
elimintation of tenofovir disoproxil fumarate (tenofovir DF) (Burckhardt and 
Burckhardt, 2011). Table 33 summarises the drug interactions between 
mycophenolate and antiretroviral drugs available in the UK. Aside from drug 
interactions with cART, interactions occur between IS drugs. An example of this 
has been demonstrated between calcineurin inhibitors and mycophenolate. 
Increased MMF exposure has been demonstrated when co-medicated with 
ciclosporin (Hubner et al., 1999, Vidal et al., 2000, Pou et al., 2001, Grinyo et 
al., 2009, Naito et al., 2009). For example, one study demonstrated that despite 
higher doses of MMF in the ciclosporin group (n=16) there was a 50% reduction 
in MPA Ctrough concentrations compared to tacrolimus group (n=14) [mean (SD) 
CsA, Tac respectively: doses 2.8±1.2 vs 0.07±0.01 mg/kg/day; 125.9±37.4 vs 
7.7±2.8 µg/L] (Gerbase et al., 2003). 
 
This chapter aims to evaluate the utility of mycophenolate TDM in HIV kidney 
transplant recipients by comparing concentration guided MMF dosing to MMF 
dosing modifications following adverse events (ADEs). 
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Table 33: Antiretroviral / Mycophenolate Drug Interaction Table 
PI DI w/ MMF NNRTI DI w/ MMF NRTI DI w/ MMF Other DI w/ MMF 
Atazanavir X Delavirdine X Abacavir X Dolutegravir X 
Cobicistat (with ATV or 
 
 Efavirenz X Didanosine  Elvitegravir/cobicistat X 
Darunavir X Etravirine  Emtricitabine  Maraviroc X 
Fosamprenavir X Nevirapine X Lamivudine  Raltegravir X 
Indinavir X Rilpivirine  Stavudine    
Lopinavir X   Tenofovir-
 
X   
Nelfinavir X   Zidovudine  X   
Ritonavir X       
Saquinavir X       
Key: PI, Protease Inhibitors; DI w/ MMF, Drug interaction with mycophenolate; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor. X – 
Theoretical or clinical evidence of drug interaction. 
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Purpose of study 
The main purpose of this chapter is to evaluate the clinical utility of 
mycophenolate therapeutic drug monitoring in HIV kidney transplantation. With 
a focus on the first 12 months post-kidney transplant, these analyses will 
assess whether concentration guided mycophenolate dosing offers a better 
strategy compared to MMF dosing modifications following adverse events.  
Primary Aim 
To evaluate the utility of mycophenolate therapeutic drug monitoring (TDM) in 
HIV kidney transplantation (HIV/KT). To address this aim the following 
hypotheses were addressed 
1.1 Hypothesis (H0) Stratified a priori by mycophenolate TDM, there are no 
differences in the rate of the first mycophenolate discontinuation between 
groups in the first year post-HIV/KT 
1.2 Hypothesis (H0)  Stratified a priori by mycophenolate TDM, there are no 
differences in the rate of MMF associated treatment limiting latent viral 
reactivations (CMV, EBV and BK reactivation) between groups in the first year 
post-HIV/KT 
1.3 Hypothesis (H0)  Stratified a priori by mycophenolate TDM, there are no 
differences in the rate of MMF associated treatment limiting cytopenias between 
groups in the first year post-HIV/KT 
1.4 Hypothesis (H0)  Stratified a priori by mycophenolate TDM, there are no 
differences in the rate of allograft rejection between groups in the first year post-
HIV/KT 
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Secondary Aims 
Aim 1: To describe mycophenolate dosing in HIV/KT in the first 12 months post-
transplant 
Aim 2: To describe mycophenolate 12h Ctrough plasma concentrations in HIV/KT 
with mycophenolate TDM over the first year post-transplant 
Aim 3: Stratified a priori by mycophenolate TDM, describe the host/graft survival  
Aim 4: To identify factors associated with (1) MMF discontinuation (2) Adverse 
events/viral reactivation (3) Acute graft rejection  
Aim 5: To explore the possible drug interactions in those co-prescribed abacavir 
and mycophenolate.  
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Definitions 
Clinical efficacy of mycophenolate use was defined by the prevention of 
allograft rejection in the first year post-transplant. Allograft rejection was 
histologically confirmed on biopsy as described in detail in Chapter 4. 
Haematological adverse events were restricted to clinician reported treatment 
limiting cytopenias. The treatment limitation was defined as mycophenolate 
treatment that was interrupted/delayed or discontinued due to the 
mycophenolate induced cytopenias. The specific cytopenias included 
neutropenia and leukopenia. Although haematological ADEs were clinician 
reported, local centre protocols commonly defined leukopenia as having a total 
white blood cell (WBC) count of less than 3,000-4,000 cells/μL; neutropenia was 
commonly defined as having a neutrophil count of <0.5 x 109 /L.  
Latent viral reactivation was clinician reported and verified by laboratory viral 
load measurements. Latent viruses included herpes simplex viruses 1 and 2, 
varicella zoster virus (VZV), human herpes viruses (HHV) 6, 7, and 8, Epstein - 
Barr virus (EBV), polyomaviruses - BK and JC viruses, and cytomegalovirus 
(CMV). Viral load detection limits and thresholds were determined at study 
centres according to local protocols. For the purposes of these analyses latent 
viral reactivation was defined as any viraemia that resulted in MMF dose 
adjustment or discontinuation and/or required antiviral therapy where applicable 
(e.g. valganciclovir to treat CMV or acyclovir for HSV). 
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Mycophenolate therapeutic drug monitoring was performed by measuring 
plasma concentrations of the active metabolite mycophenolic acid. MPA trough 
plasma concentrations (MPA C0) were defined by concentrations determined at 
12 hours or 6 hours post-dose where dose frequencies were twice or four times 
daily respectively. Analytical assays used to measure MPA C0 varied between 
centres and during the study period. Although, the most commonly used were 
Enzyme Mediated Immuno-Technique (EMIT), liquid chromatography with 
tandem mass-spectrometric detection (LCTMS) or Roche enzyme inhibition 
assays. Comparisons between immunoassays has been performed and MPA 
results by LCTMS were ~20% lower than using the EMIT assay (Shipkova et 
al., 2000, Weber et al., 2002a, van Gelder et al., 2009). This is due to the cross-
reactivity in the EMIT assay of the MPA metabolite MPA acyl glucuronide 
(MPAG) therefore requiring higher target concentrations.  MPA C0 concentration 
efficacy was defined by local protocols. Therapeutic target concentrations 
ranged from 1 – 3.5mg/L (LCTMS) or 1.3 – 4.5mg/L (EMIT) (Weber et al., 
2002a, Kuypers et al., 2010). For the purposes of this analyses target range of 
1 – 3.5mg/L was used as LCTMS immunoassay was most commonly used. 
Furthermore, immunoassays used for each MPA concentration was not 
reported only overall immunoassay choice per centre was reported.  
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6.2. Method 
Study Design 
The full details of the study methods have been previously described in Chapter 
3 (see pages 109 to 113). For this chapter, enrolled patients were stratified a 
priori by MMF TDM vs no TDM post-transplantation. Baseline patient 
characteristics were described as follows  
a. Recipient characteristics 
i. Demographics: age, gender, ethnicity 
ii. Aetiology of kidney disease 
iii. HIV parameters: CD4 count, cART regimen 
iv. Co-morbidities: diabetes, hypertension 
v. HBV/HCV/CMV serology 
b. Graft characteristics 
i. Allograft type & HLA mismatch 
ii. Donor/recipient CMV status mismatch 
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Inclusion criteria 
In addition to the overall study inclusion/exclusion criteria described in Chapter 
3, patients were included in these analyses if  
a. Mycophenolate was included in post-HIV/KT immunosuppressant drug 
therapy management 
b. Data were available for  
i. mycophenolate doses, formulations, start/stop dates, reasons for 
discontinuation  
ii. MMF associated adverse events (treatment limiting cytopenias 
(neutropenia and leukopenia) and latent viral reactivations (e.g. 
cytomegalovirus, BK virus, Epstein-Barr virus, herpes simplex 
virus)) 
iii. Post-transplant allograft outcomes - function and biopsy proven 
allograft rejection 
iv. > 3 serial post-transplant mycophenolate trough concentrations  
Exclusion criteria 
Patients were excluded if  
a. Post-transplant immunosuppressant drug therapy excluded 
mycophenolate e.g. calcineurin inhibitor monotherapy or azathioprine 
containing IS therapy 
b. <3 mycophenolate concentrations available post-transplant 
c. Mycophenolate concentrations measured post-dose or as part of 
pharmacokinetic studies (AUC) 
d. Patients with insufficient/missing/no data 
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Study Analysis 
To address the study hypothesis first descriptive analyses were used to 
summarise mycophenolate use, mycophenolate concentrations and post-
transplant allograft outcomes and adverse events.  
Secondly, stratified a priori by mycophenolate TDM comparisons were made 
between groups as outlined below. Finally, further analyses were performed to 
identify factors associated with mycophenolate discontinuation, allograft 
outcomes and adverse events. Analyses were limited to the first 12 months 
post-transplant. 
Mycophenolate Use in HIV/KT 
Descriptive analyses of mycophenolate use in HIV/KT recipients that met the 
study criteria were outlined as follows 
a. Proportion of subjects on MMF at day 1, at the end of weeks 1 and 2, 
and at the end of months 1, 2, 6 and 12.  
b. Dose at day 1 and at the end of weeks 1 and 2, and at the end of 
months 1, 2, 6 and 12. Additional information included MMF - dosing 
interval, dose changes, discontinuations and reasons for 
discontinuation/dose reduction in the first year post-KT.  
c. Stratified a priori by mycophenolate TDM, comparative analyses of 
MMF doses at weeks 1 and 2, and the end of months 1, 2, 6 and 12.  
d. Stratified a priori by mycophenolate TDM, comparative analyses of 
MMF doses at weeks 1 and 2, and end of months 1, 2, 6 and 12 for 
those that had BPAR vs those that remained rejection free in the first 
year post-KT. 
e. Stratified a priori by MMF TDM, descriptive analyses were performed 
for reasons for first MMF dose reductions. 
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Mycophenolate concentrations 
Descriptive analyses of MPA C0 concentrations were outlined as follows  
a. First measured concentration 
b. Concentrations at end of weeks 1 to 52 post-KT  
c. Concentrations below/within/above the target range at end of weeks 1 
to 52 post-KT  
d. Relationship of fixed covariates abacavir, cART choice (PI-containing 
vs PI-sparing), ethnicity, allograft rejection and CNI choice (tacrolimus 
and ciclosporin) with MPA C0 concentrations at end of weeks 1 and 2, 
and end of months 1, 2, 6 and 12 months post-KT 
Mycophenolate discontinuation and adverse events 
Stratified a priori by MMF TDM analyses were performed as follows 
a. Cumulative incidence of MMF discontinuation (KM curves) 
b. Cumulative incidence of adverse events 
i. Cumulative incidence of clinician reported cytopenias 
(neutropenia, leukopenia) 
ii. Cumulative incidence of latent viral infections (CMV, EBV and 
BK reactivation) 
iii. Cumulative incidence of death/graft survival 
iv. Cumulative incidence of acute graft rejection 
c. Descriptive analyses for reasons for MMF discontinuation 
Analyses were limited to first occurrence of events i.e. time to first MMF 
discontinuation, first post-KT infection and first allograft rejection episode. 
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Gastrointestinal adverse events were excluded from these analyses due to the 
high prevalence of non-infectious diarrhoea associated with HIV and 
antiretroviral therapy observed in HIV-positive patients (Macarthur, 2013). A 
large study from the United Kingdom reported the prevalence of diarrhoea in 
HIV-positive patients as 67% and 20% in cART treated vs treatment naïve 
respectively (n=778) (Harding et al., 2010). It would have been difficult to 
ascertain whether gastrointestinal ADEs were mycophenolate induced or due to 
HIV infection or cART. 
 
Factors associated with mycophenolate discontinuation and post-
transplant outcomes/ADE 
This section of the analyses aims to identify factors associated with  
a. MMF discontinuation 
b. Latent viral infections 
c. Haematological adverse events 
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Study Assumptions and Confounding factors 
Mycophenolate acid trough plasma concentrations reported were assumed to 
be true MPA trough concentrations (C0). 100% mycophenolate adherence was 
assumed for all enrolled HIV/KT recipients.  
Interpretation of MPA concentrations was limited by the confounding factors 
listed below.  
• Polypharmacy to include drugs that potentially interact with 
mycophenolate 
• Within/between centre MPA immunoassay sensitivity and variability over 
the study period 
• Variations within/between centres of the MPA target concentrations 
• Switching mycophenolate formulations to generic preparations or other 
formulations (e.g. oral suspensions or intravenous infusions) 
Sample size limited analyses to include adjustments for confounding factors.  
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Statistical analysis  
Prior to performing analyses, the distribution of all available mycophenolate 
doses and MPA concentrations were assessed using graphical methods to 
include histogram and skewness/kurtosis tests to test for normality. Normally 
distributed data were represented as mean (SD) and comparison of means 
using t-test statistical tests. Positively skewed data were represented as median 
(IQR) and comparisons made using Wilcoxon-rank sum (Mann-Whitney) 
statistical test. Statistical significance was considered if p value <0.05. 
Baseline recipient characteristics and reasons identified for MMF first dose 
reductions/discontinuations were analysed using univariate methods stratified a 
priori by MMF TDM vs No TDM. Statistical significance for comparing: 
proportions was tested using two-sided chi-squared test; medians was tested 
with Wilcoxon rank-sum and T-tests for means.  
Univariate cox proportional hazard regression analyses were used to identify 
factors associated with latent viral infection, haematological ADEs and first 
MMF discontinuation in the first year post-transplant. Factors that demonstrated 
statistical significance were included in multivariate regression analyses.  
Analyses of mycophenolate doses at day 1, week 1, 2, and months 1, 2, 3, 4, 6, 
and 12 post-KT were performed using a two-way analysis of variance (ANOVA), 
if data demonstrated normal distribution, to analyse differences between group 
means. Variables tested were (1) calcineurin inhibitor choice (2) mycophenolate 
TDM (3) CNI and MMF TDM interaction.   
Cumulative incidence of patient/graft survival, allograft rejection, MMF-
associated haematological ADEs and latent viral infections were estimated 
using Kaplan-Meier methods and significance tested with log rank test. 
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Stratified a priori by MMF TDM, comparative analyses of allograft function 
determined by eGFR (CKD-EPI) at selected time points were performed using 
Wilcoxon-rank sum (Mann-Whitney) statistical test.   
A multi-level mixed effect linear regression model was used to analyse repeated 
measures data, i.e renal graft function measured at days 30, 60, 120, 180 and 
365 post-KT. This mixed effect model was performed to examine whether there 
was a significant difference (p <0.05) in change of graft function from baseline 
to 1 year post-KT for patients that had MMF TDM compared to those that did 
not. The association of MMF TDM and the slopes of graft function versus time 
post-transplant were also examined using mixed-effect models allowing for a 
random intercept and slope. The analysis was performed using the xtmixed 
command in STATA (version 12.0). Graft function was expressed as eGFR 
calculated using the CKD-EPI equation.  
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6.3. Results 
Patient disposition 
Between 2005 and December 2013, 97 HIV Kidney Transplant recipients were 
identified. Those that did not meet the study inclusion criteria (N=23) included: 
one patient less than 18 years of age; four transplanted abroad (India, Belgium, 
Berlin and USA); three that acquired HIV post-transplantation; one patient who 
died during KT; four with primary non-graft function; two that received CNI 
monotherapy; two received azathioprine; and six that had no data. The six 
patients were transplanted at Oxford Radcliffe hospital (n=4), Birmingham (n=1) 
and Manchester (n=1), refer to Figure 34 for full patient disposition. All were 
referrals from external HIV centres (unknown) and received post-transplant 
follow-up at their base hospitals. Of the 74 patients that were taking 
mycophenolate, 9 were excluded from further analyses the reasons were as 
follows: At KT only 1 patient was taking mycophenolate sodium (Myfortic®) 
whereas the remaining patients took mycophenolate mofetil (Cellcept®) 
preparations; and 9 with no data on mycophenolate dosing, MMF drug 
concentration monitoring or post-KT adverse events (Manchester n=7; 
Edinburgh n=1; Bart’s & the London n=1).  
Analyses in this chapter includes those taking mycophenolate with available 
data for n=65, 23 TDM vs 42 No TDM. During the study period, four transplant 
centres performed MMF TDM. 493 MPA concentrations were performed in 23 
HIV/KT recipients in the first year post-KT. The median (IQR) MPA 
concentrations per subject were 23 (10, 27). Two patients that had <3 MPA 
concentrations available were excluded from full mycophenolate drug 
concentration analyses. However, these patients were included in statistical 
analyses where MMF TDM was categorical (Yes/No).  





























Figure 34: Patient disposition for UK HIV/KT cases stratified by 
those with Mycophenolate TDM 
Excluded 
Paediatric HIV/KT Recipient, N=1 
HIV negative at KT, N=3 
Transplanted abroad, N=4 
Primary non-graft function, N=4 
Died on allograft insertion, N=1 
No data available, N=6 
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Patient characteristics 
The MMF TDM vs. No TDM groups were well matched for baseline patient 
characteristics except for gender (p=0.02) (Table 34). Of 65 with available data 
included in the analyses, 43 were male, 51 of black ethnicity with median (IQR) 
age at KT of 44 (38, 51) years. The Median (IQR) follow-up period was 29.7 
(12.6, 51.6) months. 
Table 34: Baseline patient characteristics at kidney transplantation 
according to Mycophenolate TDM status 
Characteristics  MMF TDM 
N = 23 
MMF No TDM 
N = 42 
P value 
Age, median(IQR) Years 44(37, 50) 44 (39, 52) 0.47 
Gender, n (%) Male 11 (48) 32 (76) 0.02 
Ethnicity Black 18 (78) 33 (79) 0.97 
Cause of ESKD HIVAN 12 (52) 19 (45) 0.59 
HIV parameters     
CD4 count, median (IQR) Cells/mm3 364 (267, 527) 421 (299, 566) 0.32 
Co-morbidities     
Diabetes  3 (13) 6 (14) 0.86 
Hypertension  22 (96) 38 (90) 0.64 
Hepatitis B co-infection, n (%)  3 (13) 5 (12) 0.89 
Hepatitis C co-infection, n (%)  1 (4) 3 (7) 0.64 
Graft characteristics     
Allograft type Cadaveric 16 (70) 26 (62) 0.54 
 Living 7 (30) 16 (38)  
Delayed graft function, n (%)  5 (22) 10 (24) 0.77 
HLA mismatch, median(IQR)  3 (2, 3) 3 (2, 4) 0.57 
Donor/Recipient CMV 
mismatch status, n (%) 
D+/R- 2 (9) 2 (5) 0.53 
*Comparing medians, Wilcoxon rank-sum (Mann-Whitney) test, comparing proportions (%), two-sided chi-squared test. 
Statistically significant (p < 0.05)  
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Table 35: Baseline immunosuppression and antiretroviral drug therapy 
stratified by MMF TDM 
 MMF TDM 
N = 23 
MMF No TDM 
N = 42 
P 
value 
Mycophenolate initiation at KT, 
median(IQR)  
Dose [g/day] 
Weight based dose [g/kg/day]‡ 
Dosing interval [no. per day] 
 
 
1.5 (1.5, 2) 
0.024 (0.019, 0.031) 
2 (2, 2) 
 
 
2 (2, 2) 
0.028 (0.025, 0.032) 

















Antiretroviral therapy at KT, n (%) 
Abacavir containing cART (Yes) 










*Comparing medians, Wilcoxon rank-sum (Mann-Whitney) test; comparing proportions (%), chi-squared test. 
Statistically significant (p < 0.05)  
‡Weight unavailable for 1 male patient. Average weight of adult male patient = 70kg assumed.  
Key: CNI – calcineurin inhibitor; PI/r – ritonavir boosted; cART – combinational antiretroviral therapy  
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Mycophenolate Dosing 
The overall mycophenolate doses were not normally distributed (see Figure 35) 
therefore, data were presented as median (IQR). Initial mycophenolate doses 
used overall were similar to the general kidney transplant population (2 (1.5, 2) 
vs 2 g/day (RocheProductsLtd, 2006), respectively). The overall weight adjusted 
dose was 0.03 (0.02, 0.03) g/kg/day.  Those that had MMF TDM used 
significantly lower initiating doses compared to those without TDM (1.5 (1.5, 2) 
vs 2 (2, 2) g/day, respectively p=0.0009) (see Table 35). This could be 
explained by the differences in transplant protocols where one centre 
recommended pre-emptive MMF dose reductions of 1.5g/day to compensate for 
the known tacrolimus and mycophenolate interaction (n=15) (Hubner et al., 
1999, van Gelder et al., 2000, Miller and Williams, 2009). 12-hourly MMF dosing 
interval was most commonly used in the TDM group compared to the no TDM 
group, median (IQR) 2 (2, 2) vs 4 (2, 4) (p=0.0000). Although in later years of 
the study period (2010 to 2013), dosing interval of four times daily was 
increasingly used by centres as a strategy to avoid MMF-associated 
gastrointestinal adverse effects (e.g. diarrhoea).     
 - 258 - 
Figure 35: Histogram of overall mycophenolate dosing irrespective of 
TDM stratification 
 
Test for normality based on skewness: Skewness/Kurtosis tests for Normality - Skewness = 0.21, 
Kurtosis = 2.97, P value = 0.46. Data were normally distributed at least at the 46% level. P value 
indicates that it is not signiﬁcantly different from the kurtosis of a normal distribution at the 5% 
signiﬁcance level therefore we cannot reject the hypothesis that mycophenolate doses in the first 
year post-KT are normally distributed.  
 
Mycophenolate dose adjustments was common in the first year post-KT with 
68.8% (n=44) having a median (IQR) 2 (1.5, 4) number of dose changes 
(analysis censored at MMF discontinuation, death or date last clinic visit up to 1 
year). There was a similar proportion of patients that had MMF dose 
adjustments in the TDM vs No TDM groups (70%, n=16 vs 68%, n=28, p=0.87). 
Of the 44 that had MMF dose adjustment irrespective of TDM monitoring, 41% 
(n=18) had a dose reduction during 12 month follow-up for majority MMF-
associated latent viral infection or haematological ADRs, further details to be 
discussed. 
Analyses of MMF doses stratified by abacavir containing cART vs abacavir free 












0 .01 .02 .03 .04 .05
Weight adjusted doses (g/kg/day)
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Figure 36: Mean (+/-SD) Mycophenolate doses in the first year post-KT 
 
 
 DF Sum of Squares Mean Square F Value P Value 
Calcineurin inhibitor Choice 1 .002007677 .002007677 23.98 0.0000 
Mycophenolate TDM 1 2.1332e-06 2.1332e-06 0.03 0.8733 
MMF TDM # CNI Choice Interaction  1 .000089339 .000089339 1.07 0.3024 
Model 3 .002134115 .000711372 8.50 0.0000 
 
Graph represents mean mycophenolate weight adjusted doses. Median (IQR) patient weight was 74.5 (66.5, 81) kg. Weight was unavailable for 1 male patient. Average weight of adult male 
patient = 70kg assumed. Statistical analyses performed using two-way analysis of variances (ANOVA). Statistically significant (p < 0.05). The ANOVA model appears to be significant 
(p=0.0000). Calcineurin inhibitor choice appears to significantly affect the average mycophenolate dose used with overall higher doses being used in the ciclosporin group compared to the 
tacrolimus group. Mycophenolate TDM did not appear to impact MMF dosing even when interacting with CNI choice.   
Day 1 Week 1 Week 2 Month 1 Month 2 Month 3 Month 4 Month 6 Month 12
Ciclosporin TDM (n=8) 0.031 0.031 0.031 0.029 0.028 0.028 0.028 0.023 0.017
Ciclosporin No TDM (n=22) 0.029 0.029 0.029 0.028 0.024 0.029 0.027 0.017 0.022
Tacrolimus TDM (n=15) 0.023 0.025 0.024 0.022 0.022 0.022 0.019 0.019 0.018






































Ciclosporin No TDM (n=22)
Tacrolimus TDM (n=15)
Tacrolimus No TDM (n=19)
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Mycophenolic Acid Plasma Concentrations 
Overall mycophenolic acid concentrations were positively skewed therefore; data were presented as median (IQR) (see Figure 37). MPA concentrations achieved overall over 12 month period 
were 1.4 (0.75, 2.52) mg/L. 37%, 51% and 12% of MPA concentrations were subtherapeutic, therapeutic and supratherapeutic respectively (target range 1 to 3.5mg/L) (see Figure 37A). More 
than 50% of MPA concentrations were measured in the first 3 months post-KT (see Figure 37B). The first measured MPA concentration was 0.72 (0.29, 1.02) mg/L with a median (IQR) time to 
first concentration of 2 (1, 3) days post-KT (n=14). This excluded 9 patients that had a dose change prior to first drug concentration or if first drug concentration was > 7 days post-KT. In this 
early period frequent subtherapeutic concentrations were observed (see Figure 37C) with therapeutic concentrations being achieved by 3 months post-KT (1.02 (0.48, 2.2) mg/L). MMF TDM 
was less frequent in the late period post-transplantation (<25% of MPA concentrations). MPA concentrations demonstrated wide variability throughout the study period, refer to Figure 37C.   
 
Figure 37: Graph representing overall mycophenolic acid plasma concentrations achieved in the first year post-HIT/KT 
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Days Post-KT
95% CI Fitted values MMF Level
Reference lines (red): target range 1 - 3.5 mg/L
A. Histogram of MPA Concentrations in First year Post-KT (n=21) B. Histogram of the frequency of MPA Concentrations taken in First 
year Post-KT (n=21) 
C: Scatter plot of MPA Concentrations in First year Post-KT (n=21) 
MPA concentrations in HIV/KT patients in first year post-KT (black 
circles). The population prediction (solid line) and 95% prediction 
interval (grey section) are also shown.  
 
Test for normality based on skewness: Skewness/Kurtosis tests for 
Normality - Skewness = 1.77, Kurtosis = 7.24, P value = 0.00. Data is 
positively skewed. P value indicates that it is signiﬁcantly different from 
the kurtosis of a normal distribution at the 5% signiﬁcance level 
therefore we can reject the hypothesis that MPA concentrations in the 
first year post-KT were normally distributed.  
Test for normality based on skewness: Skewness/Kurtosis tests for 
Normality - Skewness = 0.86, Kurtosis = 2.63, P value = 0.00. Data is 
positively skewed. P value indicates that it is signiﬁcantly different from the 
kurtosis of a normal distribution at the 5% signiﬁcance level therefore we 
can reject the hypothesis that the frequencies of MPA concentrations in the 
first year post-KT were normally distributed.  
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For these analyses, each subject contributed a single MPA concentration 
measurement closest to the time points of interest (i.e weeks 1, 2, 3….) (see 
Figure 38). Therapeutic median MPA concentrations were achieved by week 5 
post-transplant and maintained thereafter up to 12 months of follow-up.  
Figure 38: Median (IQR) Mycophenolate Ctrough plasma concentrations 
categorised by weeks in first year post-KT  
 
Line graph representing the median (IQR) MPA plasma concentrations. *Concentrations excluded for patients that did 
not have a concentration measured in the first year post-KT. Where patients had no concentration values on the 
allocated day of analysis, the last available concentration was carried forward for up to a maximum of 14 days. 
Concentrations that were carried forward were restricted to period of steady state i.e. excluding week 1.   
NB: The half-life of mycophenolate is 12 (normal) - 17.9 (ESRF) hours (Ashely and Currie, 2009). It would therefore 
take approximately 2 – 4 days to reach steady state (4 to 5 half-lives). However, this does not take into account drug 
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Within the mycophenolate TDM group only, there was a significantly higher 
proportion of patients taking tacrolimus (65%, n=15) compared to ciclosporin 
(35%, n=8) (chi2 p=0.003). An analysis of MPA concentrations in the first four 
months post-KT stratified by calcineurin inhibitor choice revealed similar 
concentrations in both CNI groups (see Figure 39).  
Figure 39: Median (IQR) Mycophenolic Acid Plasma Ctrough Concentrations 
Stratified By CNI Choice for the First Four Months Post-HIV/KT 
 
Graph represents median (IQR) MPA plasma trough concentrations stratified by CNI choice. Comparisons for each time 
point was performed using Wilcoxon rank-sum (Mann-Whitney) test; weeks 4, 6, 12, and 16 p=NS. Statistical 
significance (p < 0.05).   
Week 4 6 8 12 16 
CsA, n 4 5 2 5 5 
Tac, n 9 9 8 7 9 







































Tacrolimus Lower limit target Upper limit target Ciclosporin
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Further comparisons of MPA concentrations between CsA and Tac could not be 
performed at further times points post-KT (weeks 16 to 52) due to the limited 
available samples in the ciclosporin group. An analysis of the later period post-
KT for the Tac group observed much more stable MPA concentrations 
maintained within the target range, (see Figure 40).  
Figure 40: Median (IQR) Mycophenolic Acid Plasma Ctrough Concentrations 
for HIV/KT Recipients Maintained on Tacrolimus 
 
WEEK 1 2 3 4 5 6 7 8 9 10 11 12 13 
N 12 12 10 9 11 9 9 8 6 10 9 7 6 
 
WEEK 14 16 18 20 22 24 26 28 32 37 42 46 52 
N 5 9 10 10 7 9 6 8 10 11 7 9 8 
 
Graph represents median (IQR) mycophenolic plasma concentrations for n=15 HIV/KT 
recipients being maintained on Tacrolimus IS based therapy in the first year post-KT. 
 
Analyses of MPA concentrations stratified by abacavir containing cART vs 
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Mycophenolate Discontinuation 
Overall, the proportion of patients that first discontinued mycophenolate in the 
No TDM group compared to the TDM group were similar, 51% (21/42) vs 26% 
(6/23) respectively, p=0.07. There was a significant difference between groups 
(MMF TDM vs No TDM) of patients that first discontinued MMF at month 6 and 
12 post-KT (see Figure 41). There were no statistical differences found in the 
proportion of first mycophenolate discontinuations that were attributed to latent 
viral reactivation between TDM groups, 61% (17/28) No TDM vs 17% (1/6) 
TDM, p=0.08 (see Table 36). Cytomegalovirus infection was prevalent in the No 
TDM group (40%, n=11) compared to the TDM group that had no CMV infection 
cases. This was also the case for haematological ADR as the reason for first 
MMF discontinuation, No TDM 25% (7/28) vs. TDM 67% (4/6), p=0.12.  
Figure 41: Graph representing the proportion of patients taking 
mycophenolate in the first year post-HIV/KT stratified a priori by TDM 
status  
 
* Comparing proportions (%), two-sample test of proportions. All other time points were NS (not shown). Patients were 
censored at (1) first mycophenolate discontinuation (2) last clinic visit or at 12 months (3) death 
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Latent viral reactivation 1 (17) 16 (57) 0.08 
Cytomegalovirus  - 11 (40)  
BK virus 1(17)‡ 3 (11)  
Herpes simplex virus - 3 (11)  
Haematological ADR 4 (67) 7 (33) 0.12 
Low white cell count 3 (50) 3 (11)  
Leukopenia 1 (17) -  
Neutropenia - 1 (4)  
Thrombocytopenia - 2 (7)  
Pancytopenia - 1 (4)  
Other 1 (17) 4 (19) 0.91 
MMF switched to Azathioprine, pregnancy planning - 1 (4)  
MMF stopped for acute allograft rejection with ATG - 2 (7)  
CNI toxicity switched to SrL, MMF stopped to avoid SrL+MMF 
interaction 
1 (17) 1 (4)  
*Table count stated per clinical event; patients with mixed clinical picture contributed multiple times to count, % shown number clinical 
events represent the denominator. **Missing data on n=1; ‡BK nephropathy; n=2 in TDM group and n=7 in No TDM that did not complete 





Table 37: Reasons for Mycophenolate dose reduction stratified by TDM* 
 Mycophenolate TDM 
(n=5) 
N (%) 
Mycophenolate No TDM (n=13)**  
                       N (%) 
P value 
Latent viral reactivation 5 (71) 10 (67) 0.85 
Cytomegalovirus  3 (43) 9 (60)  
BK virus 1 (14) 1 (7)  
Herpes simplex virus 1 (14) -  
Haematological ADR 1 (14) 3 (20) 0.73 
Low white cell count 1 (14) 2 (13)  
Leukopenia - 1 (7)  
Neutropenia - -  
Other 1 (14) 2 (13) 0.95 
High MMF C0 concentration 1 (14) -  
Low immunoglobulin level - 1 (7)  
Reduce pill burden - 1 (7)  
Key:  MMF C0 concentration – mycophenolate trough plasma concentration 
*Table count stated per clinical event; patients with mixed clinical picture contributed multiple times to count, % shown number clinical 
events represent the denominator. **Missing data on n=1 
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Overall, there was a similar proportion of patients experiencing mycophenolate 
dose reductions in the first year post-HIV/KT in the No TDM group compared to 
TDM group, 22% (5/23) vs. 32% (13/41) p=0.39 (Table 37). Similarities were 
also observed for MMF dose reductions attributed to latent viral reactivation in 
the TDM and No TDM groups, 71% (5/7) vs. 67% (10/15) p=0.85. There were 
no differences between groups where MMF dose reductions were performed 
due to haematological ADRs, TDM 14% vs. No TDM 20% p=0.75. In univariate 
cox-proportional hazard analyses, no factors were found to be associated with 
first mycophenolate discontinuations Table 39. Cox proportional hazard 
univariable analysis CNI choice was the only factor significantly associated with 
mycophenolate discontinuation with tacrolimus based IS therapy being 
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Table 38: Factors Associated with Mycophenolate Discontinuation in the 
First Year Post-HIV/KT 
 Univariate analysis 




















































0.91 (0.28, 3.01) 











1.59 (0.54, 4.63) 


























































Key: HR=Hazard ratio estimated from Cox proportional hazard regression model with 95CI of 
the estimated HR. CI=Confidence Interval; P=p-value; Analyses censored at first 
mycophenolate discontinuation, last clinic visit or 12 months. Statistical significance p<0.05. 
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Mycophenolate Associated Adverse Events 
Kaplan Meier analyses showed significant differences in the cumulative 
incidence of latent viral reactivation at 1 year in the MMF TDM vs No TDM 
groups was 20% and 62% respectively (p=0.003), (see Figure 42A). Although, 
in the MMF TDM group there was a higher proportion of patients that received 
CMV prophylaxis compared to the No TDM group, 74% (n=17) vs 43% (n=18), 
p=0.02. The cumulative incidence of latent viral infections at 1-year when 
adjusted for CMV prophylaxis for both MMF TDM and No TDM groups was 20% 
vs 84% respectively, p=0.0001. There was a similar incidence of MMF 
associated haematological ADRs in both groups 22% and 31% at 1-year, MMF 
TDM vs No TDM respectively (p=0.71), (see Figure 42B). 
Multivariate proportional hazards analysis showed that mycophenolate TDM, 
being on Tac based IS therapy and receiving CMV chemoprophylaxis were 
protective against post-HIV/KT latent viral infections in the first year (HR 95CI, 
0.38 (0.17, 0.85), p=0.018; 0.24 (0.08, 0.75), p=0.015; 0.33 (0.13, 0.83), 
p=0.018 respectively), (see Table 39).  
  
 - 269 - 
In the group without MMF TDM, 31% (n=13) of patients switched CNI therapy 
choice at a median (IQR) 3.3 (2.6, 5.5) months post-KT. Of the 13 patients all 
taking CsA at KT, 12 switched to Tac and 1 to SrL. The clinician reported 
reason for switching was allograft rejection (n=9), failing graft (n=1), Kaposi 
Sarcoma (n=1), nausea (n=1) and efficacy (n=1). 
 
Figure 42: Cumulative incidence of Adverse Events (AE) stratified by MMF TDM and by 
AE type in the first year post-transplantation 
 
 A: Latent Infections              B: Haematological ADR 
   
*Patients were censored at (1) date of latent viral infection or Haem ADR (2) date first stopped MMF or (3) last clinic visit 
(these included patients that did not have complete 12 month follow-up as described above.  
**Latent infection: Latent infection count includes for those that had MMF discontinuation or dose reduction. In No TDM 
group n=1 had missing data and of the remaining 41 patients, n=23 latent viral infections. Of the 18 patients without 
latent viral infections, n=6 discontinued MMF and n=3 had < 12months of follow-up. In the TDM group none had missing 
data and n=4 had latent viral infections. Of the remaining 19 patients, n=5 had discontinued MMF and n=2 had <12 
months of follow-up. All other patients’ in both groups time of follow-up was calculated to 1 year. 
**Haematological ADR: Count includes for those that had MMF discontinuation or dose reduction. In No TDM group n=1 
had missing data and of the remaining 41 patients, n=9 had Haem ADRs. Of the 32 patients without Haem ADR, n=14 
discontinued MMF and n=7 had < 12months of follow-up. In the TDM group none had missing data and n=5 had Haem 
ADRs. Of the remaining 18 patients, n=2 had discontinued MMF and n=2 had <12 months of follow-up. All other 
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Mycophenolate TDM and CNI choice were significantly associated with 
developing latent viral infections in multivariable cox-proportional hazard 
regression analyses, Table 39. There were no factors associated with first 
occurrence of MMF-associated haematological ADRs in univariate cox 
proportional hazard regression analyses, Table 40.  
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Table 39: Results from univariate and multivariate cox-proportional hazard analyses to 
identify factors associated with latent viral infections in the first year post-transplant 
 Univariate analysis Multivariate analyses 






























































1.20 (0.36, 4.01) 












0.68 (0.30, 1.56) 









































































Key: HR=Hazard ratio estimated from Cox proportional hazard regression model with 95CI of 
the estimated HR. CI=Confidence Interval; P=p-value; Analyses censored at first 
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Table 40: Results from univariate cox-proportional hazard analyses to identify factors 
associated with treatment limiting cytopenias in the first year post-transplant 
 Univariate analysis 




















































1.65 (0.36, 7.55) 











0.96 (0.29, 3.15) 


























































Key: HR=Hazard ratio estimated from Cox proportional hazard regression model with 95CI of 
the estimated HR. CI=Confidence Interval; P=p-value; Analyses censored at first 
mycophenolate discontinuation, last clinic visit or 12 months. Statistical significance p<0.05. 
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Mycophenolate TDM and Allograft Outcomes 
There was no difference in the rates of acute rejection at 1-year observed 
between groups, (see Figure 43). No differences were found in allograft 
function at the selected time points in those with mycophenolate TDM vs no 
TDM, (see Figure 44). At 1 year, the median (IQR) CKD-EPI eGFR was 48.9 
(39.9, 62.3) and 47.7 (27.1, 70.5) mL/min per 1.73 m2 in the MMF TDM group 
compared to those without MMF TDM.  
 
Figure 43: First Allograft Rejection Episodes at 1 year Post-HIV/KT 
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Figure 44: Graph representing estimated glomerular filtration rate (eGFR) 
determined by CKD-EPI post-HIV/KT stratified by Mycophenolate TDM 
 
*Ranksum test for all time points P=NS 
There were no significant differences in the change of graft function (CKD-EPI 
eGFR) from baseline to 1 year post-KT when comparing those that had no MMF 
TDM to those that did (multilevel mixed effect linear regression estimates (95CI) 
+6.4 (-4.9, +17.7) ml/min/1.732, p=0.27). The slope of eGFR over time was also 
not different between groups (interaction p=0.66). The eGFR seemed to remain 
stable throughout the follow-up period for both groups (overall change of eGFR 
MMF No TDM -0.02 (95CI -0.16, +0.10) ml/min/1.732, MMF TDM +0.01 (95CI -
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6.4. Discussion 
The need for therapeutic drug monitoring of mycophenolate in clinical practice 
has been much debated. To date the benefit of mycophenolate TDM has not 
been demonstrated in HIV kidney transplantation. The current analyses lacked 
strong evidence to demonstrate the utility of mycophenolate TDM in HIV/KT. 
First, no association was found between mycophenolate TDM and first MMF 
discontinuation rates over the initial 12 months post-KT. Second, there was no 
difference in the occurrence of haematological adverse effects, e.g. treatment 
limiting cytopenias, in the mycophenolate TDM group compared to the no TDM 
group. A study of the impact of mycophenolate TDM on allograft outcomes also 
found no effect on allograft rejection or function. However, despite these 
findings mycophenolate TDM was protective against developing latent viral 
infections even after adjusting for CMV prophylaxis in multivariate cox-
proportional hazard analyses (HR 95CI, 0.28 (0.10, 0.83), p=0.02). Other 
secondary findings found being on tacrolimus to be protective against 
developing latent viral infections (0.32 (0.14, 0.78), p=0.01). However, there 
was a large proportion of patients in the mycophenolate TDM group taking Tac 
and on CMV prophylaxis (65%, n=15). Furthermore, these patients were 
initiated on lower doses as a preemptive dosing strategy to manage the known 
tacrolimus andmycophenolate drug interaction  (Hubner et al., 1999, van Gelder 
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Mycophenolate dose and exposure 
In recent years, therapeutic drug monitoring to improve mycophenolate therapy 
outcomes has been reviewed against select criteria. The criteria have included: 
relationship between MMF exposure and clinical outcomes (e.g. allograft 
function or rejection); relationship of MMF exposure and immunosuppressive 
effect; relationship between MMF exposure and toxicity; an adequate measure 
of efficacy i.e. mycophenolic acid trough or total exposure AUC; and, target 
therapeutic MPA drug concentrations (Bullingham et al., 1998, Kuypers et al., 
2010). 
Mycophenolate dosing more recently in clinical practice has been based on 
fixed dosing 2g/day (Le Meur et al., 2007, van Gelder et al., 2008, Gaston et al., 
2009, Grinyo and Cruzado, 2009, Grinyo et al., 2009, Kamar et al., 2009, 
Kuypers et al., 2010). Where tacrolimus is co-administered, a pre-emptive dose 
adjustment of 1g/day has been used in anticipation of increased MMF exposure 
(Kuypers et al., 2003). A similar approach was observed in our study where 
initiating MMF doses for those taking CsA, Tac respectively were 2 and 1.5 
g/day. There is weak evidence that calcineurin inhibitors alter MPA exposure by 
inhibiting glucuronidation (Kobayashi et al., 2004). The increased MPA 
exposure noted with ciclosporin is thought to be due to reduced biliary excretion 
of MPA-glucuronide (Kobayashi et al., 2004). There are some analytical assays 
commonly used e.g EMIT, are known to be less specific in measuring MPA 
plasma concentrations (Schutz et al., 1998). The antibody used in the EMIT 
assay is known to cross-react with one of the glucuronide metabolites, 
AcMPAG. Therefore, MPA concentrations measured by EMIT tend to 
overestimated (Jeong and Kaplan, 2007).       
 - 277 - 
 
In a large randomised clinical study (n=901), initiating fixed MMF doses of 
2g/day coincided with total MPA exposure (AUC) of 30 to 60 mg x h/L (van 
Gelder et al., 2008). Recommended target concentrations of MPA AUC 30 to 60 
mg x h/L have demonstrated relationship with good clinical outcomes (i.e. 
allograft rejection, graft loss, MMF discontinuation) (van Gelder et al., 1999, Le 
Meur et al., 2007, van Gelder et al., 2008) and reduced MMF toxicity (van 
Gelder et al., 2006, Kuypers et al., 2008). Target trough MPA concentrations of 
1.3 and 1.9 mg/L for Tac, CsA respectively demonstrated best correlation to 
AUC >30 mg x h/L (van Gelder et al., 2006). MPA AUC < 30 mg x h/L (MPA 
Ctrough ≥ 1.3 mg/L) has been demonstrated to correctly identify ~80% patients at 
risk of early (0 to 3 months) allograft rejection (Kiberd et al., 2004).  Study 
subjects taking CsA based CNI therapy tended to take longer to achieve target 
MPA concentrations compared to those taking Tac, 51.2% vs 76.2% day 3 post-
transplantation respectively (van Gelder et al., 1999). This was also 
demonstrated in the APOMYGRE study where those taking CsA and 2g/day 
fixed dose of MMF 73, 69, and 44% achieved MPA AUC (<30mg x h/L) by days 
7, 14 and 30 post-transplant (Le Meur et al., 2007). In this study, 25% of overall 
trough MPA concentrations were ≥ 1.3 mg/L by day 30 post-HIV/KT. During the 
later period post-KT (6 to 12 months), there was minimal MMF dose change to 
maintain adequate MPA concentrations. There were no pharmacokinetic 
studies performed to determine MMF total exposure in this study. Although 
clinical studies describe standard MMF doses and concentrations achieved, 
there are other multiple factors that may impact MMF exposure. Mycophenolate 
exposure can be influenced by multiple factors resulting in wide inter/intra-
patient variability. Some of these factors include food, race, severe renal 
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impairment (GFR <25ml/min), albumin level, delayed graft function, 
concomitantly administered interacting drugs and polymorphisms of metabolic 
enzymes and multidrug resistance proteins (Staatz and Tett, 2007, Grinyo et al., 
2009). 
 
The absorption of MPA varies with the different mycophenolate formulations. 
This can result in a delayed enterohepatic recirculation of MPA resulting in 
higher and variable trough concentrations (Pawinski et al., 2013). Therefore, 
limited sampling strategies have been developed as better correlates of AUC 
albeit impractical in clinical settings (Pawinski et al., 2013, Cai et al., 2015, Yao 
et al., 2015). In this study cohort, mycophenolate exposure was determined by 
MPA plasma trough concentrations in the MMF TDM group. Overall, therapeutic 
MPA concentrations were achieved by week 5 post-KT. This delay in achieving 
therapeutic MPA concentrations has been thought to be due to late 
gastrointestinal absorption and enterohepatic recirculation of MPA observed in 
early period post-KT (Staatz and Tett, 2007). The inclusion of antibiotics, that 
affect enterohepatic recycling, in the perioperative period post-KT may also 
hinder achieving adequate MPA concentrations (Kuypers et al., 2010). Frequent 
CNI dosing alterations and changing steroid doses in the early period post-
transplant could also be contributing factors (Staatz et al., 2005, Staatz and 
Tett, 2007, Kuypers et al., 2010). There was more frequent therapeutic drug 
monitoring in the early period post-KT (>50% in first 3 months). This reflects 
general clinical practice with close monitoring in the early period post-KT when 
there is a higher risk of allograft rejection compared to the late period (>6 
months) (Kuypers et al., 2010).  
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Ciclosporin required higher doses of mycophenolate compared to tacrolimus. 
The influence of CNI choice on mycophenolate exposure has been described in 
the literature (Hubner et al., 1999, Vidal et al., 2000, Pou et al., 2001, Grinyo et 
al., 2009, Naito et al., 2009). The co-medication of ciclosporin with MMF results 
in approximately 30 to 40% lower MPA concentrations compared to tacrolimus 
(Staatz and Tett, 2007). In this cohort, we anticipated that the inclusion of 
certain antiretroviral drugs that interact with CNIs may have an added impact on 
MPA exposure. However, no relationship was found between cART choice (PI-
sparing vs PI-containing) and MPA concentrations. There is also the potential 
for altered MPA concentrations when mycophenolate is co-administered with 
antiretroviral drugs that undergo glucoronidation e.g. abacavir (UoL, 2015). 
Close monitoring of mycophenolate concentrations is recommended when be 
performed with co-administered with abacavir (UoL, 2015). However, alterations 
to MPA concentrations by abacavir have not been demonstrated in 
pharmacokinetic studies (Sankatsing SU, 2004, Millan et al., 2005). In this study 
cohort, no relationship was found between abacavir and trough MPA 
concentrations.  
At baseline patients in both groups in this study were well matched except for 
the higher proportion of male patients in the MMF no TDM group 76% (n=32) 
compared to the TDM group, 48% (n=11) (p=0.02). It has been demonstrated 
that (a) males have more rapid apparent MPA clearance than females 
(Tornatore et al., 2015) (b) males have higher glucoronidation of MPA than 
females (Morissette et al., 2001). It has also been suggested that MPA 
metabolism is reduced in females due as oestrogen competes with MPA for 
UGT binding (Morissette et al., 2001). However, clinical studies have not proved 
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gender differences for mycophenolate requirements or exposure (Pescovitz et 
al., 2003, Le Guellec et al., 2004, Staatz et al., 2005). 
 
At baseline both study groups were well matched for ethnicity, consideration of 
ethnicity on MMF exposure was given owing to the high proportion of patients of 
black ethnicity in this study cohort. Some evidence of reduced MMF efficacy 
has been demonstrated in African Americans compared to Caucasian kidney 
transplant recipients (Neylan, 1997, Schweitzer et al., 1998, Staatz and Tett, 
2007). Although, strong evidence is lacking that show the impact of ethnicity on 
MPA pharmacokinetics (Shaw et al., 2000, Pescovitz et al., 2003, Staatz and 
Tett, 2007). In this cohort, there was no relationship found between MPA 
concentrations and ethnicity (p=0.06).  
Pharmacogenetic considerations on mycophenolate disposition have been 
investigated. There are two genes prognostic of acute allograft rejection that 
have been identified, UGT1A9 and IMPDH1 genes. UGT1A9 genes occur in 
approximately 15% of Caucasians (Girard et al., 2004). Similarly, IMPDH1 
genes have been commonly reported in Caucasians of European descent 
(Sombogaard et al., 2009, Wu et al., 2010).  Although strong evidence is lacking 
on the influence of these genotypes on mycophenolate disposition (Abboudi 
and Macphee, 2012). 
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Mycophenolate Discontinuation 
Mycophenolate discontinuation especially in the first year post-transplant 
compromises the efficacy of the immunosuppression putting the allograft at risk 
of rejection. In this study, there was somewhat similar rates of MMF 
discontinuation between groups no TDM 51% (21/42) vs TDM 26% (6/23) 
respectively, p=0.07. In multivariate analyses, being on Tac was protective for 
MMF discontinuation (0.27 (0.12, 0.65), p=0.003). The impact of MMF 
discontinuation on post-KT outcomes is much debated. Some evidence 
suggests that early MMF discontinuation (up to 3 months) does not increase the 
incidence of allograft rejection at 6 months (Pascual et al., 2006, Sulowicz et al., 
2007). Whereas other evidence suggests that MMF dose reduction and 
discontinuation increases the risk of allograft rejection and graft loss (Knoll et 
al., 2003, Hardinger et al., 2004a, Tierce et al., 2005, Bunnapradist et al., 2006, 
Machnicki et al., 2008, Opelz and Dohler, 2008, Shah et al., 2008). 
 
Latent viral infection was the most common reason for MMF discontinuation in 
this study analysis. The cumulative incidence of latent viral infections at 1-year 
when adjusted for CMV prophylaxis in the MMF no TDM group was almost four 
times higher than the TDM group. A causal relationship between 
pharmacokinetic monitoring of MPA and post-transplant infections has not been 
established. One study describes an increase in the incidence of infections has 
been found with trough MPA concentrations >3mg/L (Borrows et al., 2006). By 
contrast, an MPA AUC >60mg x h/L was associated with high risk of 
haematological ADRs but not infections, specifically viral infections (Satoh et al., 
2005, Kuypers et al., 2008). Antiretroviral therapy has dramatically reduced the 
incidence of opportunistic infections. Although, HIV infected individuals with 
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CD4 T cell count < 100 cells/mm3, when reconstitution of normal immune 
responses do not occur, have an increased risk of latent viral reactivation and 
recurrence of disease (Springer and Weinberg, 2004). Furthermore, there is risk 
of end-organ disease with latent viral reactivation -e.g. CMV (Spector et al., 
1996, Springer and Weinberg, 2004). Some authors argue that this warrants 
preemptive CMV prophylaxis in HIV infection (Paltiel et al., 2001). Our data 
suggests that in the transplant setting, that irrespective of preemptive CMV 
prophylaxis MMF TDM may be beneficial in preventing latent viral infection. 
However, this association needs to be corroborated in a larger cohort. A post-
hoc analysis of CD4 T cell counts revealed counts were > 350 cells/mm3 in both 
MMF TDM and no TDM groups throughout the study period (data not shown).   
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Mycophenolate TDM & Allograft Outcomes 
Overall, there were no differences in allograft rejection rates or graft function 
observed between MMF TDM and No TDM groups. In the general KT 
population, there is conflicting evidence of the impact of mycophenolate TDM 
on allograft rejection. In a clinical study that included 549 patients considered 
‘high risk’, a difference in the incidence of AR was observed in those that 
achieved MPA AUC > vs < 30 mg hr/L respectively, 14.3% vs 7.8% (p=0.025) 
during the first month post-KT (van Gelder et al., 2010). By contrast, the 
Opticept study (n=720) intention to treat analysis did not find an association of 
MMF TDM to allograft rejection (Gaston et al., 2009). Although, a post-hoc 
analysis of the Opticept study demonstrated a significant relationship in KT 
recipients taking tacrolimus (n=590) between BPAR and MPA trough 
concentrations <1.6mg/L (p=0.001).  
The impact of mycophenolate TDM on post-transplant allograft function has 
been explored. One clinical study including 46 HIV negative kidney transplant 
recipients found trough MPA concentrations to be significantly correlated with 
creatinine clearance (Cattaneo et al., 2001). The study demonstrated that an 
MPA AUC0-12 > 40 μg/mL·h had better allograft function (85.7 mL/min) 
compared to < 40 μg/mL·h (64.5 mL/min) (Cattaneo et al., 2001).  
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Study Limitations 
The strength of this study is the well matched groups at baseline except for 
gender. However, the study had several limitations which may have affected 
inferences drawn. Firstly, analyses when assessing the sub-groups were limited 
by the small cohort size. Secondly, in the MMF TDM group variability in 
immunoassays both within and between centres could not be controlled due to 
the small sample size and lack of detailed information on assay modifications 
thoughout the study period. Also, the differences in immunoassay accuracy, 
e.g. those that measure both MPA and MPAG, is questionable. For these 
reasons, target MPA trough concentrationscan be variable. Further, the lack of 
evidence to establish the relationship of Ctrough and AUC, may have limited the 
inferences drawn from this study. The use of clinician reported data, e.g. 
treatment limiting cytopenias, meant that analyses could not be standardised 
thereby reducing bias. In addition, the variation in transplant protocols also 
meant that post-transplant management was inconsistent e.g. steroid 
withdrawal, empirical MMF dose reductions, use of pre-emptive 
chemoprophylaxis.  
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6.5. Conclusion 
There has been much debate over the utility of mycophenolate therapeutic drug 
monitoring in solid organ transplantation. HIV infected patients are considered 
to be of high immunological risk of allograft rejection. This study failed to 
provide strong evidence of the usefulness of MMF TDM in HIV/KT. The 
composite outcomes that did not support MMF TDM included: MMF 
discontinuation; mycophenolate associated haematological ADR; and post-
transplant allograft outcomes (allograft rejection and function). There was some 
benefit observed of mycophenolate TDM in the prevention of latent viral 
infections. The use of CMV prophylaxis and tacrolimus based IS therapy also 
appeared to be protective for the development of latent viral infections although, 
these findings need to be corroborated in a larger cohort.  
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Chapter 7. Conclusions & Future Work  
End-stage kidney disease is an important co-morbidity in HIV infected 
individuals. Management of ESKD in the pre-HAART era was restricted to 
conservative and dialysis treatment modalities. Both methods were associated 
with high rates of mortality. During this period, prior to the advent of effective 
antiretroviral therapy, concerns of developing opportunistic infections, HIV 
disease progression and poor patient survival were deterrents to kidney 
transplantation in HIV infected individuals. The prognosis of HIV infection was 
vastly improved with the use of HAART. Effective management of HIV and use 
of stringent selection criteria paved the way for the successful kidney 
transplantation of HIV infected individuals. With low patient numbers for both 
HIV/ESKD and kidney transplant recipients, observational cohort studies are the 
best way to glean insights that may help optimise care for these patients.   
This thesis was set out to first examine the trends of ESKD in HIV infection in 
the United Kingdom and to describe the use of and barriers to kidney 
transplantation as a treatment modality for ESKD.  The first study also sought to 
compare the patient survival outcomes by treatment modality for ESKD. To 
further prove the feasibility of HIV kidney transplantation, an in depth analysis 
was performed to describe the host and graft outcomes. Finally with the 
complexity of kidney transplantation, this thesis explores the 
immunosuppressive drug therapy management in this HIV/KT cohort.  
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Trends of ESKD in HIV Infection 
The burden of ESKD in HIV infection in the United Kingdom has continued to 
increase over the past decade. The incidence of HIV/ESKD on the otherhand 
remained unchanged. This may be reflective of an ageing HIV population and 
the chronic use of antiretroviral drugs that may contribute to the development of 
ESKD. Over a 13 year study period there was a 20-fold increase in HIV/ESKD 
despite the extensive use of antiretroviral therapy. Patients of black ethnicity 
had a 7 fold higher overall prevalence of ESKD compared to other ethnicities. 
The high prevalence of APOL-1 gene among patients of black ethnic patients 
has been implicated for the differences in ESKD rates (Behar et al., 2011, Atta 
et al., 2012, Allison, 2015, Anyaegbu et al., 2015). Aside from ethnicity, other 
patient characteristics of HIV/ESKD included longer time since diagnosis, 
having a high HIV viral load and hepatitis B/C co-infection. This highlights the 
need for earlier HIV diagnosis and earlier initiation of cART both associated with 
lower risk of developing ESKD (Allison, 2009). Other factors that were 
associated with developing ESKD included older age, prior history of AIDS 
(CDC-C) defining illness, a lower nadir and overall CD4 T cell count. HIV 
associated nephropathy continued to be the primary diagnosis of ESKD 
probably owing to the continued proportion of HIV infected patients that present 
with advanced HIV disease (Scourfield et al., 2011, HPA, 2014). Earlier, more 
robust and closer monitoring of renal function of HIV infected individuals 
maintained on cART may be one approach to reducing the rates of ESKD in this 
population. Current BHIVA guidelines (BHIVA et al., 2014) recommend eGFR in 
addition to urinalysis to detect haematuria, proteinuria or glycosuria; as a more 
accurate measure of renal function compared to serum creatinine. Urinary 
protein monitored by measuring urinary protein/creatinine ratio (uPCR) is also 
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recommended especially in patients taking nephrotoxic antiretroviral therapy 
e.g. tenofovir.  
  
 
At the end of the study, those that were eligible for KT had received an allograft. 
Poor HIV virological control was the primary reason that prevented the HIV 
infected individuals from receiving an allograft. Public health intiatives are 
necessary for earlier HIV diagnosis and ealier cART initiation. Furthermore, the 
utilisation of adherence clinics to improve behavioural outcomes and virological 
responses are warranted (Rathbun et al., 2005, Horne et al., 2007, Cooper et 
al., 2011, Charania et al., 2014, Muessig et al., 2015). One prospective, 
randomised, controlled study demonstrated this in a pharmacist led adherence 
clinic approach where there was improved adherence, 69% vs 42% (p=0.025); 
and HIV RNA levels declined to <400 copies/mL by week 16 for 100% vs 71%, 
p=0.04 of the adherent group compared to the control group respectively 
(Rathbun et al., 2005). A comparison of patient survival between dialysis and 
KT treatment modalities for HIV/ESKD patients revealed similar five year 
survival rates. Despite demonstrating that KT offers a survival benefit, other 
benefits of KT not measured in the current analysis e.g. quality of life measures, 
cardiovascular co-morbidities and health economics warrant further study.   
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HIV kidney transplantation   
This thesis confirms the feasibility of kidney transplantation in a select group of 
HIV infected individuals with well controlled HIV who are stable on antiretroviral 
drug therapy. Favourable outcomes in terms of patient and graft survival in the 
short term were observed. Longer follow-up is needed to determine the impact 
of the high rate of allograft complications on longterm allograft function and 
survival. There are different approaches for consideration in the HIV/KT 
population to reduce the rejection rates. Firstly consideration for the quality of 
donor organs although not measured in the current study. In the current 
dataset, living donors demonstrated better outcomes compared to deceased 
donor HIV kidney transplantation. However, for deceased donation donor age, 
cold ischaemic time and panel reactive antibodies are factors that are 
implicated in allograft outcomes such as delayed graft function and allograft 
rejection. Although, organ shortage can be problematic in this group that have a 
high proportion of ethnic minority patients (NHSBT, 2013). Other ways to 
combat this may be use of HIV positive organ donors (Muller et al., 2015) or 
exploring ABO incompatible transplantation (Campara et al., 2008) although, 
both approaches are not without risks. HIV positive organ donation is a 
relatively new field and risk of HIV superinfection with a new or perhaps 
resistant strain is possible. There is also risk of developing kidney disease in the 
donor for living donation (Muller et al., 2015). Although even with both of these 
new approaches, allograft rejection continues to be a challenge in the HIV+ 
cohort. Optimal post-transplant immunosuppressive management is key to 
overcoming this issue. To start with, the question of which inductive therapy is 
most effective in the HIV/KT cohort could not be addressed in the present 
dataset. Use of monoclonal or polyclonal lymphocyte depleting agents in the 
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general KT patients have proved promising with much allograft rejection rates 
as low as 7% at 1 year post-KT (Sageshima et al., 2011, 
3C.StudyCollaborativeGroup et al., 2014). Although, there has been much 
debate over the use of these agents in the HIV+ population due to the risks of 
developing opportunistic infections or serious infections requiring hospitilisation 
(Carter et al., 2006, Stock et al., 2010a) There has been some recent data to 
demonstrate that use of polyclonal lymphocyte depleting agents were not 
associated with an increase in post-HIV/KT infections (Kucirka, 2015). What 
was encouraging in the current cohort, there was no evidence of HIV disease 
progression in terms of loss of virological control and/or occurrence of AIDS 
defining illnesses. Futhermore, there were few opportunistic infections, 
tumors/neoplasm. However, the lack of serial virology data and protocol 
cytology reports limited findings. Opportunistic infections were dependent on 
clinician reporting and definition of OIs was not standardised across study 
centres. In the USA HIV/KT cohort, patients who were closely monitored for 
HPV-related anal neoplasia were found to be at a high risk of developing high 
grade squamous intraepithelial lesions (Nissen et al., 2012). For future study, 
protocol cervical and anal cytologies should be reviewed for any changes post-
HIV/KT.           
Another consideration is the choice of calcineurin inhibitor. Findings 
demonstrated that choice of calcineurin inhibitor was significantly associated 
with allograft rejection. Results demonstrated that use of tacrolimus was 
associated with a lower allograft rejection rate compared to ciclosporin based 
immunosuppression drug therapy. This suggests that that tacrolimus would be 
the preferred choice for the management of HIV kidney transplant recipients. 
This finding is consistent with data from the general KT population (Pirsch et al., 
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1997, Ferraris et al., 2004, Abou-Jaoude et al., 2005, Boratynska et al., 2006)- 
and other published HIV/KT cohorts (Stock et al., 2010b, Touzot et al., 2010). 
Despite CNIs being effective for KT management, there are concerns of CNI 
toxicity where CNI minimisation, CNI free regimens offer for attractive 
alternative strategies (Sawinski et al., 2016). The use of mTOR inhibitors in 
combination with low dose CNIs has been studied in the HIV negative KT 
population. Improved graft function and reduced CNI nephrotoxicity with low 
dose CNI are some the benefits that have been demonstrated in RCTs (Nashan 
et al., 2004, Salvadori et al., 2009, Langer et al., 2012, Bechstein et al., 2013, 
Oh et al., 2015). mTOR inhibitors have some benefit to suppressing HIV-1 
infection through by down regulating C-C chemokine receptor type 5 (CCR5) 
receptor responsible for HIV entry into CD4+ T cells (Gilliam et al., 2007, 
Heredia et al., 2008, Nicoletti et al., 2009, Donia et al., 2010). In the USA study 
cohort, the use of sirolimus, an mTOR inhibitor, was found to have the most 
significant effect in reducing HIV persistence compared to calcineurin inhibitor 
drugs, tacrolimus and ciclosporin (Stock et al., 2014).However, the use of 
mTOR inihibitors without CNIs does not have strong evidence of clinical efficacy 
in kidney transplantation (Yang and Wang, 2015).     
CNI toxicity could not be proven in the current dataset; this was probably due to 
the infrequent protocol biopsies (Krejci et al., 2010, Sharma et al., 2010). One 
protocol biopsy study in a HIV negative KT recipient cohort (n=158) of the toxic 
changes observed 52% were subclinical (Krejci et al., 2010). It has been 
suggested that surveillance or protocol biopsies are unnecessary due to their 
associated safety risks but there is some evidence for their utility in high risk 
patients (Wilkinson, 2006).     
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Calcineurin inhibitor and Antiretroviral drug interactions 
Aside from CNI choice, altered CNI exposure resulting from the co-
administration of interacting antiretroviral drugs could have been further 
implicated in AR development in our cohort. However, as this was an 
observational study robust analysis to demonstrate the relationship between 
CNI exposure and AR could not be performed. Despite this, analyses in this 
thesis described the challenges of achieving and maintaining therapeutic CNI 
Ctrough in clinical practice over the first year post-transplant in HIV kidney 
transplant recipients. The co-administration of antiretroviral drugs with 
calcineurin inhibitors resulted in unpredictable drug exposure. Frequent 
subtherapeutic Ctrough concentrations were observed in the early period post-
transplantation. This may have contributed to the high allograft rejection 
episodes observed although, would require further study to support this 
inference. Perhaps the availability of non-interacting antiretroviral agents such 
as raltegravir, dolutegravir and rilpivirine offer for alternatives to allow for the 
more widespread use of tacrolimus in the HIV infected population. Where 
switching to integrase inhibitors is not possible, there are several points to 
consider when co-medicating CNIs with interacting cART, especially for 
tacrolimus and PI-containing cART combinations.   
PI-containing cART profoundly increases Tac exposure by more than 100 fold. 
The implications of this result in  
1. Extended dosing interval 
2. Altered total drug exposure 
3. Extended time to steadystate drug concentration 
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This poses several issues, first how to initiate tacrolimus in the immediate 
period post-KT. The BHIVA (2005) guidelines recommended performing a pre-
transplant CNI trial as a dose finding strategy to use post-KT. The utility of this 
approach could not be proven in the current dataset nevertheless, this approach 
has several limitations. As discussed, differences in haemodynamics pre- and 
post-KT of the HIV+ patient that may affect total exposure of the drug; and use 
of medication peri-operatively that may affect tacrolimus absorption for 
example. Therefore, Tac initiation using the pre-KT dose finding trial may not be 
a useful strategy. The second issue with Tac initiation is the extended time to 
steadystate of Tac concentration and altered total drug exposure. The use of a 
loading dose either using a standardised single dose, e.g. 1mg or 2mg as 
previously mentioned, or reducing the dosing interval, e.g. 0.5 three times a 
week, reducing to two times a week then once a week thereafter may be 
another approach to achieve a target therapeutic Cmax and quicker time to 
steadystate. However, this approach is dependent on the Tac-PI interactions 
resulting in linear kinetics of tacrolimus (Burton, 2006). The linearity of the Tac 
kinetics when co-medicated with ritonavir based cART has been implied in a 
small PK study the tested different ranges of Tac (1mg to 6.5mg) (van 
Maarseveen et al., 2013). There is also the possibility of using smaller doses 
more frequently (e.g. 0.2mg daily, two or three times a week) by using liquid 
formulations of Tac that may offer more rapid absorption for a higher Cmax, 
minimise fluctuatioins (Cmax/Cmin) in CNI exposure and longer Tmax compared to 
immediate release capsule formulations(Burton, 2006, AstellasPharma, 2015). 
However, further study in a larger cohort is warranted to corroborate these 
approaches. For all other CNI and cART group combinations, doses described 
in this thesis could be used as a guide to initiating CNI doses post-KT.  
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Mycophenolate TDM  
Mycophenolate use is known to increase the risk of latent viral reactivation and 
other associated adverse events. Discontinuing mycophenolate would 
compromise optimal IS therapy. There has been much debate over the utility of 
mycophenolate therapeutic drug monitoring in solid organ transplantation. 
Analyses did not provide strong evidence to support the usefulness of 
mycophenolate TDM in HIV/KT determined by composite outcomes MMF 
discontinuation, MMF associated haematological ADR and post-transplant 
allograft outcomes. However, there was some evidence to support the use of 
MMF TDM in preventing latent viral infections even with CMV prophylaxis being 
taking into consideration. However, findings were limited by the small cohort 
size particularly when performing sub-group analyses. Future studies in a larger 
cohort is needed. 
In conclusion, this programme of research has demonstrated the increasing 
problem of ESKD in HIV infected individuals, especially in Black ethnic patients, 
despite the widespread use of cART. Kidney transplantation in HIV infected 
individuals is feasible albeit with a high rate of allograft rejection. However, 
optimal immunosuppressant drug treatment strategies are warranted to improve 
post-HIV/KT outcomes. CNI choice, achieving and maintaining therapeutic CNI 
Ctrough concentrations especially in the early period post-KT and utilising 
mycophenolate therapeutic drug monitoring are but some of the ways to 
optimise IS therapy and avoid allograft rejection. Other strategies such as use 
of lymphocyte depleting agents, for example alemtuzumab (anti-CD52 
monoclonal antibodies), have shown early promising results although further 
study in a larger patient cohort would firm up these observations.   
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Future studies 
This thesis has been able to address several questions in relation to kidney 
transplantation in the HIV infected population. Despite this, several research 
questions have been raised for future study summarised but not limited to the 
following 
• Study of the impact of antiretroviral drug choice on the 
incidence/prevalence of HIV/ESKD 
• Study of the impact of adherence clinic to improve the uptake of kidney 
transplantation in HIV infected patients 
• Study of impact of HIV/ESKD treatment modality on the patients’ quality of 
life 
• Imact of HIV kidney transplantation on host/graft survival at 5 and 10 years 
post-transplant and implications of allograft rejection on long-term 
outcomes 
• Study to determine the optimal donor criteria to improve HIV kidney 
transplant allograft outcomes. A background to this is would be to perform 
a paired controlled study to determine the outcome of the second kidney 
for the deceased donor HIV/KT patients. 
• Utility, safety and efficacy of lymphocyte depleting agents e.g. 
alemtuzumab and antithymocyte globulin to reduce the rates of allograft 
rejection in the HIV/KT cohort 
• Surveillance protocol biopsies with additional histopathology studies to 
determine HIV deposits in podocytes or tubular cells (Canaud et al., 2014) 
• Use of CNI minimisation and CNI-sparing immunosuppressive therapies to 
minimise CNI exposure and avoid nephrotoxicity. Study to explore the 
inclusion of mTOR inhibitors that has demonstrated anti-HIV activity and 
reduced HIV persistence post-HIV/KT (Stock et al., 2014) 
• Study of the safety and efficacy of switching to integrase inhibitors to avoid 
CNI and PI-containing cART interactions 
• Study of the safety and efficacy of HIV positive organ donation 
• Study of the safety and efficacy of ABO incompatible transplantation   
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Appendix E 
Study Centre List 
UK HIV Kidney Transplant Study Centre List 
Barts Health NHS Trust  
Brighton and Sussex University Hospitals NHS Trust 
Central Manchester University Hospitals 
Chelsea and Westminster NHS Foundation Trust  
East Kent Hospitals University NHS Foundation Trust  
Eastbourne District General 
Edinburgh, NHS Lothian 
Epsom and St Helier University Hospitals 
Garden Clinic Slough (HIV Centre) 
Gloucestershire Royal Hospital  
Guy’s and St Thomas’ NHS  Foundation Trust  
Heart of England NHS Foundation Trust, Birmingham 
HIV Services Clinic and Community, The Hillingdon Hospital  
Imperial College Healthcare NHS trust  
King’s College Hospital NHS Foundation Trust  
Lancashire Care NHS Foundation Trust  
Luton & Dunstable 
Maidstone and Tunbridge Wells NHS Trust 
Medway NHS Foundation Trust 
Mid-Cheshire Hospitals NHS Foundation Trust 
Monsall Unit, North Manchester Hospital 
Mortimer Market Centre, University College London Hospitals 
Newham University Hospital NHS Trust  
NHS Greater Glasgow and Clyde  
North Middlesex University Hospital NHS Trust 
North West London Hospitals NHS Trust  
Nottingham University Hospitals NHS Trust  
Oxford Radcliffe Hospitals NHS Trust  
Pennine Acute Hospitals NHS Trust, Manchester  
Queen Elizabeth Hospital 
Royal Berkshire NHS Foundation Trust 
Royal Free London NHS Foundation Trust  
Royal Liverpool & Broadgreen University Hospitals NHS Trust  
Spire Manchester Hospital, Salford 
St George’s Healthcare Trust and St George’s, University of 
London  
University College London  
University Hospitals Birmingham NHS Foundation Trust  
University Hospitals of Leicester NHS Trust  
University of Liverpool  
West Middlesex University Hospital NHS Trust  
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Appendix G 
Pharmacokinetic Studies 
After oral administration of TAC, whole blood concentration-time profile from 6 
HIV/KT recipients were used to derive maximal drug concentration achieved 
(Cmax), time to maximal concentration (Tmax), and the area under the 
concentration-time curve (AUC). AUCs were calculated using the linear-log 
trapezoidal method.  
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0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
Patient 1 [3TC/AZT/EFV] Week 1 Post-KT Adoport 4mg Capsule  {0.07mg/kg}
Patient 2 [3TC/ABC/RAL - Stopped PI Day 0 Post-KT] Week 4 Post-KT Tacrolimus 11mg Liquid
{0.1mg/kg}
Patient 3 [ABC/3TC/RAL/ETV] Week 13 Post-KT Adoport 7mg Capsule  {0.1mg/kg}
Patient 4 [ABC/3TC/RAL] Week 25 Post-KT Adoport 3mg Capsule  {0.03mg/kg}
Patient 5 [ABC/3TC/EFV] Week 119 Post-KT Prograf 8mg Capsule  {0.1mg/kg}
Patient 6 [ABC/3TC/EFV] Week 431 Post-KT Adoport 8mg Capsule  {0.1mg/kg}
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Table 41: Non-compartmental Pharmacokinetic Analysis - Calculated PK parameters using linear trapezoidal method 
 
  HIV Negative 
Reference 
USA Cohort** USA Cohort** USA Cohort** USA Cohort** Patient 1252 Patient 1257 Patient 1251 Patient 112001 Patient 1256 








1 13 25 120 431 
cART N/A Tac+NVP Tac+NVP Tac+EFV Tac+EFV 3TC/AZT/EFV ABC/3TC/RAL/ETV ABC/3TC/RAL 3TC/ABV/EFV ABC/3TC/EFV 
Tacrolimus PK Profile_Dose  variable variable variable variable 4mg 7mg 3mg 8mg 8mg 
Dose Frequency (hourly)      12 12 12 12 12 
Weight (kg)      50 65 93 63 91 
Weight normalised dose (mg/kg)      0.08 0.11 0.03 0.13 0.09 
Ctrough (ng/ml) pre-AUC      5.2 9.6 13 6.3 8.4 
Ctrough (ng/ml) post-AUC      5.1 8.3 16.4 5.1 NA 
Cmax (ng/ml)      26.5 23.3 18.1 14.9 65.4 
Tmax (hours)      2.2 2.0 1.0 3.0 0.5 
Kel       0.1087 0.1813 0.0964 0.1077 0.3698 
T1/2 (hours)      6.375344986 3.822393822 7.18879668 6.43454039 1.873985938 
Conc. Time zero      3.0394 3.6766 3.1092 2.7003 3.8742 
Vd (mL)      UD 177.1621523 133.9099511 537.4828329 166.1675839 
Clearance (mL/hour)      UD 32.11949822 12.90891929 57.8869011 61.44877253 
Time to steady state (hours) [5xT1/2]      31.88 19.11 35.94 32.17 9.37 
AUC (ng*h/ml/mg/kg) 2000 - 5000 2170 (936-3261) 4220(2703-6229) 3644 (3115-5157) 1911(1423-3207) 1480.02875 1035.5 3885.8 774.5 1529.8 
*UA – Unable to determine; Patient 1254 – excluded, not enough data points & on PI based cART Refer to graph;  Note that the AUC in steady state equals AUC∞ after the first dose 
**Reference: (PDRNetwork, 2011, Frassetto et al., 2013)    
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